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I.  Abstract 
 
G protein-coupled receptors (GPCRs) represent the largest family of cell surface 
receptors. However, only a fraction of the more than 800 receptors have been 
characterized to an extent that their physiological role is reasonably well understood. 
In fact, current pharmacotherapy only addresses some 60 receptors with a large 
collection of compounds that represent about 30% of the available drugs.  
It has long been known that GPCRs are subject to illegitimate expression in cancer 
cells. Presumably, hijacking the normal physiological functions of GPCRs contributes 
to all biological capabilities acquired during the multistep development of human 
cancers. With the goal of linking G protein-coupled receptors to malignant diseases, 
GPCRs were searched for that revealed high expression levels in small cell lung 
cancer (SCLC): The mRNA encoding orphan G protein-coupled receptor 19 (GPR19) 
was found to be frequently overexpressed in tissue samples obtained from patients 
with SCLC in contrast to samples derived from non-SCLC or normal lung. 
Several observations indicate that overexpression of Gpr19 confers a specific 
advantage to human lung cancer-derived cells regarding the transition through the 
cell cycle. Knockdown of Gpr19 mRNA by RNA interference reduced cell growth of 
human lung cancer cell lines and led to cell death. Cell cycle progression through 
G2/M phase was impaired and this was associated with increased protein levels of 
cyclin B1 and phosphorylated histone H3. 
Gpr19 exhibited a cell cycle-dependent expression pattern in lung cancer cell lines. 
When cell cycle distribution profiles of cells released from cell cycle arrest were 
related to Gpr19 mRNA levels, a peak Gpr19 expression was detected during S 
phase.  
The control of Gpr19 expression by E2F transcription factors, which drive gene 
expression of many genes important for cell cycle progression, was verified by 
chromatin immunoprecipitation: Antibodies directed against E2F-1 to E2F-4 allowed 
for the recovery of the Gpr19 promoter in lung cancer-derived cell lines. E2F binding 
site deletion in the Gpr19 promoter resulted in diminished luciferase reporter gene 
expression. 
This is the first example of a G protein-coupled receptor showing cell cycle phase-
specific mRNA expression. Further results point to a functional link between the cell 
cycle-dependent expression of Gpr19, a correct cell cycle passage, and cellular 
proliferation in human lung cancer-derived cells that exhibit higher than normal 
basal levels of Gpr19 mRNA. Hence, the data also validate GPR19 as a candidate 
target when overexpressed in lung cancer. 
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II.  Zusammenfassung 
 
G Protein-gekoppelte Rezeptoren (GPCRs) stellen die größte Familie zellulärer 
Oberflächenrezeptoren dar. Jedoch sind nur ein Teil der mehr als 800 Rezeptoren in 
solchem Ausmaß charakterisiert, dass deren physiologische Rolle gut verstanden 
wird. Tatsächlich werden in der heutigen Pharmakotherapie lediglich etwa 60 
Vertreter dieser Rezeptoren mit einer Vielzahl von Substanzen angegriffen, welche 
etwa 30% aller verfügbaren Medikamente ausmachen.  
Es ist schon lange bekannt, dass GPCRs eine ungewöhnliche Expression in Krebszellen 
aufweisen können. An vielen Stellen der Karzinogenese tragen sonst normale, 
physiologische Funktionen von GPCRs mutmaßlich zur Krebsprogression bei, wenn 
diese unkontrolliert und missbräuchlich in einer Zelle verwendet werden.  
Das Hauptziel dieser Arbeit besteht darin, GPCRs vermehrt in Bezug zu malignen 
Erkrankungen zu stellen. Konkret wurde nach GPCRs gesucht, die eine hohe 
Expression im kleinzelligen Lungenkarzinom aufweisen. Hierbei zeigte sich, dass die 
den G Protein-gekoppelten Rezeptor 19 (GPR19) kodierende mRNA in Proben von 
Patienten mit kleinzelligem Lungenkarzinom verglichen mit Proben anderer 
Lungenkarzinome und von untransformiertem Lungengewebe überexprimiert war.  
Desweiteren deuten einige Beobachtungen darauf hin, dass eine Gpr19 
Überexpression in von humanen Lungenkarzinomen abgeleiteten Zelllinien diesen 
einen spezifischen Vorteil im Durchschreiten des Zellzykluses bietet. Die 
Abschwächung der Gpr19 Genexpression mittels RNA Interferenz hemmte 
Lungenkarzinomszelllinien in ihrer Proliferation und führte letztlich zu deren Zelltod. Das 
Fortschreiten des Zellzykluses über die G2/M Phase hinweg war gestört, was mit einer 
erhöhten Präsenz an für diese Phasen charakteristischen Proteinmarkern (Zyklin B1, 
phosphoryliertes Histon H3) einherging.  
In den untersuchten Lungenkarzinomszelllinien war die Expression der Gpr19 mRNA 
abhängig vom Zellzyklus. Nachdem die Zellen in verschiedenen Phasen des Zell-
zykluses zunächst angehalten und danach aus dem Arrest entlassen wurden, konnte 
ein Höchststand der Gpr19 Expression während der S Phase konstatiert werden.   
Zudem zeigte sich mit Hilfe von Chromatin-Immunpräzipitation, dass die Gpr19 mRNA 
Expression in diesen Zelllinien anscheinend unter der Kontrolle von 
Transkriptionsfaktoren der E2F Familie steht. Mitglieder dieser Familie sind bekannt 
dafür, dass sie die Genexpression vieler am Zellzyklus beteiligter Gene kontrollieren. 
So konnte die Gpr19 Promotorregion bei der Anwendung von gegen E2F-1 bis 4 
gerichteten Antikörpern nachgewiesen werden. Und die Zerstörung mutmaßlicher 
E2F Bindestellen in der Gpr19 Promotorregion schwächte die Expression eines 
Luciferase Reporterkonstrukts ab.  
Diese Arbeit offenbart zum ersten Mal die vom Zellzyklus abhängige mRNA Expression 
eines Vertreters der GPCR Familie, GPR19. Desweiteren stellt sie eine funktionelle 
Verbindung zwischen dieser differenziellen Expression, einem ungehinderten 
Durchschreiten des Zellzykluses und der Proliferation von humanen 
Lungenkarzinomszelllinien her, wenn diese eine erhöhte Gpr19 Grundexpression 
aufweisen. Folglich validieren diese Daten GPR19 als mögliches Angriffsmolekül bei 
einer Überexpression im Lungenkarzinom. 
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III.  Introduction 
 
1. Cancer – a highly diverse disease 
 
Cancer is a general term used for diseases in which abnormal cells of the human 
body divide in an uncontrolled manner and are able to infiltrate healthy tissues – 
which can eventually lead to death. According to the World Health Organization 
(WHO), cancer is one of the major causes of deaths worldwide and its incidence 
rises with age1. Dozens of different cancer types exist and they are classified 
according to their tissue/organ or cell type of origin. Most cancers are grouped as 
carcinoma (derived from epithelia; accounting for 80 to 90% of all cancers), 
sarcoma (derived from cells of mesodermal origin like supportive or connective 
tissues such as bone, cartilage, fat, muscle, or blood vessels), leukemia (originating in 
blood-forming tissue such as the bone marrow), lymphoma (derived from lymphatic 
tissue), myeloma (derived from plasma cells of the bone marrow), or central nervous 
system (CNS) cancers (derived from neuronal cells). Except for leukemias, cancer is 
usually characterized by the formation of solid tumors. They are grouped into benign 
tumors (non-cancerous; non-invasive) and malignant tumors (cancerous; potential to 
invade nearby tissues and metastasize to distant organs)2, 3. 
Predictions expect 1,283,101 deaths from cancer in the European Union (EU) in 2012 
split up into 717,398 men and 565,703 women. This corresponds to standardized rates 
of 1,387/1 x 106 (men) and 847/1 x 106 (women). Yet, cancer rates in general decline 
due to improved diagnostic and treatment options (Malvezzi M et al., 2012). The 
predominant treatment options for cancer include surgery, radiation therapy, 
chemotherapy, (anti-)hormone therapy, and biological therapy (e.g., targeted 
therapy with antibodies; American Cancer Society, 2012, p.1). 
Cancer is predominantly a genetic disease. The multi-stage model of carcinogenesis 
describes the initial genetic mutation (e.g., in growth-regulatory genes) causing the 
pre-malignant transformation of a cell (initiation) followed by the proliferation of 
initiated cells (promotion) finally leading to tumor formation and autonomous growth 
(progression; Tsao AS et al., 2004; Puntoni M and Decensi A, 2009). Genetic mutations 
can occur spontaneously, for instance through deoxyribonucleic acid (DNA) 
replication errors or impairments in DNA damage recognition and/or repair. 
However, the major causes for a normal cell to become malignantly transformed are 
environment-related. This includes effects of chemical carcinogens (e.g., aromatic 
hydrocarbons, nitrosamines, or aromatic amines) often related to tobacco smoking 
and daily diet, ultraviolet or ionizing radiation (physical carcinogenesis), and tumor 
viruses (e.g., Epstein-Barr virus, Hepatitis B virus, Human Papillomavirus; biological 
carcinogenesis; Hoppe-Seyler F and Hoppe-Seyler K, 2011). On the other hand, there 
are also genetically inherited causes of cancer proven by hereditary cancer 
syndromes such as Retinoblastoma, Ataxia telangiectasia (increased risk for leukemia 
                                                
1  www.who.int/mediacentre/factsheets/fs297/en/ 
 
2  www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer 
 
3  training.seer.cancer.gov/disease/categories/classification.html 
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or breast cancer) or Familial Adenomatous Polyposis (colon adenomas; Ganjavi H 
and Malkin D, 2002). Furthermore, endogenous hormones often act as promoters by 
providing a growth stimulus to transformed cells, i.e., to cells that have accumulated 
mutations caused by initiating agents (Clayton PE et al., 2011).  
 
 
1.1.  Fundamental characteristics of cancer 
 
The development of human cancers is usually a multistep process from the 
acquisition of genetic defects (e.g., mutations, translocations, amplifications) or 
epigenetic aberrations (e.g., chromatin remodeling) in a normal cell until the 
establishment of a malignant phenotype (Croce CM, 2008). During the course of this 
process, cancer cells need to acquire some critical capabilities in order to 
successfully proliferate and survive (figure 1). These capabilities are described as the 
hallmarks of cancer by Hanahan and Weinberg and very often result from the loss of 
function of tumor suppressor genes and the gain of function of oncogenes 
(Hanahan D and Weinberg RA, 2011). Additionally, the deregulation of micro-
ribonucleic acid (RNA) genes, which do not encode proteins but whose RNA 
products regulate gene expression by RNA interference, can also contribute to 
cancer formation (Croce CM, 2008). 
 
 
 
Figure 1:  Ten capabilities are of key importance for cancers to successfully proliferate and survive. 
Among them are eight hallmarks of cancer (resisting cell death; deregulating cellular 
energetics; sustaining proliferative signaling; evading growth suppressors; avoiding immune 
destruction; enabling replicative immortality; activating invasion and metastasis; inducing 
angiogenesis) and two enabling characteristics providing the underlying rationale for these 
hallmarks (genome instability and mutation; tumor-promoting inflammation). The figure is 
adapted from Hanahan D and Weinberg RA, 2011. 
CANCER
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Cancer cells must continuously enter into and progress through the cell cycle 
(sustaining proliferative signaling) which is often achieved by the activation of 
growth factor-induced signaling pathways (Lemmon MA and Schlessinger J, 2010; 
Witsch E et al., 2010). Either growth factors and their cognate receptors or 
downstream effectors (e.g., oncogenes which, for example, encode the small 
guanosine triphosphatase (GTPase) Ras (rat sarcoma) or the transcription factor Myc 
(myelocytomatosis oncogene)) in respective signaling pathways are altered (Davies 
MA and Samuels Y, 2010; Larsson LG and Henriksson MA, 2010; Pylayeva-Gupta Y et 
al., 2011). Further, cancer cells need to become insensitive to growth-preventing 
mechanisms (evading growth suppressors). The inactivation of cell cycle regulators 
such as the tumor suppressors retinoblastoma-associated protein 1 (RB1) and/or 
tumor protein 53 (TP53) is therefore pursued by many different cancers (Chen HZ et 
al., 2009; Suzuki K and Matsubara H, 2011). Besides, cellular growth inhibition 
mediated by cell-cell contacts in normal tissues is also often abrogated in cancer 
cells (Liu Y and Dean DC, 2010).  
Another important characteristic of cancer cells is their potential to avoid apoptosis 
(resisting cell death). Damaged cells are normally removed from the pool of cells in 
a tissue by programmed cell death. However, cancer cells counteract apoptosis-
inducing mechanisms frequently by inactivation of TP53 or by shifting the balance 
between pro- (e.g., Bax and Bak) and anti-apoptotic factors (e.g., B-cell lymphoma-
leukemia gene 2 (Bcl-2)) in favor of survival (Hanahan D and Weinberg RA, 2011). The 
insensitivity to death-receptor-mediated signaling (e.g., via cluster of differentiation 
95 (CD95)/Fas) is also employed to resist apoptosis (Carey GB et al., 2000).  
In order to proliferate and produce a vast number of malignantly transformed cells, 
cancer cells must show unlimited replicative potential (enabling replicative 
immortality). Normal cells eventually enter a state of viable senescence as their 
number of cell divisions is finite. This is largely due to the shrinkage of telomeric 
sequences at the chromosome ends upon chromosomal duplication. Hence, cancer 
cells counteract the shrinkage of telomeres and therefore the induction of 
senescence mostly by the upregulation of telomerase expression (Chen CH and 
Chen RJ, 2011).    
Tumors ensure their supply with nutrients and oxygen by the formation of a tumor-
associated neovasculature (inducing angiogenesis) once this supply can no longer 
be maintained simply by diffusion. They cause existing capillaries to sprout new blood 
vessels in direction of the tumor. The most important pro-angiogenic regulators – 
often secreted by cancer cells – include vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and nitric oxide (Ziche M and Morbidelli L, 2009). 
Cancer cells frequently show the ability to disseminate from their original site of 
growth and to colonize different tissues/organ sites (activating invasion and 
metastasis). This multistep process starts with evasion from the primary tumor and 
invasion of surrounding tissue, intravasation into blood or lymphatic vessels, survival in 
the circulation, and eventually extravasation, homing to the new tissue/organ site, 
and the formation of metastases (Nguyen DX et al., 2009). The characteristic 
changes happening to transformed epithelial cells in order to disseminate and 
invade tissues can be part of a process referred to as epithelial-to-mesenchymal 
transition which includes the switch from the expression of the epithelial cell adhesion 
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molecule E-cadherin towards the mesenchymal counterpart neural (N)-cadherin 
(Yilmaz M and Christofori G, 2009). Upon formation of micrometastases, this process 
can be reversed (mesenchymal-to-epithelial transition; Thiery JP and Sleeman JP, 
2006). Additionally, extracellular matrix-remodeling enzymes such as matrix-
metalloproteinases expressed by cancer cells facilitate their penetration of the basal 
membrane and adjacent tissues (Hua H et al., 2011).  
The energy metabolism of cancer cells can be adjusted in a way that it actively 
supports uncontrolled growth and proliferation (deregulating cellular energetics). It 
has been shown that cancer cells are able to limit their energy production to 
glycolysis neglecting further adenosine triphosphate (ATP) generation from pyruvate 
oxidation in the mitochondria. Hence, they use glycolysis intermediate products for 
the production of nucleosides and amino acids therefore benefiting energetically 
when generating macromolecular structures or duplicating their organelles and 
proteins as a prerequisite for cell division. Besides, their fueling with glucose is often 
enhanced upon upregulation of glucose transporters (DeBerardinis RJ et al., 2008). 
Most cancer cells predominantly produce energy by a high rate of glycolysis 
followed by lactic acid fermentation in the cytosol. In normal cells, however, a rather 
low rate of glycolysis is followed by oxidation of pyruvate in mitochondria. The 
molecular process in tumor cells is referred to as the ‘Warburg Effect’ also known as 
aerobic glycolysis. It is an aerobic process (using oxygen), regardless of the oxygen 
level in the tumor (Koppenol WH et al., 2011).  
As cells and tissues are under constant immune surveillance, cancer cells must 
circumvent their destruction by cells of the immune system (avoiding immune 
destruction). They can achieve this by the secretion of immunosuppressive factors 
(e.g., transforming growth factor ß (TGF-ß)) and the attraction of immuno-regulatory 
cells such as regulatory T cells (Mougiakakos D et al., 2010; Yang L et al., 2010). 
The basis for acquiring these hallmarks described above is set by genome instability 
and mutation typically observed in cancer cells. This so-called enabling hallmark 
successively leads to genomic alterations in neoplastic cells finally conferring a 
selective advantage over cells with genetic integrity, which results in cell growth and 
formation of a tumor. Among the many mechanisms that increase the activity of 
oncogenes and cause the inactivation of tumor suppressor genes are for instance 
chromosomal aberrations, genomic mutations, and epigenetic events such as DNA 
or histone modifications (Hanahan D and Weinberg RA, 2011). 
Another enabling hallmark is the tumor-promoting inflammation by cells of the 
immune system. Tumor inflammation results in a stroma enriched in signaling 
molecules that can be exploited by tumor cells to sustain their proliferative response. 
Inflammatory cells infiltrate the tumor and can release factors that support the 
growth, proliferation, and invasiveness of cancer cells as well as angiogenesis 
(Grivennikov SI et al., 2010; Qian BZ and Pollard JW, 2010). Besides, the local 
concentration of reactive oxygen species can be increased through immune cells 
therefore favoring mutagenesis in adjacent cancer cells (Grivennikov SI et al., 2010). 
The heterogeneity of tumors is further supported by the idea of cancer stem cells 
observed in some tumor types. These cancer cells exhibit a phenotype of self-
renewal and give rise to more differentiated daughter cells (Cho RW and Clarke MF, 
2008). They may further express markers typical of normal tissue stem cells, be more 
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resistant to anti-tumor therapy, and account for tumor dormancy leading to the 
reestablishment of the malignancy after the end of treatment (Hanahan D and 
Weinberg RA, 2011).  
Apart from malignant cells, cells from the tumor stroma contribute significantly to the 
whole tumor mass. Among them are cancer-associated fibroblasts (CAFs) which not 
only provide a structural framework to the tumor but are further involved in tumor-
stroma crosstalk. They can support proliferation, angiogenesis, and tumor 
invasiveness therefore contributing to features characteristic of cancer (Micke P and 
Ostman A, 2005; Franco OE et al., 2010). 
Some cancers depend on the sustained activity of one or a few genes in order to 
maintain their malignant phenotype (oncogene addiction). Targeting an oncogene 
might lead to tumor regression and cell death – as observed in human epidermal 
growth factor receptor 2 (HER2)-amplified breast cancer patients treated with 
receptor-targeting antibodies like trastuzumab (Herceptin®; Brough R et al., 2011). 
This phenomenon – interference with the action of a single deregulated oncogene 
can cause inhibitory effects on proliferation and survival – is exploited by targeted 
therapy (Weinstein IB and Joe A, 2008). Besides, it is closely related to the concept of 
synthetic lethality which explains the observation that mutations in two genes can 
lead to cell death whereas mutations in either of the genes alone are compatible 
with survival. This model can be applied both to activating mutations in oncogenes 
and inhibitory mutations in tumor suppressors (Nijman SM, 2011). For instance, a 
synthetically lethal phenotype has been demonstrated for the inhibition of two tumor 
suppressors involved in DNA repair: breast cancer 1 (BRCA1) or BRCA2 and poly 
(adenosine diphosphate (ADP)-ribose) polymerase 1 (PARP1; Brough R et al., 2011). 
 
 
2. Lung cancer 
 
Lung cancer is among the leading causes of cancer-related deaths worldwide and 
strongly associated with smoking (figure 2). In the EU, lung cancer is predicted to 
account for 183,592 deaths in men and 78,658 deaths in women in the year 2012 
(Malvezzi M et al., 2012). These numbers correspond to a standardized rate of 
372/1 x 106 men (26% of total male cancer deaths; lowered by 10% compared to the 
year 2007) and 134/1 x 106 women (14% of total female cancer deaths; increased by 
7% compared to the year 2007). The relative figures for deaths arising from lung 
cancer are even higher in the United States – here, rates of 29% of total male cancer 
deaths (87,750 cases) and 26% of total female cancer deaths (72,590 cases) are 
predicted in 2012 (Siegel R et al., 2012). The most common symptoms of lung cancer 
include chest pain, bloody sputum, cough, dyspnoea, and shortness of breath 
typically resulting from local compression or invasion of thoracic areas adjacent to 
the tumor. Primary lung cancers are of epithelial origin (carcinoma; except for 
malignant mesothelioma arising from the lung pleura) and they are classified into 
two major groups based on pathological features: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC).  
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Figure 2:  Cigarette smoking is associated with the majority of lung cancer deaths in the United States. 
Annual numbers (2000 till 2004) of cancer deaths are shown by sex and cancer site/organ 
(American Cancer Society, 2012, p. 37). 
 
 
2.1.  Small cell lung cancer (SCLC)4 
 
SCLC accounts for 20% of all lung cancer cases and the WHO further defines small 
cell carcinoma (70%) and combined small cell carcinoma (30%; at least 10% of the 
tumor is characterized by a NSCLC component; Beasley MB et al., 2005; Rekhtman N, 
2010). It is almost exclusively found in smokers and characterized by a very low 
doubling time and a very aggressive phenotype (Nicholson SA et al., 2002). 
Morphological features include scant cytoplasm, finely granular chromatin, indistinct 
cell borders, absence of nucleoli, high mitotic rate, large areas of necrosis, and 
predominantly small cells (smaller than the size of three lymphocytes; Brambilla E et 
al., 2001; Rekhtman N, 2010). 
In limited-stage SCLC, the tumor has not spread beyond supraclavicular lymph 
nodes and the median survival time is 18 to 20 months (five year survival rate of 15 to 
25%; Dowell JE, 2010). However, in extensive-stage SCLC, the tumor has already 
spread beyond supraclavicular areas and the median survival time is only 7 to 12 
months (five year survival rate of 2%; Jackman DM and Johnson BE, 2005). As SCLC is 
associated with early dissemination, it has usually established distant metastasis at 
the time of diagnosis (Jackman DM and Johnson BE, 2005). Preferred sites of 
metastasis include the brain (50 to 80% of patients), liver, adrenal, bone, and bone 
marrow (Rekhtman N, 2010). Without treatment, the median survival of SCLC patients 
is two to four months from the time of diagnosis. It is generally considered as a non-
surgical disease but responsive to chemotherapy (cisplatinum (adduct formation 
with DNA) and etoposide (DNA intercalation and topoisomerase II inhibition)) and 
radiation therapy (Rekhtman N, 2010). Despite good initial response rates to first line 
chemotherapy and radiation therapy, relapse rates or disease progression within one 
year after treatment are very high (> 80% (estimated); Puglisi M et al., 2010).  
 
 
                                                
4  www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional 
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2.2.  Non-small cell lung cancer (NSCLC)5 
 
The most frequent subclasses of NSCLC are squamous cell carcinoma (30 to 40%), 
adenocarcinoma (30 to 40%), and large cell carcinoma (less than 10%; Beasley MB 
et al., 2005; Kitamura H et al., 2008). Further WHO-defined subclasses are 
adenosquamous carcinoma, carcinoma with pleomorphic, sarcomatoid or 
scromatous elements, carcinoid tumor, carcinoma of salivary gland type, and 
unclassified carcinoma. The most prominent morphological characteristics of NSCLC 
cells are a large cell size with abundant cytoplasm, prominent nucleoli and cell 
borders, and a vesicular clumpy chromatin (Rekhtman N, 2010). 
A more distinct staging system than for SCLC is applied for NSCLC as NSCLC tumors 
grow more slowly and are less likely to spread to distant body sites: 0 – tumor has not 
spread beyond the inner lining of the lung; I – tumor has not spread to lymph nodes; II 
– tumor has spread to nearby lymph nodes; III – tumor has spread to nearby tissue or 
far away lymph nodes; IV – tumor has spread to other organs such as the brain or 
liver6. The five year survival rate very much depends on the disease stage ranging 
from 49% (locally confined stage) to 2% (distant spread stage). Surgery is usually the 
treatment option of choice and shows the best curative potential for localized 
NSCLC. 
 
The correct classification of lung cancers into SCLC or NSCLC is crucial for patient 
treatment and prognosis. However, classification by pathologists is not always 
unequivocal. In a panel of SCLC-diagnosed specimen, Nicholson and coworkers 
found 28% of these samples to be misdiagnosed and to also display NSCLC 
characteristics (Nicholson SA et al., 2002). In further studies, half the patients first 
diagnosed with SCLC revealed a mixture of NSCLC and SCLC or an exclusive NSCLC 
phenotype when re-diagnosed after the completion of initial treatment (Abeloff MD 
et al., 1979; Elliott JA et al., 1987). One possible explanation was the existence of a 
NSCLC component which had not been diagnosed but was selected due to its 
inadequate responsiveness towards first line chemotherapy that had been 
administered to treat the SCLC component.   
 
 
2.3.  The neuroendocrine phenotype of lung cancer 
 
Primary lung neoplasms are often characterized by a neuroendocrine phenotype 
(25% of all lung cancers). They show histopathological features of neuroendocrine 
differentiation and stain positive for neuroendocrine markers. This neuroendocrine 
phenotype is characteristic for the vast majority of SCLC but is also observed in a 
subset of NSCLC (Beasley MB et al., 2005) – large cell neuroendocrine carcinoma 
(LCNEC; 3% of all lung cancers) are high grade neuroendocrine tumors whereas 
typical carcinoid (2% of all lung cancers) and atypical carcinoid (0.2% of all lung 
cancers) are classified as low and intermediate grade neuroendocrine tumors, 
                                                
5  www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional 
 
6  www.nlm.nih.gov/medlineplus/ency/article/007194.htm 
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respectively. In addition, the presence of neuroendocrine markers is revealed in 10 to 
20% of all NSCLC cases and they are therefore called NSCLC with neuroendocrine 
features (Rekhtman N, 2010). Of these markers, either chromogranin A7, neuron-
specific enolase8, synaptophysin9, or neural cell adhesion molecule (NCAM) is 
detected in 75 to 90% of SCLC (Guinee DG Jr et al., 1994; Dowell JE, 2010; Rekhtman 
N, 2010). Minor neuroendocrine markers found in lung cancers include dopa 
decarboxylase, calcitonin, gastrin-releasing peptide, neuromedin B, or bombesin 
receptor subtype 3 (Jackman DM and Johnson BE, 2005; Rekhtman N, 2010). 
 
 
2.4.  Molecular characterization of lung cancer 
 
Apart from the expression of neuroendocrine markers, both SCLC and NSCLC are 
characterized by several molecular abnormalities and deregulated signal 
transduction pathways. Genetic alterations are very likely to result from the multitude 
of carcinogens found as tobacco smoke constituents or their metabolites (Kitamura 
H et al., 2008). They can cause the loss of function of tumor suppressor genes or the 
gain of function of putative oncogenes.  
The vast majority of lung cancers show depletions in the short arm of chromosome 
three, an area believed harbor multiple tumor suppressor genes such as RASSF1A, a 
protein supposed to be involved in cell cycle progression from gap 1 (G1) to DNA 
synthesis (S) phase (Zabarovsky ER et al., 2002). TP53 inactivation is found in 50% of 
NSCLC and 70 to 100% of SCLC cases and leads to the evasion of cells from cell 
cycle arrest or apoptosis (Jackman DM and Johnson BE, 2005; Kitamura H et al., 2008; 
Pleasance ED et al., 2010). 
About 30% of all SCLC tumors show an amplification of the regulator of gene 
transcription Myc, which is – however – only rarely observed in NSCLC (Jackman DM 
and Johnson BE, 2005; Kitamura H et al., 2008). Besides, the protein family of receptor 
tyrosine kinases has been described to contribute to both SCLC and NSCLC 
tumorigenesis (Coulson JM et al., 2003). SCLC often shows high expression levels of c-
kit (Jackman DM and Johnson BE, 2005) and insulin-like growth factor-I receptor 
(IGF-IR). Additionally, an autocrine loop was described by the co-expression of its 
ligand, insulin-like growth factor-I (IGF-I), which finally initiates the phosphatidylinositol 
3-kinase (PI3K) – protein kinase B (PKB) pathway (Fischer B et al., 2007). Epidermal 
growth factor receptor (EGFR) gain-of-function mutations are prevalent in NSCLC 
(adenocarcinoma) but virtually absent in SCLC. Activation of the EGFR further 
involves the Ras – Raf (rapidly accelerated fibrosarcoma) – MEK (mitogen-activated 
protein (MAP)/ERK kinase) – ERK (extracellular signal-regulated kinase) and PI3K-PKB 
pathways resulting in the stimulation of cell cycle progression and cell motility and in 
the inhibition of apoptosis (Kitamura H et al., 2008). Ras mutations – however – are 
                                                
7  Chromogranin A is a precursor protein released from secretory granules that – after cleavage – gives rise to 
bioactive proteins such as pancreastatin, catestatin, and vasostatin I and II (Modlin IM et al., 2010). 
 
8  The neuron-specific enolase (γ enolase) converts 2-phospho-D-glycerate into phosphoenolpyruvate and water 
(www.uniprot.org/uniprot/P09104). 
 
9  Synaptophysin is a calcium-binding glycoprotein of presynaptic vesicles (Wiedenmann B et al., 1986). 
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only rarely found in SCLC (Fischer B et al., 2007). For SCLC, there is evidence for the 
expression of mitogenic neuropeptides such as gastrin, neurotensin, cholecystokinin, 
or arginine-vasopressin together with G protein-coupled receptors (GPCRs) to which 
these peptides bind. These autocrine signaling loops are thought to promote tumor 
proliferation and progression (Coulson JM et al., 2003). 
The RB1 regulatory pathway is among the most frequently deregulated signal 
transduction pathways in lung cancer. RB1 is the main negative regulator of the E2 
promoter binding factor (E2F) family of transcription factors at the G1-S transition of 
the cell cycle. Hyperphosphorylation of RB1 causes its dissociation from E2Fs leading 
in turn to the transcription of genes crucial for cell cycle progression. These 
phosphorylation reactions can be performed by upstream regulators of RB1 such as 
the cyclin-dependent kinase (CDK)4/cyclin D or CDK6/cyclin D complexes. On the 
other hand, the cyclin-dependent kinase inhibitor 2A (CDKN2A) can interact with 
CDK4 and CDK6 therefore preventing their D-type cyclin-mediated activation and 
the phosphorylation of RB1 (mainly attributed to CDKN2A isoform 1; Wikenheiser-
Brokamp KA, 2006; Kitamura H et al., 2008). 
SCLC and NSCLC differ in their mode of RB1 pathway deregulation. In many SCLC 
tumors, RB1 protein function is lost due to Rb1 gene deletion or inactivating mutations 
(Jackman DM and Johnson BE, 2005; Kitamura H et al., 2008; Pleasance ED et al., 
2010). Rb1 mutations occur at a frequency comparable to that seen in 
retinoblastoma which is also characterized by a neuroendocrine phenotype 
(Wikenheiser-Brokamp KA, 2006). In contrast, mutations in the gene encoding RB1 are 
only seen in 15 to 30% of NSCLC (Wikenheiser-Brokamp KA, 2006). Besides, a high 
number of LCNEC (68%) show mutations in Rb1 therefore reflecting the shared 
pathological phenotype with SCLC (Beasley MB et al., 2003). Additionally, E2F-1 
overexpression occurs in nearly all SCLC tumors and is less prevalent in NSCLC 
(Wikenheiser-Brokamp KA, 2006; Kitamura H et al., 2008). The same histology-specific 
expression pattern was observed for E2F-3 (Cooper CS et al., 2006). On the other 
hand, NSCLC preferentially renders RB1 inactive by hyperphosphorylation as a result 
of p16 (CDK4 inhibitor family) gene inactivation (30 to 70% of NSCLC cases) and/or 
cyclin D1 overexpression (30 to 60% of NSCLC cases) – two events very rarely 
observed in SCLC (Wikenheiser-Brokamp KA, 2006; Kitamura H et al., 2008).  
 
 
3. Cell cycle 
 
The mammalian cell cycle is a succession of strictly ordered cellular events that finally 
lead to the separation of genetically identical daughter cells. It is generally divided 
into DNA synthesis/chromosomal replication (S phase) and separation of sister 
chromatids (mitosis; M phase). Gap phases prior to S (gap 1 phase (G1)) and M (gap 
2 phase (G2)) phases prepare the cell for growth (doubling of cell volume, organelle 
and protein content), DNA replication and mitosis. Mitosis can be further subdivided 
into pro- (nuclear envelope breakdown; chromosome condensation), prometa- 
(attachment of mitotic spindle to chromosome kinetochore), meta- (chromosome 
alignment in metaphase plate), ana- (sister chromatid separation), and telophase 
(chromosome decondensation and mitotic ring ingression) followed by cytokinesis 
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(Hochegger H et al., 2008). CDK activation not only depends on cyclin binding but 
also on the action of CDK activating kinase (CAK) which catalyzes Thr 
phosphorylation in the CDK activating loop. CDK/cyclin complexes are rendered 
inactive upon inhibitory phosphorylations performed by membrane-associated 
Tyr/Thr kinase 1 (MYT1) and Wee1-like kinase (WEE1) on the CDK subunit. These 
phosphate residues are in turn removed by cell division cycle (CDC)25 phosphatases 
(Castedo M et al., 2002). Besides, the activity of the CDK/cyclin complexes is 
negatively controlled by CDK inhibitors (CKIs) such as inhibitors of CDK4 
(INK4)/CDKN2A proteins (p16INK4A, p15INK4B, p18INK4C, p19INK4D) and p21, p27, or p57 
(Chen HZ et al., 2009; Malumbres M and Barbacid M, 2009). 
Different types of cyclins with varying preference for CDKs exist. During early G1 
phase, D-type cyclins (D1, D2, D3) associate with CDK4 and CDK6 which activate 
growth-stimulating proteins and prepare the cell for DNA replication (Malumbres M 
and Barbacid M, 2009). E-type cyclins (E1, E2) complex with CDK2 in late G1 phase 
and drive the cell into S phase. Complex formation between CDK2 and cyclin A2 
(A1 in germ cells) is observed during S phase, while cyclin A2 preferentially binds to 
CDK1 during S-G2 transition to ensure the completion of S phase and transition to 
mitosis (Malumbres M and Barbacid M, 2009). The major type of CDK/cyclin complex 
for G2-M progression and regulation of mitosis is formed by B-type cyclins (B1, B2) 
and CDK1 which is then called the maturation-promoting factor (MPF). CDK1/cyclin 
B catalyzes the phosphorylation of various proteins that are, for instance, involved in 
chromatin condensation, breakdown of the nuclear envelope, mitotic spindle 
formation, or actin reorganization (Castedo M et al., 2002). CDC25 and WEE1 are 
targets of CDK1/cyclin B resulting in phosphatase activation and kinase inhibition 
and therefore generating a feedback loop for rapid CDK1/cyclin B activity at the 
onset of mitosis (Hochegger H et al., 2008). Attachment of the mitotic spindles to 
kinetochores of condensed chromosomes aligned at the metaphase plate triggers 
the activation of the E3 ubiquitin ligase anaphase-promoting complex/cyclosome 
(APC/C) which induces the rapid ubiquitination and proteasomal degradation of 
cyclin B, a prerequisite for M phase progression (Hochegger H et al., 2008).  
 
 
3.2. Cell cycle checkpoints 
 
The progression of the cell cycle can be stalled at different checkpoints due to 
unfavorable cellular conditions like the loss of genomic integrity leading to cell cycle 
arrest. Hence, checkpoints guarantee the fidelity of cell division and cells are given 
the opportunity to correct arrest-causing events (Clarke PR and Allan LA, 2009). 
Major checkpoints exist at entry into S phase (G1-S transition) and mitosis (G2-M 
transition) as well as during S phase (intra-S checkpoint) and in M phase (metaphase-
to-anaphase transition; spindle assembly checkpoint). Upon activation, they stop the 
action of CDK/cyclin complexes at respective stages of the cell cycle (Poehlmann A 
and Roessner A, 2010).  
The G1/S checkpoint controls the entrance of cells into the phase of DNA replication 
(S phase). Members of the retinoblastoma protein family (RB1, retinoblastoma-like 
protein 1 (p107), and retinoblastoma-like protein 2 (p130)) are the key regulators of 
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checkpoint control during G1 progression. RB1, for example, binds to activator E2F 
transcription factors and inhibits their transcription-activating performance on genes 
important for G1-S progression (Polager S and Ginsberg D, 2008; Poznic M, 2009; 
Brown KC et al., 2010). Hyperphosphorylation of RB1 by CDK4 or CDK6 in complex 
with D-type cyclins (D1, D2, or D3) or CDK2/cyclin E prevents it from binding to E2Fs 
(Wikenheiser-Brokamp KA, 2006; Kitamura H et al., 2008; Chen HZ et al., 2009). Both 
the inactivation of CDC25 and the transcription of CKIs favor the inhibition of E2Fs by 
RB1 and therefore prohibit cells from entering S phase (Poehlmann A and Roessner A, 
2010). 
DNA damage like double-strand breaks or single-stranded regions of DNA is sensed 
by Ataxia telangiectasia mutated (ATM) and Ataxia telangiectasia and RAD3-
related (ATR) leading to the activation of checkpoint kinase 1 (CHK1) and CHK2 and 
effector protein phosphorylation mainly at the G1/S, intra-S, and G2/M checkpoints. 
CDC25 phosphatases are among the CHK effectors and targeted for ubiquitination 
and proteasomal degradation upon phosphorylation therefore preventing the 
removal of inhibitory phosphates on CDKs. Besides, TP53 stabilization and activation 
result from direct or indirect ATM activation leading in turn to the transcription of CKIs 
(e.g., p21) – a crucial factors in the G1/S and G2/M checkpoints (Poehlmann A and 
Roessner A, 2010). Additionally, the mitogen-activated kinase (MAPK) p38 can 
induce CDC25 inactivation, TP53 stabilization, and CKI gene expression in both G1/S 
and G2/M checkpoints (Poehlmann A and Roessner A, 2010). Apart from damaged 
DNA, the G2/M checkpoint is also triggered by incomplete DNA replication (Castedo 
M et al., 2002).  
Correct chromosomal segregation is monitored by the spindle assembly checkpoint. 
Unaligned chromosomes lead to the inhibition of separase-mediated separation of 
cohesin-trapped sister chromatids. Bipolar chromosome attachment to the mitotic 
spindle activates the APC/C cofactor CDC20 and causes APC/C-mediated 
destruction of B-type cyclins as well as activation of separase. Sister chromatid 
cohesion is terminated by cleavage of cohesin therefore assisting metaphase-to-
anaphase transition (Waizenegger IC et al., 2000; Clarke PR and Allan LA, 2009; 
Malumbres M and Barbacid M, 2009; Pines J, 2011). At the end of mitosis, APC/C 
further targets members of the mitotic kinase family (e.g., Aurora kinases, polo-like 
kinase 1(PLK1)) for destruction (Pines J, 2011). 
The induction of cell cycle arrest upon DNA damage or distraction of mitosis may not 
necessarily lead to the elimination of arrest-causing factors and cell cycle 
progression. In case of severe genomic or cellular damage with low chances of 
proper repair, cells are subject to programmed cell death. However, this balance is 
often shifted in favor of detrimental survival in several malignancies (Clarke PR and 
Allan LA, 2009). 
In fact, the vast majority of cells in multicellular organisms do not continuously cycle. 
These quiescent cells enter a paused stage (G0 phase) but can be reactivated upon 
mitogenic stimulation (Clarke PR and Allan LA, 2009). In addition, many differentiated 
cells are no longer capable of dividing at all. Hence, enhanced poliferation is 
caused by recruiting cells from G0 into G1 phase due to elevated levels of growth 
factors or due to activating mutations. Alternatively or concomitantly, gatekeepers 
are progressively eliminated. This process relieves checkpoint controls, further 
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enhances the propensity of cells to proliferate and increases the genomic instability 
of the cancer cells. Accordingly, cancer cells can accumulate further activating 
mutations. 
 
 
4. G protein-coupled receptors (GPCRs) 
 
The human complement of GPCRs consists of more than 800 members and the 
defining features of this protein family are the hydrophobic core of seven 
transmembrane (7TM)-spanning α-helices and their eponymous action, i.e., the 
activation of their cognate heterotrimeric G protein(s) (Fredriksson R et al., 2003; 
Krishnan A et al., 2012). Genes encoding GPCRs account for more than 2% of the 
total human genes (Fredriksson R et al., 2003). Exact numbers vary from about 800 to 
850 due to uncertainties arising mostly from pseudogenes of pheromone and 
odorant receptors, and there are still about 150 orphan receptors lacking an 
endogenous ligand (Gruber CW et al., 2010). 
All GPCRs share a common structure. They harbor an extracellular amino-terminus, 
seven transmembrane helices, which are connected by alternating intracellular and 
extracellular flexible loops, and an intracellular carboxy-terminus. Apart from the 
amino- and carboxy-terminus, most structural variability is observed in the 
extracellular loops of these receptors, which are involved in ligand binding and 
receptor activation. Their flexibility contributes notably to the conformational diversity 
of a GPCR (Peeters MC et al., 2011).   
The plasma membrane is home to most GPCRs. They are exported to the plasma 
membrane via the classical secretory pathway (synthesis at the endoplasmic 
reticulum, processing in the Golgi apparatus, export to the plasma membrane from 
the trans-Golgi network) where they are capable of initiating signal transduction 
upon activation (Achour L et al., 2008). However, there are also GPCRs which mostly 
reside in intracellular vesicles from where they can initiate downstream signaling 
cascades (e.g., G protein-coupled receptor 6 (GPR6); Padmanabhan S et al., 2009; 
Prasad BM et al., 2010). Typical posttranslational modifications of GPCRs include 
phosphorylation, glycosylation, and the attachment of a lipid membrane anchor10.  
GPCRs are involved in diverse physiological functions such as neurotransmission, 
smooth muscle and cardiac contraction, blood pressure regulation, hormone 
secretion, or immune responses (Dorsam RT and Gutkind JS, 2007; Rozengurt E, 2007). 
As diverse as their physiological roles is the nature of their ligands ranging from 
photons, ions, and biogenic amines over nucleotides and peptides to odorants, 
hormones, and bioactive lipids (Ji TH et al., 1998). In addition, extracellular proteases 
can cleave the amino-terminus of protease-activated receptors (PARs) therefore 
generating a new amino-terminus capable of acting as the receptor’s own ligand 
(Arora P et al., 2007).  
                                                
10  S-palmitoylation of GPCRs can occur at Cys residues of the intracellular carboxy-terminus. A C16 fatty acid chain 
is covalently attached (thiolester linkage) and anchors the carboxy-terminus to the inner layer of the plasma 
membrane therefore generating a ‘fourth intracellular loop’ (Marchese A et al., 2008). 
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GPCRs have gained much interest as well-druggable targets. They could be 
associated with multiple disease areas, e.g., malignant, neurodegenerative, 
infectious, cardiovascular, psychiatric, and immunological diseases, and about half 
of today’s drug targets are in fact GPCRs (Lundstrom K, 2009). However, only about 
60 members of this large receptor family are currently targeted by drugs approved 
for clinical use (Gruber CW et al., 2010).  
 
 
4.1.  Classification of GPCRs 
 
Based on their primary sequence and similarities in structure, vertebrate GPCRs are 
divided into five families: glutamate, rhodopsin, adhesion, frizzled/taste2, and 
secretin receptors form the so-called GRAFS classification system (Fredriksson R et al., 
2003; Krishnan A et al., 2012). The rhodopsin family contains by far the most GPCRs 
(683 members in humans) and it was therefore subdivided into four subfamilies (α, β, 
γ, and δ). Most family members are characterized by short amino-termini and the 
presence of two motives which are important for their functional integrity (Krishnan A 
et al., 2012): E/DRY at the boundary of transmembrane (TM) region 3 and 
intracellular loop region 2 (Rovati GE et al., 2007) and NPxxY11 at the boundary of TM 
region 7 and the intracellular carboxy-terminus (Bockaert J et al., 2004). Odorant 
receptors (part of the δ subgroup) constitute the largest subgroup among human 
rhodopsin GPCRs and they comprise more than 350 members (Spehr M and Munger 
SD, 2009). The adhesion family of GPCRs (33 members in humans) is characterized by 
large extracellular amino-terminal regions which are composed of multiple structural 
protein domains (e.g., epidermal growth factor (EGF)-like, leucine-rich repeats, 
immunoglobulin (Ig)). Members of this family are heavily glycosylated. Upon receptor 
synthesis at the endoplasmic reticulum, most amino-terminal tails of adhesion GPCRs 
are autocatalytically cleaved at a conserved G protein-coupled receptor 
proteolytic site (GPS) but reassemble with their remaining 7TM receptor in a non-
covalent manner at the cell surface (Yona S et al., 2008). GPCRs of the glutamate 
family (22 members in humans) also have a very long amino-terminus involved in the 
binding of endogenous ligands. Besides, the majority of human glutamate receptors 
have a conserved Cys-rich domain in the amino-terminus (Krishnan A et al., 2012). A 
closely related GPCR family, the secretin receptors (15 members in humans), share 
with adhesion GPCRs the long amino-terminus important for peptide hormone ligand 
interaction, thus they lack the GPS domain. Most family members contain conserved 
Cys residues that stabilize an amino-terminal structure by the formation of three Cys-
bridges (Lagerström MC and Schiöth HB, 2008; Krishnan A et al., 2012). Members of 
the frizzled/taste2 family (10 members in humans) act as receptors for wingless – int-1 
(Wnt) proteins and are also characterized by a long amino-terminus (Krishnan A et 
al., 2012). Besides, the smoothened receptor (involved in patched/sonic hedgehog 
signaling) is included in the frizzled/taste2 GPCR family though not being a frizzled 
receptor (Lagerström MC and Schiöth HB, 2008). In addition, pheromone and cyclic 
adenosine monophosphate (cAMP) receptors extend the classification system to 
GPCRs found only in non-mammalian species (Gruber CW et al., 2010). 
                                                
11  The amino acid positions indicated with ‘x’ in the NPxxY motif allow the presence of any amino acid.  
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4.2.   Classical GPCR signaling and GPCR-interacting proteins (GIPs) 
 
Upon ligand-induced receptor activation, GPCRs expose intracellular moieties that 
can interact with membrane-anchored heterotrimeric G-proteins and facilitate the 
exchange of guanosine diphosphate (GDP) to guanosine triphosphate (GTP) in the α-
subunit. This leads to a conformational change and causes the dissociation and 
activation of α- and βγ-subunits followed by stimulation of multiple downstream 
signaling cascades (Dorsam RT and Gutkind JS, 2007). The exchange of GTP for GDP 
is favored by guanine nucleotide exchange factors (GEFs) and hindered by guanine 
nucleotide dissociation inhibitors (GDIs; Gruber CW et al., 2010). Signal termination 
results from GTP hydrolysis performed by the intrinsic GTPase activity of the α-subunit 
leading to a reassociation of α- and βγ-subunits (reformation of the heterotrimeric G 
protein). This reaction is assisted by GTPase-activating proteins (GAPs). 
Various isoforms of  Gα (20), Gβ (5), and Gγ (12) have been described in mammals 
which can be assembled in multiple combinations giving rise to a diverse set of 
heterotrimeric G proteins (Gruber CW et al., 2010). Thus, the canonical signaling 
features of heterotrimeric G proteins are attributed to four different Gα subgroups 
whose members are defined on the basis of amino acid sequence homology. 
Activation of Gαs/olfactory leads to the stimulation of adenylyl cyclase and the formation 
of cAMP which in turn activates protein kinase A (PKA). Activation of 
Gαi/o/transducin/gustducin inhibits adenylyl cyclase12. Gαq/11/14/15/16 activation engages 
phospholipase Cß (PLCß) which breaks down phosphatidylinositol-4,5-bisphosphate 
(PIP2) at the inner layer of the plasma membrane into the second messengers 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol leading to the activation of 
protein kinase C (PKC) and Ca2+ release from intracellular stores. PKC in turn 
phosphorylates regulators of calcium signaling such as calmodulin. Gα12/13 
engagemant activates small GTP-binding proteins of the Ras-homology (Rho) family 
which activate Rho-associated coiled-coil-containing protein kinase (ROCK) 
therefore affecting the actin cytoskeleton (Cotton M and Claing A, 2009; Gruber CW 
et al., 2010). The Gßγ subunits can also transmit signals to activate effectors like PLCß, 
PI3K, or the G protein-coupled inward rectifier potassium (GIRK) channel (Woehler A 
and Ponimaskin EG, 2009). 
GPCRs are not only capable of interacting with G proteins, their key mediators of 
downstream signal transduction, but also with many accessory proteins named 
GPCR-interacting proteins (GIPs). GIPs are involved in the correct folding of GPCRs, 
fine tuning of GPCR-mediated signaling responses (including the type of G protein 
recruited), receptor trafficking (to specific cellular compartments or the plasma 
membrane), receptor complex formation, oligomerization, or desensitization 
(Bockaert J et al., 2004; Ritter SL and Hall RA, 2009). GPCR kinases (GRKs) can 
phosphorylate the receptor which results in the recruitment of ß-arrestins. They in turn 
can serve as scaffolding proteins and lead to the formation of a signaling complex 
which can, for instance, involve the human Rous sarcoma virus oncogene homolog 
Src, ERK, apoptosis signaling kinase 1 (ASK1), or Jun amino-terminal kinase 3 (JNK3; 
                                                
12  Transducin and gustducin activate phosphodiesterases (PDEs) leading to the hydrolysis of cyclic guanosine 
monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), respectively (Catty P et al., 1992; 
Margolskee RF, 2002). 
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Bockaert J et al., 2004; Luttrell DK and Luttrell LM, 2004). Receptor activity-modifying 
proteins (RAMP1, 2, and 3) regulate ligand binding to GPCRs and GPCR trafficking to 
the cell surface (Cooray SN et al., 2009; Ritter SL and Hall RA, 2009). The carboxy-
terminus of GPCRs can serve as a PDZ13 ligand that interacts with PDZ domains of 
diverse proteins involved in signal transduction. PDZ-binding proteins were shown to 
play a role in receptor clustering, signal transduction, desensitization, or recycling to 
the plasma membrane (Bockaert J et al., 2004).     
In addition, GPCRs have demonstrated their ability to transactivate growth factor 
receptors like the EGFR leading to the activation of MAPK, janus kinase (JAK)/signal 
transducer and activator of transcription (STAT), and PI3K signaling pathways 
(Rozengurt E, 2007; Cotton M and Claing A, 2009). A link between G proteins and 
gene transcription was established by the observation that Gß5 could shuttle 
between the plasma membrane and the nucleus and Gßγ was described to directly  
interact with histone deacetylase (HDAC)4 and 5 (Spiegelberg BD and Hamm HE, 
2007). Surprisingly, G protein-coupled receptor 30 (GPR30) was found to act as a 
transcription factor in the nucleus (Madeo A and Maggiolini M, 2010).  
GPCRs are believed to harbor very flexible conformations. Ligands that bind with 
different affinities stabilize a particular receptor conformation therefore favoring the 
interaction with specific effectors of signal transduction (Schröder R et al., 2010). This 
model explains the possible coupling of a GPCR to different G proteins or G protein 
independent effectors (Rosenbaum DM et al., 2009). Nevertheless, considerable 
crosstalk and bifurcations between the signals transduced by different Gα isoforms as 
well as Gβγ subunits and GPCRs themselves exist (figure 4; Woehler A and Ponimaskin 
EG, 2009).   
 
 
4.3.  GPCR oligomerization 
 
GPCRs can associate with other GPCRs forming either homo- or heteromers – often 
observed in a tissue-specific manner. Examples for GPCR heteromerization include 
the gamma-aminobutyric acid type B receptor 1 (GABA-B-R1) and GABA-B-R2, ß1-ß2 
adrenergic receptors, D1-D2 dopamine receptors, 2A-3 somatostatin receptors, 
angiotensin type 1 receptor (AT1R) and the ß2-adrenergic receptor, serotonin 2A 
receptor (5-HT2A) and metabotropic glutamate receptor 2 (mGluR2), or the 
chemokine14 receptors CC chemokine receptor 2 (CCR2) and CXC chemokine 
                                                
13  PDZ stands for the three proteins in which this domain was identified first: PSD-95 (postsynaptic density protein 95), 
DLP (Drosophila discs large protein), and the tight junction protein ZO-1 (zonula occludens protein 1; Bockaert J et 
al., 2004). The Simple Modular Architecture Research Tool (SMART) database reports PDZ domains in 364 human 
proteins (smart.embl-heidelberg.de).  
 
14  Chemokines are defined as small secreted, chemoattractant proteins with low molecular weight (8 to 14 
kilodaltons (kDa)). The biological activity of chemokines is exerted upon binding to their respective GPCR(s). They 
regulate migration/chemotaxis and activation status of responsive cells and are involved in a number of different 
processes including leukocyte migration/homing, lymphoid organ development, inflammation, allergy, 
angiogenesis, wound healing, cancer development, and cancer metastasis. Chemokines are subdivided into 
four groups depending on a conserved amino-terminal Cys motif. The ‘C only chemokine’ lymphotactin is 
characterized by only one cysteine, the CC chemokines bear two adjacent cysteines whereas cysteines in CXC 
and CX3C chemokines are separated by one or three amino acid(s), respectively (Yoshie O et al., 2001; Stievano 
L et al., 2004). 
III. Introduction 
31 
 
          
 
Figure 4: Most downstream players of GPCR signaling are interconnected. Activation of a GPCR leads 
to the initiation of downstream signaling cascades involving both Gα(isoforms s, i/o, q, 12/13) and Gßγ 
subunits of heterotrimeric G proteins. They mediate the activation (→) or inhibition (┬) of a 
number of effectors including membrane-associated ion channels (G protein-coupled 
inward rectifier potassium (GIRK) channel, N- and P/Q-type Ca2+ channels) and adenylyl 
cyclase (AC) as well as phosphodiesterases (PDEs), GTPase-activating proteins (GAPs), Tyr- 
and Ser/Thr-protein kinases (Tyr and Ser Thr PKs), guanine nucleotide exchange factors 
(GEFs), small GTPases, dynamin, phospholipases, phosphatidylinositol 3-kinases (PI3Ks), and 
proteins involved in cytoskeleton organization (ezrin/radixin/moesin (ERM) binding proteins, 
tubulin). Many bifurcations to different types of effectors exist among functional 
heterotrimeric G protein subunits and the preferred modes of action are often cell-type 
specific. However, these effectors can also be activated directly upon recruitment to the 
activated GPCR in a G protein independent manner (or via ß-arrestin). The figure is adapted 
from Woehler A and Ponimaskin EG, 2009. 
 
receptor 4 (CXCR4), to name but a few (Marshall FH et al., 1999; Percherancier Y et 
al., 2005; Franco R et al., 2007; Rozenfeld R and Devi LA, 2010). These complexes 
mainly differ from their monomeric partners in terms of ligand binding and specificity, 
preference of G protein activation and signal transduction as conformational 
changes are induced in interacting receptors upon oligomerization (Rozenfeld R and 
Devi LA, 2011). In fact, it is thought that the majority of GPCRs can form homo- or 
heterodimers, which seems to occur at an early stage of receptor trafficking to the 
plasma membrane (Franco R et al., 2007; Achour L et al., 2008). This is particularly 
true for the glutamate GPCR family, whose members exist as constitutive dimers 
often interconnected by a disulfide bridge (Pin JP et al., 2005). 
 
 
 
 
GPCR
Plasma 
membrane
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4.4.  Endocytosis of GPCRs from the plasma membrane 
 
GPCRs residing on the plasma membrane are rapidly desensitized following ligand-
induced activation (figure 5). Most receptors are internalized by clathrin-coated pit 
formation. Upon phosphorylation of their carboxy-terminus and the intracellular loop 
3 by GRKs, ß-arrestins are recruited and bind to phosphorylated residues. This in turn 
leads to the binding of clathrin and the adaptor protein complex 2 (AP2) and the 
receptor is internalized into clathrin-coated pits through the action of the large G 
protein dynamin (Hanyaloglu AC and von Zastrow M, 2008). Internalization can also 
occur as the result of receptor ubiquitination (Marchese A et al., 2008).  
Internalized GPCRs present in endosomes may on the one hand be destined to 
proteasomal degradation in lysosomes. On the other hand, GPCRs can be recycled 
back to the plasma membrane following dephosphorylation and resensitization and 
promote rapid recovery of cellular response mechanisms (Hanyaloglu AC and von 
Zastrow M, 2008). Besides, internalized GPCRs such as sphingosine-1-phosphate 
receptor 1 (S1PR1; Gi-coupled) or thyroid-stimulating hormone (TSH) receptors (Gs-
coupled) have been shown to keep on modifying the production of the second 
messenger cAMP from intracellular compartments. GPCRs are further capable of 
signaling via the MAPK or PI3K pathway once internalized. The concept that 
activated receptors on the plasma membrane continue signaling after sequestration 
into endosomes was also described for receptor tyrosine kinases (e.g., EGFR) and 
might in general lead to the generation of ‘signaling endosomes’ (Jalink K and 
Moolenaar WH, 2010).   
 
 
 
Figure 5: GPCRs are sequestered from the plasma membrane upon ligand-induced receptor 
activation. (A) Ligand binding leads to the activation of Gα (a) and Gβγ (b) subunits which 
can mediate signal transduction causing cellular responses. G protein-coupled receptor 
kinases (GRKs) phosphorylate the carboxy-terminus and the intracellular loop 3 of the 
activated GPCR which prevents further activation of heterotrimeric G proteins and enables 
binding of ß-arrestins (ßarr). Subsequently, clathrin and adaptor protein complex 2 (AP2) 
proteins are recruited for clathrin-coated pit formation and receptor internalization into 
endosomes. However, GPCRs can continue signaling from endosomal compartments (c). (B) 
Internalized GPCRs can be sorted for destruction from early endosomes over multivesicular 
bodies (MVBs) into lysosomes. In contrast, GPCRs can be recycled back to the plasma 
membrane leading to the quick resensitization of a cell to the respective extracellular 
ligand. Figures are adapted from Hanyaloglu AC and von Zastrow M, 2008; ADP – adenosine 
diphosphate; ATP – adenosine triphosphate. 
A B
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4.5.  GPCRs are involved in cell cycle regulation and cancer 
 
It has long been known that illegitimate expression of GPCRs occurs in tumor cells 
(Schorr I and Ney RL, 1971). Several arguments support the assumption that GPCRs 
may also be specifically targeted to limit the growth of cancer cells. Signaling 
pathways controlled by GPCRs promote proliferation, survival, cell migration and 
metastasis, angiogenesis, inflammation, and subversion of the immune system 
(Dorsam RT and Gutkind JS, 2007; Spiegelberg BD and Hamm HE, 2007; Borensztajn KS 
and Spek CA, 2008; Hurst JH and Hooks SB, 2009; Wu X et al., 2009; Lappano R and 
Maggiolini M, 2011). Their unrestrained exploitation – mostly seen by overexpression of 
GPCRs – can in turn contribute to the malignant transformation of cells (Li S et al., 
2005; Rozengurt E, 2007; Spiegelberg BD and Hamm HE, 2007). Besides, the 
uncontrolled action of GPCR-associated G proteins or regulators of G protein 
signaling (RGS) that accelerate the intrinsic GTPase activity of Gα subunits (GAPs) was 
described to contribute to tumorigenesis (Hurst JH and Hooks SB, 2009). And the 
crosstalk of activated GPCRs and receptor tyrosine kinases like the EGFR leading to 
their transactivation is a proven concept in the progression of many cancers 
(Lappano R and Maggiolini M, 2011). Downstream signaling mediators whose 
pathway activation can be initiated by activated GPCRs and that contribute to 
cancer cell proliferation, survival, or migration and angiogenesis include PKA, Ras-
Raf-MEK-ERK, PKB-mammalian target of rapamycin (mTOR)-ribosomal protein S6 
kinase (p70S6K), Rho-ROCK, JAK/STAT, or PI3K (Lappano R and Maggiolini M, 2011). 
The involvement in cell cycle control was shown for several GPCRs and GPCR-
associated proteins. For instance, the H4 histamine receptor was found to mediate a 
reversible cell cycle arrest in growth factor-induced hematopoietic progenitor cells 
(Petit-Bertron AF et al., 2009). An essential role in the regulation of prostate tumor 
growth by affecting cell cycle control was assigned to GRK5 (Kim JI et al., 2012). The 
transactivation of the EGFR by GPCRs established a link to cell cycle progression and 
various endogenous GPCR agonists were reported to induce the expression of 
cyclins and modulate RB1 phosphorylation (Rozengurt E, 2007).  
Furthermore, viruses have hijacked GPCRs from the host genome and adapted them 
to drive cells into S phase and/or to promote immune evasion (Cannon M, 2007; 
Beisser PS et al., 2008; Martin D and Gutkind JS, 2008). Cancer-causing viruses like 
Kaposi’s sarcoma-associated herpesvirus (KSHV) were described to encode for 
constantly active GPCRs (Hurst JH and Hooks SB, 2009). The human cytomegalovirus 
(CMV) encodes a chemokine GPCR (US28) capable of stimulating proliferation 
pathways and is associated with glioblastoma, colon and breast cancer (Lappano R 
and Maggiolini M, 2011). 
In general, non-viral GPCRs were also attributed to play a role in the development of 
various human cancers such as lung, breast, or prostate cancer. Overexpression of 
prostate-specific G protein-coupled receptor (PSGR) was detected in prostate 
tumors and prostate intraepithelial neoplasms (Weng J et al., 2005). PSGR was 
therefore discussed as a biomarker for urine-based prostate cancer detection (Rigau 
M et al., 2010). CCR2 and its ligand CC chemokine ligand 2 (CCL2) were proposed 
to contribute to prostate cancer carcinogenesis. CCR2 expression could be 
correlated with prostate cancer progression (Lu Y et al., 2007). Inactivation of the 
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CCL2/CCR2 auto- or paracrine axis could counteract prostate cancer metastasis to 
the bone and prevent prostate cancer cell growth (Lu Y et al., 2006; Lu Y et al., 
2009). In lung squamous cell carcinoma, G protein-coupled receptor 87 (GPR87) was 
identified to be overexpressed (Gugger M et al., 2008) and to contribute to the 
viability of tumor cells (Glatt S et al., 2008). A poorly-described member of the 
adhesion family of GPCRs, orphan G protein-coupled receptor 110 (GPR110), was 
found to be overexpressed in lung and prostate adenocarcinomas and 
characterized as a proto-oncogene (Lum AM et al., 2010). Likewise, the chemokine 
receptor CXCR4 was proposed to contribute to lung cancer metastasis (Burger JA et 
al., 2011). However, CXCR4 has been most prominently described in breast cancer. 
High CXCR4 expression in breast cancer could be correlated with poor prognosis 
and prevalence for bone metastasis as bone marrow stromal cells highly express the 
CXCR4 ligand CXCL12 (CXC chemokine ligand 12; Burger JA and Kipps TJ, 2006; 
Luker KE and Luker GD, 2006; Rose AA and Siegel PM, 2010). It is conceivable that 
CXCR4 might exert its effects in conjunction with CXC chemokine receptor 7 (CXCR7; 
heterodimerization), which binds CXCL12 with ten times higher affinity than CXCR4 
and was also linked to breast and lung cancer cell proliferation and metastatic 
tendency (Maksym RB et al., 2009). In SCLC cells, it was suggested that an autocrine 
loop sustained RhoA activation via the engagement of a GPCR (Touge H et al., 
2007). Wnt proteins and their cognate GPCRs have been implicated in the 
transduction of signals in multiple cancers such as colon or lung carcinoma 
(Lappano R and Maggiolini M, 2011). In addition, the G protein-coupled receptors 
GRPR (gastrin-releasing peptide receptor), NMB-R (neuromedin B receptor), 
prostaglandin-E2 receptors, and the CXC chemokine receptor 2 (CXCR2) were 
reported to contribute to lung cancer tumorigenesis (Dorsam RT and Gutkind JS, 
2007; Lappano R and Maggiolini M, 2011). 
 
 
5. G protein-coupled receptor 19 (GPR19) 
 
5.1.  Gene and protein information  
 
As a member of the large G protein-coupled receptor family, the gene encoding 
human Gpr19 (National Center for Biotechnology Information (NCBI) gene 
identification number (ID) 2842 15, Ensembl gene ID ENSG00000183150 16, NCBI mRNA 
accession number NM_006143 17, UniProt protein ID Q15760 18, NCBI protein reference 
sequence ID NP_006134.1 19) is located on the reverse strand of chromosome 12 
(short arm; 12p12.3) at position 12,849,121 to 12,813,995. It is composed of four exons 
(spliced transcript length of 1743 bases) with the last one harboring the intronless 
                                                
15  http://www.ncbi.nlm.nih.gov/gene/2842 
 
16  http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000183150;r=12:12813825-12849141 
 
17  http://www.ncbi.nlm.nih.gov/nuccore/NM_006143.2 
 
18  http://www.uniprot.org/uniprot/Q15760 
 
19  www.ncbi.nlm.nih.gov/protein/NP_006134 
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coding sequence (CDS) that gives rise to a 415 amino acid protein predicted to 
have topological characteristics of 7TM receptors (figure 6; extracellular amino-
terminus, seven transmembrane regions with alternating cytoplasmic/intracellular 
and extracellular loops, cytoplasmic carboxy-terminus). Additional expected 
features include sites of glycosylation and a disulfide bond bridging extracellular 
loops 1 and 2. The carboxy-terminus further contains multiple Ser and Thr residues 
which could be phosphorylated by GPCR kinases for reasons of receptor activity 
regulation. It also harbors the consensus sequence of a type I PDZ-binding motif 
(amino acids TFV) at the very carboxy-terminal end (Liu M and Horowitz A, 2006). The 
possibility of palmitoylation on carboxy-terminal Cys residues (lipid membrane 
anchor) and for PKC-mediated phosphorylation of the intracellular loops is also 
based on the primary sequence of GPR19 (O’Dowd BF et al., 1996). GPR19 further 
contains a strict cholesterol consensus motif20 (Phe103, Lys182, Ile184, Trp188) and 
 
 
 
Figure 6:  Primary sequence and predicted topological features of GPR19. The amino acid sequence is 
based on UniProt protein ID Q15760. All highlighted features (external amino (N)-terminus, 
transmembrane (TM), intracellular loop (IL) or extracellular loop (EL) regions, cytoplasmic 
carboxy (C)-terminus; sites of glycosylation (Glyc); disulfide bridge between two Cys 
residues; positions of potential DRY, NPxxY, or PDZ binding motives) are hypothetical and 
have not been experimentally verified. N-linked glycosylation sites were predicted using the 
NetNGlyc 1.0 algorithm21. 
                                                
20  Cholesterol is an essential part of the cellular plasma membrane. Appart from its necessity for the membrane’s 
physicochemical properties, it also ensures correct functioning or stabilization of membrane-spanning receptors 
by direct interaction. This is the case for the ß2-adrenergic and the serotonin 1A receptor, both members of the 
GPCR family (Hanson MA et al., 2008; Paila YD et al., 2009). A cholesterol consensus motif consisting of four 
consensus sites was defined to be crucial for GPCR-cholesterol interaction. The amino acid numbering system of 
Ballesteros and Weinstein was used to specify these positions (Ballesteros JA and Weinstein H, 1995). Site 1 covers 
positions 4.39 to 4.43 in/near TM region 4 and requests Arg or Lys at least once. Sites 2 and 3 are also in TM 
region 4 and must be either occupied by Trp or Tyr (4.50) and Ile, Leu, or Val (4.46). TM region 2 harbors site 4 
(2.41) which requests Phe or Tyr (Hanson MA et al., 2008; Paila YD et al., 2009). 
 
21  www.cbs.dtu.dk/services/NetNGlyc/ 
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was therefore suggested to have cholesterol binding properties (Hanson MA et al., 
2008). Parts of the genomic sequence (table 15), the mRNA and the protein 
sequence of GPR19 are listed in the Appendix section.  
Twenty-four single nucleotide polymorphisms (SNPs) lying within the CDS of Gpr19 are 
listed according to Ensembl22, with half of them affecting the protein sequence 
(amino acid substitution). An overview of these non-synonymous SNPs including 
frequency of occurrence and predicted effects of amino acid substitution on the 
protein’s function is given in the Appendix section (table 16). 
 
 
5.2.  Expression of Gpr19  
 
In normal tissues, Gpr19 was found most prominently expressed in the central nervous 
system, the ovaries, and the testis (Vassilatis DK et al., 2003; Hoffmeister-Ullerich SA et 
al., 2004). Abundant mRNA levels were detected in the brain of human, mouse, and 
rat. The human brain regions with the strongest signals detected included the 
caudate nucleus, putamen, and thalamus (O’Dowd BF et al., 1996). The regions of 
the mature mouse brain with highest Gpr19 expression were functionally distinct 
including specific parts of the olfactory bulb, cerebral cortex (mostly layers 2 and 6), 
hippocampus, hypothalamus, and cerebellum. During mouse embryogenesis, 
highest Gpr19 mRNA expression levels could be seen prominently in the developing 
CNS (neuroepithelium, neural plate) starting from embryonic day 8.5. As embryonic 
development continued, the areas with highest Gpr19 signals were the ones 
containing dividing cells (lining of the neural canal; ventricles) and cells undergoing 
differentiation (ventral horns of the spinal cord). Besides, overall Gpr19 signals in the 
adult mouse brain declined after embryogenesis (Hoffmeister-Ullerich SA et al., 2004). 
In addition, Gpr19 mRNA expression levels were high in murine cells involved in the 
sperm maturation process: Hoffmeister-Ullerich and coworkers assigned high Gpr19 
expression to spermatogonia stem cells (Hoffmeister-Ullerich SA et al., 2004). In 
contrast, Rossi and coworkers identified murine spermatocytes as the primary source 
of Gpr19 mRNA (Rossi P et al., 2004). Furthermore, a meta-analysis found Gpr19 to be 
upregulated in human embryonic stem cells (hESC) but on the other hand failed to 
detect it in non-hESC tissues including the CNS (Assou S et al., 2007).  
 
 
5.3.  Signal transduction of GPR19 
 
To date, GPR19 remains an orphan GPCR, its endogenous ligand has not been 
identified, yet. Most approaches to answer this question were based on primary 
sequence comparisons with other GPCRs whose ligands are known. Human GPR19 
shows sequence similarity to dopamine D2 and neuropeptide Y GPCRs. 
Catecholaminergic receptors mediate ligand binding with the help of an aspartic 
acid residue located within TM region 3. As GPR19 lacks this aspartic acid residue, its 
                                                                                                                                                      
 
22  useast.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?g=ENSG00000183150;r=12:12813825-12849141# 
NON_SYNONYMOUS_CODING_tablePanel 
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endogenous ligand is unlikely to be aminergic (O’Dowd BF et al., 1996). Comparing 
TM regions of known GPCRs, GPR19 was assigned to be a member of the rhodopsin 
family of GPCRs (Vassilatis DK et al., 2003) though it does neither harbor a strict NPxxY 
nor E/DRY motif. However, based on the whole protein sequence, GPR19 could not 
be assigned to any of the GPCR GRAFS families (Fredriksson R et al., 2003). Due to its 
phylogenetic proximity to receptors activated by peptides, GPR19 was proposed to 
have a peptide ligand and might as well be an endo-GPCR (activated by an 
endogenous ligand; Vassilatis DK et al., 2003) 
GPR19 was proposed to signal via Gi therefore inhibiting adenylyl cyclase but neither 
via Gs nor Gq as determined by a transcription-based reporter assay and receptor 
activation using transient receptor overexpression (Bresnick JN et al., 2003). Besides, 
Gpr19 mRNA expression in the murine striatum and hippocampus was found to be 
attenuated when cAMP-responsive element modulator (CREM) and cAMP-
responsive element binding protein (CREB) had been inactivated in these animals 
(Lemberger T et al., 2008).  
 
 
5.4.  Functional implications for GPR19 
 
Based on its chromosomal location, Gpr19 was postulated to play a role in cancer 
development as it resides in a region that is frequently rearranged in childhood 
leukemia and to a lesser extent in other neoplasms. In acute lymphoblastic leukemia 
(ALL), a hemizygous deletion of the short arm of chromosome 12 was observed in 15 
to 47% of the children examined (Montpetit A and Sinnett D, 1999). The deleted 
12p12.3 region just excluded Gpr19 but contained the gene cyclin-dependent 
kinase inhibitor 1B (Cdkn1B) with both genes being separated by about 40 kilobases. 
Additionally, high levels of mRNA encoding GPR19 were found in metastatic 
melanoma (Li S et al., 2005) showing a sixfold increased expression of Gpr19 in 
comparison to melanomas-in-situ/thin melanomas and a fivefold increased 
expression when basal and squamous cell carcinoma had also been included (Riker 
AI et al., 2008). In a genome-wide short interfering ribonucleic acid (siRNA screen, 
human Gpr19 was identified as a potential cell division gene (Neumann B et al., 
2010).  
 
 
6. Project definition 
 
Despite the fact that the human genome encodes more than 800 G protein-
coupled receptors, the conceptual integration of GPCRs into the multistep process 
of tumorigenesis – compared to, for instance, receptor tyrosine kinases or 
downstream effector kinases and phosphatases – remains sparse. Hence, the basic 
rationale of this thesis project was the search for GPCRs that are associated with 
malignant diseases in general and lung cancer in particular. Pioneer expression 
profiling studies allowed the identification of several GPCRs that revealed high mRNA 
expression levels in SCLC patient samples relative to NSCLC or normal lung controls. 
One of these receptors that had so far been only poorly characterized became the 
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focus of this work: orphan receptor GPR19. Apart from gene expression data, the 
functional characterization of GPR19 was elusive and neither an endogenous ligand 
nor details about downstream signaling had been unraveled. Thus, the goal was to 
investigate underlying biological functions of GPR19 focusing on its potential 
contribution to tumorigenesis. 
The first inquiries included in silico analyses regarding the tissue and cell line 
expression of Gpr19 as well as phylogenetic analyses (orthologs and paralogs). 
Human lung cancer-derived cell lines were selected and proliferation studies were 
performed with a loss-of-function (RNA interference) and gain-of-function (expression 
plasmid transfection) phenotype for GPR19. Due to the lack of mechanistic data, a 
potential autocrine receptor stimulation combined with G protein coupling (Gi/o) was 
explored here. Similarly, the GPR19 loss- and gain-of-function phenotypes were 
investigated for their influence on the cell cycle in lung cancer-derived cell lines. 
Further examinations comprised the expression of Gpr19 during the course of the cell 
cycle as well as its transcriptional regulation.  
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IV.  Materials 
 
1. Devices and accessory 
 
Standard plastic lab ware for molecular biology and cell culture were from Becton 
Dickinson, Corning, Eppendorf, Greiner Bio-One, and Thermo Fisher Scientific, if not 
specified differently.  
 
Table 1:  Overview of used materials, devices, and accessory including manufacturing company and 
product code (if applicable; arranged in alphabetical order).  
 
Name Manufacturer Product code 
Adhesive optical seal film BZ0 Biozym 712350 
Agarose gel casting kit Hoefer HE 47-10 
Agarose gel electrophoresis unit Maxi-Plus 
standard submarine, horizontal Hoefer SUB25 
Agarose gel electrophoresis unit Mini submarine, 
horizontal Hoefer HE 33 
Amersham™ Hyperfilm™ MP GE Healthcare 28906844 
Autoradiography cassette Amersham™ 
Hypercassette™ (18 x 24 cm; 24 x 30 cm) GE Healthcare 
RPN 1263 
RPN 11643 
Backing tape, black PerkinElmer 6005189 
Cell culture flask, 75 cm2, collagen IV-coated Becton Dickinson  354523 
Cell culture plate (6 well, poly-D-lysine-coated; 
BioCoat®) Becton Dickinson 356413 
Cell culture plate (96 well, poly-D-lysine-coated; 
BioCoat®) Becton Dickinson 354632 
Cell strainer (40 µm; nylon) Becton Dickinson Falcon™ 352340 
Cell viability analyzer  Vi-Cell™ XR Beckman Coulter  
Centrifuge 5415R Eppendorf  
Centrifuge 5801R Eppendorf  
Centrifuge Heraeus Megafuge 40R Thermo Fisher Scientific  
CloneSelect™ Imager Molecular Devices  
Criterion™ XT precast gel, 10% Bis-Tris, 18 well, 30 µl 
of sample per slot Bio-Rad 345-0112 
Criterion™ XT precast gel, 10% Bis-Tris, 26 well, 15 µl 
of sample per slot Bio-Rad 345-0113 
Criterion™ XT precast gel, 4-12% Bis-Tris, 18 well, 
30 µl of sample per slot Bio-Rad 345-0124 
Criterion™ XT precast gel, 4-12% Bis-Tris, 26 well, 
15 µl of sample per slot Bio-Rad 345-0125 
CryoTube™ vial (1.8 ml) Nunc 109804 
Dry incubator IPS  
Electroporation cuvette Lonza VKA-1001 
Electroporation device  Amaxa™ Nucleofector™ 
2b, single cuvette-based Lonza AAB-1001 
Filtration plate MultiScreen Millipore MAHVN4510 
Flow cytometry accessory FACSCalibur Becton Dickinson  
Freezing container Nalgene® Mr Frosty Sigma Aldrich C-1562 
GeneChip® Fluidics Station 450 Affymetrix  
GeneChip® Human Exon 1.0 ST Array Affymetrix 900649 
GeneChip® Hybridization Oven 640 Affymetrix  
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Name Manufacturer Product code 
GeneChip® Scanner 3000 Affymetrix  
Genetic Analyzer 3130xl Life Technologies  
High content screening reader ArrayScan® VTI Thermo Fisher Scientific  
Image analyzer G:Box Chemi Syngene  
Imager Gel iX INTAS Science Imaging Instruments  
Incubator shaker Multitron Infors HT  
Laser scanning microscope (LSM) 510 Carl Zeiss MicroImaging  
Microplate OptiPlate™-96 (96 well, white, opaque) PerkinElmer 6005290 
Mounting medium VECTASHIELD, hardset, with 4',6-
diamidino-2-phenylindole (DAPI) Vector Laboratories H-1500 
Multilabel Reader EnVision™, 2101 PerkinElmer  
Multilabel Reader VICTOR™ X5, 2030 PerkinElmer  
Nucleic Acid PrepStation ABI Prism® 6100 Life Technologies  
Optical reaction plate (96 well) MicroAmp® Life Technologies N801-0560 
Optical reaction plate (96 well) with barcode Life Technologies 4306737 
Orbital shaker IKA® MTS 2/4 digital IKA-Werke  
Orbital shaker Multi PSU-20 Biosan  
PCR system GeneAmp® 9700 Life Technologies  
Phase contrast microscope Leica DMIL Leica Microsystems  
pH-meter S20 SevenEasy™ Mettler Toledo  
Pipettor CyBi®-Well, 96 channel CyBio  
Polyvinylidene fluoride (PVDF) membrane 
sandwich Immuno-Blot® Bio-Rad 162-0238 
Power supply PowerPac HC Bio-Rad 164-5052 
Protein A Sepharose™ CL-4B beads GE Healthcare 17-0780-01 
Protein gel chamber Criterion™ Cell Bio-Rad 165-6001 
Quantitative PCR machine Mx2005P Stratagene  
Reaction folders Thermo Fisher Scientific 10483064 
Roller mixer Stuart® SRT6D Bibby Scientific  
Rotor for test tubes (10 rounds per minute) NeoLab 2-1175 
Scintillation counter Packard Tri-Carb 1900CA PerkinElmer  
Scintillation vial Sarstedt 73.662.500 
Sonicator Misonix Ultrasonic Liquid Processor S-4000 
(microplate horn; indirect sonication) Qsonica  
Spectrophotometer NanoDrop™ 8000 Thermo Fisher Scientific  
Spectrophotometer SpectraMax® Plus 384 Molecular Devices  
Splash guard Life Technologies 4311758 
SulfoLink immobilization kit for peptides Thermo Fisher Scientific 44999 
Syringe needle Sterican®, 26 G B. Braun Melsungen 4657683 
Thermal shaker Thermomixer comfort Eppendorf 5355000.011 
Total RNA Purification Tray Life Technologies 4305673 
Wave platform shaker Polymax 2040 Heidolph Instruments  
Wet blot chamber Criterion™ Blotter Bio-Rad 170-4070 
X-ray film processor OPTIMAX® Protec 1170-1-0000 
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2. Software 
 
Table 2:  Overview of used software including manufacturing company (arranged in alphabetical 
order).  
 
Name Manufacturer 
2030 Manager, version 4.0 PerkinElmer 
ArrayScan® VTI (500 series), version 5.6.2.1 Thermo Fisher Scientific 
CellQuest™ Pro, version 4.0.2 Becton Dickinson 
CloneSelect™ Imager, version 1.3 Molecular Devices 
Genesis, version 1.5.0  University of Graz, Austria 
GeneSnap, version 7.08 Syngene 
GeneTools, version 4.01 Syngene 
GeNorm applet for Microsoft® Excel®, version 3.5 University of Ghent, Belgium 
GraphPad Prism®, version 5.04 GraphPad Software 
FlowJo, version 7.5 Tree Star 
Foundation Data Collection, version 3.0 (sequencing 
analysis) Life Technologies 
INTAS GDS INTAS Science Imaging Instruments 
iViewTM , version 1.0.182.1 Thermo Fisher Scientific 
Lasergene, Protean application, version 9.1.0 DNASTAR 
Lasergene, SeqMan II application, version 9.1.0 DNASTAR 
Leica Application Suite, version 2.8.1 Leica Microsystems 
LSM Image Examiner, version 4.2.0 Carl Zeiss MicroImaging 
MxPro, version 4.1 Stratagene 
NanoDrop™ 8000, version 2.0.0 Thermo Fisher Scientific 
Sequencing Analysis, version 5.3.1 Life Technologies 
SoftMax® Pro, version 5.2 Molecular Devices 
Spotfire® DecisionSite®, version 9.1.2 TIBCO 
Vi-Cell™ XR, version 2.03 Beckman Coulter 
Wallac EnVision™ Manager, version 1.12 PerkinElmer 
ZEN 2008, version 5.0 Carl Zeiss MicroImaging 
 
 
3. Chemicals 
 
All chemicals and solvents were purchased from Carl Roth, Merck, Riedel-de-Haën, 
and Sigma Aldrich, if not declared differently. 
 
 
4.  Kits, enzymes, and reagents 
 
Table 3: Overview of used kits, enzymes, and reagents including manufacturing company and 
product code (arranged in alphabetical order). 
 
Name Manufacturer Product code 
(-)-N6-(2-phenylisopropyl)adenosine (R-PIA; 5 mM 
in dimethyl sulphoxide (DMSO) Sigma Aldrich P4532 
2-chloro-N6-cyclopentyladenosine (CCPA; 5 mM in 
DMSO) Sigma Aldrich C7938 
[2,8-3H]Adenine PerkinElmer NET063005MC 
Absolute RNA Wash Solution Life Technologies 430554 
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Name Manufacturer Product code 
Accumax™ Sigma Aldrich A7089 
Adenosine 3′,5′-cyclic monophosphate sodium 
salt monohydrate (cyclic adenosine 
monophosphate (cAMP); 100 mM in deionized 
water) 
Sigma Aldrich A6885 
Adenosine deaminase (ADA; 5 mg/ml; 
200 units/mg) 
Roche Applied 
Science 10102105001 
Agarose powder for gel electrophoresis Serva Electrophoresis 11404 
alamarBlue® solution Life Technologies DAL1100 
Albumin bovine fraction V Serva Electrophoresis 11945.04 
Aluminum oxide Sigma Aldrich 199974 
Ampicillin (100 mg/ml in deionized water) Sigma Aldrich A9518 
Aphidicolin from Nigrospora sphaerica (1mM in 
DMSO) Sigma Aldrich A0781 
Bionic buffer (10x) Sigma Aldrich B6185 
Bovine serum albumin (BSA; 50 mg/ml) Life Technologies 15561-020 
Bronchial epithelial cell growth medium (BEGM) Lonza CC3170 
Cation exchange resin Dowex AG 50W-X4, 100-
200 µm dry mesh size, 4% crosslinkage, hydrogen 
form 
Bio-Rad 142-1341 
Cell lysis buffer (10x) Cell Signaling Technology 9803 
Competent bacteria JM109, > E8 colony forming 
units (cfu)/µg Promega L2001 
Complementary-deoxyribonucleic acid (cDNA) 
synthesis kit iScript™ Bio-Rad 170-8891 
Corticotropin-releasing hormone (CRH; 100 µM in 
deionized water) 
PolyPeptide 
Laboratories SC060 
CryoStor® CS10 BioLife Solutions 210102 
Cycle Sequencing kit BigDye® Terminator v3.1 Life Technologies 4336919 
Deoxyribonucleic acid (DNA) ladder plus 
O’GeneRuler, 100 base pairs (bp) 
Thermo Fisher 
Scientific SM1153 
Doxorubicin Sigma Aldrich D1515 
Dulbecco’s modified eagle’s medium (DMEM; 
with 4.5 g/L glucose, with L-glutamine) Lonza BE12-604F 
Dulbecco’s phosphate-buffered saline (DPBS; 1x); 
[-] MgCl2, [-] CaCl2 Life Technologies 14190 
DY-647-phalloidin (200 units/ml in methanol) Dyomics 647-33 
Eagle’s minimum essential cell growth medium 
(EMEM) Lonza BE12-662F 
Electroporation suspension Amaxa™ Cell Line 
Nucleofector™ Kit V Lonza VCA-1003 
Escherichia coli FastMedia™ AMP X-GAL 
(ampicillin resistance) InvivoGen fas-am-x 
Escherichia coli FastMedia™ KAN Agar 
(kanamycin resistance) InvivoGen fas-kn-s 
Ethidium bromide solution (10 mg/ml) Sigma Aldrich E1510 
FACSClean Becton Dickinson 340345 
FACSFlow Becton Dickinson 342003 
FACSRinse Becton Dickinson 340346 
Fetal bovine serum (FBS) Life Technologies 26140 
Formaldehyde (36.5-38%) Sigma Aldrich F8775 
Formamide Sigma Aldrich F9037 
Forskolin from Coleus forskohlii (10 mM in DMSO) Sigma Aldrich F6886 
G protein-coupled receptor 6 (GPR6)-derived 
peptide TAAGGPDTGEWGPPAAX 
Peptide Specialty 
Laboratory  
Synthesis on 
demand 
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Name Manufacturer Product code 
GeneChip® Hybridization Wash and Stain Kit Affymetrix 900720 
Glycerol (99%) Sigma Aldrich G5516 
Glycogen (20 mg/ml) Roche Applied Science 10901393001 
Goat serum Dako X0907 
Hank’s balanced salt solution (HBSS) Life Technologies 14170 
Hoechst 33342 (10 mg/ml in deionized water) Life Technologies H3570 
Hydroxyurea (1 M in deionized water) Sigma Aldrich H8627 
Imidazol Carl Roth X998.4 
Kanamycin (50 mg/ml in deionized water) Sigma Aldrich K1876 
Loading Dye solution Orange (6x) Thermo Fisher Scientific R0631 
Luciferase substrate Beetle-Juice  PJK 102511 
Luria Bertani (LB) broth liquid medium Life Technologies 10855 
Nocodazole (10 mM in DMSO) Sigma Aldrich M1404 
Nucleic Acid Purification Elution Solution Life Technologies 4305893 
Nucleic Acid Purification Lysis Solution (2x) Life Technologies 4305895 
Paraformaldehyde (16%) Electron Microscopy Sciences 15700 
PCR mix JumpStart™ REDTaq® ReadyMix™ 
Reaction Mix Sigma Aldrich P0982 
Perchloric acid, 60% in water Sigma Aldrich 77234 
Pertussis toxin from Bordetella pertussis (0.2 mg/ml)  Sigma Aldrich P2980 
Phenol/chloroform/isoamylalcohol (PCI; pH 8 after 
addition of equilibration buffer) Sigma Aldrich P2069 
Phosphodiesterase IV inhibitor Ro-20-1724 (100 mM 
in DMSO) Calbiochem 557502 
Plasmid Maxi kit, EndoFree® Qiagen 12362 
Ponceau S solution Sigma Aldrich P7170 
Propidium iodide (1 mg/ml) Sigma Aldrich P4864 
Protease inhibitor Complete, tablets, 
ethylenediaminetetraacetic acid (EDTA)-free 
Roche Applied 
Science 04693132001 
Protein concentration assay (5x) Bio-Rad 500-0006 
Protein ladder PageRuler™, prestained Thermo Fisher Scientific SM0671 
Protein ladder PageRuler™ plus, prestained Thermo Fisher Scientific SM1811 
Protein loading buffer pack Thermo Fisher Scientific R0891 
Proteinase K Life Technologies 25530-015 
Reduced serum medium opti-MEM® I Life Technologies 31985 
Ribonuclease (RNase) A, Concert (20 mg/ml) Life Technologies 12091-039 
RNA Purification Wash Solution 1 Life Technologies 4305891 
RNA Purification Wash Solution 2 Life Technologies 4305890 
RNaseZap® solution Ambion AM9780 
Roswell Park Memorial Institute (RPMI) 1640 with 
GlutaMAX™ cell culture medium Life Technologies 61870 
Running buffer XT MES (20x) Bio-Rad 161-0789 
Running buffer XT MOPS (20x) Bio-Rad 161-0788 
Scintillation solution Rotiszint® eco plus Carl Roth 0016.3 
Secondary immunoglobulins donkey anti rabbit, 
Alexa555 Life Technologies A31572 
Secondary immunoglobulins goat anti mouse 
Alexa488 Life Technologies A11017 
Secondary immunoglobulins polyclonal goat anti-
mouse (horseradish peroxidase (HRP)-conjugated) Dako P0447 
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Name Manufacturer Product code 
Secondary immunoglobulins polyclonal goat anti-
rabbit (HRP-conjugated) Dako P0448 
Secondary immunoglobulins polyclonal rabbit 
anti-goat (HRP-conjugated) Dako P0449 
Sephadex-G50 Sigma Aldrich G5050 
siRNA buffer (5x) Thermo Fisher Scientific 
B-002000-UB-
100 
siRNA transfection reagent Lipofectamine® 
RNAiMAX Life Technologies 13778-075 
Skim milk powder  Sigma Aldrich 70166 
Super optimal broth with catabolic repressor 
(SOC) medium Life Technologies 15544-034 
TaqMan® Gene Expression Master Mix Life Technologies 4369016 
Transfection reagent Lipofectamine™ 2000 Life Technologies 11668-019 
Transfection reagent TurboFect™ (in vitro)  Thermo Fisher Scientific R0531 
Tris-buffered saline (TBS; 10x) Bio-Rad 170-6435 
Tris/glycine (TG) buffer (10x) Bio-Rad 161-0771 
Triton X-100 (10%) Fluka 93443 
Trypsin-EDTA Life Technologies 043-90317FU 
Tween 20 solution (10%) Bio-Rad 161-0781 
Water, diethyl pyrocarbonate (DEPC)-treated, 
nuclease-free Ambion AM9916 
Western Blotting Detection Reagents Amersham™ 
ECL™  GE Healthcare RPN 2106 
Western Blotting Detection System Amersham™ 
ECL™ Plus  GE Healthcare RPN 2132 
Wheat germ agglutinin (WGA), Alexa Fluor® 647 
conjugate (1 mg/ml in DPBS) Life Technologies W32466 
 
 
5. Buffers and solutions 
 
All buffers were prepared using deionized water, if not specified differently. 
 
Table 4: Overview of used thematically-sorted buffers and solutions showing commonly-used name, 
concentrations, and ingredients (arranged in alphabetical order). 
 
Name Composition 
Adenylyl cyclase/cyclic adenosine monophosphate (cAMP) assay 
Imidazol buffer 20 mM imidazol, 200 mM NaCl, pH 7.4 
Bacteria glycerol stock 
Glycerol solution 1:1 mixture of glycerol (50%; diluted from 99% with deionized water) and LB liquid medium containing selective antibiotic 
Chromatin immunoprecipitation (ChIP) 
Dilution buffer 
16.7 mM Tris, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 
0.01% sodium dodecyl sulfate (SDS), pH 8.0; 1 protease 
inhibitor tablet per 50 ml 
Elution buffer 100 mM NaHCO3, 1% SDS 
HI salt buffer 500 mM NaCl, 50 mM Tris, 0.1% SDS, 1% NP40, pH 8.0 
LiCl buffer 250 mM LiCl, 50 mM Tris, 0.5% NaDeoxycholate, 1% NP40, pH 8.0 
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Name Composition 
Lysis buffer 1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.0; 1 protease inhibitor tablet per 50 ml 
Protein A beads buffer TE buffer containing 1 mg/ml BSA, 0.1 %NaN3 
Proteinase K buffer 10 mM Tris HCl, 20 mM CaCl2, 50% glycerol, pH 7.5 
Radio immunoprecipitation 
assay (RIPA) buffer 
150 mM NaCl, 50 mM Tris, 0.1% SDS, 1% NP40, 
0.5% NaDeoxycholate, pH 8.0 
TE buffer 10 mM Tris, 1 mM EDTA, pH 8.0 
Confocal microscopy 
WGA staining solution WGA solution (1 mg/ml), diluted to 5 µg/ml with HBSS 
Deoxyribonucleic acid (DNA) sequencing 
Sequencing mix 1:1 mixture of dye-containing buffer and dilution buffer (Life Technologies; 4336919) 
High content screening 
Antibody-containing 
staining solution (primary or 
secondary) 
5% BSA in DPBS 
Blocking buffer 1% goat serum, 2% BSA in DPBS 
Fixation buffer 7.4% formaldehyde, 0.2% Triton® X-100 in DPBS 
Luciferase Assay 
Luciferase cell lysis buffer 
Cell lysis buffer (10x; Cell Signaling Technology; 9803), diluted 
to 1x with deionized water, 1 protease inhibitor tablet per 
50 ml, stored at -20°C 
Reconstituted Beetle-Juice Beetle-Juice containing supplied D-luciferin and adenosine triphosphate (ATP), stored at -80°C 
Oligonucleotide reconstitution 
Short interfering ribonucleic 
acid (siRNA) buffer (1x)  
siRNA buffer (5x), diluted to 1x with DEPC-treated nuclease-
free water 
Ribonucleic acid (RNA) preparation 
RNA lysis buffer (1x) Nucleic Acid Purification Lysis Solution, diluted to 1x with DPBS 
Western Blot 
Blocking buffer TBS-T containing 5% skim milk 
ECL™ plus Western Blotting 
Detection solution 
39:1 mixture of reagents RPN2132V1 and RPN2132V2 (GE 
Healthcare) 
HEPEX Complete lysis buffer 
20 mM HEPES23, 100 mM NaCl, 5 mM EDTA,1 mM Na3VO4, 
30 mM NaF, 5% glycerol, 0.1% SDS, 1% Triton X-100, 1 mM 
glycerophosphate, 1 mM dithiothreitol (DTT), pH 7.4; 1 
protease inhibitor tablet per 50 ml, stored at -20°C 
Normal ECL™ Western 
Blotting Detection solution 
1:1 mixture of both detection reagents (GE Healthcare; 
RPN 2106) 
Primary antibody solution TBS-T containing 5% skim milk with primary antibody at respective dilution indicated in table 9. 
Reducing protein loading 
buffer (4x)  
5x protein loading buffer, 20x reducing agent (2 M DTT); both 
reagents combined to 4x 
Secondary antibody 
solution 
TBS-T containing 5% skim milk with respective secondary 
antibodies (1:2,000 dilution). 
TBS-T buffer TBS (1x), 0.1% Tween 20 
Towbin buffer TG buffer (1x), 10% methanol 
 
 
 
                                                
23  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
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6. Plasmid constructs 
 
G protein-coupled receptor 19 (GPR19) expression constructs were purchased from 
OriGene Technologies. The GPR19 complementary-deoxyribonucleic acid (cDNA) 
had been cloned into the pCMV6-XL5 expression vector downstream of a 
cytomegalovirus (CMV) promoter (GPR19 true clone). A construct encoding a turbo 
green fluorescent protein (tGFP)24-tagged version of GPR19 and the G protein-
coupled receptor 6 (GPR6; carboxy-terminal tag) had been constructed by cloning 
the GPR19/GPR6 coding sequence (CDS) into the pCMV6-AC-GFP expression vector 
(GPR19-tGFP; GPR6-tGFP).  
The codon-optimized GPR19 expression construct was purchased from GeneArt (Life 
Technologies) and had been cloned into the pcDNA3.1 (+) expression vector 
downstream of a CMV promoter (pCMV-pcDNA3.1 (+); GPR19 (codon-optimized)). 
The codon-optimized messenger ribonucleic acid (mRNA) sequence encoding 
GPR19 is shown in the Appendix section. 
Sequence-verified expression constructs for murine corticotropin-releasing hormone 
receptor 1 (CRHR1)-enhanced yellow fluorescent protein (eYFP25; pEYFP-N1-CRHR1) 
and A1-adenosine receptor (A1R)-eYFP (pEYFP-N1-A1R) were a kind gift from Prof. 
Michael Freissmuth of the Medical University of Vienna. The modified firefly luciferase 
expression plasmid pGL3-Basic was from Promega and cloning of Gpr19 promoter 
fragments (300 or 1,000 base pairs (bp) upstream of the Gpr19 open reading frame 
(ORF)) or the CMV promoter into the multiple cloning region ahead of the luciferase 
CDS was performed by GeneArt (Life Technologies). In addition, a minimal promoter 
fragment of the herpes simplex virus thymidine kinase (TK) promoter (mini-TK) was 
introduced into all luciferase reporter constructs for basal luciferase expression. 
Besides, potential E2 promoter binding factor (E2F) transcription factor binding sites 
at positions -15 and/or -185 upstream of the Gpr19 ORF were deleted in pGL3-Basic-
300GPR19-miniTK constructs. Expression vectors are listed in table 5 and all empty 
vectors are schematically shown in figure 7 to figure 11. 
 
Table 5: Overview of used expression vectors (arranged in alphabetical order). 
 
Expressed gene Vector Escherichia Coli selection 
A1R-eYFP pEYFP-N1 Kanamycin 
CRHR1-eYFP pEYFP-N1 Kanamycin 
 pCMV6-XL5 Ampicillin 
GPR19 (codon-optimized) pCMV-pcDNA3.1 (+) Ampicillin 
GPR19 (true clone) pCMV6-XL5 Ampicillin 
GPR19-tGFP pCMV6-AC-GFP Ampicillin 
GPR6-tGFP pCMV6-AC-GFP Ampicillin 
Luciferase pGL3-Basic-miniTK Ampicillin 
Luciferase pGL3-Basic-300GPR19-miniTK Ampicillin 
                                                
24  Turbo green fluorescent protein (tGFP) has a molecular weight of 26 kDa, its excitation maximum is at 482 nm and 
its emission maximum is at 502 nm. The protein has no known cellular toxicity and is brighter than enhanced green 
fluorescent protein (eGFP; www.evrogen.com/products/TurboGFP/TurboGFP_Detailed_description.shtml). 
 
25  The enhanced yellow fluorescent protein (eYFP) has an excitation maximum at 513 nm and an emission 
maximum at 527 nm (www.liv.ac.uk/physiology/ncs/catalogue/Cloning/pEYFP-N1-Map.htm). 
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Expressed gene Vector Escherichia Coli selection 
Luciferase pGL3-Basic-1000GPR19-miniTK Ampicillin 
Luciferase pGL3-Basic-CMV-miniTK Ampicillin 
Luciferase pGL3-Basic-300GPR19-miniTK (mut 15) Ampicillin 
Luciferase pGL3-Basic-300GPR19-miniTK (mut 185) Ampicillin 
Luciferase pGL3-Basic-300GPR19-miniTK (mut 15+185) Ampicillin 
tGFP pCMV6-AC-GFP Ampicillin 
 
 
 
 
Figure 7:  Schematic representation of the OriGene Technologies pCMV6-AC-GFP expression vector 
(PS100010; RG207204 for pCMV6-AC-GPR6-GFP, accession number NM_005284.2 and 
RG220379 for pCMV6-AC-GPR19-GFP, accession number NM_006143.1). 
 
 
 
 
Figure 8:  Schematic representation of the OriGene Technologies pCMV6-XL5 expression vector 
(PCMV6XL5; SC126612-20 for pCMV6-XL5-GPR19 (true clone), accession number 
NM_006143.1). 
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Figure 9:  Schematic representation of the Promega pGL3-Basic luciferase expression vector (E1751). 
 
 
 
 
Figure 10:  Schematic representation of the Life Technologies pcDNA3.1 (+/-) expression vector (V790-
20). 
 
 
 
 
Figure 11:  Schematic representation of the Clontech Laboratories pEYFP-N1 expression vector (6006-1). 
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7.  DNA oligodeoxynucleotides  
 
DNA oligodeoxynucleotides were purchased from Metabion and Sigma Aldrich.  
 
Table 6: Overview of used thematically-sorted oligodeoxynucleotide/primer sequences showing 
name, sequence, and genomic or plasmid target (arranged in alphabetical order. fow – 
forward primer; rev – reverse primer.  
 
Name Sequence (5‘-3‘) Target 
Chromatin immunoprecipitation polymerase chain reaction (PCR; 10 µM) 
15fow1 CTCAACGCCACGGAAAACC Promoter Gpr19 (-15) 
15rev1 CTACAACCTCATTAATCGGCT Promoter Gpr19 (-15) 
185fow1 CCAAGGTGATAAACTGGCTG Promoter Gpr19 (-185) 
185rev1 GAGCCAGACGCATGCGCAA Promoter Gpr19 (-185) 
3184fow1 CTTGGGCTCAAGGGATATTC Promoter Gpr19 (-3184) 
3184rev3 GAAAACATACATATTAGGGCCA Promoter Gpr19 (-3184) 
3769fow1 GTGCAGTGGCTCATACCTG Promoter Gpr19 (-3769) 
3769rev3 CCATCTACTGGCATGTTTGC Promoter Gpr19 (-3769) 
ALBfow2 GTAATGTCCCCAATATCCTCC Promoter albumin 
ALBrev1 CCCAAACCAGTACTAATTCCC Promoter albumin 
CDC6fow1 CCCGGATGTAGATTCCCTC Promoter Cdc6 
CDC6rev1 CCTCGAGCAATCCTCTTCTT Promoter Cdc6 
CDSfow1 CATCGTGGGTCTTTGATGCA CDS Gpr19 
CDSrev1 GGATATCCATGTGATAGCTGT CDS Gpr19 
Plasmid sequencing (GPR6/GPR19 expression plasmids; 10 µM) 
GPR6-1 GACGTGCTCCTGTGCGT Gpr6 
GPR6-2 GCTGGAACTGCCTGGCA Gpr6 
GPR6-3 CCTACAACTCCATGATCAAT Gpr6 
GPR19-1 CAACTACTTTGTGGTCTCCA Gpr19 
GPR19-2 CACTTCTTGGTGGGCTTTG Gpr19 
GPR19-3 CCTCTATGAAATGTTACCGAA Gpr19 
GPR19-4 GGCCACAGCCAGCATCTT Gpr19 
GPR19-5 CAGTCATTGTAACTATTTCCT Gpr19 
GPR19opti-1 CCAACTACTTCGTGGTGTC Gpr19 (codon-optimized) 
GPR19opti-2 GCGTGCTGATCATCCTGTT Gpr19 (codon-optimized) 
GPR19opti-3 GCTTACACCATCACCACCA Gpr19 (codon-optimized) 
tGFP CTTCAGCCCCTACCTGCT Gfp 
Vfow1 GCTACAACAAGGCAAGGCT pCMV-pcDNA-3.1 (+) 
Vfow2 CCATGGTGATGCGGTTTTG pCMV-pcDNA-3.1 (+) 
Vfow3 CGACTCACTATAGGGAGAC pCMV-pcDNA-3.1 (+) 
Vrev1 GCTATTGTCTTCCCAATCCT pCMV-pcDNA-3.1 (+) 
VT1.5 GGACTTTCCAAAATGTCG pCMV6-AC-GFP/XL5 backbone 
XL39 ATTAGGACAAGGCTGGTGGG pCMV6-AC-GFP/XL5 backbone 
Plasmid sequencing (luciferase assay; 10 µM) 
CMVfow1 GTAAACTGCCCACTTGGC Promoter CMV 
GPR19-300-fow1 CTCAACGCCACGGAAAACC Promoter fragment Gpr19 
GPR19-1000-fow1 CATTACGAATTACACGTCAAG Promoter fragment Gpr19 
GPR19-1000-fow2 CCTGGACTGGTAAACAAAC Promoter fragment Gpr19 
pGL3fow1 GTGTGAATCGATAGTACTAAC pGL3 Basic backbone 
pGL3fow2 CTAACATACGCTCTCCATC pGL3 Basic backbone 
pGL3rev1 GCCCATATCGTTTCATAGC pGL3 Basic backbone 
pGL3rev2 GAAATGCCCATACTGTTGAG pGL3 Basic backbone 
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8. Short interfering ribonucleic acids (siRNAs)  
 
Table 7: Overview of used siRNA oligonucleotides in mRNA knockdown experiments (arranged in 
alphabetical order). Oligonucleotides (19mers) contained a 3’-dTdT (double 
deoxythymidine triphosphate) overhang. GPR19 – G protein-coupled receptor 19; PLK1 – 
polo-like kinase 1.   
 
Name Target Target sequence (5’-3’) 
Accession 
number Manufacturer Product code 
CTL #1 none   Thermo Fisher Scientific D-001810-10 
GPR19 Dh3 Gpr19 AAACUACGUUGGCAUUUCA NM_006143 Thermo Fisher Scientific 
ON-TARGETplus J-005553-
08 
GPR19 Sig2 
(CTL #2) Gpr19 
CAGCAUCUUCUUUGGGAUU NM_006143 Sigma Aldrich SASI_Hs02_00340980, SASI_Hs02_00340980_AS 
GPR19 Sig3 Gpr19 CCACUUCUUGGUGGGCUUU NM_006143 Sigma Aldrich SASI_Hs01_00133100, SASI_Hs01_00133100_A 
GPR19 Sig4 
(GPR19 #1) Gpr19 
CUGACCUUCUCAUCAGCGU NM_006143 Sigma Aldrich SASI_Hs01_00133104, SASI_Hs01_00133104_AS 
GPR19 Sig5 
(GPR19 #2) Gpr19 
CUCAGUCUACCACCAACUA NM_006143 Sigma Aldrich SASI_Hs01_00133101, SASI_Hs01_00133101_AS 
PLK1 Plk1 GUCUCAAGGCCUCCUAAUA NM_005030 Sigma Aldrich SASI_Hs01_00194343, SASI_Hs01_00194343_AS 
 
 
9. TaqMan® assays  
 
Table 8: Information about TaqMan® assays used in reverse transcription quantitative real-time PCR 
(RT-qPCR; arranged in alphabetical order). Assays were purchased from Life Technologies. 
FAM™ – 6-carboxyfluorescein; MGB – minor groove binder; NFQ – non-fluorescent 
quencher; TAMRA – tetramethylrhodamine; VIC™ (trademark). 
 
 
 
Gene 
symbol Gene name
NCBI gene 
reference (different 
transcript variants)
Chromosome Assay ID Part number
Reporter 
dye
Reporter 
quencher
Amplicon 
length [bp]
Assay 
location [bp] Assay design
Actb ß-actin NM_001101.2 7 4326315E VIC NFQ-MGB 171 53
Amplicon spans exons 
and probe does not 
span exons.
B2m ß-2-microglobulin NM_004048.2 15 4326319E VIC NFQ-MGB 75 409 Probe spans exons.
Ccnb1 Cyclin B1 NM_031966.2 5 Hs00259126_m1 4331182 FAM NFQ 104 723 Probe spans exons.
Ccne1 Cyclin E1 NM_001238.1 19 Hs00233356_m1 4331182 FAM NFQ 101 368 Probe spans exons.
Chrm3
Muscarinic cholinergic 
receptor 3
NM_000740.2 1 Hs00265216_s1 4331182 FAM NFQ 72 1891
Both primers and 
probe map within a 
single exon.
Cypa Cyclophilin A NM_021130.3 7 4326316E VIC NFQ-MGB 98 433
Amplicon spans exons 
and probe does not 
span exons.
Gapdh
Glyceraldehyde-3-
phosphate 
dehydrogenase
NM_002046.3 12 4326317E VIC NFQ-MGB 122 157
Amplicon spans exons 
and probe does not 
span exons.
Gpr19
G protein-coupled 
receptor 19
NM_006143.2 12 Hs00272049_s1 4331182 FAM NFQ 98 691
Both primers and 
probe map within a 
single exon.
Hprt1
Hypoxynthine-guanine 
phosphoribosyl 
transferase 1
NM_000194.1 X 4326321E VIC NFQ-MGB 100 649 Probe spans exons.
Lpar1
Lysophosphatidic acid 
receptor 1
NM_057159.2 
(NM_001401.3)
9 Hs00173500_m1 4331182 FAM NFQ 73 472 (394) Probe spans exons.
Plk1 Polo-like kinase 1 NM_005030.3 16 Hs00153444_m1 4331182 FAM NFQ 91 872 Probe spans exons.
Rnase P (H1) RNase P (H1) NR_002312.1 14 4316844 VIC TAMRA 87 41
Both primers and 
probe map within a 
single exon.
Rpl32 Ribosomal protein L32
NM_001007073.1 
(NM_001007074.1; 
NM_000994.3)
3 Hs00851655_g1 4331182 FAM NFQ 146 597 (617; 498)
Both primers and 
probe map within a 
single exon.
Rplp0
Large ribosomal protein 
P0
NM_001002.3 12 4326314E VIC NFQ-MGB 105 268
Amplicon spans exons 
and probe does not 
span exons.
Tfr Transferrin receptor NM_003234.1 3 4326323E VIC NFQ-MGB 105 1784
Amplicon spans exons 
and probe does not 
span exons.
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10.  Primary antibodies 
 
Table 9:  Overview of used thematically-sorted antibodies (arranged in alphabetical order). E2F – E2 
promoter binding factor; GAPDH – glyceraldehyde-3-phosphate dehydrogenase; GPR19 – 
G protein-coupled receptor 19; IgG – immunoglobulin G; PARP1 – poly (adenosine 
diphosphate (ADP) ribose) polymerase 1; pH3 – phosphorylated histone H3; tGFP – turbo 
green fluorescent protein. 
 
Antigen Species Isotype 
Concen-
tration 
[mg/ml] 
Dilution Manufacturer Product code 
Chromatin immunoprecipitation 
E2F-1 (C-20) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-193 X 
E2F-2 (C-20) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-633 X 
E2F-3 (C-18) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-878 X 
E2F-4 (C-20) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-866 X 
E2F-5 (E-19) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-999 X 
E2F-6 (H-50) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-22823 X 
E2F-7 (H-300) rabbit polyclonal IgG 2  
Santa Cruz 
Biotechnology sc-66870 X 
Isotype 
control rabbit 
Polyclonal 
IgG 1  
Cell Signaling 
Technology 2729 
High content screening 
Cyclin B1 mouse IgG1 0.5 1:250 
Becton 
Dickinson 
Biosciences 
554176 
pH3 (Ser10) rabbit polyclonal 1 1:500 Millipore 06-570 
α-tubulin mouse IgG1 1 1:1,000 Sigma Aldrich T-6199 
Western Blot 
GAPDH mouse IgG1  2 1:10,000 Abcam ab8245 
GPR19 rabbit polyclonal 1 1:1,000 Abcam ab75558 
GPR19 rabbit polyclonal 1 1:1,000 Genway Biotech 18-461-10271 
GPR19 rabbit polyclonal 1 1:1,000 Imgenex IMG-71507 
GPR19 rabbit polyclonal 1 1:1,000 Imgenex IMG-71508 
GPR19 rabbit polyclonal 1 1:1,000 LifeSpan Biosciences LS-A97 
GPR19 rabbit polyclonal 1 1:1,000 Novus Biologicals NLS97 
GPR19 rabbit polyclonal 1 1:1,000 Novus Biologicals NLS98 
GPR19 goat polyclonal 0.2 1:500 Santa Cruz Biotechnology sc-74634 
GPR19 goat polyclonal 0.2 1:500 Santa Cruz Biotechnology sc-74635 
GPR19 rabbit polyclonal 0.04 1:500 Sigma Aldrich HPA013955 
GPR19 rabbit polyclonal 1 1:1,000 Sigma Aldrich SAB4501254 
GPR19 rabbit polyclonal 1 1:1,000 Thermo Fisher Scientific PA1-20406 
PARP1 rabbit polyclonal 0.05 1:2,000 Cell Signaling Technology 9542 
tGFP mouse IgG2b 1.47 1:2,000 OriGene Technologies TA150041 
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11. Cell lines 
 
Human lung-derived cell lines were obtained from American Type Culture Collection 
(ATCC) or European Collection of Cell Cultures (ECACC).  
 
Table 10: Overview of used human cell lines (small cell lung cancer (SCLC), non-small cell lung 
cancer (NSCLC), normal lung, human embryonic kidney (HEK)-293; arranged by histology 
and in alphabetical order). BEGM – bronchial epithelial cell growth medium; DMEM – 
Dulbecco’s modified eagle’s medium; EMEM – Eagle’s minimum essential cell growth 
medium; FBS – fetal bovine serum; NCI – National Cancer Institute; RPMI – Roswell Park 
Memorial Institute. 
 
 
 
 
12. Animals  
 
The immunization of rabbits with human GPR19 peptides was performed by Peptide 
Specialty Laboratories. 
 
Table 11: Human GPR19 peptides were used for immunization of rabbits in order to generate GPR19-
specific antisera. Aberrances from the human GPR19 primary sequence are indicated in 
red (Cys). Those Cys residues were introduced for reasons of peptide coupling to affinity 
column matrices.   
 
Rabbits GPR19 peptides used for immunization (amino- to carboxy-terminus) 
#1, #2 AQLWHPHEQDYKKSSLVC (extracellular loop 3) KPTLYSIYNANFRRGMKETFC (carboxy-terminus) 
#3, #4 YQKVIKYIWRIGTDGRTVC (intracellular loop 3) RRTMNIVPRTKVKTIKMC (intracellular loop 3) 
#5, #6 CTETATPLPSQYLMELSEEHSWMS (amino-terminus) CIDRFYTIVYPLSFKVSREKAKKM (intracellular loop 2) 
#7, #8 
MSSMKCYRSNAYTITTSSRMAKKN (carboxy-terminus) 
YVGISEIPSMAKTITKDSIYDSC (carboxy-terminus) 
FDREAKEKKLAWPINSNPPNTFVC (carboxy-terminus) 
Cell line Source Number Biosafety Morphology Organ Disease (histology)
Derived from 
metastatic site
Gender Age [y] Ethnicity
Growth 
properties
Growth medium
COR‐L88 ECACC 92031917 1 Lung SCLC; carcinoma Pleural effusion Male 55 Caucasian
Semi‐adherent 
aggregates
RPMI 1640 GlutaMAX + 
10% FBS
DMS 114 ATCC CRL‐2066 1 Lung SCLC; carcinoma Male 68 Caucasian Adherent
RPMI 1640 GlutaMAX + 
10% FBS
DMS 53 ATCC CRL‐2062 1 Epithelial Lung SCLC; carcinoma Male 54 Caucasian Adherent
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H209 ATCC HTB‐172 1 Epithelial Lung SCLC; carcinoma Bone marrow Male Caucasian
Aggregates in 
suspension
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H345 ATCC HTB‐180 1 Epithelial Lung SCLC; carcinoma Bone marrow Male 64 Caucasian
Aggregates in 
suspension
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H446 ATCC HTB‐171 1 Epithelial Lung SCLC; carcinoma Pleural effusion Male 61 Caucasian
Adherent 
aggregates
RPMI 1640 GlutaMAX + 
10% FBS
SHP‐77 ATCC CRL‐2195 1 Epithelial
Lung (apical 
portion of 
upper lobe of 
the left lung)
SCLC; carcinoma Male 54 Caucasian
Suspension and 
loosely adherent 
aggregates
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H1703 ATCC CRL‐5889 1 Epithelial Lung
NSCLC; 
adenocarcinoma; 
squamous cell
Male 54 Caucasian Adherent
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H2122 ATCC CRL‐5985 1
Epithelial and 
rounded
Lung
NSCLC; 
adenocarcinoma; 
squamous cell
Pleural effusion Female 46 Caucasian Adherent
RPMI 1640 GlutaMAX + 
10% FBS
NCI‐H2170 ATCC CRL‐5928 1 Lung
NSCLC; squamous 
cell carcinoma
Male Adherent
RPMI 1640 GlutaMAX + 
10% FBS
BEAS‐2B ATCC CRL‐9609 2 Epithelial Lung Normal (bronchus) Adherent
RPMI 1640 GlutaMAX + 
10% FBS
CCD‐8Lu ATCC CCL‐201 1 Fibroblast Lung Normal (fibroblast) Male 48 Caucasian Adherent EMEM + 10% FBS
IB3‐1 ATCC CRL‐2777 2 Epithelial Lung
Cystic fibrosis 
(bronchus)
Male 7 White Adherent
BEGM                 
(no gentamycin‐
amphotericin B 
supplement)           
+ 10% FBS
NuLi‐1 ATCC CRL‐4011 2 Epithelial Lung Normal (bronchus) Adherent
BEGM                 
(no gentamycin‐
amphotericin B 
supplement)           
+ 10% FBS
WI‐38 ATCC CCL‐75 1 Fibroblast
Lung 
(embryonic)
Normal (fibroblast) Female
Fetus (3 
months)
Caucasian Adherent EMEM + 10% FBS
HEK‐293 ATCC CRL‐1573 2 Epithelial
Kidney 
(embryonic)
Normal Fetus Adherent DMEM + 10% FBS
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V.  Methods 
 
All experiments were carried out at room temperature, if not indicated differently. 
Centrifugation of 15 and 50 ml conical tubes was done in an Eppendorf 5801R 
centrifuge; 1.5 and 2 ml reaction tubes were centrifuged in an Eppendorf 5415R 
centrifuge. Cell culture plates and microplates were centrifuged in an Heraeus 
Megafuge 40R.  
 
 
1. Molecular biology and biochemistry (in vitro analyses) 
 
1.1.  Nucleic acid reconstitution  
 
Tubes containing nucleic acids were briefly centrifuged in order to collect the 
lyophilisate at the tube bottom. Respective stock solutions (10 µM for 
deoxyribonucleic acid (DNA) oligodeoxynucleotides; 20 µM for short interfering 
ribonucleic acids (siRNAs); 100 ng/µl for plasmid constructs) were generated using 
nuclease-free water or 1x siRNA buffer (placement of nucleic acid solution on an 
orbital shaker at 300 rounds per minute (rpm) for 30 min in order to ensure good 
resuspension of lyophilisates), aliquoted, and stored at -20°C. 
 
 
1.2.  Nucleic acid concentration measurement – NanoDrop™ 
 
Nucleic acid quantification was done using the NanoDrop™ 8000 spectrophoto-
meter and corresponding software (nucleic acid method). Samples (1 µl) were 
pipetted onto the water-initialized system optics and either DNA-50 or RNA-40 sample 
types were selected26. The spectrophotometer had been blanked with 1 µl of the 
respective solution buffer.  
 
 
1.3.  Isolation of total RNA from cultured cells 
 
The ABI Prism® 6100 Nucleic Acid PrepStation was used to isolate total RNA from 
cultured cells (96 well format) according to the manufacturers’ instructions. The 
growth medium was aspirated from cells grown in 96 well plates (suspension cells 
were first pelleted by centrifugation (250 x g, 5 min)) and the cells were subjected to 
lysis in 200 µl of 1x RNA lysis buffer. Cell lysis was enforced by pipetting the lysate up 
and down multiple times and by freezing the lysate at -20°C.  
                                                
26  An optical density (OD) of 1 at 260 nm wavelength (OD260) corresponds to either 50 µg/ml of double-stranded 
DNA or 40 µg/ml of single-stranded RNA based on absorbance measured in a spectrophotometer using a 
cuvette with a light path length of 1 cm). The purity of the nucleic acid solution was assessed by the 
OD260/OD280 ratio. High purity samples were considered to lie within the range of 1.8 to 2 with protein 
contaminations lowering this ratio (peak absorbance at 280 nm wavelength).  
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After thawing, the lysate was transferred onto a Total RNA Purification Tray pre-
wetted with 40 µl of RNA Purification Wash Solution 1. The ‘waste’ position of the 
station was covered by a splash guard and vacuum application (20%, 2 min) at that 
position was used to suck the lysate through the purification tray filter unit. Samples 
were washed with 500 µl of RNA Purification Wash Solution 1 (20% vacuum, 2 min) 
and 650 µl of RNA Purification Wash Solution 2 (80% vacuum, 3 min). For digestion of 
filter-bound DNA, 50 µl of Absolute RNA Wash Solution (DNase treatment) were 
applied per slot (incubation for 15 min). Samples were further subjected to washing 
with RNA Purification Wash Solution 2 (400 µl; incubation for 5 min followed by 20% 
vacuum, 2 min; twice 300 µl, 20% vacuum, 2 min). The filter units were dried (90% 
vacuum, 5 min), any residual liquid was touched off at the ‘waste’ position, and the 
tray was transferred to the ‘collection’ position on top of an archive 96 well Optical 
Reaction Plate. RNA was eluted using 100 µl of Nucleic Acid Purification Elution 
Solution (20% vacuum, 2 min) and any residual liquid was touched off into the 
archive plate at the ‘collection’ position. RNA solutions were stored at -20°C (short-
term). 
 
 
1.4.  Complementary-deoxyribonucleic acid (cDNA) synthesis 
 
For cDNA synthesis from isolated total RNA, the iScript™ cDNA synthesis kit from Bio-
Rad was used. Per reaction, 15 µl of RNA were mixed with 4 µl of 5x iScript reaction 
mix (contains oligo-deoxythymidine triphosphate (oligo-dT)) and random hexamer 
primers) and 1 µl of iScript™ reverse transcriptase (ribonuclease (RNase) H+). cDNA 
was synthesized in a GeneAmp® polymerase chain reaction (PCR) System 9700 (Life 
Technologies) under the following conditions: 5 min at 25°C, 30 min at 42°C, 5 min at 
85°C, holding at 4°C. The resulting cDNA was diluted with nuclease-free water (1:5 to 
1:8) for direct use in quantitative polymerase chain reaction (qPCR) applications. 
 
 
1.5.  Reverse transcription quantitative real-time polymerase chain 
reaction (RT-qPCR) gene expression and data analysis 
 
The TaqMan® technology27 from Life Technologies was used for performance of RT-
qPCR with an Mx2005P qPCR machine. Per reaction, 10 µl of TaqMan® Gene 
Expression Master Mix were mixed with 1 µl of 6-carboxyfluorescein (FAM™)- (gene of 
interest) and VIC™-labeled (reference gene) TaqMan® assays each (duplexing) 
                                                
27  The TaqMan® technology allows polymerase chain reaction (PCR) product detection with the help of a probe 
which hybridizes specifically to complementary-DNA amplification products in between the binding sites of the 
forward and reverse primers. A reporter dye (5’) and a non-fluorescent quencher (NFQ; 3’) are attached at the 
respective probe ends. Besides, a minor groove binder (MGB) at the 3’ end is included for melting temperature 
increase. In an intact probe, the NFQ is in close proximity to the reporter dye and suppresses its fluorescence 
signal. During each PCR amplification cycle, any DNA-bound probe is destroyed (exonuclease activity of the 
DNA polymerase). The NFQ can no longer quench the dye’s signal, which results in the accumulation of 
fluorescence with each amplification cycle. This fluorescence signal is product-specific as only DNA-bound 
probes are erased therefore leaving any non-specific amplification undetected (www3.appliedbiosystems.com/ 
cms/groups/mcb_support/documents/generaldocuments/cms_042996.pdf). 
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together with 8 µl of diluted cDNA (reporter concentration: 5 µM; primer forward and 
reverse concentration: 18 µM). Gene-specific TaqMan® assays for expression analysis 
of human genes were purchased from Life Technologies and assay features are 
listed in table 8. The G protein-coupled receptor 19 (GPR19)-detecting assay was 
selected based on its property to lie entirely within the Gpr19 coding sequence 
(CDS) of exon four. PCR initiation conditions were 2 min at 50°C (required for optimal 
AmpErase® uracil-N-glycosylase (UNG) activity28) and 10 min at 95°C (AmpliTaq 
Gold® DNA polymerase activation) followed by 40 cycles of 15 sec at 95°C (duplex 
denaturation) and 1 min at 60°C (primer annealing and elongation; data collection).  
RT-qPCR data analysis was done using the software MxPro. Fluorescence signals were 
automatically baseline-corrected. Data collection thresholds were set in the log-
linear dynamic signal range and resulting quantification cycle (Cq) values of the 
reference gene and the gene of interest were converted into relative expression 
ratios (2-(Cq gene of interest – Cq reference gene) = 2-∆Cq; relative quantification). For qPCR assays 
with comparable efficiency, this method was equally precise as when relative 
messenger ribonucleic acid (mRNA) levels were determined on the basis of a 
standard curve. Pairwise duplexing was done for all genes of interest against all 
selected reference genes and they were normalized by geometric averaging. 
Relative expression ratios were normalized against a control sample (e.g., untreated 
cells) in the respective experimental setup (2-∆∆Cq method; Livak KJ and Schmittgen 
TD, 2001). Assay controls (either devoid of template or lacking reverse transcriptase) 
were included in all experiments and gave negative results (detection signals higher 
than Cq 38 which was above the detection range of any sample signal). 
 
 
1.6.  Preparation of bacterial culture plates (selective medium) 
 
FastMedia™ agar powder (Luria Bertani (LB)-based; containing ampicillin or 
kanamycin as selective antibiotic) was dissolved in 200 ml of deionized water by 
microwave-heating until clearance of the medium was reached. 20 ml of resulting 
liquid medium was poured into petri dishes (10 cm diameter) and allowed to harden. 
Dishes were then incubated at 37°C (dry incubator) for several hours to remove 
superfluous liquid from the growth medium and stored at 4°C. 
 
 
1.7.  Bacterial transformation  
 
50 µl of competent bacteria and 20 ng of plasmids were mixed and incubated on 
ice for 30 min. Bacteria were heat-shocked at 42°C (water bath) for 45 sec and 
                                                
28  The enzyme uracil-N-glycosylase (UNG) is applied to prevent any carryover PCR product amplification whose 
synthesis was performed with deoxyuridine triphosphate (dUTP). UNG removes uracil from deoxyuridine 
monophosphate (dUMP)-containing DNA resulting in apyrimidinic sites. During the HotStartTaq DNA polymerase 
activation step, UNG gets inactivated and molecular cleavage at abasic sites destroys any contaminating 
molecules (www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generalocuments/cms_ 
042996.pdf; www.qiagen.com/literature/render.aspx?id=104373). 
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incubated on ice for 2 min. 950 µl of super optimal broth with catabolic repressor 
(SOC) medium were added onto transformed bacteria followed by shaking at 
250 rpm at 37°C (incubator shaker) for 1 h. Bacteria were pelleted by centrifugation 
at 3,300 x g for 2 min and 850 µl of the supernatant were discarded. Pelleted 
bacteria were resuspended in remaining medium, 100 µl were distributed onto 
prewarmed petri dishes containing LB growth medium with selective antibiotic, and 
incubated upside down at 37°C (dry incubator) for 12 to 16 h. 
 
 
1.8.  Bacteria culture  
 
Colonies grown on agar plates were picked with a toothpick and cultured in 3 ml of 
LB broth liquid medium containing a selective antibiotic (ampicillin: 100 µg/ml final 
concentration; kanamycin: 25 µg/ml final concentration) in an incubator shaker 
(250 rpm, 8 h, 37°C). The starter culture was transferred into an Erlenmeyer flask 
containing 240 ml of LB broth liquid medium with the respective antibiotic and 
cultured in an incubator shaker (250 rpm, 16 h, 37°C). 
 
 
1.9.  Bacteria glycerol stock  
 
Bacteria from 5 ml of the starter culture were pelleted by centrifugation (3,300 x g, 
2 min) and the supernatant was discarded. Bacteria were resuspended in 1.7 ml of 
glycerol solution, transferred into a 1.8 ml CryoTube™ vial, and stored at -80°C. 
 
 
1.10.  Plasmid preparation (Maxi Prep)  
 
The EndoFree® Plasmid Maxi kit was used for plasmid preparation. Bacteria were 
pelleted by centrifugation (4,500 x g, 10 min, 4°C), the supernatant was completely 
removed, and they were subjected to alkaline lysis: The bacteria pellet was 
resuspended in 10 ml of buffer (P1) containing RNase A (100 µg/ml) and 10 ml of lysis 
buffer (P2) was added. The solution was mixed thoroughly by vigorously inverting the 
tube five times followed by incubation for 5 min. After addition of 10 ml of chilled 
neutralization buffer (P3), the solution was again mixed thoroughly by vigorously 
inverting the tube five times and poured into the barrel of a QIAfilter Cartridge 
(incubation for 10 min). The lysate was filtered through the cartridge, 2.5 ml of 
endotoxin removal buffer ER were added, and the solution was incubated on ice for 
30 min.  
The sample was applied onto a Qiagen-tip 500 column, which had been 
equilibrated with 10 ml of buffer QBT, and the column was allowed to empty by 
gravity flow. The column was washed twice with 30 ml of buffer QC and the DNA was 
eluted with 15 ml of buffer QN. DNA precipitation was done by adding 0.7 volumes 
of isopropanol to the eluate. The solution was mixed, incubated for 2 min, and 
centrifuged (16,000 x g, 30 min, 4°C). After removal of the supernatant, the plasmid 
DNA pellet was washed with 70% of ethanol (centrifugation: 16,000 x g, 10 min), air-
dried, dissolved in 450 µl of buffer TE, and stored at -20°C. 
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1.11.  Plasmid sequencing  
 
Linear amplification for plasmid sequencing was performed using 4 µl of sequencing 
mix, 0.5 µl of sequencing primer (10 µM stock), and 0.3 to 0.7 µg of DNA. The reaction 
mix was filled to 10 µl with nuclease-free water. Start conditions were 1 min at 96°C 
followed by 28 cycles of 15 sec at 96°C (duplex denaturation), 10 sec at 53°C (primer 
annealing), 90 sec at 60°C (elongation), and completed by a final elongation step 
for 2 min at 72°C. Reaction products were diluted with an equal volume of deionized 
water and stored at -20°C till sample purification by Sephadex gel filtration was 
performed. For this purpose, a 10% slurry of Sephadex-G50 was prepared in deionized 
water and incubated for 2 h (soaking). 400 µl per well were filled into a MultiScreen 
filtration plate which was pre-dried by vacuum filtration and excess water was 
removed by centrifugation at 900 x g for 4 min. A sample collection plate 
(MicroAmp® optical 96 well reaction plate) was filled with 30 µl of formamide per 
well and placed underneath the filtration plate. Diluted linear amplification reaction 
products were transferred onto the wells of the filtration plate and filtered into the 
formamide-containing wells of the sample collection plate (centrifugation: 900 x g, 
4 min). The plate was sealed with a silicone rubber gasket, locked with a snap-on lid, 
and loaded into the 3130xl Genetic Analyzer for sequencing. Sequences were 
analyzed using the SeqMan II application from the Lasergene software package. 
 
 
1.12.  Phenol/chloroform/isoamylalcohol (PCI)/chloroform DNA 
extraction 
 
An equal volume of basic PCI (pH 8.0) was added to the DNA-containing aqueous 
solution and mixed by vigorous shaking. Due to a density greater than the one of 
water (> 1 kg/m3), organic and aqueous phases were separated by centrifugation 
(16,000 x g, 5 min) with the upper aqueous phase containing nucleic acids and 
proteins being collected at the organic/aqueous interface. The aqueous phase was 
transferred into a new 2 ml reaction tube and the sample was subjected to another 
round of PCI DNA extraction. In order to remove any residual phenol, the procedure 
was repeated using chloroform instead of PCI. 
 
 
1.13.  Isopropanol/sodium acetate/glycogen DNA precipitation 
 
For DNA precipitation, 0.1 volumes of sodium acetate (pH 5.2; 3 M), 0.7 volumes of 
isopropanol, and 20 µg of glycogen (20 mg/ml) were added per sample, mixed by 
vigorous shaking, and incubated for 2 min. Centrifugation (16,000 x g, 15 min) was 
used to pellet the DNA at the bottom of the reaction tube and the supernatant was 
discarded. The DNA pellet had been washed with 3 volumes of 100% ethanol 
(centrifugation: 16,000 x g, 5 min; removal of supernatant) and air-dried before it was 
resuspended in 10 mM Tris (pH 7.2) and stored at -20°C. 
 
 
V. Methods 
58 
 
1.14.  Chromatin immunoprecipitation (ChIP) 
 
Cells (5 x 107) were resuspended in 20 ml of culture medium. Crosslinking of proteins 
on nucleic acids was performed using formaldehyde (1% final concentration). The 
formaldehyde-containing cell suspension was rotated on a roller mixer at 60 rpm for 
10 min. Crosslinking was stopped by application of 1 ml of 2.5 M glycin solution 
(rotation for 5 min). Cells were pelleted (centrifugation: 250 x g, 5 min, 4°C) and the 
supernatant was discarded. They were washed twice with 20 ml of Dulbecco’s 
phosphate-buffered saline (DPBS; 4°C; centrifugation: 250 x g, 5 min, 4°C; removal of 
supernatant), lysed in 1 ml of lysis buffer, transferred into a 2 ml reaction tube, and 
incubated at 4°C for 16 h.  
The chromatin solution was subjected to multiple rounds of sonication to shear 
genomic DNA. The number, duration, and intensity of sonication pulses varied 
among different cell lines. In order to remove cellular debris, the lysate was 
centrifuged (16,000 x g, 5 min, 4°C) and the supernatant was transferred into a new 
2 ml reaction tube. 
350 µg of chromatin were applied per immunoprecipitation reaction and 3.5 µg 
were stored at 4°C as input control sample until the DNA was harvested. The 
respective lysate volume was diluted tenfold in dilution buffer and 5 µg of the 
respective antibody solution were added. Immunoprecipitation was performed on a 
test tube rotor (10 rpm) at 4°C for 16 h. Immune complexes were harvested with 
protein A sepharose CL-4B beads that target rabbit immunoglobulins. For 
preparation of beads, 0.02 g were dissolved in 100 µl of deionized water and washed 
three times with 1 ml of TE buffer (centrifugation: 500 x g, 3 min; removal of 
supernatant). Washed beads were resuspended in 100 µl of protein A beads buffer 
which resulted in a final volume of about 200 µl (dissolved beads).  
The harvest of immune complexes was done by addition of protein A beads-
containing solution (100 µl) and rotation on a test tube rotor (10 rpm) at 4°C for 2 h. 
Beads were collected by centrifugation (500 x g, 3 min; removal of supernatant) and 
washed with radio immunoprecipitation assay (RIPA) buffer (1 ml; rotation at 4°C for 
10 min; centrifugation: 500 x g, 3 min; removal of supernatant), HI salt buffer (1 ml; 
rotation at 4°C for 10 min; centrifugation: 500 x g, 3 min; removal of supernatant), LiCl 
buffer (1 ml; rotation at 4°C for 10 min; centrifugation: 500 x g, 3 min; removal of 
supernatant), and twice with TE buffer (1 ml; rotation at 4°C for 10 min; 
centrifugation: 500 x g, 3 min; removal of supernatant). Immune complexes were 
eluted with 200 µl of freshly prepared elution buffer (twice; rotation at room 
temperature for 15 min; centrifugation: 500 x g, 3 min; collection of supernatant in 
new 2 ml reaction tube)29. The input control sample was included from now on in 
subsequent steps and diluted with elution buffer (400 µl). 
Samples were adjusted to 200 mM NaCl and RNase A was added to a final 
concentration of 300 µg/ml followed by incubation on a thermal shaker (300 rpm) at 
                                                
29  Washing of the antibody-bound beads was performed with buffers containing mild detergents (NaDeoxycholate, 
NP40, sodium dodecyl sulfate (SDS)) and different types of salts (NaCl, LiCl) in order to effectively disrupt weak 
non-specific interactions. Antigens are released from antibody binding upon induction of a pH-shift by the 
application of an acidic elution buffer (www.millipore.com/catalogue/item/17-611#; www.proteinguru.com/ 
protocols/IP%20guide2.pdf). 
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37°C for 1 h in order to remove any contaminating RNA. Reversal of protein-DNA 
crosslinking was performed on a thermal shaker (300 rpm) at 65°C for 16 h. For protein 
digestion, proteinase K (20 mg/ml in proteinase K buffer; 500 µg/ml final 
concentration) was applied and the solution was adjusted to 9 mM 
ethylenediaminetetraacetic acid (EDTA) and 35 mM Tris (pH 6.5). Protein digestion 
was done by incubating the solution on a thermal shaker (300 rpm) at 45°C for 1 h. 
DNA was recovered by PCI/chloroform extraction, precipitated using 
isopropanol/sodium acetate/glycogen, and resuspend in 100 µl of 10 mM Tris 
(pH 7.2). 
 
 
1.15.  Chromatin fragmentation control 
 
In order to examine the successful fragmentation of chromatin by sonication, the 
lysate was diluted (1:20) in deionized water and the RNA was digested by addition of 
RNase A (300 µg/ml final concentration) and incubation on a thermal shaker 
(300 rpm) at 37°C for 1 h. Protein digestion and reversal of protein-DNA crosslinking 
was done using proteinase K (500 µg/ml final concentration) and incubating the 
solution on a thermal shaker (300 rpm) at 65°C for 6 h. The DNA was recovered by 
PCI/chloroform extraction, precipitated using isopropanol/sodium acetate/ 
glycogen, and resuspend in 40 µl of 10 mM Tris (pH 7.2).  
20 µl of the DNA solution were mixed with 4 µl of 6x Orange Loading Dye solution and 
half the sample was loaded onto a slot of a 2% agarose gel for DNA separation by 
agarose gel electrophoresis. 5 µl of O`GeneRuler 100 base pairs (bp) DNA Ladder 
Plus were applied onto a slot as size marker. 
 
 
1.16.  ChIP PCR 
 
ChIP PCR was performed using 2 µl of DNA solution, 0.5 µl of respective forward and 
reverse primer solution (10 µM stock), 12.5 µl of 2x JumpStart™ REDTaq® ReadyMix™ 
Reaction Mix, and 9.5 µl of nuclease-free water per reaction in a GeneAmp® PCR 
System 9700. PCR start conditions were 45 sec at 95°C followed by 32 to 36 cycles of 
15 sec at 95°C (duplex denaturation), 15 sec at 59°C (primer annealing), and 40 sec 
at 72°C (elongation). In the end, a final elongation step was performed (3 min at 
72°C) and the reaction was stopped by incubation at 4°C. Agarose gel 
electrophoresis (2% agarose gel) was performed using 10 µl of the PCR sample. 5 µl 
of O`GeneRuler 100 bp DNA Ladder Plus were applied onto a slot as size marker. 
 
 
1.17.  Agarose gel electrophoresis of nucleic acids 
 
PCR products were size-separated by agarose gel electrophoresis. For small DNA 
residues (< 1 kilobase), a 2% agarose gel was used. Agarose powder and 1x Bionic 
buffer were mixed and boiled in a microwave on maximal intensity. The clear 
agarose solution was allowed to cool down for 5 min and ethidium bromide was 
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added to a final concentration of 0.5 µg/ml. The solution was poured into an 
agarose gel casting kit with slot-forming combs and allowed to become solid. This 
solidified gel was placed into a horizontal agarose gel unit and covered with 1x 
Bionic buffer. Samples and size standard were loaded into slots and a charge of 5 V 
per centimeter gel length was applied for 90 to 120 min. DNA-representing bands 
were visualized by ultraviolet light due to ethidium bromide intercalation and 
recorded and analyzed using a Gel iX imager. 
 
 
1.18.  Microarray sample preparation   
 
RNA from human small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), 
and normal lung samples was purchased from OriGene Technologies. Detailed 
sample information is listed in table 12. Affymetrix microarray analysis was performed 
on the Human Exon 1.0 ST Array platform. SCLC and normal lung samples were 
prepared and hybridized on chips following the GeneChip® Whole Transcript Sense 
Target Labeling Assay manual from Affymetrix omitting the ribosomal RNA reduction 
step by the Boehringer Ingelheim RCV gene expression core facility. In brief, 300 ng 
of total RNA were applied for first cycle cDNA synthesis (first and second strand). 
After in vitro transcription, 10 µg of antisense copy RNA were subjected to second 
cycle cDNA synthesis followed by hydrolysis of copy RNA by RNase H. The sense 
strand cDNA (5.5 µg) was fragmented, biotin end-labeled, and hybridized on a 
microarray at 45°C in a GeneChip® Hybridization Oven for 16 h. Microarrays were 
washed and stained in a GeneChip® Fluidics Station using the GeneChip 
Hybridization Wash and Stain Kit and signals were recorded in a GeneChip® Scanner 
3000. NSCLC sample preparation and hybridization was performed by Atlas Biolabs. 
 
 
1.19.  Cell lysis for protein extraction 
 
After removal of the culture medium from adherent cells, 300 µl of HEPEX lysis buffer 
were added per 1 x 106 cells and lysis was allowed to occur at 4°C for 15 min. Cells 
were scraped off the culture well bottom, transferred into a reagent test tube, and 
frozen at -20°C. The lysate was thawed, cellular debris was collected at the tube 
bottom by centrifugation (16,000 x g, 5 min, 4°C), and the supernatant was 
transferred into a new reaction tube and stored at -20°C.  
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Table 12: Detailed information for NSCLC, SCLC, and normal lung RNA samples from OriGene 
Technologies. TNM30 – tumor, lymph node, metastasis (tumor staging system); AJCC31 – 
American Joint Committee on Cancer (tumor grading system); na – not assessed. 
 
 
 
 
                                                
30  The TNM tumor staging system evaluates the size of the tumor (T1 to T4), the disease spread to regional lymph 
nodes (number and extent of affected lymph nodes; N1 to N3), and the involvement of distant metastasis (M0 – 
no metastasis; M1 – present metastasis; MX – no information about metastasis; http://www.cancer.gov/ 
cancertopics/factsheet/detection/staging). 
 
31  The AJCC tumor grading systems evaluates the differentiation status of cancer cells from G1 (well-differentiated; 
low grade) to G4 (poorly differentiated; high grade; http://www.cancer.gov/cancertopics/factsheet/detection/ 
tumor-grade). 
 
Abbreviation Catalog number Case ID
Sample pathology 
from pathology 
verification
Tissue of 
(origin/finding) Appearance
% 
Tumor
% 
Normal
% 
Lesion
% Tumor 
hypercellular 
stroma
% Tumor 
hypo/acellular 
stroma
% 
Necrosis
Sample pathology 
verification notes Age [y] Gender Race Tumor grade TNM
Normal #1 CR561576 CU0000005278 Within normal limits Lung / Lung Normal 0 100 0 0 0 0 95% alveoli, 5% bronchioles 72 Female na Not applicable Not applicable
Normal #2 CR562424 CI0000018461 Within normal limits
Lung: right upper 
lobe / Lung: right 
upper lobe
Normal 0 100 0 0 0 0
90% alveoli, 5% 
bronchioles, 5% 
fibrovascular septa
66 Female Caucasian Not applicable Not applicable
Normal #3 CR561107 CI0000008641 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
90% alveoli, 5% 
bronchioles, 5% 
fibrovascular septa
49 Female Caucasian Not applicable Not applicable
Normal #4 CR560571 CI0000013181 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
85% alveoli, 5% 
bronchioles, 10% 
fibrovascular septa
66 Male Caucasian Not applicable Not applicable
Normal #5 CR561589 CU0000005332 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
85% alveoli, 5% 
bronchioles, 10% 
fibrovascular tissue
65 Male na Not applicable Not applicable
Normal #6 CR560046 CI0000000104 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
91% alveoli, 1% 
bronchioles, 8% 
fibrovascular tissue
61 Female Black Not applicable Not applicable
Normal #7 CR559282 CI0000006947 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
90% alveoli, 5% 
bronchioles, 5% 
fibrovascular septa
62 Female Caucasian Not applicable Not applicable
Normal #8 CR560573 CI0000013164 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
90% alveoli, 3% 
bronchioles, 7% 
fibrovascular septa
64 Male Caucasian Not applicable Not applicable
Normal #9 CR560259 CI0000000029 Within normal limits Lung / Lung Normal 0 100 0 0 0 0 95% alveoli, 5% bronchioles 38 Female Caucasian Not applicable Not applicable
Normal #10 CR561643 CU0000005265 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
90% alveoli, 5% 
bronchioles, 5% 
fibrovascular tissue
78 Male na Not applicable Not applicable
Normal #11 CR561388 CU0000005967 Within normal limits Lung / Lung Normal 0 100 0 0 0 0 90% alveoli, 10% fibrovascular septa 80 Male na Not applicable Not applicable
Normal #12 CR560698 CI0000007037 Within normal limits Lung / Lung Normal 0 100 0 0 0 0 95% alveoli, 5% fibrovascular septa 65 Female Caucasian Not applicable Not applicable
Normal #13 CR559249 CI0000005593 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
85% alveoli, 5% 
bronchioles, 10% 
fibrovascular septa
76 Male Caucasian Not applicable Not applicable
Normal #14 CR560495 CI0000013452 Within normal limits Lung / Lung Normal 0 100 0 0 0 0
90% alveoli, 5% 
bronchioles, 5% 
fibrovascular septa
70 Female Caucasian Not applicable Not applicable
NSCLC #1 CR560583 CI0000013181 Adenocarcinoma of lung Lung / Lung Tumor 50 0 0 50 0 0 Tumor stroma (cellular): inf lammatory cells 66 Male Caucasian
AJCC G3: poorly 
dif ferentiated
pT2pN0pMX
NSCLC #2 CR560096 CI0000009937 Adenocarcinoma of lung Lung / Lung Tumor 90 0 0 0 10 0 48 Female Black AJCC G3: poorly dif ferentiated pT2pN0pMX
NSCLC #3 CR560574 CI0000013164 Adenocarcinoma of lung Lung / Lung Tumor 60 0 15 20 0 5
Tumor stroma (cellular): 
desmoplastic reaction, 
inf lammatory cells; lesion 
(15%): pneumonia, post-
obstructive 100%; 
inf lammation: moderate 
mixed inf lammatory 
inf iltrate
64 Male Caucasian AJCC G3: poorly 
dif ferentiated
pT2pN0pMX
NSCLC #4 CR561441 CU0000006152 Adenocarcinoma of lung Lung / Lung Tumor 90 0 0 5 0 5 72 Female na AJCC G3: poorly dif ferentiated pT1pN2pMX
NSCLC #5 CR561028 CI0000008195 Carcinoma of lung,         large cell Lung / Lung Tumor 85 0 0 5 0 10 56 Female Black
AJCC G3: poorly 
dif ferentiated
pT2pN2pMX
NSCLC #6 CR561109 CI0000008641 Carcinoma of lung, neuroendocrine Lung / Lung Tumor 70 0 0 15 0 15 Tumor: large cell type 49 Female Caucasian Not reported pT2pN0pMX
NSCLC #7 CR561590 CU0000005332 Carcinoma of lung,         non-small cell Lung / Lung Tumor 90 0 0 10 0 0 65 Male na
AJCC G3: poorly 
dif ferentiated
pT2pN1pMX
NSCLC #8 CR560266 CI0000000029 Carcinoma of lung, squamous cell Lung / Lung Tumor 80 0 0 20 0 0 38 Female Caucasian Not reported pT2pN0pMX
NSCLC #9 CR561170 CI0000007511
Carcinoma of lung, 
squamous cell Lung / Lung Tumor 90 0 0 7 0 3 59 Male Caucasian
AJCC G2: 
moderately 
dif ferentiated
pT2pN0pMX
NSCLC #10 CR562233 CU0000000135 Carcinoma of lung, squamous cell Lung / Lung Tumor 90 0 0 5 0 5 80 Male na Not reported pT2pN0pMX
NSCLC #11 CR561641 CU0000005265 Carcinoma of lung, squamous cell Lung / Lung Tumor 50 5 0 40 0 5 78 Male na
AJCC G2: 
moderately 
dif ferentiated
pT2pN1pMX
NSCLC #12 CR560051 CI0000000104 Adenocarcinoma of lung Lung / Lung Tumor 70 0 0 15 15 0 61 Female Black
AJCC G2: 
moderately 
dif ferentiated
pT1pN0pMX
NSCLC #13 CR560699 CI0000007037 Adenocarcinoma of lung Lung / Lung Tumor 50 0 0 45 0 5 65 Female Caucasian
AJCC G2: 
moderately 
dif ferentiated
pT1pN0pMX
NSCLC #14 CR560830 CI0000005602 Adenocarcinoma of lung Lung / Lung Tumor 90 0 0 10 0 0 74 Male Caucasian AJCC G3: poorly dif ferentiated pT2pNXpMX
NSCLC #15 CR561632 CU0000005115 Adenocarcinoma of lung Lung / Lung Tumor 90 0 0 5 5 0 59 Female na AJCC G3: poorly dif ferentiated pT2pN0pMX
NSCLC #16 CR561735 CU0000005387 Carcinoma of lung,          large cell Lung / Lung Tumor 85 0 0 10 0 5 79 Female na Not reported pT2pN1pMX
SCLC #1 CR562270 CI7000000173 Carcinoma of lung,         small cell Lung / Lung Tumor 75 0 0 20 0 5
Tumor stroma (cellular): 
desmoplastic reaction
74 Male Caucasian Not reported pT1pN0pMX
SCLC #2 CR560494 CI0000013452 Carcinoma of lung,        small cell Lung / Lung Tumor 95 0 0 2 0 3 70 Female Caucasian Not reported pT2pN0pMX
SCLC #3 CR562708 CU0000001180 Carcinoma of lung,          small cell Lung / Lung Tumor 35 0 0 63 0 2
Tumor: morphologically 
consistent w ith large cell 
neuroendocrine carcinoma 
of the lung (intermediate 
subtype of small cell 
carcinoma of lung); other 
features/comments: 
sample contains chronic 
inf lammatory cells in 
stromal component
71 Male na Not reported pT2pN0pMX
SCLC #4 CR562578 CI0000021816 Carcinoma of lung,           small cell Lung / Lung Tumor 50 5 0 0 5 40 68 Male Caucasian Not reported pT1pN2pMX
SCLC #5 CR562629 CI0000019503 Carcinoma of lung,           small cell
Lung: left upper lobe 
/ Lung: left upper 
lobe
Tumor 40 0 0 0 0 60
Tumor: only small cell 
carcinoma seen in this 
section
61 Male Caucasian
AJCC G3: poorly 
dif ferentiated pT4pN0pMX
SCLC #6 CR560848 CI0000005593 Carcinoma of lung,            small cell Lung / Lung Tumor 75 0 0 20 0 5 76 Male Caucasian Not reported pT4pN2pMX
SCLC #7 CR561968 CU0000014767 Carcinoma of lung,          small cell, metastatic
Lung: right middle 
lobe / Lymph node
Tumor 50 0 0 5 5 40 63 Male na AJCC G3: poorly 
dif ferentiated
pT1pN1pMX
SCLC #8 CR560068 CI0000009518
Carcinoma of lung,            
small cell Lung / Lung Tumor 85 0 0 5 0 10 54 Male Caucasian Not reported pT2pN2pMX
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1.20.  Protein concentration determination 
 
Protein concentrations were determined using a Bradford-based protein assay32. 2 µl 
of the protein lysate were diluted with 200 µl of the protein concentration assay 
solution (1x) in a 96 well test plate and absorbance at 595 nm was measured with a 
spectrophotometer. Absorbance values were correlated to those of a bovine serum 
albumin (BSA) standard curve ranging from 500 µg/ml to 1.95 µg/ml in order to 
obtain protein concentrations of the samples. 
 
 
1.21.  Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE)  
 
Equal amounts of protein were diluted in 4x reducing loading buffer (1x final) and 
boiled at 95°C for 5 min33. Samples (and 5 to 10 µl of the respective PageRuler™ 
protein ladder) were loaded onto slots of Criterion™ XT precast protein separation 
gels assembled in a Criterion™ Cell protein gel chamber which had been filled with 
either XT MES (1x) or MOPS (1x) running buffer. Protein electrophoresis was performed 
by application of a constant charge (150 V).  
 
 
1.22.  Immunoblotting (Western Blot) 
 
The gel containing separated proteins was assembled with an Immuno-Blot® 
polyvinylidene fluoride (PVDF) membrane which had been equilibrated with 
methanol for 10 sec. Both the membrane and the gel were transferred into Towbin 
buffer and fixed between absorbent filter paper and a foam pad on both sides in a 
gel holder cassette. Membrane transfer of proteins was done using a Criterion™ 
Blotter wet blot chamber filled with Towbin buffer at a constant current intensity of 
900 mA for 30 to 50 min depending on the number of applied blotting cassettes. 
The membrane was incubated on an orbital shaker (70 rpm) for 1 h in blocking 
buffer. Specific protein detection was done by incubating the membrane in primary 
antibody solution at 4°C for 16 h (wave platform shaker, 20 rpm) followed by washing 
in TBS-T buffer for 10 min (three times). Respective horseradish peroxidase (HRP)-
conjugated secondary antibodies were applied to the membrane for 1 h (orbital 
shaker; 70 rpm). The membrane was washed in TBS-T buffer for 10 min (three times), 
rinsed with deionized water, and soaked either with normal ECL™ (1 min) or ECL™ 
plus (2 min) Western Blotting Detection solution. Excess detection reagent was 
drained off the membrane and after transfer into a reaction folder, 
chemiluminescence signals were detected using light sensitive films (Amersham™ 
                                                
32  The Coomassie blue dye preferentially binds to aromatic and basic amino acid residues. Upon protein binding, its 
absorbance maximum is shifted from 465 nm to 595 nm (labs.fhcrc.org/fero/Protocols/BioRad_Bradford.pdf). 
 
33  Denaturation and negative charging of proteins is achieved by boiling of cell lysates in a sodium dodecyl sulfate 
(SDS)-containing loading buffer – a prerequisite for their subsequent size/weight separation by polyacrylamide 
gel electrophoresis (PAGE).   
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Hyperfilm™) in an autoradiography cassette34.  Exposure times varied considerably 
depending on the protein amount loaded or primary antibodies used. They had 
been optimized to prevent oversaturated signals. Films were developed using an 
OPTIMAX® X-ray film processor. Alternatively, chemiluminescence signals were 
detected using a G:Box Chemi image analyser and the software GeneSnap for 
image acquisition and GeneTools for image analysis. 
Equal protein loading/transfer was examined by Ponceau S solution application to 
the membrane for 1 min and the membrane was rinsed with deionized water until a 
stained band pattern appeared (red protein bands)35. 
 
 
1.23.  Luciferase reporter assay36 
 
Cells were washed with DPBS and lysed using 60 µl of 1x lysis buffer (shaking on an 
orbital shaker (500 rpm, 4°C)). 20 µl of the lysate were transferred into wells of a white 
96 well microplate (OptiPlate™) and 100 µl of reconstituted Beetle-Juice® (ambient) 
were added per well. The light signal (glow) was measured in an EnVision™ 2101 
Multilabel Reader (2 sec) after 10 min. 
 
 
1.24.  Antiserum purification on affinity peptide columns 
 
Peptides immobilized on SulfoLink affinity column matrices via a Cys residue were 
provided by Peptide Specialty Laboratories. 1 mg of the respective peptide was 
coupled to 0.5 ml of the column matrix. The matrix was equilibrated with 10 ml of 
DPBS. The rabbit serum (5 ml) was diluted with an equal volume of DPBS and 
incubated with 0.5 ml of the peptide-bound matrix (resuspended in 4 ml of DPBS) on 
a roller mixer (30 rpm) at 4°C for 16 h. The suspension was transferred back to an 
affinity column and the flow-through was applied onto the column a second time. 
Washing of the column was performed first with 10 ml of DPBS (three times) followed 
by 10 ml of 10 mM Na3PO4 (pH 6.8; twice). Column-peptide-bound antibodies were 
eluted in ten fractions using 0.5 ml of 0.1 M glycin (pH 2.4) each and collected in 
reaction test tubes containing 35 µl of 2 M K2HPO4 for neutralization of the eluate. The 
protein concentration of each fraction was determined using a Bradford-based 
protein assay. Fractions with highest protein concentrations were pooled and split in 
100 µl portions. An equal volume of glycerol and NaN3 to a final concentration of 
                                                
34  The application of luminol-based ECL™ Western Blotting detection solutions results in enhanced 
chemiluminescence through the oxidation of luminol which is catalyzed by the peroxidase of horseradish 
peroxidase (HRP)-labeled secondary antibodies bound to primary antibodies allowing for the detection of 
respective antigens on the membrane (www.gelifesciences.com/aptrix/upp01077.nsf/Content/Products?Open 
Document&moduleid= 46853). 
 
35  Due to its negative charges, Ponceau S binds to positively charged protein groups. It further binds to non-polar 
protein regions (www.sigmaaldrich.com/etc/medialib/docs/Sigma-Aldrich/Product_Information_Sheet/p7170pis. 
Par.0001.File.tmp/p7170pis.pdf). 
 
36  Firefly luciferase catalyzes the oxidation of luciferin to oxyluciferin with the help of adenosine triphosphate (ATP) 
and oxygen emitting light in the green to yellow spectrum (www.promega.com/resources/product-guides-and-
selectors/protocols-and-applications-guide/bioluminescent-reporters/). 
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0.05% were added and aliquots were stored at -20°C. Columns were regenerated 
upon washing with 10 ml of 10 mM Na3PO4 (pH 6.8), 10 ml of 1 M DPBS-based NaCl 
(twice), and 10 ml of DPBS containing 0.05% NaN3 (twice) and stored at 4°C. 
 
 
2. Cellular biology (in vivo analyses) 
 
2.1.  Antiserum generation against human GPR19 
 
Rabbits were immunized with human GPR19 peptides in order to generate specific 
antisera against GPR19. Peptide synthesis and immunizations were performed by 
Peptide Specialty Laboratories. GPR19 peptides with which respective animals had 
been immunized are listed in table 11. Immunizations (0.2 µmol total peptide coupled 
to maleimide-activated keyhole limpet hemocyanin as peptide carrier) were done 
on day 0 with complete Freund’s adjuvant and on days 28, 42, and 56 with 
incomplete Freund’s adjuvant. Animals were sacrificed on day 70 (final bleed). 
 
 
2.2.  Cell culture 
 
Frozen cells were thawed at 37°C, cultured without antibiotics in normal growth 
medium (Roswell Park Memorial Institute (RPMI) 1640 with GlutaMAX™, 10% fetal 
bovine serum (FBS; heat-inactivated at 55°C for 1 h)) except for IB3-1 and NuLi-1 
(bronchial epithelial cell growth medium (BEGM), 10% FBS), CCD-8Lu and WI-38 
(Eagle’s minimum essential cell growth medium (EMEM), 10% FBS), and HEK-293 
(Dulbecco’s modified eagle’s medium (DMEM), 10% FBS), and maintained in the 
logarithmic growth phase. NuLi-1 cells were cultured in collagen IV-coated flasks. 
Trypsin-EDTA was used for detachment of adherent cells from the bottom of any 
culture device. Cells growing in aggregates in suspension were dissociated by 
incubation in an equal volume of Accumax™ at 37°C for 10 min and squeezed 
through a 26 G needle. Remaining cell clumps were removed by filtering the 
suspension through a cell strainer. Cell numbers and viability was assessed using the 
Vi-Cell™ XR cell viability analyzer. Cell lines were cultured in incubators at 37°C, 5% 
CO2, and 95% humidity and discarded when a high passage number (> 40) was 
reached. They were authenticated using short tandem repeat analysis and tested for 
mycoplasma contamination on a regular basis by the Boehringer Ingelheim 
Genomics Core Facility.  
 
 
2.3.  Freezing of cells 
 
Cells (5 x 106) were pelleted by centrifugation (250 x g, 5 min), resuspended in 1 ml of 
CryoStor® solution, and transferred into a 1.8 ml CryoTube™ vial. Freezing was done 
at a cooling rate of -1°C/min in a freezing container filled with isopropanol at -80°C 
and cells were finally stored in liquid nitrogen. 
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2.4.  siRNA transfection (96 well culture plate) 
 
Reverse transfection of cells was done using Lipofectamine® RNAiMAX in a 96 well 
cell culture plate. 0.3 µl of transfection reagent were mixed with 20 µl of siRNA-
containing opti-MEM® I reduced serum medium (2 to 60 nM final siRNA 
concentration) and transfection complexes were allowed to form for 20 min. 100 µl 
of the cell suspension containing 2,000 to 3,500 NCI-H1703 or 10,000 DMS 53 cells 
were added per well. In order to reduce toxicity caused by the transfection 
procedure, 80 µl of normal growth medium were added per well 8 h after 
transfection.  
 
 
2.5.  Forward plasmid transfection (6 well culture plate) 
 
Transfection of HEK-293 cells with expression plasmids in 6 well culture plates was 
performed using TurboFect™ transfection reagent. Cells (2.5 to 3 x 105) were seeded 
in 1.8 ml of DMEM containing 10% FBS into wells of a poly-D-lysine-coated37 6 well cell 
culture plate 8 h prior to transfection. 2 µg of plasmid DNA (0.5 µg of the plasmid of 
choice (each); the empty vector control plasmid pCMV6-XL5 was used to account 
for the residual amount of plasmid DNA) were diluted in 200 µl of serum-free DMEM 
followed by addition of TurboFect™ transfection reagent (3 µl). The solution was 
mixed and transfection complexes were allowed to form for 20 min. The transfection 
solution was added onto cells and the medium was changed to DMEM containing 
10% FBS 4 h after transfection. 
 
 
2.6.  Reverse plasmid transfection (8 well chamber slide) 
 
HEK-293 cells were reverse-transfected with turbo green fluorescent protein (tGFP)- or 
enhanced yellow fluorescent protein (eYFP)-tagged receptor-encoding plasmids in 
chambers of a BioCoat™ poly-D-lysine-coated 8 well culture slide using TurboFect™ 
transfection reagent. 0.1 µg of plasmid DNA (0.05 µg of the plasmid of choice, 
0.05 µg of the empty vector control plasmid (pCMV6-XL5)) were diluted in 20 µl of 
serum-free DMEM followed by addition of TurboFect™ transfection reagent (0.45 µl). 
The solution was mixed and transfection complexes were allowed to form for 20 min 
at the well bottom. Cells (10,000 in 200 µl of DMEM containing 10% FBS) were added 
per chamber. 
Reverse transfection of DMS 53 and NCI-H2170 cells was performed with 
Lipofectamine™ 2000. Per chamber, 0.6 µl of transfection reagent were diluted in 
25 µl of opti-MEM® I and incubated for 5 min. Diluted plasmid DNA (0.2 µg in 25 µl of 
opti-MEM® I) was added to the diluted transfection reagent, mixed, and incubated 
for 20 min to allow the formation of transfection complexes. Cells (10,000 in 100 µl of 
culture medium (RPMI 1640 with GlutaMAX™ containing 10% FBS)) were added per 
chamber and 200 µl of fresh culture medium were added 8 h later. 
                                                
37  Poly-D-lysine can be used to facilitate the attachment of cells to plastic surfaces. 
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2.7.  Electroporation 
 
Plasmid transfer into DMS 53, HEK-293, and NCI-H1703 cells was done using the single 
cuvette-based Nucleofector™ system. Cells (5 to 6 x 105) were resuspended in 100 µl 
of Amaxa™ Cell Line Nucleofector™ Kit V solution, mixed with 2.5 to 5 µg of DNA, 
and transferred into an electroporation cuvette. Electroporation was performed 
using program X-005 for DMS 53 and NCI-H1703 cells and program Q-001 for HEK-293 
cells. Electroporated cells were flushed out of the cuvette with prewarmed normal 
growth medium. Cells were seeded in culture plates and the medium was changed 
the day after transfection. The medium change was not performed in luciferase 
reporter assays.   
 
 
2.8.  Cell cycle arrest (synchronization) 
 
For arresting cells at different stages of the cell cycle 1 x 105 cells were seeded in 
wells of a 6 well culture plate followed by 24 h incubation with hydroxyurea (arrest at 
gap 1 (G1)-DNA synthesis (S) phase transition; final concentration: 1 mM), aphidicolin 
(arrest at G1-S transition; final concentration: 2.5 µM), or nocodazole (arrest at mitosis 
(M) phase; final concentration: 300 nM). Cells were released from cell cycle arrest by 
washing off the arrest-causing agent and subsequent culturing using normal growth 
medium.   
 
 
2.9.  Flow cytometry – cell cycle analysis 
 
For cell cycle analysis, siRNA-transfected cells seeded in wells of a 96 well culture 
plate or cell cycle-arrested cells seeded in wells of a 6 well culture plate were 
detached from the well bottom, pelleted, resuspended in 4 ml of 70% ethanol 
(fixation; -20°C), and stored at -20°C for at least 24 h. Cells from six wells were pooled 
when they had been grown in 96 well plates. Fixed cells were washed with DPBS and 
subjected to RNase A treatment (1 mg/ml final concentration) for 5 min followed by 
propidium iodide38 DNA staining (50 µg/ml final concentration). Data collection was 
done using a FACSCalibur flow cytometer and at least 10,000 cells were recorded, if 
possible. The flow rate was kept below 200 counts per second in order to assure 
proper separation of detected cells. Data were analyzed with FlowJo software. The 
Watson Pragmatic model (Watson JV et al., 1987) was chosen as curve fitting 
algorithm for cell cycle analysis in order to classify cells into the different phases of 
the cell cycle. This model fits G1 and gap 2 (G2)/M phase populations with Gaussian 
                                                
38  Propidium iodide is frequently used to stain nucleic acids and to differentiate between alive and dead cells. This 
intercalating agent and fluorescent dye can only enter cells that have lost their plasma membrane integrity and 
become permeable. In addition, propidium iodide can be utilized to determine the DNA content of fixed 
(permeabilized) cells in flow cytometric cell cycle analyses. As it both binds to DNA and RNA, ribonuclease 
treatment is necessary in order to account for a specific signal resulting from its binding to DNA. Fluorescence is 
enhanced about 20 to 30 fold when propidium iodide has bound to nucleic acids. Its excitation maximum then 
lies at 535 nm wavelength with an emission maximum at 617 nm (www.biolegend.com/propidium-iodide-solution-
2651.html; probes.invitrogen.com/media/pis/mp01304.pdf). 
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curves and the S phase exactly based on the propidium iodide area signal 
(fluorescence channel 2 (FL2)-area (A)) histogram. Cell doublets were removed prior 
to analysis (doublet discrimination mechanism (DDM) on the FL2 (propidium iodide) 
signal: gating on singlets on a propidium iodide area (FL2-A) versus width (FL2-W) 
signal graph). 
 
 
2.10.  Flow cytometry – transfection optimization 
 
Turbo GFP-plasmid-transfected cells seeded in wells of a 6 well culture plate were 
removed from the culture dish, pelleted, and washed with DPBS. The cell pellet was 
resuspended in 400 µl of propidium iodide solution (50 µg/ml in DPBS) and subjected 
to flow cytometric analysis. Turbo GFP positive, propidium iodide negative cells were 
determined using a fluorescence channel 1 (FL1; tGFP)-height (H) versus 
fluorescence channel 2 (FL2; propidium iodide)-H dot plot with quadrant statistics.  
 
 
2.11.  Proliferation – alamarBlue® 
 
The alamarBlue® assay solution was added to the culture medium (1:10 dilution) of 
cells grown in 96 well culture plates. Fluorescence signals arising from the indicator 
dye resazurin (dark blue; non-fluorescent) being reduced to resorufin (pink; 
fluorescent) by metabolically active cells were recorded using a 2030 Multilabel 
Reader VICTOR™ X5 (560 excitation/590 emission nm filter settings). The cells’ 
metabolic activity corresponds to the number of living cells which is proportional to 
the amount of fluorescence measured.  
 
 
2.12.  Proliferation – confluence  
 
Cellular proliferation was assessed by 96 well confluence determination using a 
CloneSelect™ Imager. Focus and brightness levels were kept constant during time 
series measurements and cell detection method 1 was applied.  
 
 
2.13.  Immunofluorescence labeling 
 
siRNA-transfected cells cultured in black poly-D-lysine-coated 96 well culture plates 
were fixed for 10 min with an equal volume of fixation buffer, washed twice with 
DPBS (CyBi®-Well 96 channel pipettor), and incubated in 50 µl of blocking buffer for 
5 min followed by twice DPBS washing. Cells were stained for cyclin B1 and 
phosphorylated histone H3 (pH3) or for tubulin with 50 µl of antibody-containing 
staining solution for 1 h and washed with 0.01% Tween in DPBS and DPBS only. They 
were incubated in 50 µl of secondary antibody and Hoechst-containing staining 
solution (goat anti mouse Alexa488, 1:2,000 dilution; donkey anti rabbit, Alexa555, 
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1:4,000 dilution; Hoechst 3334239, 1:1,500 dilution) for 1 h. For actin filament staining, 
DY-647-phalloidin (1:100 dilution) was included (Capani F et al., 2001). Cells were 
washed with 0.01% Tween in DPBS and DPBS only and 180 µl of DPBS were added per 
well. The plate was sealed with black backing tape and stored at 4°C. 
 
 
2.14.  High content screening (HCS) 
 
Fluorescence-based cell staining detection was done with an ArrayScan® VTI HCS 
reader. Six wells per reaction condition and 36 fields per well were recorded, each 
with multiparameter fluorescence, at 20x magnification. Multiple numerical feature 
values (e.g., object area and shape, signal intensity) for each signal within an optical 
field were generated using the software ArrayScan® VTI. The total number of 
detected cells per well was in the range of 300 to 1,000 depending on siRNA 
treatment and time after siRNA transfection. Measurements were performed with the 
following settings and features: 
 
Settings: 
- Acquisition camera mode: standard 
- Autofocus interval: 2 
- Background correction: 0 
- Fields per well: 36 (maximal) 
- Filter set: XF93 
- Fixed exposure time (set to 25% the saturation of negative controls) 
- Fixed threshold (adjusted to staining intensities) 
- Nuclear smooth factor channel1: 0 
- Objective: 20x magnification 
- Segmentation channel1: 6 
 
General features of detection channels 1, 2, 3, and 4: 
- Hoechst 33342 staining40:  
• cellsperfieldch1    
• objectareach1 41 
• objecttotalintench1 42 
• objectvarintench1 43 
• nucfragch2 44 
                                                
39  The cell permeable dye Hoechst 33342 stains DNA by preferential binding to the DNA minor groove in adenine-
thymine-rich regions. It is excited by ultraviolet light (excitation maximum at 350 nm when bound to DNA) and 
emits fluorescent light in the blue spectrum (emission maximum at 461 nm) being sensitive to chromatin state and 
DNA conformation (tools.invitrogen.com/content/sfs/manuals/mp21486.pdf; www.thermoscientific.com/ 
ecomm/servlet/productsdetail_11152_L10704_92518_13575985_-1). 
 
40  Both channels 1 and 2 detected Hoechst 33342 DNA staining. However, channel 1 was used for nuclei detection 
and channel 2 detected nuclear subfragmentation of objects identified in channel 1. 
 
41  Total nuclear area. 
 
42  Total intensity: sum of intensities of a detected object. 
 
43  Variance: standard deviation of pixel intensities in a detected object. 
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• totalintench2 
- Alexa488 (pH3/tubulin staining):  
• totalintench3 
-  Alexa555/Phalloidin647 (cyclin B1/actin staining):  
• totalintench4 
 
The data were processed and visualized by Spotfire® DecisionSite® and iView™. For 
cell cycle analysis, the relative amount (percentage) of cells in sub G1 (ccy_psub2n), 
G1 (ccy_p2n), S (ccy_ps), G2/M (ccy_p4n), and above G2/M (ccy_pabove4n) 
phases was calculated on the basis of Hoechst 33342 DNA staining (nuclear area, 
fragmentation and shape, total and average signal intensity).  
Changes in cellular population parameters, e.g., intensities of pH3, cyclin B1, actin, or 
tubulin staining were determined by a Kolmogorov-Smirnov (KS) goodness-of-fit 
analysis (KS statistic) as described (Giuliano KA et al., 2004). In brief, population 
density distributions of replicate wells (immunofluorescence histograms) were 
transformed into cumulative distribution frequency plots. The KS statistic value for 
each experimental condition was calculated as the maximal height difference (d) 
between its cumulative distribution function and the one from all controls combined 
(Perlman ZE et al., 2004).  
Principal component analysis (PCA) and multidimensional scaling (MDS)45 of 
recorded data were performed in order to select Gpr19 siRNAs with minimal off-
target effects. The following parameters obtained from Hoechst 33342 (channel 1 
and channel 2; MDS only), actin (channel 3), and tubulin (channel 4; PCA only) 
stainings were used for PCA and MDS (KS statistic (d)):  
 
PCA: 
- d_entropych3 and d_entropych4 46 
- d_spotfibercountch3 and d_spotfibercountch4 47 
- d_spotfibertotalareach3 and d_spotfibertotalareach4 48 
- d_totalintench3 and d_totalintench4 
- d_varintench3 and d_varintench4 
 
 
 
                                                                                                                                                      
44  Nuclear fragmentation. 
 
45  Principal component analysis (PCA) and multidimensional scaling (MDS) are methods of data reduction. Both 
methods aim at reducing the dimensionality of a data set (i.e., they convert a high-dimensional data set into one 
with fewer variables) without notable loss of information. Using linear combinations, correlated original variables 
are transformed into a final small set of uncorrelated variables (usually three dimensions) which are called 
principal components. Here, PCA neglects the variations when multiple variables are combined. However, MDS 
takes these variations into consideration and attempts to preserve distances between pairs of variables 
(astor.som.jhmi.edu/~cope/687/pdf/pca-mds.pdf; www.math.uwaterloo.ca/~aghodsib/courses/f10stat946/ 
notes/lec10-11.pdf). 
 
46  Entropy: distribution of pixel intensities in a detected object. 
 
47  Spot fiber count: number of detected fibers. 
 
48  Spot fiber total area: area of detected fibers. 
 
V. Methods 
70 
 
MDS: 
- d_nucavgintench1 49    -    d _spotfibertotalareach3  
- d_nucentropych1 50    -    d_totalintench3 
- d_nucperimch1 51    -    d_varintench3 
- d_nuctotalareach1    -    ccy_psubG1 
- d_nucshapelwrch1 52    -    ccy_p2N 
- d_nucshapep2ach1 53   -    ccy_pS 
- d_nucfragch2    -    ccy_p4N 
- d_entropych3    -    ccy_pabove4N 
- d_spotfibercountch3 
 
The proliferation index refers to identified cellular objects per field. The following 
parameters were integrated into the apoptotic index54: 
 
- ccy_psubG1     -    r_gr_nucshapep2ach1 
- r_gr_nucavgintench1   -    r_gr_sm_nucentropych1 
- r_gr_nuctotalareach1    -    r_gr_nucfragch2 
- r_gr_nucperimch1 
 
 
2.15.  Confocal microscopy 
 
Cells grown on chamber slides were fixed with paraformaldehyde (4% final 
concentration) for 10 min and washed three times with Hank’s balanced salt solution 
(HBSS). Membrane staining was done for 10 min with wheat germ agglutinin (WGA)55 
staining solution. Cells were washed twice with HBSS and the chambers were 
removed from the glass slide. They were mounted with DAPI56-containing mounting 
medium and a glass cover slip and incubated at 4°C for at least 10 h. Confocal 
microscopy analysis was performed on a Zeiss Laser Scanning Microscope (LSM) 510 
(60x magnification) using the software ZEN 2008 and LSM Image Examiner.  
 
                                                
49  Nuclear average signal intensity. 
 
50  Nuclear entropy. 
 
51  Nuclear perimeter. 
 
52  Length versus width ratio of a nuclear object. 
 
53  Discrepancy between actual nuclear perimeter line and smoothed perimeter line (ellipse). 
 
54   Apart from the relative number of cells assigned to the sub G1 phase of the cell cycle, data were compared to 
control samples and the percentage lying above (gr = greater) or below (sm = smaller) was determined 
(r = responder). 
 
55  Wheat germ agglutinin (WGA) selectively detects N-acetyl glucosamine and N-acetyl neuraminic acid residues 
often present on proteins of the plasma membrane (Wright CS, 1984; Prasad BM et al., 2010). 
 
56   DAPI (4',6-diamidino-2-phenylindole) preferentially stains double-stranded DNA by favoring binding to the DNA 
minor groove in adenine-thymine-rich regions. It is excited by ultraviolet light (excitation maximum at 358 nm 
when bound to DNA) and emits fluorescence light in the blue spectrum (emission maximum at 461 nm). DAPI is 
often used in multilabel fluorescence applications to stain cellular nuclei (probes.invitrogen.com/media/ 
pis/mp01306.pdf). 
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2.16.  Phase contrast microscopy  
 
Pictures of cells were recorded (20x magnification) and processed using a Leica 
DMIL phase contrast microscope. 
 
 
2.17. Adenylyl cyclase/cyclic adenosine monophosphate (cAMP) 
assay 
 
Assays measuring the formation of cAMP from adenosine triphosphate (ATP) by 
adenylyl cyclase were performed with adherent cells grown in wells of a poly-D-
lysine-coated 6 well culture plate (a schematic overview is given in figure 12). The 
growth medium was removed and cells were radioactively labeled by incubation 
with 1 ml of [3H]adenine labeling medium (1 µCi/ml; 27.78 nM in culture medium 
containing 10% FBS) at 37°C for 16 h. Removal of labeling medium was followed by 
starvation of cells with 1 ml of growth medium lacking FBS at 37°C for 90 min. 
Starvation medium further contained a phosphodiesterase IV inhibitor (Ro-20-1724 57; 
100 µM) and adenosine deaminase (ADA58; 1 U/ml). After removal of the starvation 
medium, cells were incubated with 1 ml of stimulation medium containing Ro-20-
1724 (100 µM) and ADA (1 U/ml) at 37°C for 30 min. Cells were lysed using 1 ml of 
2.5% perchloric acid containing surplus unlabeled cAMP59 (100 µM) and incubated 
at 4°C for 40 min. Leaving behind cellular debris, the lysate was removed from the 
tilted culture well and neutralized with 110 µl of 4.2 M KOH solution which resulted in 
salt precipitation. 
Separation of cAMP from ATP was performed by sequential chromatography using 
Dowex anion resin and alumina oxide columns60. The Dowex slurry was prepared by 
saturating the resin (500 g) with 500 ml of deionized water. 500 ml of 1 M HCl were 
added and the supernatant was poored off after incubation for 10 min. The 
suspension was washed three times with 1 l of deionized water followed by 
incubation in 500 ml of 1 M NaOH for 10 min. After pooring off the supernatant, the 
slurry was resuspended in deionized water (1:1 suspension). 2 ml of the Dowex 
suspension were added per separation column (5 ml pipet tip into which glass wool 
had been filled) and the slurry was washed with 3 ml of 1 M HCl and three times with 
                                                
57  The selective inhibitor of cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase IV, Ro-20-1724, 
prevents the hydrolysis of cAMP. 
 
58  Adenosine deaminase (ADA) was present here to destroy adenosine released from cells. 
 
59  In order to counteract the hydrolysis of 3H-labeled cyclic adenosine monophosphate (cAMP) by cyclic 
nucleotide phosphodiesterases, a vast excess of unlabeled cAMP was added to the lysis buffer in this experiment. 
 
60  The separation of the cyclic 3’,5’-adenosine monophosphate (cAMP) from 2’, 3’, or 5’ adenosine 
monophosphate (AMP), adenosine diphosphate (ADP), and adenosine triphosphate (ATP) can be achieved by 
sequential chromatography (Dowex cation exchange resin and neutral alumina columns) as described 
(Salomon Y et al., 1974; Johnson RA and Salomon Y, 1991). ATP and ADP are eluted earlier and 5’-AMP is eluted 
later than cAMP from the Dowex column (Krishna G et al., 1968). Utilizing this elution profile, one can capture the 
elution fraction containing most cAMP. Further sample cleanup is achieved by applying this fraction to hydrous 
aluminum oxide columns to which multivalent ions preferentially bind. At neutral pH, cAMP is a univalent anion 
whereas ATP, ADP, and AMP are all multivalent anions. This only allows cAMP but neither AMP nor ADP nor ATP to 
pass the alumina column (Ramachandran J, 1971; White AA and Zenser TV, 1971). 
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5 ml of deionized water. For preparation of alumina columns, 0.75 g of aluminum 
oxide were mixed with 3 ml of 100 mM imidazole and incubated for 12 to 16 h. The 
solution was poured into a separation column which was washed four times with 5 ml 
of imidazol buffer followed by two washing steps with 5 ml of deionized water. As 
Dowex and alumina columns were reused multiple times, respective washing steps 
had been performed each time before the sample was applied (column 
regeneration). 
 
 
 
Figure 12: Schematic overview of the different cell treatments during an adenylyl cyclase assay.   
 
Prior to sample loading onto Dowex columns, the salt precipitate was concentrated 
at the tube bottom by centrifugation (5,000 x g, 10 sec). 970 µl of the clear 
supernatant were loaded onto a Dowex column and columns were washed twice 
with 1 ml of deionized water. They were placed on top of the Alumina columns and 
cAMP was eluted with 2 ml of deionized water (twice). Alumina columns were 
placed on top of scintillation vials and cAMP was eluted with 3 ml of imidazol buffer 
(twice). The eluate was mixed with 10 ml of liquid scintillation solution and radioactive 
decay was measured in a liquid scintillation counter for 3 min. 
 
 
3. In silico analyses 
 
3.1.  Phylogenetic analysis 
 
Proteins which are evolutionary related to GPR19 were searched for using the basic 
local alignment search tool (BLAST) algorithm (2.2.26+)61. Full-length sequences were 
aligned using ClustalW2 62 for multiple sequence alignment and displayed as 
phylogenetic tree. 
 
 
 
                                                
61  blast.ncbi.nlm.nih.gov/Blast.cgi 
 
62  www.ebi.ac.uk/Tools/msa/clustalw2/ 
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3.2.  Microarray gene expression analysis and hierarchical clustering 
(heat map) 
 
Raw (CEL) files were robust multichip average (RMA)-normalized using the affy 
package in R/Bioconductor (Irizarry RA et al., 2003). Quality control was performed 
by visual inspection of box plots, minus-average (MA)63-plots, and density plots of the 
normalized data. 
Genes encoding proteins with G protein-coupled receptor (GPCR) activity (which 
included GPCRs and GPCR-associated proteins) were selected on the basis of Gene 
Ontology (GO)64 number 0004930 and their microarray expression values in NSCLC, 
SCLC, and normal lung samples were extracted. Only one probe set was chosen per 
gene resulting in 773 genes. Geometric mean values across all normal lung samples 
were calculated and used for normalization of NSCLC and SCLC patient sample 
expression values. A cluster analysis of the log 2-transformed normalized expression 
data was performed using the hierarchical clustering method (average linkage 
clustering, Euclidean distance) from Genesis (Sturn A et al., 2002).  
 
 
3.3.  Gene expression profiling (databases) 
 
Gene expression levels of Gpr19 (probe set 207183_at) in various human normal and 
cancerous tissues were investigated by utilization of the Gene Logic BioExpress® 
database65 as described (Dolznig H et al., 2005; Glatt S et al., 2008). The database 
constitutes of expression data generated with Affymetrix GeneChip® technology 
(chip sets Human Genome U133A and Human Genome U133B, Human Genome 
U133 plus 2.0). Chip data analysis was performed with the statistical algorithm of 
Affymetrix Microarray Suite version 5.0 software. In order to allow for comparisons 
between chips, a global scaling factor was used for multiplication of the raw 
expression intensities. Both the lowest and highest 2% of the non-normalized 
expression values were removed and the mean of the remaining values was 
calculated (trimmed mean). The scaling factor is definded by Gene Logic as 100 
divided by the trimmed mean. The comparison of the absolute signal intensities of 
corresponding perfect match and mismatch oligonucleotides allowed for the 
calculation of absent and present calls (oligonucleotide-specific background 
normalization).  
For the investigation of Gpr19 (probe set NM_006142_at) gene expression levels in 
various human lung-derived cell lines, a proprietary Boehringer Ingelheim gene 
expression database was utilized. The database constitutes of expression data 
generated with Affymetrix GeneChip® technology (Human Exon 1.0 ST Array). CEL 
files were RMA-normalized and data were inspected as described in 3.2. 
 
                                                
63  Minus-average (MA) plots are used for visualization of the average (A) logarithmic signal intensities versus the 
differences in these intensities (minus, M; Göhlmann H and Talloen W, 2009). 
 
64  www.geneontology.org 
 
65  www.genelogic.com/knowledge-suites/bioexpress-system 
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3.4.  Copy number analysis 
 
Deletions and amplifications of genomic regions in lung-cancer derived cell lines 
were detected using single nucleotide polymorphism (SNP) microarray analysis as 
part of a proprietary Boehringer Ingelheim cell line database. The data had been 
collected using the Affymetrix GeneChip® Human Mapping 250K Nsp array which 
covers the human genome with 2.62 x 105 SNPs. DNA copy numbers had been 
determined using the gain and loss analysis of DNA (GLAD) algorithm (Hupé P et al., 
2004).  
 
 
3.5.  Statistical data analysis 
 
GraphPad Prism® was used for statistical data analysis. Comparisons between 
multiple test groups were either done using the non-parametric Kruskal Wallis test 
followed by Dunn’s multiple comparison test or by one way analysis of variance 
(ANOVA) followed by Tukey’s test. For the comparison of two test groups, a t test with 
Welch’s correction was applied. The level of uncertainty in rejecting the null 
hypothesis is indicated by significance values *p < 0.05, **p < 0.01, ***p < 0.001, and 
****p < 0.0001, respectively. 
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VI.  Results 
 
1. Phylogenetic analyses of G protein-coupled receptor 19 
(GPR19) 
 
1.1.  Orthologs 
 
A protein basic local alignment search tool (BLAST) search was performed with the 
human GPR19 protein sequence to examine the similarity to predicted or putative 
GPR19 proteins from various species. The GPR19 receptors from different species 
were the best hits ranging from a total score of 859 to 140. However, there were also 
five proteins not explicitely called GPR19 in Branchiostoma floridae (hypothetical 
protein BRAFLDRAFT_69363), Drosophila mojavensis (GI24301), Equus caballus 
(predicted: similar to hCG2039474), Nematostella vectensis (unnamed predicted 
protein), and Strongylocentrotus purpuratus (predicted: similar to G protein-coupled 
receptor) included in these best scoring hits. The accession numbers for all these 
proteins are depicted in table 13 and full-length sequences were aligned using 
ClustalW2 for multiple sequence alignment (figure 13). 
 
Table 13:  (Predicted/probable/putative GPR19) proteins from various species were identified by BLAST 
using the human GPR19 protein sequence as reference. Shown are the species, National 
Center for Biotechnology Information (NCBI) protein reference sequence accession 
numbers, and protein annotation; results are arranged in alphabetical order. 
 
Species Accession number Protein (BLAST annotation) 
Ailuropoda melanoleuca  
(giant panda) XP_002918034.1 Predicted: probable G protein-coupled receptor 19-like 
Anolis carolinensis (green anole) XP_003228174.1 Predicted: probable Gprotein-coupled receptor 19-like 
Bos taurus (cow) NP_001094684.1 Probable G protein-coupled receptor 19 
Branchiostoma floridae  
(Florida lancelet) XP_002591081.1 Hypothetical protein BRAFLDRAFT_69363 
Callithrix jacchus  
(white-tufted-ear marmoset) XP_002752176.1 Predicted: probable G protein-coupled receptor 19 
Canis lupus familaris (dog) XP_003433621.1 Predicted: probable G protein-coupled receptor 19 
Cavia porcellus (guinea pig) XP_003470461.1 Predicted: probable G protein-coupled receptor 19-like 
Danio rerio (zebrafish) NP_957288.1 Probable G protein-coupled receptor 19 
Drosophila mojavensis (fly) XP_001999054.1 GI24301 
Equus caballus (horse) XP_001496867.1 Predicted: similar to hCG2039474 
Gallus gallus (chicken) XP_003643346.1 Predicted: probable G protein-coupled receptor 19-like 
Heterocephalus glaber  
(naked mole-rat) EHB14318 Putative G protein-coupled receptor 19 
Homo sapiens (human) NP_006134.1 Probable G protein-coupled receptor 19 
Loxodonta africana  
(African elephant) XP_003405704.1 Predicted: probable G protein-coupled receptor 19-like 
Macaca mulatta (rhesus monkey) XP_001085321.1 Predicted: probable G protein-coupled receptor 19 
Meleagris gallopavo (turkey) XP_003202592.1 Predicted: probable G protein-coupled receptor 19-like 
Mus musculus (mouse) NP_001161166.1 Probable G protein-coupled receptor 19 isoform a 
Mustela putorius furo (domestic 
ferret) AER99336.1 Putative G protein-coupled receptor 19 
Nematostella vectensis  
(starlet sea anemone) XP_001639290.1 Predicted protein 
Nomascus leucogenys  
(northern white-cheeked gibbon) XP_003265718.1 Predicted: probable G protein-coupled receptor 19-like 
Oreochromis niloticus (nile tilapia) XP_003448851.1 Predicted: probable G protein-coupled receptor 19-like 
Pan troglodytes (chimpanzee) XP_001153454.1 Predicted: G protein-coupled receptor 19 
Pongo abelii (Sumatran orangutan) XP_002822997.1 Predicted: probable G protein-coupled receptor 19-like 
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Species Accession number Protein (BLAST annotation) 
Rattus norvegicus (rat)  NP_542146.1 Probable G protein-coupled receptor 19 
Saccoglossus kowalevskii  
(acorn worm) XP_002741289.1 Predicted: G protein-coupled receptor 19-like 
Strongylocentrotus purpuratus (sea 
urchin) XP_001200143.1 Predicted: similar to G protein-coupled receptor 
Taeniopygia guttata (bird) XP_002193564.1 Predicted: similar to G protein-coupled receptor 19 
Xenopus tropicalis (frog) NP_001016208.1 G protein-coupled receptor 19 
 
 
 
 
Figure 13:  The GPR19 protein is conserved during evolution. The phylogenetic tree of GPR19 proteins 
from various species (ClustalW2) included orthologs that were identified by a BLAST search 
using human GPR19 as reference. Full-length amino acid sequences of the receptors were 
aligned. Relative branch lengths are indicative of evolutionary distances between GPR19 
proteins from different species.  
 
Based on the phylogenetic tree of GPR19 orthologs, this G protein-coupled receptor 
(GPCR) is present in a vast variety of animals (metazoa), the common kingdom of all 
species that gave a positive BLAST result. However, GPR19 is not only found in 
mammalia (e.g., Homo sapiens, Mus musculus), amphibia (Xenopus tropicalis), and 
other chordata/craniata/vertebrata (e.g., Gallus gallus) but also in the phyla of 
arthropoda (Drosophila mojavensis), hemichordata (Saccoglossus kowalevskii), 
echinodermata (Strongylocentrotus purpuratus), and cnidaria (Nematostella 
vectensis). The very diverse spectrum of species in which GPR19 was found points to 
a rather general but essential role of this receptor in cell biology. In addition, GPR19 
seems to be highly conserved among euarchontoglires (supra-primates), as these 
species reside on a separate branch of the phylogenetic tree.  
The ortholog classification of GPR19 identifies this GPCR as a highly conserved protein 
not only present in mammals but also in evolutionary distant species such as the sea 
anemone of the cnidaria phylum. 
Euarchontoglires
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1.2.  Paralogs 
 
The BLAST search was repeated for GPR19 proteins from Homo sapiens, Pan 
troglodytes, Macaca mulatta, Mus musculus, and Danio rerio in order to search for 
GPR19-related GPCRs within the proteome of these species. The best scoring hits 
according to the maximum score are listed in table 14 and full-length protein 
sequences underlying the listed accession numbers were used for the generation of 
phylogenetic trees using ClustalW2 (paralogs; figure 14 and figure 15). Proteins 
residing on the same branches might have evolved from genome duplications of a 
common ancestor and acquired different cellular functions with time. A comparison 
of putative paralogs might therefore generate hypotheses on the physiological roles 
of uncharacterized GPCRs and on their candidate cognate ligands. 
 
Table 14:  GPCRs were identified by species-specific GPR19 similarity search (BLAST) in Homo sapiens, 
Pan troglodytes, Macaca mulatta, Mus musculus, and Danio rerio. The best scoring hits 
(maximum score) were selected and are listed in alphabetical order. Protein sequences 
used for phylogenetic tree analysis (NCBI reference sequence accession numbers) and 
exemplary ligands for all GPCRs are shown.  
 
 
 
Phylogenetic trees for Homo sapiens, Pan troglodytes, Macaca mulatta, Mus 
musculus, and Danio rerio (figure 14 and figure 15) include either 30 (Homo sapiens) 
or 16 (other species) best BLAST search hits and GPR19. Generally speaking, most 
Abbreviation Receptor Ligand (example) Homo sapiens Pan troglodytes Macaca mulatta Mus musculus Danio rerio
5HT2AR 5-hydroxytryptamine receptor 2A Serotonin (biogenic amine) NP_000612.1
5HT4R 5-hydroxytryptamine receptor 4 Serotonin (biogenic amine) NP_000861.1 NP_032339.2
ADRA1B Alpha-1B adrenergic receptor Adrenaline (biogenic amine) NP_000670.1 NP_001122161.1
ADRB2 Beta-2 adrenergic receptor Adrenaline (biogenic amine) NP_000015.1 NP_001182193.1 NP_001036239.1 NP_031446.2 NP_001082940.1
CCKAR Gastrin/cholecystokinin type A receptor Gastrin (peptide) NP_000721.1 XP_526545.1 XP_001084186.1 XP_002663361.2
CCKBR Gastrin/cholecystokinin type B receptor Gastrin (peptide) NP_795344.1
DRD2 Dopamine receptor D2 Dopamine (biogenic amine) NP_000786.1
DRD3 Dopamine receptor D3 Dopamine (biogenic amine) NP_387512.3
GALR1 Galanin receptor type 1 Galanin (peptide) NP_001471.2 XP_523975.2 XP_001086740.1 NP_032108.1 XP_696215.1
GALR2 Galanin receptor type 2 Galanin (peptide) NP_003848.1 XP_523721.1 XP_001103768.1 NP_034384.3 XP_001339169.1
GALR3 Galanin receptor type 3 Galanin (peptide) NP_003605.1
GnIHR1 Gonadotropin-inhibitory hormone receptor 1
Gonadotropin-inhibitory     
hormone (peptide) NP_001165167.1
GnIHR2 Gonadotropin-inhibitory hormone receptor 2
Gonadotropin-inhibitory     
hormone (peptide) NP_001165168.1
GnRHR3 Gonadotropin-releasing hormone receptor 3
Gonadotropin-releasing     
hormone (peptide) NP_001170921.1
GPR19 GPR19 Orphan NP_006134.1 XP_001153454.1 XP_001085321.1 NP_001161166.1 NP_957288.1
GPR83 GPR83 Orphan NP_057624.3 XP_522151.2 XP_001088588.1 NP_034417.1 XP_001342488.1
HCRTR1 Orexin receptor type 1 Orexin (peptide) NP_001516.2 XP_524646.2 XP_001099090.1 NP_945197.2
HCRTR2 Orexin receptor type 2 Orexin (peptide) NP_001517.2 XP_518552.2 XP_001109616.1 NP_945200.1
HRH2 Histamine H2 receptor Histamine (biogenic amine) NP_071640.1
KISS1R KiSS-1 receptor Kisspeptin (peptide) NP_115940.2
LOC Hypothetical protein LOC243407 (7TM receptor) Orphan NP_780733.2
NK2R (TACR2) Substance-K receptor (tachykinin receptor 2) Tachykinin (peptide) NP_001048.2 XP_507831.2 XP_001110044.1 NP_033340.3
NK3R Neuromedin-K receptor Neuromedin (peptide) NP_001050.1
NPFFR1 Neuropeptide FF receptor 1 Neuropeptide FF NP_071429.1 XP_001107552.2 NP_001170982.1 NP_001082858.1
NPFFR2 Neuropeptide FF receptor 2 Neuropeptide FF NP_004876.2 XP_001158813.1 NP_573455.2 XP_690069.4
NPFFR2.1 Neuropeptide FF receptor 2.1 Neuropeptide FF NP_001098579.1
NPSR1 Neuropeptide S receptor 1 Neuropeptide S NP_997055.1 XP_001168798.1 NP_001028114.1
NPY2R Neuropeptide Y receptor type 2 Neuropeptide Y NP_000901.1 NP_001012655.1 NP_001028004.1 NP_032757.2 XP_001343301.2
NPY2Rlike Neuropeptide Y receptor type 2-like, LOC795311 Neuropeptide Y XP_001332759.1
OPRM1 Mu-type opioid receptor isoform             MOR-1B5 Beta-endorphin (peptide) NP_001138758.1 NP_001027996.1
PGR15L G protein-coupled receptor 15-like (neuropeptide Y receptor activity) Orphan NP_001028533.1
QRFPR Orexigenic neuropeptide QRFP receptor QRFP (peptide) NP_937822.2 XP_001143462.1 XP_001920042.2
SSR1 Somatostatin receptor type 1 Somatostatin (peptide) NP_001040.1 XP_522831.1 XP_001091429.1 NP_033242.1
SSR2 Somatostatin receptor type 2 Somatostatin (peptide) NP_001041.3 XP_001167728.1 XP_001085574.1 NP_033243.2
SSR4 Somatostatin receptor type 4 Somatostatin (peptide) NP_001043.2 XP_525282.1 XP_001095303.1 NP_033245.2
SSR5 Somatostatin receptor type 5 Somatostatin (peptide) NP_001044.1 XP_510725.2 XP_695365.1
TAAR2 Trace amine-associated receptor 2 Tryptamine (biogenic amine) NP_001028252.1 XP_001103648.2
V1BR Vasopressin V1b receptor Vasopressin (peptide) NP_000698.1
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GPCRs retrieved from the BLAST search were called close relatives of GPR19 in more 
than one species and only few were uniquely present in a single species. Those 
GPCRs mainly existed in Danio rerio – the examined species which is evolutionary 
most distant from all the others. These findings further point to an evolutionary 
conserved history of GPR19 across species borders. Additionally, the GPCRs called as 
best hits by the BLAST search in all species are activated either by biogenic amines or 
by peptides (or are still orphan receptors). 
In the Homo sapiens phylogenetic tree, GPR19 resides on an individual branch with 
its closest neighbors being GPCRs activated by biogenic amines (TAAR2, ADRA1B, 
ADRB2, HRH2, 5HT4R, DRD2, DRD3, and 5HT2AR) on the one hand and GPCRs 
activated by peptides (NPSR1, V1BR, CCKAR, CCKBR, GALR1, GALR2, GALR3, KISS1R, 
OPRM1, SSR1, SSR4, SSR2, SSR5, QRFPR, etc.; except for orphan receptor GPR83) on 
the other hand (figure 14). GPR19 exactly ‘separates’ these two GPCR subclasses 
according to the nature of their known ligands, its branch is not assigned to belong 
to any of them.   
 
 
Figure 14:  Human GPR19 resides on an individual branch between biogenic amine- and peptide-
activated GPCRs. The phylogenetic tree shows 30 GPCRs and GPR19 (?; best hits based on 
maximum score from BLAST protein search for GPR19 similarity) from Homo sapiens 
(ClustalW2). Receptor abbreviations are specified in table 14. 
 
Closest relatives to the Pan troglodytes and Macaca mulatta GPR19 protein are 
almost exclusively GPCRs which have been described to be activated by peptides – 
except for ADRB2 and TAAR2 (activated by biogenic amines; figure 15). In both 
species, GPR19 shares a very open branch with NPSR1. In the Mus musculus 
phylogenetic tree, GPR19 resides on a single branch between 5HT4R and ADRB2 
receptors on the one hand and galanin and somatostatin receptors on the other 
hand. As observed in Homo sapiens, GPR19 again seems to ‘separate’ receptors 
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activated by biogenic amines from the ones activated by peptides in these species. 
This was not observed for the GPR19 protein of Danio rerio, whose closest relatives 
are – nevertheless – receptors activated by galanin and somatostatin.   
 
 
 
 
 
Figure 15:  GPR19 has closest similarity to GPCRs activated by biogenic amines or peptides in different 
species. The phylogenetic trees show 16 GPCRs and GPR19 (?; best hits based on maximum 
score from BLAST protein search for GPR19 similarity) from Pan troglodytes, Macaca mulatta, 
Mus musculus, and Danio rerio (ClustalW2). Receptor abbreviations are specified in table 14. 
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Phylogenetic tree analyses of potential GPR19 paralogs in five different species 
revealed its similarity to GPCRs activated by biogenic amines and peptides. Except 
for Danio rerio, GPR19 could be considered as an evolutionary connector between 
GPCRs activated by biogenic amines on the one hand and those activated by 
peptides on the other hand as its phylogenetic distance to both these groups is 
rather balanced.    
 
 
2. Method development 
 
2.1.  Reference gene selection 
 
When utilizing reverse transcription quantitative real-time polymerase chain reaction 
(RT-qPCR) for examination of the relative expression level of a gene of interest, results 
can vary considerably depending on the selected reference gene. This is particularly 
true when expression levels of genes from cells at different stages of the cell cycle 
are analyzed. For example, increases in the message of glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) – a reference gene frequently used in RT-qPCR 
data normalization – were reported to be cell cycle-specific (Mansur NR et al., 1993). 
According to the guidelines for ‘minimum information for publication of quantitative 
real-time PCR experiments’ (MIQE; Bustin SA et al., 2009), a single reference gene for 
normalization has to be avoided. Instead, data should be normalized against 
multiple reference genes that had been tested for stable expression.  
Different frequently used reference genes (Actb66, B2m67, Cypa68, Gapdh69, Hprt1 70, 
Rplp0 71, Rnase P72, Tfr73) were tested for stable expression in representative 
                                                
66  ß-actin (ACTB; NCBI gene ID 60; UniProt protein ID P60709) belongs to the ß group of the three main vertebral 
groups of actins (α, ß, and γ) and plays an important role in the cellular contractile apparatus. Upon 
polymerization, actins are involved in a number of cellular physiological events including cellular structure, 
motility, and integrity (www.ncbi.nlm.nih.gov/gene/60; www.uniprot.org/uniprot/P60709). 
 
67  ß-2-microglobulin (B2M; NCBI gene ID 567; UniProt protein ID P61769) is part of the class I major histocompatibility 
complex (MHC). In association with the MHC class I heavy chain, it forms the MHC class I dimer which is involved 
in presenting peptide antigens to cells of the immune system (www.ncbi.nlm.nih.gov/gene/567; www.uniprot.org/ 
uniprot/P61769). 
 
68  Cyclophilin A (CYPA; also known as peptidylprolyl isomerase A (PPIA); NCBI gene ID 5478; UniProt protein ID 
P62937) is a member of the peptidyl-prolyl cis-trans isomerase family of enzymes. These enzymes are involved in 
catalyzing cis-trans isomerization of proline imidic peptide bonds. They therefore assist in the acceleration of 
protein folding (www.ncbi.nlm.nih.gov/gene/5478; www.uniprot.org/uniprot/P62937). 
 
69  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; NCBI gene ID 2597; UniProt protein ID P04406) is an 
enzyme involved in cellular carbohydrate metabolism. It is composed of four identical 36 kDa subunits and 
catalyzes the conversion of glyceraldehyde-3-phosphate into 3-phosphoglycerol phosphate in the presence of 
nicotinamide adenine dinucleotide (NAD; oxidative phosphorylation). In addition, the enzyme also possesses 
nitrosylase activity mediating cysteine-S-nitrosylation of nuclear target proteins and was therefore supposed to 
play a role in nuclear functions such as transcription, RNA transportation, or DNA replication. Two different 
isoforms of GAPDH exist arising from two different transcript variants (www.ncbi.nlm.nih.gov/gene/2597; 
www.uniprot.org/uniprot/P04406). 
 
70  The protein encoded by the hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1; NCBI gene ID 3251; 
UniProt protein ID P00492) gene forms a homotetrameric transferase. It catalyzes the transfer of the  
5-phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate to either hypoxanthine or guanine giving rise to 
inosine or guanosine monophosphate. Its main cellular role is elucidated during the purine salvage pathway in 
which it is crucial for purine nucleotide generation (www.ncbi.nlm.nih.gov/gene/3251; www.uniprot.org/uniprot/ 
P00492). 
VI. Results 
81 
 
complementary-deoxyribonucleic acid (cDNA) sample panels as proposed by 
Vandesompele and coworkers (Vandesompele J et al., 2002; GeNorm74 applet for 
Microsoft® Excel®). For each possible reference gene, all samples were normalized 
to the sample in which this gene was detected first, i.e., most highly expressed 
(relative expression ratio). This was done for all reference genes. Expression values of 
one reference gene were compared with those of all other reference genes (gene 
expression instability measure M or average pairwise variation: standard deviation of 
logarithmically transformed expression ratios)75. Genes with high M values are less 
stably expressed than genes with low M values and should not be considered as 
reference genes in a respective sample set. 
When testing for stable expression of reference genes, the outcome tremendously 
depends on the sample set used. The data shown in figure 16 included samples from 
small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells 
subjected to different synchronization conditions, which were collected at various 
time points after release from cell cycle arrest. Results displayed in figure 17 are 
based on a representative set of cDNA samples which included different untreated 
or short interfering ribonucleic acid (siRNA)-transfected SCLC and NSCLC cell lines 
(up to 60 nM final siRNA concentration).  
The most stably expressed reference genes in the example illustrated in figure 16 
(synchronized cells harvested at various time points after release from cell cycle 
arrest) were Rplp0 and Cypa followed by Actb and Hprt1. Reference genes Gapdh, 
Rnase P or B2m were unstably expressed. Hprt1, Cypa, and Rplp0 were also called 
stable expression genes in the second sample set examined (figure 17; untreated or 
siRNA-transfected cells). Besides, Tfr was characterized by stable expression whereas 
Rnase P, Actb, or B2m were unstably expressed.  
 
                                                                                                                                                      
 
71  Protein synthesis takes place at ribosomes. Eucaryotic ribosomes are composed of a small 40 S and a large 60 S 
subunit. About 80 proteins and 4 RNA species make up for an entire ribosome and the large ribosomal protein P0 
(RPLP0; NCBI gene ID 6175; UniProt protein ID P05388) is a phosphoprotein member of the 60 S subunit. In 
conjunction with the ribosomal phosphoproteins P1 and P2, RPLP0 is part of a preformed pentameric complex 
(dimers of P1 and P2, P0 monomer; www.ncbi.nlm.nih.gov/gene/6175; www.uniprot.org/uniprot/P05388). 
 
72  The catalytic riboprotein ribonuclease P (RNase P) utilizes its endonuclease activity to maturate the 5’ end of 
precursor transfer ribonucleic acids (tRNAs). Nuclear forms of this enzyme have been assigned a role in tRNA 
gene transcription by RNA polymerase III. It consists of multiple protein subunits (Jarrous N and Reiner R, 2007) and 
one RNA species with catalytic activity. In the present RT-qPCR application, the RNA part of RNase P termed H1 is 
detected (NCBI gene ID 85495 (http://www.ncbi.nlm.nih.gov/gene/85495); products.appliedbiosystems.com/ 
ab/en/US/adirect/ab?cmd=catNavigate2&catID=601337). 
 
73  The transferrin receptor (TFR); NCBI gene ID 7037; UniProt protein ID P02786) is involved in the cellular uptake of 
iron by receptor-mediated endocytosis. TFR is expressed at the cell surface of most cells in the human body as a 
homodimer with the monomer being a single-pass type II membrane glycoprotein. Once coupled to its ligand, 
one iron-loaded serum transferrin per subunit, the ligand-receptor complex is internalized and iron ions are 
released by acidification in endosomes. Receptor recycling to the cell surface and exposure to neutral pH results 
in the dissociation of transferrin from the receptor (Lambert LA and Mitchell SL, 2007; www.ncbi.nlm.nih.gov/ 
gene/7037; www.uniprot.org/uniprot/P02786) 
 
74  medgen.ugent.be/~jvdesomp/genorm/ 
 
75  Two perfect internal control genes would exhibit an identical gene expression ratio in all samples of a sample set 
independent from any experimental influence (with the assumption that both genes are not co-regulated). 
However, if the expression of one gene or of both these genes was influenced by experimental conditions, 
increased variations in their relative expression ratios would correspond to decreased expression stability 
(Vandesompele J et al., 2002). 
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Figure 16:  Reference genes Cypa, Rplp0, Actb, and Hprt1 are stably expressed in synchronized cells. 
Average expression instability values M of possible reference genes (Actb, B2m, Cypa, 
Gapdh, Hprt1, Rnase P, Rplp0, Tfr) were determined calculating pairwise variations among 
reference genes using the GeNorm applet for Microsoft® Excel®. The sample set included 
cDNA samples from different SCLC and NSCLC cell lines synchronized at gap 1(G1)-DNA 
synthesis (S) phase transition or gap 2 (G2)/mitosis (M) phase of the cell cycle which were 
collected at different time points (0 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 36 h, or 48 h) after 
release from the cell cycle arrest.   
 
 
 
 
Figure 17:  Reference genes Hprt1, Tfr, Cypa, and Rplp0 are stably expressed in untreated or siRNA-
transfected cells. Average expression instability values M of possible reference genes (Actb, 
B2m, Cypa, Gapdh, Hprt1, Rnase P, Rplp0, Tfr) were determined calculating pairwise 
variations among reference genes using the GeNorm applet for Microsoft® Excel®. The 
sample set included cDNA samples from different SCLC and NSCLC cell lines which had 
been treated with different Gpr19 and polo-like kinase 1 (Plk1) siRNAs at various 
concentrations (up to 60 nM) collected on days 2 and 3 after transfection .   
 
For different sample sets such as different cell lines, different siRNAs, different siRNA 
concentrations, or different synchronization conditions, the results for stable 
expression of possible reference genes discussed here varied slightly. However, all 
sample sets tested identified Gapdh, Rnase P, or B2m as unstable reference genes. 
They were therefore not used in RT-qPCR analyses. In contrast, Actb, Cypa, Hprt1, 
Rplp0, and Tfr were predominantly among the stably expressed reference genes. This 
was particularly true for sample sets that exclusively contained samples of the SCLC 
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cell line DMS 53 or the NSCLC cell line NCI-H1703 – the two major cell lines used for 
subsequent experimental studies. 
Stable expression of reference genes is not the only criterion when choosing the 
genes for normalization of the genes of interest. Similar assay efficiencies and low 
differences in quantification cycles (Cq) between reference genes and genes of 
interest are also crucial to obtain robust expression data. A low difference in Cq 
values is equal to an expression of these genes at comparable levels. Generally 
speaking, Rplp0, Hprt1, and Tfr were found to be rather ‘late’ (non-abundantly 
expressed) reference genes in the samples tested, whereas Cypa and Actb were 
detected rather ‘early’. Therefore, the final utilization of reference genes also 
considered a mix of genes from both these types. The dynamic range and the PCR 
efficiency of a TaqMan® assay had been determined for both reference gene and 
gene of interest assays by an input sample dilution series prior to any experimental 
application of these assays. These assay characteristics also influenced the final 
selection of reference genes, as both parameters should be similar for reference 
gene and gene of interest assays. 
For reasons described above, both reference genes Cypa and Hprt1 were used for 
knockdown confirmations in subsequent Gpr19 siRNA experiments. Actb, Cypa, 
Hprt1, and Rplp0 were used when gene of interest expression over the course of the 
cell cycle and Gpr19 expression in human NSCLC, SCLC, and normal lung RNA 
samples were examined. Here, slight changes in gene expression are of greater 
importance than for the confirmation of a messenger ribonucleic acid (mRNA) 
knockdown – the reason why four reference genes were selected. This is in 
accordance with the suggestion by Vandesompele and coworkers: At least three 
reference genes should be used for RT-qPCR data normalization which are ideally 
not co-regulated, i.e., whose gene products are involved in different cellular 
processes (Vandesompele J et al., 2002).  
 
 
2.2.  Selection of Gpr19-targeting siRNAs 
 
RNA interference76 has become a popular technique for the induction of gene 
silencing (loss-of-function phenotype) since its discovery in Caenorhabditis elegans 
by Fire and coworkers (Fire A et al., 1998). However, up-front crucial validation of 
different siRNAs destined to knock down a specific gene is imperative.  
                                                
76  The block of gene expression at the messenger ribonucleic acid (mRNA) level using sequence-specific double-
stranded RNA molecules such as short interfering ribonucleic acids (siRNAs) is referred to as RNA interference. 
Transfected double-stranded RNA oligonucleotides are first cleaved into fragments of 21 to 23 nucleotides in 
length (with 3’ overhangs of two nucleotides) by a ribonuclease III enzyme called Dicer or – in case they are 
already at the appropriate size – directly incorporated into a large cytoplasmic enzyme complex named the 
RNA-induced silencing complex (RISC). A small double-stranded RNA binding protein called R2D2 assists Dicer in 
the assembling of siRNA with RISC and both proteins are replaced by an Argonaute protein in the mature RISC 
that then includes only one siRNA strand. Complementary base-pairing guides the mature RISC to target mRNAs 
where cleavage is mediated by the Argonaute component of RISC with cleaved mRNAs being degraded by 
cytoplasmic exo- and endonucleases. A perfect complementarity between an siRNA and its target mRNA is 
required for mRNA cleavage whereas imperfect base-pairing only results in the repression of translation. The gene 
silencing effect induced by transfection of synthetic siRNAs is only transient with mRNA knockdown typically 
lasting for a couple of days (Downward J, 2004; Hammond SM, 2005; Sontheimer EJ, 2005; Sontheimer EJ and 
Carthew RW, 2005; Tomari Y and Zamore PD, 2005; Liu Q and Paroo Z, 2010). 
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Multiple siRNAs directed against Gpr19 were purchased from Dharmacon (Thermo 
Fisher Scientific; Dh3) and Sigma Aldrich (Sig2, Sig3, Sig4, Sig5). They were assayed for 
their ability to knock down Gpr19 on the mRNA level using RT-qPCR (relative to the 
reference genes Cypa and Hprt1) and for their effect on proliferation as determined 
by CloneSelect™ Imager well confluence measurement. NCI-H1703 cells (NSCLC) 
were siRNA-transfected using Lipofectamine® RNAiMAX (96 well culture plate; 
reverse transfection; 3,000 cells per well; 20 nM final siRNA concentration). Tested 
samples also included untreated, mock (transfection reagent only)-, and non-target 
siRNA-transfected cells. Gpr19 mRNA levels were assessed on day 2 after transfection 
and confluence was recorded for six days at regular intervals starting 10 h after 
transfection. NCI-H1703 cells endogenously express Gpr19 mRNA at a high level, 
which is specified later (figure 31). 
Gpr19-targeting siRNAs Dh3, Sig2, Sig3, Sig4, and Sig5 were complementary to the 
Gpr19 mRNA sequence (perfect matching). Yet, only siRNAs Dh3, Sig4, and Sig5 but 
neither Sig2 nor Sig3 reduced the mRNA level of Gpr19 (figure 18). Importantly, those 
siRNAs knocking down Gpr19 also caused growth inhibition of transfected cells as 
their gain in well confluence over time was only modest (Dh3) or not existing (Sig4, 
Sig5; figure 19). Cells transfected with Gpr19 siRNAs Sig2 and Sig3 that did not cause 
Gpr19 downregulation revealed a similar proliferative capacity as untreated, mock-, 
and non-target siRNA-treated controls.   
 
 
 
Figure 18:  Gpr19-targeting siRNAs Dh3, Sig4, and Sig5 cause efficient knockdown of Gpr19 mRNA. For 
each sample (triplicates), Gpr19 mRNA knockdown in NCI-H1703 cells was assessed by RT-
qPCR on day 2 after siRNA transfection (normalized against reference genes Cypa and 
Hprt1) and geometric mean values were calculated (untreated or mock (transfection 
reagent only)-transfected cells; cells treated with non-target siRNA or Gpr19-targeting siRNAs 
Dh3, Sig2, Sig3, Sig4, Sig5; 20 nM). Shown are the results from a representative experiment, 
two additional experiments gave concurrent results. 
 
Those siRNAs that have proven their efficiency in silencing a target gene might 
nevertheless exhibit diverging phenotypic effects on the molecular or cellular level, 
which might be explained by so-called off-target effects not related to the 
knockdown of the target gene (Collinet C et al., 2010). Using methods of 
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multiparametric data integration, this issue was addressed for Gpr19-targeting siRNAs 
Dh3, Sig4, and Sig5 that successfully silenced Gpr19 and inhibited cell proliferation.     
NCI-H1703 cells were siRNA-transfected as described above and multiple parameters 
linked to the cytoskeleton of a cell derived from actin and tubulin staining (specified 
in the Methods section) were recorded on day 3 after transfection (high content 
screen (HCS) with the ArrayScan® VTI HCS reader). For characterization of the 
applied siRNAs, a principal component analysis (PCA) was performed reducing the 
dimensionality of the data to three variables (principal components; figure 20).  
 
 
 
Figure 19:  Cell proliferation (confluence) is inhibited by those siRNAs that cause Gpr19 mRNA 
knockdown. Cell proliferation was determined by measuring confluence, i.e., % of total well 
area covered by cells. Shown is the time course after siRNA transfection (20 nM); data are 
mean values + standard deviation (error bars) of three wells per condition (96 well plate) 
from a representative experiment for untreated, mock (transfection reagent only)-, non-
target siRNA-, and Gpr19-targeting (Dh3, Sig2, Sig3, Sig4, Sig5) siRNA-treated NCI-H1703 cells. 
Only siRNAs Dh3, Sig4, and Sig5 knocked down Gpr19 message successfully (figure 18). Two 
additional experiments gave concurrent results. 
 
Control cells (untreated, mock-treated) and cells treated with siRNAs that did not 
reduce Gpr19 mRNA levels (non-target, Sig2, Sig3) showed similar actin and tubulin 
cytoskeleton characteristics as indicated by the close proximity of their principal 
components. However, the transfection of cells with Sig3 siRNA seemed to influence 
the cytoskeleton of these cells in a different way – this data point was most distant 
from the other controls. Therefore, potential off-target effects were considered 
negligible only for the non-target and Sig2 siRNAs.  
The principal components for cells transfected with Gpr19-silencing siRNAs Dh3, Sig4, 
and Sig5, however, differed considerably from all controls not affecting Gpr19 mRNA 
levels. Most notably, data points accounting for these three siRNAs were not only far 
from the control data points but also from each other. This indicates that they might 
mediate heterogeneous effects on the cytoskeleton.  
In order to characterize these ambiguous consequences of Gpr19-targeting siRNAs 
Dh3, Sig4, and Sig5, their cellular effects were further examined in a second 
multiparameter study, for which siRNAs were applied at different concentrations and 
cells were harvested at different time points after transfection. NCI-H1703 cells were 
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transfected with 2 nM, 8 nM, 20 nM, or 60 nM of respective siRNAs and analyzed on 
days 1, 2, 3, and 4 after transfection by HCS. Multiple parameters derived from 
nuclear (deoxyribonucleic acid (DNA), Hoechst 33342) and cytoskeleton (actin) 
staining (specified in the Methods section) were recorded and subjected to 
multidimensional scaling (MDS) which reduced the dimensionality of the data to 
three variables (figure 21).   
 
 
 
Figure 20:  Gpr19 silencing siRNAs differ in their effect on the cytoskeleton from controls that do not 
affect Gpr19 mRNA levels. A principal component analysis (PCA) incorporating parameters 
from actin and tubulin stainings (high content screening) is shown for untreated, mock 
(transfection reagent only)-, non-target siRNA-, and Gpr19-targeting (Dh3, Sig2, Sig3, Sig4, 
Sig5) siRNA-treated NCI-H1703 cells (20 nM siRNA concentration, day 3 after transfection). 
The dimensionality of the data was reduced to three principal components (PCA 1, PCA 2, 
PCA 3) Only siRNAs Dh3, Sig4, and Sig5 knocked down Gpr19 message successfully 
(figure 18). 
 
MDS revealed similar influences on cellular parameters (nucleus, actin cytoskeleton) 
for siRNAs Sig4 and Sig5 in contrast to siRNA Dh3. Data points of Sig4 and Sig5 moved 
into opposite directions with time relative to the data points of Dh3 for all siRNA 
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concentrations examined. This discrimination was most obvious on days 3 and 4 after 
transfection.   
 
The characterization of siRNAs directed against Gpr19 led to the selection of the 
following oligonucleotides, which were used in subsequent RNA interference 
experiments: For downregulation of Gpr19 mRNA, oligonucleotides Sig4 and Sig5 
were applied (they were termed GPR19 #1 and GPR19 #2, respectively). The pool of 
non-target siRNAs (termed CTL #1) served as transfection control sample. 
Oligonucleotide Sig2, which had been designed against Gpr19 but did not cause 
Gpr19 mRNA downregulation and behaved similarly to untreated, mock-, and non-
target siRNA- treated samples in the PCA, was included as an additional control 
(CTL #2). 
 
 
   
Figure 21:  Sig4 and Sig5 siRNAs affect cellular parameters differently than Dh3. The results from 
multidimensional scaling (MDS) incorporating cellular parameters from nuclear and actin 
stainings (high content screening) are shown for NCI-H1703 cells transfected with Gpr19-
targeting siRNAs Dh3 (red), Sig4 (blue), and Sig5 (yellow). siRNAs were applied at different 
concentrations (2 nM, 8 nM, 20 nM, 60 nM) and cells were analyzed on days 1, 2, 3, and 4 
after transfection (indicated by the size of the cubes). The dimensionality of the data was 
reduced to three parameters (mds_1, mds_2, mds_3). 
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2.3.  GPR19 antiserum validation 
 
A prerequisite for the quantification of the GPR19 protein in Western Blot applications 
is its detection by a specific antiserum. In order to obtain GPR19-specific antisera, 
rabbits were immunized with GPR19-derived peptides as specified in the Materials 
and Methods sections. The Protean application of the Lasergene software was used 
for topological feature prediction of the GPR19 protein based on its primary 
sequence and assisted in the selection of peptides used for immunization (figure 22, 
table 11). Secondary structures ((amphipathic77) alpha-helices, (amphipathic) beta-
sheets, turn and coil regions) were identified using various algorithms according to 
Chou and Fasman (Chou PY and Fasman GD, 1978), Garnier and Robson (Garnier J 
et al., 1978), or Eisenberg (Eisenberg D et al., 1982). Besides, a Kyte-Doolittle 
hydrophobicity plot was utilized which aims at separating clusters of highly charged 
amino acids (mostly exposed to an aqueous environment) from strongly 
hydrophobic clusters (mostly found in transmembrane regions or in the interior of a 
protein; Kyte J and Doolittle RF, 1982). In fact, most regions with a positive 
hydrophobicity index were also called potential transmembrane regions by UniProt 
(see figure 6). According to Karplus and Schultz, flexible regions are more easily 
accessible as they are less likely found in the protein core and can be identified by 
local entropic energy potentials (Karplus PA and Schulz GE, 1985). Likewise, the 
surface probability of a protein region can be indicated by calculating the solvent 
accessibility of amino acid side chains (Emini EA et al., 1985). The algorithm 
underlying the calculation of an antigenic index integrates many of these 
parameters originating from physicochemical properties of amino acids such as 
flexibility, hydropathy, and surface/solvent accessibility (Jameson BA and Wolf H, 
1988). 
On the basis of this primary structure analysis, GPR19 peptides used for immunization 
of rabbits were chosen to lie near the amino- or carboxy-terminus, in the predicted 
intracellular loop regions 2 or 3, or in the predicted extracellular loop region 3 
(table 11). These regions are characterized by high antigenicity and low 
hydrophobicity. Regions with high hydrophobicity (equal to transmembrane regions), 
however, were excluded from peptide selection.  
The rabbit sera of the final bleeding were investigated for GPR19 detection on 
Western Blots after they had been affinity-purified using the peptides administered for 
immunization. Protein lysates from SCLC-derived cell lines DMS 53, NCI-H446, and SHP-
77 were tested. Detection was either performed with unblocked purified serum, 
serum blocked with the GPR19 peptide used for purification, or serum blocked with 
an unspecific non-GPR19 peptide. As a representative example, the Western Blot 
signals resulting from the antiserum of animal #1 purified with one of the peptides 
used for immunization (AQLWHPHEQDYKKSSLVC) are shown in figure 23. All signals 
(bands) that were at an appropriate size (according to UniProt, the predicted 
molecular weight of GPR19 is 47.7 kilodaltons (kDa)) disappeared when the 
antiserum had been blocked with the GPR19 peptide. This was not the case when 
                                                
77  Amphipathic secondary protein structures project mainly hydrophilic residues on one surface and hydrophobic 
side chains on the opposite surface.  
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the antiserum had been blocked unspecifically. Therefore, the purified antiserum 
might be utilized to detect the GPR19-containing peptide used for animal 
immunization on Western Blots.  
 
 
 
Figure 22:  The GPR19 primary sequence (415 amino acids) shows regions with high antigenicity. Several 
algorithms (Garnier-Robson; Chou-Fasman; Eisenberg; Karplus-Schulz) as part of the Protean 
application (Lasergene, DNASTAR) were used to identify secondary structures such as 
(amphipathic) alpha-helices, (amphipathic) beta-sheets, turn or coil regions based on the 
amino acid sequence of GPR19. Additionally, the hydrophobicity (Kyte-Doolittle), antigenic 
index (Jameson-Wolf), and surface probability (Emini) of different GPR19 regions was 
predicted. High hydrophobicity indicated the presence of transmembrane regions (dotted 
lines separate the amino (N)-terminus, transmembrane (TM), intracellular loop (IL), and 
extracellular loop (EL) regions, and the carboxy (C)-terminus according to UniProt).  
 
The specificity for GPR19 detection was assessed using lysates from human 
embryonic kidney (HEK)-293 cells that transiently overexpressed GPR19 (untagged or 
tagged with turbo green fluorescent protein (tGFP)). As specified later, untreated 
HEK-293 cells do virtually not express Gpr19 mRNA (see figure 31). Signals were 
compared to the ones derived from cells that had been transfected with the empty 
vector backbone therefore only expressing tGFP. Transfected plasmids had been 
verified by sequencing. Various commercially available GPR19 antibodies offered for 
immunoblot and immunohistochemistry applications (table 9 in the Materials section) 
and purified GPR19 antisera from rabbit immunizations were tested for specific 
GPR19 detection on Western Blots (figure 24). Results for the GPR19 antiserum derived 
from animal #1, which had been purified with either of the two peptides used for 
immunization, are shown as a representative example.  
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Figure 23:  Purified GPR19 antiserum detects the GPR19 peptide used for immunization. For Western 
Blotting, protein lysates (30 µg) from three lung cancer-derived cell lines (DMS 53, SHP-77, 
NCI-H446) were loaded onto lanes of a Criterion™ XT gel (18 well, 10% Bis-Tris, XT MOPS 
running buffer) and separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE). Primary antibody solutions were applied using either unblocked 
purified antiserum of animal #1, antiserum blocked with the GPR19 peptide used for 
purification (AQLWHPHEQDYKKSSLVC), or antiserum blocked with an unspecific non-GPR19 
peptide (TAAGGPDTGEWGPPAAX, part of G protein-coupled receptor 6 (GPR6; irrelevant 
block) at an overall serum dilution of 1:1,500. High performance liquid chromatography 
(HPLC)-purified and lyophilized peptides were dissolved in dimethyl sulphoxide (DMSO) and 
incubated at 600 rounds per minute (rpm) for 1 h with the purified antiserum at a molar ratio 
of 1:10 (antiserum:peptide) assuming an average antibody weight of 150 kDa78 (Chari RV, 
2008). The predicted molecular weight of GPR19 is 47.7 kDa; the size marker is shown in kDa.  
 
Except for GPR19 antibodies purchased from Abcam (ab75558) and Sigma Aldrich 
(SAB4501254), no differences in band signals were observed for any tested GPR19 
antibody, regardless of whether lysates were obtained from GPR19, GPR19-tGFP, or 
tGFP-only overexpressing cells. This was also true for purified antisera which 
specifically detected GPR19 peptides in former blocking experiments. However, in 
lysates obtained from GPR19-tGFP overexpressing cells, ab75558 and SAB4501254 
revealed signals that were not recovered in the tGFP-only control (mostly above 
120 kDa). In addition, this high molecular weight pattern was recorded when an 
antibody directed against tGFP was applied for protein detection (figure 24A, lower 
row, seventh blot). Signals in the range of 120 to 250 kDa, that were absent in the 
control, were also observed in the lysates from GPR19 (true clone) overexpressing 
cells. But none of these signals could be attributed neither to a single GPR19 (the 
predicted molecular weight of GPR19 is 47.7 kDa) nor to a single GPR19-tGFP 
molecule (the predicted molecular weight of tGFP is 26 kDa; the fusion 
 
                                                
78   1 Da = 1 g/mol. 
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Figure 24:  Most GPR19 signals from protein overexpression lysates are unspecific. (A) For Western 
Blotting, protein lysates (10 µg) from HEK-293 cells transiently transfected with plasmids either 
encoding GPR19 (true clone), GPR19-tGFP (turbo green fluorescent protein), or tGFP-only 
(pCMV6-AC-GFP) harvested on day 2 after transfection were loaded onto lanes of a 
Criterion™ XT gel (18 well, 4-12% Bis-Tris, XT MOPS running buffer) and separated by SDS-
PAGE. Primary antibody solutions containing commercially available GPR19, tGFP, or 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies (listed are manufacturers 
and product number) or purified GPR19 antisera (shown are antisera derived from animal #1 
(continued on next page) 
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after purification with either peptide AQLWHPHEQDYKKSSLVC (1) or 
KPTLYSIYNANFRRGMKETFC (2)) were used for protein detection (dilutions of antibodies are 
indicated in table 9 in the Materials section, purified GPR19 antisera were applied at a 
dilution of 1:500). The predicted molecular weight of GPR19 is 47.7 kDa, 26 kDa for tGFP, and 
36 kDa for GAPDH (monomer; detection expected at 40 kDa according to the antibody 
manufacturer); the size marker is shown in kDa. (B) The transfection efficiency for GPR19-tGFP 
in comparison to GPR19 (true clone) was assessed on day 2 after transfection using flow 
cytometry (dot plot for tGFP (fluorescence channel 1 (FL1)-height (H)) and propidium iodide 
(fluorescence channel 2 (FL2)-H) signals, the data point density is reflected by different 
colors ranging from blue (low density, single data points) to red (high data point density); 
figures refer to the relative number of cells in the upper left quadrant (tGFP positive, 
propidium iodide negative)).  
 
protein is therefore expected to have a molecular weight of 73.7 kDa). The loading 
of equal protein amounts was confirmed by GAPDH detection (comparable signal 
intensities for all conditions; figure 24A, lower row, last blot). Successful HEK-293 
transfection was verified by flow cytometry (figure 24B) revealing 44% of successfully 
transfected and alive cells. 
 
The GPR19 antibodies from Abcam (ab75558) and Sigma Aldrich (SAB4501254) were 
further evaluated for the detection of endogenous GPR19 in NCI-H1703 cells 
(Western Blot). This cell line was found to strongly express Gpr19 mRNA as depicted 
later (figure 31). Further, Next Generation Sequencing identified no mutation in the 
gene encoding GPR19 in NCI-H1703 cells (proprietary Boehringer Ingelheim Next 
Generation Sequencing cell line genomic database; data not shown). In addition, 
Gpr19 mRNA had been knocked down using Gpr19-targeting siRNAs. Endogenous 
GPR19 levels were examined in control siRNA-treated samples. Both antibodies 
showed a band pattern that – according to the predicted molecular weight of 
GPR19 of 47.7 kDa – might contain single bands reflecting the detection of GPR19 in 
control siRNA-treated samples (figure 25A). However, these antibodies failed to 
detect GPR19 protein knockdown mediated by siRNAs that successfully diminished 
the Gpr19 message as verified by RT-qPCR (figure 25B): None of the detected signals 
showed a declined intensity. The loading of equal protein amounts was confirmed 
by GAPDH detection (comparable signal intensities for all conditions).  
 
Taken together, validation experiments of various commercially available antibodies 
against GPR19 were unable to detect GPR19 on Western Blots reliably. In addition, 
rabbit antisera raised against nine different GPR19 peptides located in the amino- or 
carboxy-terminus, predicted intracellular loop regions 2 or 3, or the predicted 
extracellular loop region 3 did not allow specific detection on Western Blots, either. 
Due to the lack of an antibody detecting GPR19 protein, effective knockdown of 
Gpr19 mRNA by Gpr19-targeting siRNAs was assessed by RT-qPCR in subsequent 
experiments.  
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Figure 25:  GPR19 antibodies do not detect GPR19 knockdown in NCI-H1703 cells. (A) For Western 
Blotting, protein lysates (10 µg) from NCI-H1703 cells transfected with control (CTL #1) or 
GPR19 siRNAs #1 or #2 harvested on day 3 after transfection were loaded onto lanes of a 
Criterion™ XT gel (18 well, 4-12% Bis-Tris, XT MOPS running buffer) and separated by SDS-
PAGE. Primary antibody solution containing GPR19 or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibodies (listed are manufacturers and product number) were 
used for protein detection (dilutions of antibodies are indicated in table 9 in the Materials 
section). The predicted molecular weight of GPR19 is 47.7 kDa and 36 kDa for GAPDH 
(monomer; detection expected at 40 kDa according to the antibody manufacturer); the 
size marker is shown in kDa. (B) For each sample (triplicates), Gpr19 mRNA knockdown was 
assessed by RT-qPCR on day 2 after siRNA transfection (normalized against reference genes 
Cypa and Hprt1) and geometric mean values were calculated relative to an untreated 
control sample (not included in the graph). 
 
 
3. Gpr19 gene expression  
 
3.1.  Gpr19 mRNA levels are high in SCLC patient samples 
 
Many GPCRs control signaling pathways that regulate cell growth, proliferation, and 
differentiation. It has long been known that tumor cells may express GPCRs in an 
aberrant or illegitimate fashion (Schorr I and Ney RL, 1971). In an unbiased approach, 
gene expression levels of genes encoding proteins with GPCR activity (GPCRs and 
GPCR-associated proteins) defined by the Gene Ontology (GO) number 0004930 
were investigated in a series of human SCLC, NSCLC, and normal lung RNA samples. 
Patient samples were obtained from OriGene Technologies and sample details are 
listed in table 12 in the Methods section. They were analyzed by Affymetrix 
microarray analysis (Human Exon 1.0 ST Array). This survey also included the large 
GPCR subfamily of odorant receptors, because these may be expressed in tissues 
other than the olfactory epithelium and may have other functions than detecting 
odors (Spehr M and Munger SD, 2009); in fact, they can occur in neoplasms such as 
prostate cancers (Neuhaus EM et al., 2009).  
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Hierarchical clustering identified Gpr19 among the mRNAs which encode proteins 
with GPCR activity showing a message overexpression mostly in SCLC but not in 
NSCLC samples relative to normal controls (figure 26). This cluster further included 
orphan GPCRs (G protein-coupled receptors 158 (GPR158) and 173 (GPR173)), 
metabotropic glutamate receptor family members 2 and 8 (GRM2, GRM8), the 
dopamine receptor D2 (DRD2), and a member of the taste receptor family involved 
in the perception of bitterness (taste receptor type 2 member 31 (TAS2R31)). In 
addition, non-classical GPCRs called by GO number 0004930 were also found in this 
cluster, e.g., the cadherin superfamily-assigned cadherin, epidermal growth factor 
(EGF)  laminin A G-type seven-pass receptor 3 (CELSR3)79 which could be involved in 
contact-mediated cellular communication. Apart from the above mentioned 
cluster, various other clusters existed in which mRNAs encoding proteins with GPCR 
activity were for example downregulated in both SCLC and NSCLC samples (green 
coloring, found in the lower part of the full heat map of figure 26, left panel). 
 
High Gpr19 mRNA levels in SCLC samples were verified by a direct comparison with 
those seen in samples from NSCLC and normal lung (figure 27, left panels). The same 
result was obtained through RT-qPCR analysis (figure 27, right panels). Almost all 
individuals of the SCLC sample set showed high Gpr19 expression relative to the 
NSCLC or normal lung controls. 
 
 
3.2.  Gpr19 is overexpressed in SCLC and pancreas islet cell carcinoma 
 
The BioExpress® database (Gene Logic) was utilized for examination of Gpr19 
expression in various human normal and cancerous tissues. Two different Affymetrix 
array platforms (Human Genome U133A and Human Genome U133B array sets 
(figure 28); Human Genome U133 plus 2.0 array (figure 29)) were available. 
Expression studies on both platforms revealed high Gpr19 mRNA expression 
predominantly in the central nervous system (CNS; cerebral cortex, cerebellum, 
spinal cord). The CNS had been described before as the primary site of Gpr19 
expression (O’Dowd BF et al., 1996; Vassilatis DK et al., 2003; Hoffmeister-Ullerich SA et 
al., 2004). In addition, Gpr19 mRNA levels were prominent in samples from SCLC and 
pancreas islet cell carcinoma. Both these carcinoma types are mainly characterized 
by a neuroendocrine phenotype and the presence of neuroendocrine markers 
(Wiedenmann B et al., 1986; Nakakura EK and Bergsland EK, 2007; Modlin IM et al., 
2010). 
 
                                                
79  CELSR3 (NCBI gene ID 1951; UniProt protein ID Q9NYQ7) is a member of the flamingo subfamily of the cadherin 
protein superfamily which is composed of non-classical-type cadherins. Its ectodomain contains nine cadherin 
domains (C), seven epidermal growth factor (EGF)-like repeats (E) and two laminin A G-type repeats (L). In 
addition, it harbors  seven transmembrane domains (S) and is the third receptor assigned to this subfamily (R3; 
www.ncbi.nlm.nih.gov/gene/1951; www.uniprot.org/uniprot/Q9NYQ7). 
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Figure 27:  Gpr19 is overexpressed in samples from SCLC patients. The results for Gpr19 gene expression 
from Affymetrix GeneChip® analysis (Human Exon 1.0 ST Array; probe set NM_006143_at) 
and RT-qPCR analysis of human NSCLC, SCLC, and normal lung samples are shown per 
histological group. Expression data are either combined for all cases per group (upper 
panels; box (interquartile range; middle 50% of all expression values) and whiskers (minimum-
maximum) plot with median (central bar)) or are shown for each individual sample (lower 
panels). RT-qPCR was performed for Gpr19 normalized against reference genes Actb, Cypa, 
Hprt1, and Rplp0 and geometric mean values were calculated. This analysis did not include 
all 14 normal lung samples due to sample limitations. Statistically significant differences were 
determined by a Kruskal-Wallis test followed by Dunn’s multiple comparison (**p < 0.01; 
***p < 0.001).  
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Figure 28:  Gpr19 expression is high in SCLC and pancreas islet cell carcinoma and in the central 
nervous system (CNS; part 1). Gpr19 gene expression was determined by Affymetrix 
GeneChip® analysis (Human Genome U133A and Human Genome U133B array sets; probe 
set 207183_at) in human tissues (green = normal; red = cancer; yellow = metastasis). 
Expression data are represented as box (interquartile range; middle 50% of all expression 
values) and whiskers (extend to 1.5 times the interquartile range) plots with median (central 
bar) and outliers (open circles; expression values above and below the whisker limits). 
Sample numbers are indicated in brackets. Data were extracted from the BioExpress® 
database (Gene Logic). 
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Figure 29:  Gpr19 expression is high in SCLC and pancreas islet cell carcinoma and in the central 
nervous system (CNS; part 2). Gpr19 gene expression was determined by Affymetrix 
GeneChip® analysis (Human Genome U133 plus 2.0 array; probe set 207183_at) in human 
tissues (green = normal; red = cancer; yellow = metastasis). Data were extracted from the 
BioExpress® database (Gene Logic) and visualization was done as described in the legend 
of figure 28. 
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3.3.  Gpr19 mRNA expression is high in SCLC cell lines 
 
In order to quantify Gpr19 expression in lung-derived cell lines, the proprietary 
Boehringer Ingelheim cell line gene expression database was utilized. It contains 
expression data generated with Affymetrix GeneChip® technology (Human Exon 1.0 
ST array) and data for 21 human SCLC and 45 human NSCLC cell lines were 
extracted (figure 30). Furthermore, Gpr19 expression levels were measured by RT-
qPCR in a partially overlapping set of NSCLC (3), SCLC (7), and normal lung (5)-
derived cell lines and in HEK-293 cells (figure 31). Equal numbers of cells had been 
applied for RNA preparation.  
 
 
 
Figure 30:  Gpr19 expression in SCLC cell lines is higher than in NSCLC cell lines (microarray). Gpr19 
gene expression was determined by Affymetrix GeneChip® analysis (Human Exon 1.0 ST 
Array; probe set NM_006142_at) in various human SCLC and NSCLC cell lines. Expression 
data are either combined for all cases per histological group (upper left panel; box 
(interquartile range; middle 50% of all expression values) and whiskers (10 to 90 percentile) 
plot with median (central bar) and outliers (filled circles; expression values above and below 
the whisker limits) or are shown for each individual cell line (SCLC cell lines – upper right 
panel; NSCLC cell lines – lower panel). Statistically significant differences were determined 
by a t test with Welch’s correction (**p < 0.01). These data are part of a proprietary 
Boehringer Ingelheim gene expression database. 
 
In both methods, the expression pattern of Gpr19 described in the analysis of SCLC-, 
NSCLC-, and normal lung-derived samples was recapitulated, i.e., cell lines 
originating from SCLC (such as NCI-H187, NCI-H378, or NCI-H446) had higher Gpr19 
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expression levels than those derived from NSCLC (and from normal lung). However, 
high levels of Gpr19 mRNA were also seen in some NSCLC cell lines (e.g., Calu-1, 
HCC-827, NCI-H1623, NCI-H1703, or NCI-H661) and an immortalized lung epithelial 
cell line derived from a cystic fibrosis patient (IB3-1). Gpr19 expression was absent in 
HEK-293 cells. 
 
 
 
Figure 31:  Gpr19 expression is high in many SCLC cell lines (RT-qPCR). Gpr19 gene expression was 
determined by RT-qPCR in various human NSCLC-, SCLC-, and normal lung-derived cell lines 
and in HEK-293 (cell line features are specified in table 10 in the Materials section). Expression 
values were normalized against reference genes Actb, Cypa, Hprt1, and Rplp0 and 
geometric mean values were calculated. 
 
One reason for increased gene expression could be a genomic amplification of the 
respective chromosomal area. Various SCLC and NSCLC cell lines were investigated 
for their copy number status of Gpr19 (figure 32). These data are part of a proprietary 
Boehringer Ingelheim cell line database and were collected from the analysis of 
Affymetrix single nucleotide polymorphism (SNP) arrays. They do therefore not cover 
all cell lines examined for Gpr19 gene expression (figure 30 and figure 31). Schematic 
representations of chromosome 12 for some cell lines investigated showing areas of 
genomic amplification or deletion are displayed in figure 33. A normal sample should 
harbor two copies per genomic region (except for sexual chromosomes X and Y in 
males). Cancer cells might have lost (copy number 0 or 1) or gained (copy number 
greater than 3) genomic DNA regions. Complexity is further increased as cancer cells 
are often not diploid (Hupé P et al., 2004). 
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Figure 32:  Gpr19 copy numbers can vary in NSCLC and SCLC cell lines. Copy numbers for Gpr19 in 
various SCLC and NSCLC cell lines are based on single nucleotide polymorphism (SNP) data 
from Affymetrix GeneChip® Human Mapping 250K Nsp arrays. These data are part of a 
proprietary Boehringer Ingelheim cell line database and cell line DNA copy numbers had 
been analyzed using the gain and loss analysis of DNA (GLAD) algorithm (Hupé P et al., 
2004). Called deletions (red bars) and amplifications (blue bars) are highlighted.   
 
Most lung cancer-derived cell lines showed a normal genomic copy number for 
Gpr19. However, the Gpr19 copy number in SCLC cell line DMS 53 and NSCLC cell 
line NCI-H1703 was increased (figure 32 and figure 33), whereas it was decreased in 
NSCLC cell lines NCI-H1666, NCI-H1781, and NCI-H1993. This genomic amplification of 
the Gpr19 locus in DMS 53 and NCI-H1703 cells could account for the Gpr19 
expression levels seen in these cell lines. On the other hand, Gpr19 expression in NCI-
H187 and NCI-H446 cells was very high (figure 30) but amplification of the Gpr19 
locus could not be detected (figure 32 and figure 33). Genomic amplification of 
Gpr19 might therefore contribute to Gpr19 mRNA expression in lung cancer-derived 
cell lines but could not be considered the only cause for high Gpr19 message levels. 
 
Finally, Next Generation Sequencing did not retrieve mutations in the gene encoding 
GPR19 in any lung cancer-derived cell line, which is included in the proprietary 
Boehringer Ingelheim Next Generation Sequencing cell line genomic database 
(data not shown). Among them are also NSCLC cell line NCI-H1703 and SCLC cell 
line DMS 53, the major cell lines used in subsequent studies.  
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Figure 33:  Gpr19 can be located in chromosomal areas that had undergone amplification. The 
schematic representation shows the positions of single nucleotide polymorphisms (SNPs) 
covered by the Affymetrix GeneChip® Human Mapping 250K Nsp array on chromosome 12 
for SCLC cell lines DMS 53, NCI-H187, and NCI-H446 and NSCLC cell line NCI-H1703. Filled 
circles represent a single SNP and are colored according to a normal (green) or higher than 
normal (blue) genomic copy number using the GLAD algorithm. Areas of normal or 
increased copy numbers were grouped, which is indicated by a black horizontal line. Filled 
circles in red (NCI-H187) indicate a focal deletion and crosses represent outliers. The 
chromosomal position of the Gpr19 gene is shown by a red vertical line.   
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4. GPR19 localizes to the cytoplasmic membrane 
 
As a member of the seven transmembrane (7TM)-spanning family of GPCRs, GPR19 is 
recruited to cellular membranes. This does not exclusively imply the cytoplasmic 
membrane of a cell, as GPCRs have been described to mediate signal transduction 
from intracellular compartments as well (e.g., G protein-coupled receptor 6 (GPR6; 
Padmanabhan S et al., 2009; Prasad BM et al., 2010)).  
The subcellular localization of GPR19 was investigated by transient transfection of 
lung cancer-derived NCI-H2170 (NSCLC) and DMS 53 (SCLC) cells with an expression 
plasmid encoding a tGFP-tagged variant of GPR19. Transfected plasmids had been 
verified by sequencing. Confocal microscopy pictures were recorded on the first day 
after transfection clearly indicating a distinct thin line signal for GPR19-tGFP, which 
might represent the plasma membrane (figure 34A and B, middle panels). 
Additionally, some cells revealed a strong signal coming from an area lying close to 
the nucleus – a possible hint for the endplasmic reticulum, the site for the generation 
of proteins that are later destined for sorting through the secretory pathway, for 
instance to the cytoplasmic membrane (figure 34A, middle panel). In contrast, the 
signals derived from the expression of tGFP-only (figure 34A and B, left hand panels) 
and tGFP-tagged GPR6 (figure 34A and B, right hand panels), a GPCR mostly found 
in intracellular membrane compartments, were distributed throughout the cell and 
not indicative of the cytoplasmic membrane (no thin line signal).   
 
 
 
Figure 34:  GPR19-tGFP expression indicates receptor localization to the plasma membrane. The NSCLC 
cell line NCI-H2170 (A) and the SCLC cell line DMS 53 (B) were transiently transfected with 
expression plasmids (0.2 µg per well of an 8 well chamber slide) encoding either turbo green 
fluorescent protein (tGFP)-only (pCMV6-AC-GFP; left hand panels; green), GPR19-tGFP 
(pCMV6-AC-GPR19-GFP; middle panels; green), or G protein-coupled receptor 6 (GPR6)-
tGFP (pCMV6-AC-GPR6-GFP; right hand panel; green). Cells were fixed and mounted with 
DAPI-containing mounting medium (nuclear staining; blue) on the first day after transfection. 
Fluorescent signals were recorded by confocal microscopy at 60x magnification (bar 
represents 10 µm). Experiments were repeated yielding concurrent results. 
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In order to verify the potential subcellular localization of GPR19-tGFP to the plasma 
membrane, HEK-293 cells were transiently transfected with the GPR19-tGFP 
expression plasmid and sugar derivatives (N-acetyl glucosamine; N-acetyl 
neuraminic acid) mostly found on cell surface proteins were co-stained with 
Alexa Fluor® 647-conjugated wheat germ agglutinin (WGA; Prasad BM et al., 2010) 
for confocal microscopy analysis the next day (figure 35A). Merging of both the tGFP 
(GPR19; green) and the WGA (membrane; red) signal identified a clear overlay 
(yellow). The same result was obtained when a plasmid encoding the murine 
enhanced yellow fluorescent protein (eYFP)-tagged corticotropin-releasing hormone 
receptor 1 (CRHR1), a GPCR that is known to localize to the cytoplasmic membrane 
(Aguilera G et al., 2004), had been transfected into HEK-293 cells (figure 35B). 
Therefore, the conclusion that transient overexpression of GPR19 leads to its 
localization to the cytoplasmic membrane is justified.  
 
 
 
Figure 35:  GPR19-tGFP colocalizes with WGA-stained plasma membrane proteins. HEK-293 cells were 
transiently transfected with expression plasmids (0.05 µg per well of an 8 well chamber slide) 
encoding either GPR19-tGFP (turbo green fluorescent protein; A; pCMV-AC-GPR19-GFP; 
green) or the murine CRHR1-eYFP (enhanced yellow fluorescent protein; B; pEYFP-N1-CRHR1; 
green). On the first day after transfection, cells were fixed, membrane-stained using wheat 
germ agglutinin (WGA; red), and mounted with DAPI-containing mounting medium (nuclear 
staining; blue). Fluorescent signals were recorded by confocal microscopy at 60x 
magnification (bar represents 10 µm). Merge panels combine signals from DAPI, WGA, and 
tGFP/eYFP, respectively. Experiments were repeated yielding concurrent results. 
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5. Proliferation  
 
5.1.  RNA interference-mediated knockdown of Gpr19 reduces cell 
proliferation 
 
The prominent expression of Gpr19 in SCLC and in several lung cancer-derived cell 
lines suggested that this receptor might play a crucial role in cell proliferation and/or 
survival. Accordingly, the effect of Gpr19 knockdown on proliferation in lung cancer-
derived cell lines NCI-H1703 (NSCLC) and DMS 53 (SCLC) was investigated. These cell 
lines were chosen based on their well-detectable Gpr19 mRNA expression (figure 31) 
and because they grew as monolayers. Most SCLC cell lines including COR-L88, NCI-
H209, NCI-H345, NCI-H446, and SHP-77 that express Gpr19 at high levels failed to 
grow as adherent monolayers but formed (floating) clusters. This growth behavior 
rendered them less amenable to experimental manipulations, in particular to 
transfection with siRNAs. GPR19 is an orphan receptor, its physiological ligand is not 
known and there is no antagonist. Hence, RNA interference was employed to 
examine the role of this receptor in supporting cell proliferation.  
NCI-H1703 (3,500 cells) and DMS 53 (10,000 cells) were either treated with siRNAs 
targeting Gpr19 mRNA for destruction (GPR19 #1, GPR19 #2), control siRNAs (CTL #1, 
CTL #2) or with transfection reagent only (mock) or left untreated. Additional positive 
controls included the cytotoxic anthracycline doxorubicin80 and an siRNA directed 
against Plk181 which were supposed to exhibit a dramatically reduced proliferation 
behavior (Fornari FA et al., 1994; Spänkuch-Schmitt B, Wolf G et al., 2002). The extent 
of well surface covered by adherently growing cells (confluence) was monitored to 
quantify cell proliferation. Images of wells covered by NCI-H1703 and DMS 53 cells 
were captured and analyzed at regular intervals after treatment using the 
CloneSelect™ Imager (figure 36). Well thumbnails (pictures of the well bottom and 
cellular detection by the selected detection algorithm) served as the basis for 
confluence calculation (figure 37, shown for NCI-H1703 cells). Measurements started 
                                                
80   Doxorubicin is frequently used as chemotherapeutic agent in the treatment of malignant diseases which is mainly 
based on two different modes of action. On the one hand, doxorubicin intercalates into DNA double strands 
therefore inhibiting DNA replication and gene transcription. In addition, it inhibits the enzyme topoisomerase II 
which is crucial for unwinding of supercoiled DNA structures during replication. Hence, the ligation of 
topoisomerase II-induced DNA strand breaks is prevented (Fornari FA et al., 1994). 
  
81  Polo-like kinases (PLKs) are highly conserved during evolution and play essential roles in the cell cycle. Four 
mammalian members (PLK1, PLK2, PLK3, and PLK4) have been described – all harbor an amino-terminal Ser/Thr-
kinase domain and a carboxy-terminal polo-box domain (PBD; composed of one or two polo-boxes that can 
bind phosphorylated target proteins). They are involved in centrosome and centriole biogenesis, in the regulation 
of mitosis entry and mitotic chromosomes, and the promotion of mitotic exit and cytokinesis. Their activity can be 
regulated at different levels, e.g., via transcription, phosphorylation, proteasomal degradation, or protein 
interaction (Archambault V and Glover DM, 2009).  
Human PLK1 (NCBI gene ID 5347; UniProt protein ID P53350) is found overexpressed in many cancers and is 
associated with tumorigenesis. Its expression and activity (phosphorylation at Thr210) is highest during mitosis and 
it localizes to different subcellular structures such as centrosomes (prophase), kinetochores (prometa-
/metaphase), the central spindle (anaphase), or the mid-body (telophase). It primarily regulates the transition 
from meta- to anaphase (spindle assembly checkpoint, sister chromatid separation) and mitotic exit (initiation of 
cleavage furrow ingression) by phosphorylation of various target proteins such as CDC25, cyclin B1, the 
anaphase-promoting complex/cyclosome (APC/C), or proteins involved in microtubule dynamics (Strebhardt K 
and Ullrich A, 2006; Petronczki M et al., 2008). 
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10 h after treatment and lasted until day 6 (right panels of figure 36 show results of 
three experiments at day 6). At this time point, untreated, mock-, and control siRNA-
treated cells had already reached a high extent of confluence, i.e., a plateau phase 
with more than 80% well confluence. Plk1 siRNA-transfected and doxorubicin-treated 
cells did not grow (absent gain in confluence over time). For cells transfected with 
either Gpr19-targeting siRNAs #1 or #2, the increase in well confluence was 
modest/not existing. This observation showed that cell proliferation was inhibited.  
 
 
 
Figure 36:  Cell proliferation is inhibited by Gpr19-targeting siRNAs (confluence measurement). Cell 
proliferation was determined by measuring confluence, i.e., % of total well area covered by 
cells. Shown is the time course after siRNA transfection (20 nM) or addition of doxorubicin 
(1 µM); data are mean values + standard deviation (error bars) of three wells per condition 
(96 well plate) from a representative experiment for untreated, mock (transfection reagent 
only)-, siRNA (CTL #1 and #2, Gpr19-targeting #1 and #2, Plk1-targeting)-, and doxorubicin 
(Dox)-treated NSCLC cell line NCI-H1703 and SCLC cell line DMS 53. Two additional 
experiments gave similar results. The right hand graphs illustrate the results from the last 
confluence measurement on day 6 after transfection from the three individual experiments 
(arithmetic mean values are indicated by the horizontal lines). Statistically significant 
differences across all experimental groups were determined by one way analysis of 
variance (ANOVA) followed by Tukey’s test. GPR19 #1 and GPR19 #2 p values refer to the 
least significant one from the comparison with CTL #1 and CTL #2 (**p < 0.01; ***p < 0.001). 
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The negative influence on cell proliferation of Gpr19-targeting siRNAs could be 
confirmed using a second type of proliferation assay (alamarBlue® viability testing), 
which allows a correlation between the cells’ metabolic activity and the number of 
living cells as an indication of cell proliferation. Cells had been transfected with 
siRNAs or treated with doxorubicin as described above and the metabolic activity of 
cells was determined three and six days later (figure 38). In order to minimize data 
variation, the time points of fluorescence intensity measurement after application of 
alamarBlue® on days 3 and 6 after treatment were comparable for repeated 
experiments and within the dynamic range of the assay. There was a clear-cut 
reduction in metabolically active cells transfected with siRNAs targeting Gpr19 
compared to untreated, mock-, and control siRNA-treated samples. Cells treated 
with Plk1 siRNA or doxorubicin did not grow which was indicated by low numbers of 
metabolically active cells (low fluorescence intensity). In both cell lines, the effect 
was more pronounced on day 6 than on day 3.  
 
 
 
Figure 37:  Cell proliferation is inhibited by Gpr19-targeting siRNAs indicated by confluence thumbnails. 
Confluence for NCI-H1703 cells (thumbnail visualization: Pictures of the well bottom and 
cellular detection by cell detection method 1) subjected to siRNA transfection (20 nM) or 
doxorubicin (Dox; 1 µM) treatment as described in the legend of figure 36 was determined 
on days 3 and 6 after treatment. 
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Figure 38:  Cell proliferation is inhibited by Gpr19-targeting siRNAs (alamarBlue®). Cell proliferation was 
assessed by measuring cell viability with alamarBlue® on days 3 and 6 after siRNA 
transfection (20 nM) or doxorubicin (1 µM) application for NCI-H1703 and DMS 53 cells 
treated as described in the legend of figure 36 in three independent experiments (data 
points are mean values of three wells per condition and experiment (96 well plate)); 
arithmetic mean values of results from all three experiments are indicated by the horizontal 
lines. Statistically significant differences across all experimental groups were determined by 
one way ANOVA followed by Tukey’s test. GPR19 #1 and GPR19 #2 p values refer to the 
least significant one from the comparison with CTL #1 and CTL #2 (*p < 0.05; **p < 0.01; 
***p < 0.001).  
 
In order to directly visualize the effect on proliferation, pictures of cells from all 
different experimental conditions were recorded on days 3 and 6 after treatment 
using phase contrast microscopy (figure 39). NCI-H1703 showed a similar amount of 
dead cells upon Gpr19 knockdown compared to Plk1 knockdown and doxorubicin 
treatment. This was already the case on day 3 after treatment and became also 
apparent for DMS 53 cells on day 6. In contrast, both mock-treated cells and cells 
treated with control siRNAs showed no obvious phenotypic effect relative to the 
untreated control. The effective knockdown of Gpr19 mRNA by Gpr19-targeting 
siRNAs was verified using RT-qPCR for all these experiments (figure 40). 
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Figure 39:  Cell proliferation is inhibited by Gpr19-targeting siRNAs (microscopy). Phase contrast 
microscopy pictures (20x magnification) of NCI-H1703 (A, B) and DMS 53 (C, D) cells 
subjected to siRNA transfection (20 nM) or doxorubicin (Dox; 1 µM) application as 
described in the legend of figure 36 were determined on days 3 (A, C) and 6 (B, D) after 
treatment (bar represents 100 µm). 
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Figure 40:  Gpr19 knockdown is successful upon Gpr19 siRNA treatment. Gpr19 mRNA knockdown 
was assessed by RT-qPCR on day 3 after siRNA transfection (normalized against reference 
genes Cypa and Hprt1, geometric mean of triplicates per condition; data are mean 
values + standard deviation (error bar) of three experiments) for cells treated as described 
in the legend of figure 36. 
 
 
5.2.  Poly (adenosine diphosphate (ADP)-ribose) polymerase 1 (PARP1) 
cleavage reveals apoptosis induction upon Gpr19 knockdown 
 
The knockdown of Gpr19 message inhibited cell proliferation and caused cell death 
in NCI-H1703 and DMS 53 cells. It was therefore examined whether siRNA-mediated 
Gpr19 knockdown might lead to the induction of apoptosis in these cells.  
NCI-H1703 and DMS 53 cells were either left untreated or transfected with control, 
Gpr19, or Plk1 siRNAs. Protein lysates were harvested on days 2, 3, and 4 after 
transfection and investigated for PARP1 cleavage by Western Blot (figure 41A). The 
detection of cleaved PARP1 is indicative of apoptosis induction. PARP1 (116 kDa) is 
involved in DNA repair and its cleavage at the onset of apoptosis results from the 
activation of caspases 3 and 7 producing a carboxy-terminal 89 kDa fragment 
(Soldani C and Scovassi AI, 2002). Gpr19 knockdown by siRNAs resulted in the 
cleavage of PARP1 in both NCI-H1703 and DMS 53 cells. Apoptosis induction 
became more prominent with time. Apoptosis was also induced upon Plk1 message 
downregulation. The effective knockdown of Gpr19 mRNA in both cell lines was 
confirmed by RT-qPCR (figure 41B). 
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Figure 41:  Gpr19 knockdown induces apoptosis indicated by poly (ADP-ribose) polymerase 1 (PARP1) 
cleavage. (A) Protein lysates from untreated (Untr), control (CTL #1 and #2), Gpr19 
(GPR19 #1 and #2), or Plk1 (PLK1) siRNA-transfected NCI-H1703 and DMS 53 cells were 
collected on days 2, 3, and 4 after transfection (20 nM final siRNA concentration). Proteins 
(10 µg) were separated by SDS-PAGE (Criterion™ XT gel; 26 well, 10% Bis-Tris, XT MOPS (1x) 
running buffer) and primary antibody solutions containing either glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; loading control for equal protein amounts) or 
(cleaved) PARP1 antibodies were used for protein detection (dilutions of antibodies are 
indicated in table 9 in the Materials section). (B) For each sample (triplicates), Gpr19 mRNA 
knockdown was assessed by RT-qPCR on day 2 after siRNA transfection (normalized against 
reference genes Cypa and Hprt1) and geometric mean values were calculated for NCI-
H1703 (upper panel) and DMS 53 (lower panel) cells. The experiment was repeated yielding 
concurrent results. 
 
 
5.3.  Transient GPR19 overexpression does not influence cell 
proliferation 
 
The anti-proliferative effect of Gpr19 knockdown was unequivocal. It was therefore 
examined whether transient transfection of plasmids encoding GPR19 (GPR19 (true 
clone), GPR19 (codon-optimized), GPR19-tGFP) could provide an advantage to 
proliferation in HEK-293 cells, which had been characterized by the absence of 
Gpr19 mRNA (figure 31). HEK-293 cells had been transfected in 6 well culture plates 
(3 x 105 cells per well) by forward plasmid transfection and 5,000 cells were seeded 
into wells of a poly-D-lysine-coated 96 well culture plate the next day. Non-GPR19 
encoding plasmids (empty vector; tGFP only) as well as untreated, mock 
(transfection reagent only)- and doxorubicin-treated cells were included as controls. 
Expression plasmids had been verified by sequencing.  
The proliferation of HEK-293 cells was assessed through the relative amount of well 
surface covered by these cells (confluence) which was recorded at regular intervals 
starting 24 h after transfection (8 h after seeding into wells of a 96 well culture plate). 
Measurements lasted until day 4 after transfection (figure 42A; the right hand panel 
shows the results of three experiments at the endpoint on day 4). At this time point, a 
plateau phase with more than 80% confluence had been reached by untreated 
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Figure 42:  Transient overexpression of GPR19 does not provide an advantage to proliferation (HEK-293). 
(A) Cell proliferation was determined by confluence measurement. Shown is the time course 
after plasmid transfection (forward transfection) or addition of doxorubicin (1 µM); data are 
mean values + standard deviation (error bars) of four wells per condition (96 well plate) from 
a representative experiment for untreated, mock (transfection reagent only)-, control 
plasmid (pCMV6-XL5 (empty vector), pCMV6-AC-GFP (turbo green fluorescent protein 
(tGFP)))-, GPR19 plasmid (GPR19 (true clone), GPR19 (codon-optimized), GPR19-tGFP)-, or 
doxorubicin-treated HEK-293 cells. Two additional experiments gave similar results. The right 
hand graph illustrates the results from the last confluence measurement on day 4 after 
(continued on next page) 
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transfection from the three individual experiments (arithmetic mean values are indicated by 
the horizontal lines). (B) Cell proliferation in HEK-293 cells was assessed by measuring cell 
viability with alamarBlue® on days 3 and 6 after plasmid transfection or doxorubicin 
application in three independent experiments (data points are mean values of four wells per 
condition and experiment (96 well plate)); arithmetic mean values of results from all three 
experiments are indicated by the horizontal lines. Differences across all experimental groups 
(A, right panel; B) were determined by one way ANOVA followed by Tukey’s test. 
Comparisons between GPR19 (true clone)/GPR19 (codon-optimized)/GPR19-tGFP- and 
empty vector/tGFP-transfected samples were statistically non-significant. (C) The 
transfection efficiency for GPR19-tGFP in comparison to untreated cells was assessed on day 
2 after transfection using flow cytometry (dot plot for tGFP (fluorescence channel 1 (FL1)-
height (H)) and propidium iodide (fluorescence channel 2 (FL2)-H) signals, the data point 
density is reflected by different colors ranging from blue (low density, single data points) to 
red (high data point density); figures refer to the relative number of cells in the upper left 
quadrant (tGFP positive, propidium iodide negative). 
 
and mock-treated cells whereas doxorubicin-treated cells did not grow (absent gain 
in confluence over time). The gain in confluence for all the cells that had been 
transfected with expression plasmids was less prominent than for untreated or mock-
treated cells and reached about 60% of the total well area. There were no 
differences regarding the gain in confluence between cells transiently 
overexpressing GPR19 and cells that had been transfected with control plasmids. 
Similarly, when comparing confluence levels at the last time point examined from 
three individual experiments, minor differences between the results from cells 
transfected with either GPR19 or control plasmids were statistically non-significant.    
The independence from GPR19 overexpression of HEK-293 proliferation could be 
confirmed by the alamarBlue® cell viability assay. Cells had been treated as 
described above and their metabolic activity was assessed on days 3 and 6 after 
treatment (figure 42B). Fluorescence intensity measurements were performed at 
comparable time points after alamarBlue® addition to prevent high data variation 
and measurements were within the dynamic range of the assay. 
GPR19 overexpression did not result in increased metabolic and therefore 
proliferative activity of HEK-293 cells compared to untreated, mock-, or control 
plasmid-treated cells independent from the examined time point (day 3 and day 6) 
after transfection. The effective transfection of HEK-293 cells with expression plasmids 
was verified by flow cytometry detecting the tGFP-tagged version of GPR19. This 
method revealed 44.1% of successfully transfected and alive cells (figure 42C). 
 
The results obtained from proliferation experiments in GPR19 overexpressing HEK-293 
cells were verified in alamarBlue® assays using the NSCLC cell lines NCI-H1703 
(figure 43), which was shown to express high levels of Gpr19 mRNA (figure 31). 
Expression plasmids had been introduced into NCI-H1703 cells by electroporation: 
2.5 µg of plasmid DNA had been applied to 5 x 105 cells and 4,000 cells had been 
seeded per well of a poly-D-lysine-coated 96 well culture plate.  
As was the case for HEK-293 cells, the number of metabolically active NCI-H1703 
cells did not increase upon GPR19 overexpression neither on day 3 nor on day 6 after 
treatment (figure 43A). In fact, the burden of plasmid transfection negatively 
affected cell proliferation in NCI-H1703 cells – untreated and mock-treated cells 
showed higher metabolic activity than cells transfected with any plasmid. The 
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transfection efficiency was again controlled by flow cytometry revealing 33.7% of 
successfully transfected and alive cells (figure 43B). 
 
 
 
Figure 43:  Transient overexpression of GPR19 does not provide an advantage to proliferation (NCI-
H1703). (A) Cell proliferation in NCI-H1703 cells was assessed by measuring cell viability with 
alamarBlue® on days 3 and 6 after plasmid transfection (electroporation) or doxorubicin 
(1 µM) application in three independent experiments as described in the legend of figure 42. 
Comparisons between GPR19 (true clone)/GPR19 (codon-optimized)/GPR19-tGFP (turbo 
green fluorescent protein)- and empty vector/tGFP-transfected samples were statistically 
non-significant. (B) The transfection efficiency for GPR19-tGFP in comparison to untreated 
cells was assessed on day 2 after transfection using flow cytometry as described in the 
legend of figure 42. 
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6. G protein coupling of GPR19  
 
6.1.  GPR19 does not couple to a pertussis toxin-sensitive G protein 
 
The growth inhibitory action of Gpr19-directed siRNAs can be accounted for by two 
scenarios that are not necessarily mutually exclusive: (i) When overexpressed GPR19 
might display strong constitutive activity and engage its cognate G protein(s) in the 
absence of an agonist (an activation mechanism discussed for GPCRs by Schütz and 
Freissmuth (Schütz W and Freissmuth M, 1992)). (ii) GPR19-expressing cells might also 
synthesize and release the agonist; knockdown of the mRNA encoding the receptor 
would then disrupt the resulting autocrine loop. GPR19 was described to couple to Gi 
(Bresnick JN et al., 2003). Accordingly, its activation and onset of signal transduction 
would lead to the inhibition of adenylyl cyclase and therefore to reduced levels of 
cellular cyclic adenosine monophosphate (cAMP).  
Both hypotheses described above were addressed using adenylyl cyclase assays 
which measure the amount of radioactively-labeled cAMP production upon cellular 
stimulation. HEK-293 cells seeded in 6 well culture plates (2.5 x 105 cells per well) were 
transiently transfected with expression plasmids encoding GPR19 (true clone) and/or 
the CRHR1 82 (Gs-coupled) and/or the A1-adenosine receptor (A1R83, Gi-coupled) 
and labeled with [3H]adenine the next day (figure 44). The transfection efficiency 
was controlled by visual inspection of a control well transfected with a GPR19-tGFP 
expression construct and plasmids had been verified by sequencing. Cells were 
starved and then subjected to stimulation with normal medium (Roswell Park 
Memorial Institute (RPMI) 1640 with GlutaMAX™, 10% fetal bovine serum (FBS)) or 
conditioned medium from either NCI-H1703 or NCI-H345 cells that highly express 
Gpr19 mRNA (figure 31). Conditioned media were supernatants from cultured cells 
which had been cleared from cells and cellular debris by centrifugation (250 x g, 
5 min) and stored at -80°C. Stimulation conditions selectively contained the CRHR1 
agonist corticotrophin-releasing hormone84 (CRH; 100 nM) in order to stimulate cAMP 
production in CRHR1-transfected cells. Besides, the A1R agonists CCPA85 and R-PIA86 
                                                
82  The corticotropin-releasing hormone receptor 1 (CRHR1; NCBI gene ID 1394, UniProt protein ID P34998) belongs to 
the secretin family of G protein-coupled receptors (GPCRs). It binds neuropeptides of the corticotropin-releasing 
hormone family and is mostly found in the brain (pituitary gland). Upon ligand-induced receptor activation, 
heterotrimeric G proteins (Gs) that activate adenylyl cyclase and therefore stimulate cyclic adenosine 
monophosphate (cAMP) production trigger signal transduction pathways leading to pituitary 
adrenocorticotropin hormone secretion which mainly regulates behavioral and autonomic responses to stress 
(Aguilera G et al., 2004; Pioszak AA et al., 2008; www.ncbi.nlm.nih.gov/gene/1394; www.uniprot.org/uniprot/ 
P34998). 
 
83  The A1-adenosine receptor (A1R; NCBI gene ID 134, UniProt protein ID P30542) belongs to the rhodopsin family of 
G protein-coupled receptors (GPCRs) and is ubiquitously expressed with highest levels found in various regions of 
the brain. Upon receptor activation by adenosine, heterotrimeric G proteins (Gi) are recruited leading to the 
inhibition of adenylyl cyclase and therefore the attenuation of cyclic adenosine monophosphate (cAMP) 
formation (Wojcik M et al., 2010; Wei CJ et al., 2011; www.ncbi.nlm.nih.gov/gene/134; www.uniprot.org/ 
uniprot/P30542). 
 
84  Corticotropin-releasing hormone is a neuropeptide composed of 41 amino acids with an amidated carboxy-
terminus (Pioszak AA et al., 2008). 
 
85  2-chloro-N6-cyclopentyladenosine 
 
86  (-)-N6-(2-phenylisopropyl)adenosine 
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were included to inhibit cAMP production in A1R-transfected cells. Labeling, 
starvation, and stimulation solutions could further contain pertussis toxin87 (PTX; 
100 ng/ml) in order to inhibit the activity of Gi/o. 
HEK-293 cells co-expressing CRHR1 and GPR19 did not decrease their cAMP level 
when treated with CRH and conditioned medium compared to CRH and normal 
medium (figure 44A, left and centerfold set of bars), which was independent of 
pertussis toxin. Normal medium alone resulted in barely detectable cAMP levels (with 
and without PTX). In contrast, pretreatment with pertussis toxin further augmented 
CRH-induced cAMP levels in these samples. This effect could be attributed to the 
CRHR1 as it also appeared when this receptor had been transfected into HEK-293 
cells alone (figure 44B). This phenomenon could be explained by the fact that – at 
high agonist occupancy – CRHR1 also engages Gi (Milan-Lobo L et al., 2009). 
However, A1R agonists CCPA and R-PIA elicited a prominent inhibition of CRH-
induced cAMP production in cells co-expressing CRHR1 and A1R (figure 44A, right 
hand set of bars).  
 
 
 
Figure 44:  Conditioned medium does not affect cAMP levels in Gpr19-expressing HEK-293 cells. HEK-
293 cells were transiently transfected with plasmids (0.5 µg) driving the expression of (A) 
corticotrophin-releasing hormone receptor 1 (CRHR1; pEYFP-N1-CRHR1) and GPR19 (true 
clone) or the A1-adenosine receptor (A1R; pEYFP-N1-A1R) or (B) CRHR1 alone. Cells were 
subsequently labeled with [3H]adenine and treated with pertussis toxin (PTX; 100 ng/mL) for 
16 h as indicated. Cells were stimulated with CRH (0.1 µM) in the absence and presence of 
conditioned media (CM) from NCI-H345 and NCI-H1703 cells or control medium (medium; 
RPMI 1640 with GlutaMAX™, 10% FBS) for 30 min. As a positive control, CRH-induced cAMP 
accumulation was inhibited via stimulation of the co-expressed A1R by the agonists CCPA 
(1 µM) and R-PIA (1 µM). Data (counts per minute (CPM)) are mean values + standard 
deviation (error bar) of triplicates per condition. The absolute CPM in A and B are not 
comparable (different experiments). Experiments were repeated yielding concurrent results. 
                                                
87  Persussis toxin (PTX) from Bordetella pertussis affects cellular adenylyl cyclase activity and potassium channels. It 
binds to the α-subunit of heterotrimeric G proteins (e.g., Gαi and Gαo) and catalyzes ADP-ribosylation therefore 
blocking the G protein in the guanosine diphosphate (GDP)-bound, inactive state. Hence, these G proteins are 
unable to open potassium channels or to inhibit the activity of adenylyl cyclase which leads in turn to increased 
levels of cellular cyclic adenosine monophosphate (cAMP; Burns DL, 1988; www.sigmaaldrich.com/catalog/ 
product/sigma/p7208? lang=de&region=AT). 
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Pertussis toxin was also used to examine whether GPR19 could couple to Gi in a 
constitutive manner, when expressed in the NSCLC cell line NCI-H1703. Cells 
(3.5 x 105) were seeded in 6 well culture plates and labeled with [3H]adenine 8 h 
later. They were starved and then subjected to stimulation with normal medium 
(RPMI 1640 with GlutaMAX™, 10% FBS) or conditioned medium from cultured NCI-
H1703 cells. The stimulation medium selectively contained PTX or forskolin88 (10 µM), 
an activator of adenylyl cyclase. 
Inactivation of Gi and Go proteins by pretreatment with pertussis toxin did not 
enhance forskolin-induced cAMP accumulation in NCI-H1703 cells, regardless of 
whether they were kept in fresh medium or challenged with conditioned medium 
(figure 45). ADP-ribosylation of Gαi/Gαo by pertussis toxin prevents a receptor from 
accessing the G protein’s carboxy-terminus (blocked interaction; Seifert R and 
Wieland T, 2006) and should have unmasked constitutive inhibition of cAMP 
accumulation through GPR19. In addition, conditioned medium did not affect cAMP 
levels compared to conditions in which cells were treated with normal medium 
(independent of PTX or forskolin).    
 
 
 
Figure 45:  Pertussis toxin and conditioned medium do not affect cAMP levels in NCI-H1703 cells. NCI-
H1703 cells were labeled with [3H]adenine in the absence and presence of pertussis toxin 
(PTX; 100 ng/mL) for 16 h and subsequently stimulated with forskolin (10 µM) in the absence 
and presence of conditioned media (CM) from NCI-H1703 cells or control medium (medium; 
RPMI 1640 with GlutaMAX™, 10% FBS) for 30 min. Data (counts per minute (CPM)) are mean 
values + standard deviation (error bar) of triplicates per condition. Experiments were 
repeated yielding similar results. 
 
Taken together, conditioned medium did neither affect agonist- (i.e., CRH-)induced 
cAMP accumulation in HEK-293 cells that co-expressed GPR19 and the CRHR1 nor 
forskolin-mediated cAMP accumulation in NCI-H1703 cells which were found to 
express high levels of Gpr19 mRNA.  
 
                                                
88  The diterpene forskolin is found in the plant Coleus forskohlii and directly activates adenylyl cyclase independent 
of Gs leading to a rise in cellular cyclic adenosine monophosphate (cAMP) levels in a vast number of different 
cell types (Insel PA and Ostrom RS, 2003; www.mdidea.com/products/proper/proper00905.html). 
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7. Cell cycle effects of GPR19 
 
7.1.  The relative number of cells in gap 2 (G2)/mitosis (M) phase 
increases upon Gpr19 knockdown (flow cytometry) 
 
Knockdown of Gpr19 reduced cell proliferation in NCI-H1703 and DMS 53 cells. 
However, it was unclear whether loss of Gpr19 message could influence the 
progression of cells through the cell cycle and which phase would mainly be 
affected by the loss of Gpr19 mRNA. 
To address these issues, NCI-H1703 cells (3,500 cells per well of a 96 well culture plate) 
were either left untreated or transfected with control (CTL #1, CTL #2), Gpr19 (#1, 
#2), or Plk1 siRNAs. On days 2, 3, and 4 after transfection, cells were harvested (cells 
from replicate wells of three plates treated with the same conditions were pooled) 
and flow cytometry was done to analyze the distribution of cells in different stages of 
the cell cycle (figure 46A and B). Effective knockdown of Gpr19 mRNA was 
confirmed by RT-qPCR (figure 46C). The relative number of cells in G2/M phase 
increased over time when cells had been treated with Gpr19 siRNAs in comparison to 
untreated or control siRNA-treated cells. This increase in the G2/M population 
occurred at the expense of cells that were in DNA synthesis (S) phase while the 
proportion of cells in gap 1 (G1) phase was less affected. As anticipated, knockdown 
of Plk1 caused a pronounced arrest of cells harboring a DNA content characteristic 
of the G2/M phase (Spänkuch-Schmitt B, Bereiter-Hahn J et al., 2002; Liu X and 
Erikson RL, 2003). Here, the propidium iodide DNA staining analyzed by flow 
cytometry did not allow for the discrimination between cells in G2 or M phase. 
 
This experiment was also performed in DMS 53 cells (10,000 cells per well of a 96 well 
culture plate) using untreated cells or cells transfected with control siRNA CTL #1, 
Gpr19 siRNA GPR19 #2 (most effective depletion of Gpr19 mRNA) or Plk1 siRNA and 
cell cycle effects were investigated on day 3 after transfection (figure 47). The 
outcome here was similar to the result yielded with NCI-H1703 cells. Nevertheless, in 
comparison to results from NCI-H1703 cells, the changes in cell cycle populations 
were less prominent on day 3 after transfection (figure 47A and B). However, the 
percentage of cells to which a G2/M phase DNA content had been assigned 
increased relative to the control sample. Besides, the amount of cells in S and G1 
phase was decreased. Effective Gpr19 mRNA knockdown was again confirmed by 
RT-qPCR (figure 47C).  
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Figure 46:  The relative number of NCI-H1703 cells with G2/M phase DNA content increases upon Gpr19 
knockdown (flow cytometry). (A, B) The cell cycle distribution (G1, S, G2/M phase) of NCI-
H1703 cells (mean values + standard deviation (error bar) of three experiments) was 
determined staining the cellular DNA with propidium iodide and quantifying the distribution 
by flow cytometry on days 2, 3, and 4 after siRNA transfection (untreated cells; CTL #1 and 
#2, GPR19 #1 and #2, PLK1; 20 nM). Cellular debris had been excluded in a forward versus 
side scatter dot plot. The profiles of DNA content were analyzed using the cell cycle tool 
(Watson model) of FlowJo (A); this model approximates G1 (green) and G2/M (blue) phase 
populations with Gaussian curves and calculates the S phase population (yellow) exactly 
based on the DNA content histogram of propidium iodide (fluorescence channel 2 (FL2)-
area (A)); the purple line represents the calculated sum of G1, S, and G2/M cells based on 
the Watson model). For each day and cell cycle phase, differences across all experimental 
groups were tested for significance using one way ANOVA followed by Tukey’s test (B). 
GPR19 #1 and GPR19 #2 p values refer to the least significant one from the comparison with 
CTL #1 and CTL #2 (*p < 0.05; **p < 0.01). (C) Relative Gpr19 mRNA levels on day 2 after 
transfection were determined by RT-qPCR (normalized against reference genes Cypa and 
Hprt1, geometric mean value of triplicates per condition; data are mean values + standard 
deviation (error bar) of three experiments). 
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Figure 47:  The relative number of DMS 53 cells with G2/M phase DNA content increases upon Gpr19 
knockdown (flow cytometry). (A, B) The cell cycle distribution (G1, S, G2/M phase) of DMS 53 
cells (mean values + standard deviation (error bar) of three experiments) was determined 
staining the cellular DNA with propidium iodide and quantifying the distribution by flow 
cytometry on day 3 after siRNA transfection (untreated cells; CTL #1; GPR19 #2; PLK1; 20 nM). 
Cellular debris had been excluded in a forward versus side scatter dot plot. The profiles of 
DNA content were analyzed using the cell cycle tool (Watson model) of FlowJo as 
described in the legend of figure 46 (A). Differences across all experimental groups were 
tested for significance using one way ANOVA followed by Tukey’s test. GPR19 #2 p values 
refer to the comparison with CTL #1 (*p < 0.05; ***p < 0.001). (C) Relative Gpr19 mRNA levels 
on day 3 after transfection were determined by RT-qPCR (normalized against reference 
genes Cypa and Hprt1, geometric mean value of triplicates per condition; data are mean 
values + standard deviation (error bar) of three experiments). 
 
 
7.2.  The relative number of cells in G2/M phase increases upon Gpr19 
knockdown (high content screening) 
 
The observations obtained from flow cytometry according to which cells treated with 
Gpr19 siRNAs revealed an increased number of cells with a DNA content typical for 
the G2/M phase were verified by an independent approach that relied on HCS of 
cells. These experiments were only performed with NCI-H1703 cells because DMS 53 
cells were not suitable for imaging with the ArrayScan® VTI HCS reader. They tend to 
grow in clusters at a certain cell density which made it difficult to detect single 
nuclei. NCI-H1703 cells (2,000 cells per well of a black poly-D-lysine-coated 96 well 
culture plate) were transfected with control (CTL #1, CTL #2), Gpr19- (#1, #2), or Plk1-
targeting siRNAs or left untreated and analyzed on days 2, 3, and 4 after 
transfection. The number of detected cells per well was in the range of 300 to 1,000. 
However, for Plk1 siRNA-transfected samples, this was only valid on day 2 after 
transfection due to the high cellular toxicity caused by the knockdown. For this 
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reason, data obtained from Plk1 siRNA-treated samples were omitted in statistical 
analyses.   
On the basis of Hoechst 33342 DNA staining, cell cycle analysis by HCS confirmed the 
results obtained by flow cytometry (figure 48). Cell populations treated with Gpr19 
siRNA increased their fraction of cells with a DNA content characteristic of the G2/M 
phase over time (figure 48A). Cell cycle profiles from HCS analysis reflected the 
population shifting in Gpr19 siRNA-treated samples (figure 48B). Both the increase in 
relative cell number of G2/M and the decrease of G1 phase were significant for cells 
treated with Gpr19 siRNA #2. This increasing number of cells in G2/M phase was not 
at the expense of the cells in S phase, which, however, was the case when shifts in 
 
 
 
Figure 48:  High content screening identifies an increased number of cells in G2/M phase upon Gpr19 
knockdown. (A) Visualization of cell cycle distribution analysis (sub G1, G1, S, G2/M, above 
G2/M) of NCI-H1703 cells on days 2, 3, and 4 after siRNA transfection (untreated cells (blue 
lines); CTL #1 and #2, GPR19 #1 and #2, PLK1 (red lines)) based on Hoechst 33342 DNA 
staining, ArrayScan® VTI analysis). One representative experiment out of three is shown. 
Data from each well of a 96 well culture plate are represented by a single line (six replicates 
per condition). (B) Relative number of cells with G1, S, and G2/M DNA content, data are 
mean values + standard deviation (error bar) of three experiments. For each day post 
transfection and cell cycle phase, differences across experimental groups – except for PLK1 
(strong antimitotic effect of the mRNA knockdown) were tested for significance using one 
way ANOVA followed by Tukey’s test. GPR19 #1 and GPR19 #2 p values refer to the least 
significant one from the comparison with CTL #1 and CTL #2 (*p < 0.05; **p < 0.01; 
***p < 0.001). (C) Gpr19 mRNA knockdown was assessed by RT-qPCR on day 2 after siRNA 
transfection (normalized against reference genes Cypa and Hprt1, geometric mean value 
of triplicates per condition; data are mean values + standard deviation (error bar) of three 
experiments). 
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cell cycle population distributions had been determined by flow cytometry 
(figure 46C). The high variation for Plk1 siRNA-treated samples might result partly from 
the fact that only few cells were left for HCS detection due to the high toxicity of the 
knockdown and subsequent washing-off during sample preparation. Knockdown of 
Gpr19 mRNA by Gpr19-targeting siRNAs was effective as monitored by RT-qPCR 
(figure 48C). 
 
 
7.3.  Cells show increased levels of cyclin B1 and phosphorylated 
histone H3 upon Gpr19 knockdown 
 
The HCS approach for the investigation of cell cycle impairments caused by Gpr19 
knockdown further included the protein staining of cells for the G2/M phase marker 
cyclin B1 and the mitosis marker phosphorylated histone H3. A Kolmogorov-Smirnov 
(KS statistic) test was used to evaluate the distribution of cells that stained positive for 
phosphorylated histone H3 and cyclin B1 at each time point investigated after siRNA 
transfection. Cyclin B1 exerts its function in conjunction with cyclin-dependent kinase 
(CDK)1 during late G2 phase and early mitosis (Brown NR et al., 2007). Histone H3 
phosphorylation at Ser10 correlates with chromosome condensation during early 
mitosis with phosphorylation levels starting to rise in late G2 phase and 
dephosphorylation occurring in ana- and telophase (Hendzel MJ et al., 1997).  
This evaluation confirmed the increase in G2/M-arrested cells upon Gpr19 
knockdown (figure 49A and B). Figure 49C and D show representative pictures from 
the HCS based on Hoechst 33342 DNA staining and cells stained positive for 
phosphorylated histone H3 and cyclin B1, respectively, on day 3 after transfection. 
The level of both immunoreactivity for phosphorylated histone H3 and cyclin B1 
increased in cells upon Gpr19 knockdown. This effect was most prominent on days 3 
and 4 after transfection. The G2/M block induced by the Plk1 siRNA also resulted in 
increased levels of phosphorylated histone H3 and cyclin B1.  
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Figure 49:  Gpr19 knockdown increases immunoreactivity for phosphorylated histone H3 (pH3) and 
cyclin B1. The protein levels of cyclin B1 (marker for the G2/M phase) and of phosphorylated 
histone H3 (marker for mitosis) were determined by HCS (ArrayScan® VTI analysis) after siRNA 
transfection (untreated cells; CTL #1 and #2, GPR19 #1 and #2, PLK1; 20 nM). (A, B) 
Kolmogorov-Smirnov (KS) statistic for pH3- (A) and cyclin B1-positive (B) cellular staining on 
days 2, 3, and 4 after siRNA transfection (mean values + standard deviation (error bar) of 
three experiments). For each day, differences across experimental groups – except for PLK1 
(strong antimitotic effect of the mRNA knockdown) – were tested for significance using one 
way ANOVA followed by Tukey’s test. GPR19 #1 and GPR19 #2 p values refer to the least 
significant one from the comparison with CTL #1 and CTL #2 (*p < 0.05; **p < 0.01; 
***p < 0.001). (C, D) Images of immunostaining for pH3 (C, yellow) and cyclin B1 (D, red) in 
one representative field of 36 (maximal) fields per well (96 well culture plate). Objects 
encircled in green represent cells which were detected based on Hoechst 33342 staining. 
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7.4.  Cells show impairments in cell division upon Gpr19 knockdown 
 
Manipulations that interfere with transition of cells through G2/M phase might result in 
aberrant cell division. Accordingly, it was examined whether Gpr19 knockdown 
elicited morphological changes that were consistent with impaired chromosomal 
segregation. HCS was indicative of abnormal DNA content in NCI-H1703 cells that 
had been treated with siRNAs directed against Gpr19. Visual inspection revealed an 
excess of polylobed and binucleated cells upon Gpr19 knockdown in comparison to 
untreated or control siRNA-treated cells (figure 50).     
 
 
7.5.  High content screening data support inhibited proliferation upon 
Gpr19 knockdown 
 
In good agreement with results obtained from confluence measurements, 
alamarBlue® cell viability testing and morphological cell characterization by phase 
contrast microscopy (figure 36, figure 38, figure 39), HCS identified inhibited 
proliferation of cells treated with Gpr19 or Plk1 siRNAs on days 3 and 4 after 
transfection (figure 51A). The proliferation index parameter was based on the 
number of detected cells per field and analyzed by a KS statistic. On the other hand, 
the proliferation index for untreated or control siRNA-transfected cells was almost 
unaltered over time.  
Through the combination of multiple parameters obtained from Hoechst 33342 
nuclear DNA staining of cells (parameters are specified in the Methods section), the 
HCS approach also allowed for the calculation of an apoptotic index described as 
KS statistic (figure 51B). NCI-H1703 cells transfected with siRNAs knocking down 
Gpr19 were characterized by an increasing apoptotic index relative to their 
untreated or control siRNA-transfected counterparts on days 3 and 4 after 
transfection – an effect also observed and expected in Plk1 siRNA-treated cells 
(Spänkuch-Schmitt B, Bereiter-Hahn J et al., 2002).  
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Figure 50:  Binucleated and polylobed nuclei are detected in cells upon Gpr19 knockdown. Nuclear 
morphology was determined by HCS 3 days after transfection with siRNA (untreated cells; 
CTL #1 and #2, GPR19 #1 and #2, PLK1; 20 nM); binucleated and polylobed nuclei-
containing cells (white arrows) are highlighted. Objects encircled in green represent cells 
which were detected on the basis of DNA staining with Hoechst 33342. Many polylobed cells 
were automatically excluded from further analyses (indicated by the lack of green edge 
coloring). 
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Figure 51:  Cells treated with siRNAs knocking down Gpr19 show a diminished proliferation index and an 
increased apoptotic index. Proliferation (A; cells per field) and apoptotic indices (B; multiple 
parameters specified in the Methods section) are based on the data fom high content 
screening of NCI-H1703 cells transfected with siRNAs (untreated cells; CTL #1 and #2, 
GPR19 #1 and #2, PLK1; 20 nM) and described using a KS statistic on days 2, 3, and 4 after 
siRNA transfection (mean values + standard deviation (error bar) of six replicates from one 
representative experiment out of three). For each day, differences across experimental 
groups – except for PLK1 (strong antimitotic effect of the mRNA knockdown) – were tested 
for significance using one way ANOVA followed by Tukey’s test. GPR19 #1 and GPR19 #2 p 
values refer to the least significant one from the comparison with CTL #1 and CTL #2 
(***p < 0.001). Two additional experiments gave similar results. 
 
 
7.6.  The distribution of cells in different phases of the cell cycle is 
unaltered upon transient GPR19 overexpression 
 
The knockdown of Gpr19 message resulted in an increased number of cells with a 
DNA content characteristic of the G2/M phase. Hence, it was investigated whether 
transient overexpression of GPR19 in HEK-293 cells, which do not express Gpr19 mRNA 
endogenously (figure 31), might influence the relative distribution of cells in different 
stages of the cell cycle.  
HEK-293 cells were either left untreated or transfected in 6 well poly-D-lysine-coated 
culture plates (2.5 x 105 cells per well) with plasmids encoding for GPR19 (GPR19 (true 
clone), GPR19 (codon-optimized), GPR19-tGFP) or control plasmids (empty vector, 
tGFP only). Expression plasmids had been verified by sequencing and cells were 
subjected to flow cytometric analysis on days 2, 3, and 4 after transfection 
(figure 52A and B). The effective transfection of HEK-293 cells with expression 
plasmids was verified detecting the tGFP-tagged version of GPR19 in non-fixed cells 
(figure 52C). 
Cells that had been transfected with any plasmid showed a decreased relative 
number of S phase cells compared to untreated control cells. However, there was no 
difference in cell cycle profiles between GPR19-overexpressing and control plasmid-
transfected HEK-293 cells. Hence, transient GPR19 overexpression did not influence 
the distribution of cells in different phases of the cell cycle at any time point 
examined.  
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Figure 52:  Transient overexpression of GPR19 does not influence the distribution of cells in the cell cycle 
phases (HEK-293). (A, B) The cell cycle distribution (G1, S, G2/M phase) of HEK-293 cells was 
determined staining the cellular DNA with propidium iodide and quantifying the distribution 
by flow cytometry on days 2, 3, and 4 after plasmid transfection (untreated, mock 
(transfection reagent only)-, control plasmid (pCMV6-XL5 (empty vector), pCMV6-AC-GFP 
(turbo green fluorescent protein (tGFP)))-, or GPR19 plasmid (GPR19 (true clone), GPR19 
(codon-optimized), GPR19-tGFP)-treated cells). Cellular debris had been excluded in a 
forward versus side scatter dot plot. The profiles of DNA content were analyzed using the cell 
cycle tool (Watson model) of FlowJo as described in the legend of figure 46. (C) The 
transfection efficiency for GPR19-tGFP in comparison to untreated cells was assessed on 
day 2 after transfection using flow cytometry (dot plot for tGFP (fluorescence channel 1 
(FL1)-height (H)) and propidium iodide (fluorescence channel 2 (FL2)-H) signals, the data 
point density is reflected by different colors ranging from blue (low density, single data 
points) to red (high data point density); figures refer to the relative number of cells in the 
upper left quadrant (tGFP positive, propidium iodide negative). The experiment was 
repeated yielding concurrent results. 
 
This experiment was also performed with the NSCLC cell line NCI-H1703. Unlike HEK-
293 cells, NCI-H1703 cells revealed high endogenous levels of Gpr19 mRNA 
(figure 31). Electroporation was used for the transfer of expression plasmids into NCI-
H1703 cells (6 x 105 cells; 2.5 µg of plasmid DNA) and 1.5 x 105 cells were seeded into 
wells of a 6 well culture plate. On days 2, 3, and 4, cells were harvested for flow 
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cytometric analysis (figure 53A and B) and the transfection efficiency was again 
controlled using non-fixed cells (figure 53C). 
 
 
 
 
Figure 53:  Transient overexpression of GPR19 does not influence the distribution of cells in the cell cycle 
phases (NCI-H1703). (A, B) The cell cycle distribution (G1, S, G2/M phase) of NCI-H1703 cells 
was determined staining the cellular DNA with propidium iodide and quantifying the 
distribution by flow cytometry on days 2, 3, and 4 after plasmid transfection (untreated, 
mock (transfection reagent only)-, control plasmid (pCMV6-XL5 (empty vector), pCMV6-AC-
GFP (turbo green fluorescent protein (tGFP)))-, or GPR19 plasmid (GPR19 (true clone), GPR19 
(codon-optimized), GPR19-tGFP)-treated cells) as described in the legends of figure 46 and 
figure 52. (C) The transfection efficiency for GPR19-tGFP in comparison to untreated cells 
was assessed on day 2 after transfection as described in the legend of figure 52. The 
experiment was repeated yielding concurrent results. 
 
In accordance with the results obtained from plasmid-transfected HEK-293 cells, 
plasmid-transfected NCI-H1703 cells did not differ in their cell cycle profiles, either – 
regardless of whether they overexpressed any form of GPR19 or had been 
transfected with a control plasmid. Thus, no influence of transient GPR19 
overexpression on the cell cycle profile of these cells was observed on days 2, 3, or 4 
after plasmid transfection. In contrast, allplasmid-transfected NCI-H1703 cells showed 
an increased relative number of cells in S phase compared to their untreated 
counterparts. 
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8. Cell cycle-dependent expression of Gpr19 mRNA 
 
8.1.  Gpr19 mRNA expression peaks during S phase 
 
Proteins involved in cell cycle progression – cyclins and CDKs are among the most 
prominent representatives – can be functionally regulated by various means such as 
phosphorylation, subcellular localization, interaction with other proteins, or de novo 
synthesis (Ohtsubo M et al., 1995; Brown NR et al., 2007). Observations from Gpr19 
mRNA knockdown experiments are consistent with the hypothesis that this GPCR 
might play a role during the G2/M phase of the cell cycle. Therefore, the potential 
differential expression of Gpr19 mRNA during the course of the cell cycle was 
investigated using cell synchronization89. Different incubation times and 
concentrations of all chemical agents applied in subsequently described 
experiments had been optimized in order to guarantee minimal toxicity to cells and 
sufficient release from the induced arrest.  
DMS 53 and NCI-H1703 cells were treated with hydroxyurea for 24 h to synchronize 
them at the G1-S transition90. Samples were taken at various time points after release 
from cell cycle arrest for DNA content analysis by flow cytometry. Upon removal of 
hydroxyurea, DMS 53 (figure 54, upper panel) and NCI-H1703 cells (figure 55, upper 
panel) moved subsequently through the cell cycle in an essentially synchronous 
fashion: The number of cells in S phase rapidly accumulated and the DNA content 
shifted from 2n (G1 phase, G1/S boundary) to 4n (G2/M phase) within 10 h. After 
12 h, the vast majority of cells had reached the G2/M phase of the cell cycle. At 
later time points (24 h, 36 h, and 48 h), the effect of hydroxyurea was lost and the cell 
cycle distribution in the population approached that seen in an asynchronously 
growing culture. RNA was also extracted at these time points and the message levels 
                                                
89  Cells can be arrested at different stages of the cell cycle using tools that trigger various cell cycle 
control/checkpoint mechanisms. This so-called synchronization of cultured cells is often reversible. A well-
synchronized cell population is characterized by its uniform movement through the cell cycle for a short period of 
time (hours) when culture conditions have been set back to normal. However, the synchronization effect on cells 
strongly depends on the synchronization method but also on the tissue type from which a cell line was derived 
and on the individual cell line used. When using chemical agents, different concentrations and incubation times 
can influence the characteristics of arrested cells. They can further exhibit adverse cellular consequences apart 
from synchronizing the culture of cells such as induction of replication stress or DNA damage responses. On the 
other hand, non-invasive synchronization methods, e.g., serum deprivation or contact inhibition, can be 
controlled less strictly. Moreover, cancer cells are less amenable to these methods and metabolic perturbations 
can occur. In any case, whole-culture synchronization methods can only result in the majority of cells being cell 
cycle-arrested (Davis PK et al., 2001; Cooper S et al., 2006; Darzynkiewicz Z et al., 2011). 
 
90  Hydroxyurea blocks cells in the S phase of the cell cycle and they accumulate at the G1-S transition (Davis PK et 
al., 2001). It functions as an inhibitor of DNA synthesis by interfering with ribonucleoside diphosphate reductase – a 
rate-limiting enzyme in deoxyribonucleoside triphosphate (dNTP) synthesis (Hendricks SP and Mathews CK, 1998). 
This enzyme’s catalytically essential free tyrosyl radical at its active site gets quenched by hydroxyurea (Lassmann 
G et al., 1992; Yarbro JW, 1992). The conversion of ribonucleoside diphosphates into dNTPs is stalled and cells are 
stuck in G1/S phase. Synchronized cells can be released from G1/S arrest upon removal of hydroxyurea from the 
growth medium (www.cancer.gov/drugdictionary/?CdrID=40685; www.hiv.ch/rubriken/therapie/medikamente/ 
hydrea.htm). 
The fact that hydroxyurea can directly cause apoptosis and interfere with DNA repair is of major therapeutical 
interest (Gui CY et al., 1997). It also keeps cells in a radiation-sensitive pre-DNA synthesis stage rendering them 
more susceptible towards irradiation. For this reason, hydroxyurea has shown efficiency in the treatment of 
melanoma, chronic myelocytic leukemia, or squamous cell carcinoma of the head and neck (www.drugs.com/ 
pro/hydroxyurea.html; www.nlm.nih.gov/medlineplus/druginfo/meds/a682004.html). 
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of several genes were determined by RT-qPCR (figure 54 and figure 55, lower panels). 
The levels of mRNA encoding cyclin E1 91 were elevated while cells were at the G1/S 
boundary and subsequently declined to reach a nadir after 12 h in both DMS 53 and 
NCI-H1703 cells. In contrast, a peak in cyclin B1 92 mRNA expression was seen after 
12 h, i.e., coincident with the accumulation of cells in the G2/M phase of the cell 
cycle. These results were anticipated as cyclin B1 and cyclin E1 show a known cyclic 
pattern of mRNA expression over the course of the cell cycle. Expression levels of E-
type cyclins are highest prior to S phase entry, fall during S phase, and remain low 
during G2/M phase (Ohtsubo M et al., 1995; Maity A et al., 1997; Penelova A et al., 
2005) whereas cyclin B1 message is low in G1 phase, rises during S phase, and peaks 
at G2/M phase (Maity A et al., 1995; Maity A et al., 1997). Both patterns were 
recapitulated here.  
The mRNA of ribosomal protein L32 (Rpl32)93 encodes a ribosomal protein and does 
not vary through the cell cycle (Maity A et al., 1995; Maity A et al., 1997). 
Accordingly, Rpl32 was used as an internal control. In addition, the cell cycle-
dependent changes in mRNAs encoding two different GPCRs, namely the 
lysophosphatidic acid receptor 1 (Lpar1)94 for NCI-H1703 cells and the muscarinic 
cholinergic receptor 3 (Chrm3)95 for DMS 53 cells were examined. The expression of  
 
                                                
91  Cyclin E1 (CCNE1; NCBI gene ID 898; UniProt protein ID P24864) is involved in the regulation of the G1-S transition 
of cells. It forms a complex with cyclin-dependent kinase 2 (CDK2) leading to autophosphorylation and therefore 
activation of the kinase function. The activated kinase is required for G1-S transition of the cell cycle. Cyclin E1 
accumulates at the G1/S boundary due to its cell cycle-dependent transcription profile and it is rapidly 
degraded by ubiquitination when cells progress through S phase. Two distinct isoforms exist which arise from 
alternatively spliced transcript variants (Ohtsubo M et al., 1995; Geng Y et al., 1996; Won KA and Reed SI, 1996; 
www.ncbi.nlm.nih.gov/gene/898; www.uniprot.org/uniprot/P2864). 
 
92  Cyclin B1 (CCNB1; NCBI gene ID 891, UniProt protein ID P14635) is involved in the regulation of mitosis. It is part of 
the maturation-promoting factor (MPF) upon binding to CDK1 allowing the kinase to become active. This 
complex is translocated to the nucleus where phosphorylation reactions necessary for mitotic onset are 
performed. Levels of cyclin B1 accumulate during G2 phase and are rapidly destroyed in late mitosis. Two 
transcripts (alternative transcription start sites) encoding cyclin B1 exist. One is constitutively expressed whereas 
expression of the other one is cell cycle-regulated with message accumulation during G2/mitosis (Pines J and 
Hunter T, 1989; Castedo M et al., 2002; Porter LA and Donoghue DJ, 2003; www.ncbi.nlm.nih.gov/gene/891; 
www.uniprot.org/uniprot/P14635). 
 
93  Protein synthesis takes place at ribosomes. Eukaryotic ribosomes are composed of a small 40 S and a large 60 S 
subunit. About 80 proteins and 4 RNA species make up for an entire ribosome. The ribosomal protein L32 (RPL32; 
NCBI gene ID 6161; UniProt protein ID P62910) belongs to the L32E ribosomal protein family and is a member of 
the 60 S subunit. An identical primary sequence is encoded by alternatively spliced transcript variants 
(www.ncbi.nlm.nih.gov/gene/6161; www.uniprot.org/uniprot/P62910). 
 
94  The most common forms of lysophosphatidic acid (LPA) produced from membrane phospholipids are 16:0, 18:0, 
18:1, and 20:4-LPA. These bioactive lipid molecules can bind to and activate GPCRs of the rhodopsin-like LPA 
receptor subfamily such as lysophosphatidic acid receptor 1 (LPAR1; NCBI gene ID 1902; UniProt protein ID 
Q92633). LPA receptors differ in their tissue distribution with LPAR1 being ubiquitously expressed in humans. 
Receptor activation leads to the coupling of Gi/o, Gq/11, or G12/13 proteins finally resulting in cellular proliferation 
and survival as well as cytoskeletal rearrangements and migration. LPAR1 stimulation has been shown to promote 
tumor progression in gastrointestinal cancer and further evidence also points to a role in breast and ovarian 
cancer (Aziziyeh AI et al., 2009; www.ncbi.nlm.nih.gov/gene/1902; www.uniprot.org/uniprot/Q92633). 
 
95  The muscarinic cholinergic receptor 3 (CHRM3; NCBI gene ID 1131; UniProt protein ID P20309) belongs to the 
muscarinic acetylcholine (ACh) receptor subfamily within rhodopsin G protein-coupled receptors (GPCRs). 
Members of this subfamily mediate responses to their prototypical ligand ACh mainly in the central and 
peripheral nervous system. On a cellular level, they inhibit adenylyl cyclase, break down phosphoinositides, and 
modulate potassium channels upon ligand-induced activation. CHRM3 itself plays a physiological role in the 
(continued on next page) 
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Figure 54:  Gpr19 mRNA is differentially expressed over the course of the cell cycle and peaks during S 
phase (hydroxyurea arrest) in DMS 53 cells. DMS 53 cells were treated with hydroxyurea 
(1 mM) for 24 h and therefore arrested at the G1-S transition. Following release of the block, 
the DNA content was determined at regular time points by propidium iodide staining and 
flow cytometry (upper panel; fluorescence channel 2 (FL2)-area (A) histogram) and the 
corresponding expression profiles of the indicated genes (encoding the ribosomal protein 
L32 (RPL32), cyclin E1, cyclin B1, and the GPCRs GPR19 and muscarinic cholinergic 
receptor 3 (CHRM3)) were determined by RT-qPCR (lower panel). The gene of interest mRNA 
expression was normalized against four reference genes (Actb, Cypa, Hprt1, Rplp0). Gene 
expression plots show mRNA levels (geometric mean value) relative to control samples 
(untreated (Untr) cells) with error bars indicating 95% confidence intervals. Gpr19 mRNA 
expression at each time point post release was compared to the mRNA expression of non-
differentially expressed Rpl32 using a t test with Welch’s correction (*p < 0.05; **p < 0.01; 
***p < 0.001). The experiment was repeated yielding concurrent results. 
 
Lpar1 in DMS 53 cells and Chrm3 in NCI-H1703 cells was either not detectable or only 
present at high quantification cycles (> 37 Cq) rendering these data error-prone. 
These mRNAs remained essentially constant over time – with some limitations at few 
                                                                                                                                                      
secretion of glandular tissue and the contraction of smooth muscle tissue. Besides, activation of the muscarinic 
ACh receptor family in general and CHRM3 in particular was proposed to contribute to colon carcinogenesis 
(Belo A et al., 2011; www.ncbi.nlm.nih.gov/gene/1131; www.uniprot.org/uniprot/P20309). 
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time points assessed – therefore serving as undifferentially expressed controls. The 
expression of Gpr19 mRNA, however, was cell cycle-dependent: Gpr19 mRNA levels 
rose when the synchronized cells moved through S phase, peaked after 6 to 8 h, and 
started to decline as cells reached G2/M phase, i.e., after 10 h (figure 54 and 
figure 55, lower panels). At later time points (24 h, 36 h, and 48 h), mRNA levels did 
not differ appreciably from those seen in untreated control cells (open bar in the 
lower panels of figure 54 and figure 55), regardless of which mRNA was examined. 
This is consistent with the fact that the cell population grew again asynchronously at 
this stage. 
 
 
 
 
Figure 55:  Gpr19 mRNA is differentially expressed over the course of the cell cycle and peaks during S 
phase (hydroxyurea arrest) in NCI-H1703 cells. NCI-H1703 cells were treated with 
hydroxyurea (1 mM) for 24 h and therefore arrested at the G1-S transition. Following release 
of the block, the DNA content was determined at regular time points by propidium iodide 
staining and flow cytometry (upper panel; fluorescence channel 2 (FL2)-area (A) histogram) 
and the corresponding expression profiles of the indicated genes (encoding the ribosomal 
protein L32 (RPL32), cyclin E1, cyclin B1, and the GPCRs GPR19 and lysophosphatidic acid 
receptor 1 (LPAR1)) were determined by RT-qPCR (lower panel). Data analysis was 
performed as outlined in the legend of figure 54 (*p < 0.05; **p < 0.01). The experiment was 
repeated yielding concurrent results. 
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The possibility was addressed that differential Gpr19 mRNA expression was due to the 
chemical treatment of cells with hydroxyurea, i.e., an off-target effect unrelated to 
its effect on the cell cycle. The expression study was therefore repeated with DMS 53 
cells using the DNA replication inhibitor aphidicolin96 that also causes cells to arrest at 
the G1-S transition (Pedrali-Noy G et al., 1980). 
Cell cycle profiles and the degree of synchronization resembled those of 
hydroxyurea-treated cells (figure 56, upper panel). The amount of cells in S phase 
was also highest at 2, 4, 6, and 8 h after release and returned back to normal at 24, 
36, and 48 h. Similarly, mRNA profiles were also comparable (figure 56, lower panel). 
Most importantly, following aphidicolin-induced synchronization, the time-
dependent changes in Gpr19 mRNA levels recapitulated those seen in hydroxyurea-
treated cells. Expression of cyclin B1 and cyclin E1 mRNAs over the course of the cell 
cycle followed their expected patterns, Rpl32 and Chrm3 expressions were 
unaltered. 
 
Hydroxyurea and aphidicolin allowed the synchronous passage of cells from the G1-
S transition over S and G2/M phases finally reaching a normal cell cycle population 
profile. In order to better compare Gpr19 expression levels between cells in G1 and 
G2/M phase, NCI-H1703 and DMS 53 cells were arrested during mitosis using 
nocodazole97 (figure 57). Samples of untreated cells and cells at 0, 4, 24, and 48 h 
after nocodazole block release were examined. Cells arrested with nocodazole 
harbored a DNA content characteristic of the G2/M phase and did not go through 
another round of synchronous cell cycling. Instead, the G2/M population declined 
with time at the expense of a rising G1 population (figure 57A and B, upper panels). 
Gpr19, Rpl32, Lpar1, and Chrm3 mRNA levels remained almost unaltered at all time 
points after nocodazole-induced cell cycle block release compared to the 
respective untreated control sample (figure 57A and B, lower panels). Expression of 
cyclin E1 was decreased when cells were found with a DNA content characteristic of 
the G2/M phase, whereas cyclin B1 expression was increased here. Message levels 
                                                
96  Aphidicolin is a diterpene fungal metabolite from Nigrospora sphaerica which targets the cellular DNA replication 
process by inhibition of α and δ-polymerases. Cultured cells are prevented from entering S phase and 
accumulate at the G1-S transition or are blocked in S phase. Aphidicolin does not hinder the synthesis of neither 
deoxyribonucleoside triphosphates (dNTPs) nor DNA polymerases. Hence, a quick recovery and onset of 
synchronous cell cycle progression is favored upon removal of this cell cycle block-inducing agent from the 
culture medium (Pedrali-Noy G et al., 1980; www.enzolifesciences.com/fileadmin/reports/els_b56aaf7f2b.pdf). 
 
97  The anti-neoplastic agent nocodazole exerts its biological effects by interaction with tubulin heterodimers and by 
increasing tubulin guanosine triphosphatase (GTPase) activity four- to fivefold and therefore affecting 
microtubule dynamics (Mejillano MR et al., 1996). Cells exposed to nocodazole exhibit suppressed dynamic 
instability of microtubules with reduced elongation and shortening velocities and a net decrease in turnover. 
Microtubules enter a so-called attenuated or paused state with little overall change in length (Vasquez RJ et al., 
1997). Besides their role in controlling the movement of cellular organelles and vesicles, correct microtubule 
function and dynamics is a prerequisite for cells to coordinate the arrangement of chromosomes during mitosis. 
Treatment with nanomolar concentrations of nocodazole causes an arrest of cells in mitosis (metaphase) 
typically detected by a G2/M phase-specific DNA content upon propidium iodide DNA staining in flow 
cytometry. The mitotic checkpoint, which ensures that chromosomes are properly attached to the mitotic spindle 
before anaphase can occur, is triggered. These effects are reversible by ablation of nocodazole (Samson F et al., 
1979; Zieve GW et al., 1980; Jordan MA et al., 1992; Burke DJ, 2000). In contrast, there are also reports that 
nocodazole-treated cells lack some features of synchronized cultures such as a narrow cell size range, for 
instance (Cooper S et al., 2006). 
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of cyclin B1 reclined back to their initial levels (untreated cells) when the mitosis-
arrested cell population shifted towards a normal cell cycle profile.  
 
Taken together, the examination of Gpr19 mRNA expression over the course of the 
cell cycle revealed a peak in expression when most cells were in S phase.  
 
 
 
 
 
Figure 56:  GPR19 mRNA is differentially expressed over the course of the cell cycle and peaks during S 
phase (aphidicolin arrest) in DMS 53 cells. DMS 53 cells were treated with aphidicolin (3 µM) 
for 24 h and therefore arrested at the G1-S transition. Following release of the block, the DNA 
content was determined at regular time points by propidium iodide staining and flow 
cytometry (upper panel; fluorescence channel 2 (FL2)-area (A) histogram) and the 
corresponding expression profiles of the indicated genes (encoding the ribosomal protein 
L32 (RPL32), cyclin E1, cyclin B1, and the GPCRs GPR19 and muscarinic cholinergic 
receptor 3 (CHRM3)) were determined by RT-qPCR (lower panel). Data analysis was 
performed as outlined in the legend of figure 54 (**p < 0.01; ****p < 0.0001). The experiment 
was repeated yielding concurrent results. 
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Figure 57:  Gpr19 mRNA expression is nearly unaltered during G1 and G2/M phase (nocodazole arrest). 
DMS 53 (A) and NCI-H1703 (B) cells were treated with nocodazole (300 nM) for 24 h and 
therefore arrested during mitosis. Following release of the block, the DNA content was 
determined at regular time points by propidium iodide staining and flow cytometry (upper 
panels; fluorescence channel 2 (FL2)-area (A) histogram) and the corresponding expression 
profiles of the indicated genes (encoding the ribosomal protein L32 (RPL32), cyclin E1, 
cyclin B1, and the GPCRs GPR19, lysophosphatidic acid receptor 1 (LPAR1), or muscarinic 
cholinergic receptor 3 (CHRM3)) were determined by RT-qPCR (lower panels). The gene of 
interest mRNA expression was normalized against four reference genes (Actb, Cypa, Hprt1, 
Rplp0). Gene expression plots show mRNA levels (geometric mean value) relative to control 
samples (untreated (Untr) cells) with error bars indicating 95% confidence intervals. 
Experiments were repeated yielding concurrent results. 
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8.2.  Relative Gpr19 mRNA levels correlate with the amount of cells in S 
phase 
 
Gpr19 expression levels at various time points after hydroxyurea block release were 
further examined for correlation with the relative number of cells in G1, S, and G2/M 
phase for both DMS 53 and NCI-H1703 cells (figure 58). The proportion of cells at 
different stages of the cell cycle was determined using the Watson curve fitting 
model from FlowJo. As hydroxyurea arrested cells at the G1-S transition, it was 
impossible to precisely discriminate between G1 and S phase populations at 0 h and 
2 h after release of the hydroxyurea-induced block. These data points were therefore 
omitted. In both cell lines, Gpr19 message levels correlated with the relative number 
of cells in S phase. Conversely, Gpr19 mRNA levels were inversely related to the 
fraction of G1 cells. In contrast, no correlation could be observed between the 
amount of cells in G2/M phase and Gpr19 mRNA expression. 
 
 
 
Figure 58:  Relative Gpr19 mRNA levels correlate with the amount of cells in S phase. The correlation 
analysis incorporated Gpr19 expression levels determined over the course of the cell cycle 
from hydroxyurea-arrested DMS 53 and NCI-H1703 cells (see figure 54 and figure 55) plotted 
as a function of the relative number of cells in G1, S, and G2/M phase. Data from untreated 
cells and cells at 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 36 h, and 48 h after hydroxyurea-induced 
block release were included. Shown are the results of linear regressions; squared correlation 
coefficient values (R2) are given for each plot. 
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9. Gpr19 gene regulation 
 
9.1.  In silico analysis of the Gpr19 promoter reveals E2 promoter 
binding factor (E2F) binding 
 
The data from cell cycle-dependent Gpr19 expression analysis suggested that 
accumulation of the mRNA encoding Gpr19 was initiated as soon as cells progressed 
from G1 to S phase. Members of the E2F family of transcription factors are known to 
boost transcription from E2F-targeted promoter sites during late G1 or early S phase 
(Wells J et al., 2000), e.g., the component of the pre-replicative complex cell division 
cycle 6 (Cdc6; Brown KC et al., 2010) and Myc (myelocytomatosis oncogene; 
Rabinovich A et al., 2008). As Gpr19 mRNA expression was shown to peak during S 
phase, the possible involvement of the E2F family of transcription factors in regulating 
its expression was investigated. 
The Gpr19 promoter region (5 kilobases (kb) of the 5’ upstream sequence ahead of 
the open reading frame (ORF)) was examined for potential E2F binding sites in silico 
using ConSite98 and the University of California, Santa Cruz (UCSC) genome 
browser99. The consensus DNA recognition sequence for E2F transcription factors is  
5’-T-T-T-G/C-G/C-C-G-C-3’ (Rabinovich A et al., 2008). Results from both databases 
were based on computational data and had not been biologically verified. 
Four potential E2F binding sites (-15 (5’-T-T-T-A-G-C-G-C-3’), -185 (5’-T-T-T-G-C-T-G-C-
3’; reverse strand), -3184 (5’-T-T-T-G-G-C-C-C-3’), and -3769 base pairs (bp; 5’-T-T-T-G-
G-C-T-C-3’) upstream of the Gpr19 ORF) were retrieved from the ConSite search and 
only the one at position -15 was called by the UCSC genome browser search. 
However, these hypothetical E2F binding sites did not strictly follow the consensus 
DNA recognition sequence for E2F transcription factors. When investigating the same 
promoter region (5 kb of the 5’ upstream sequence ahead of the ORF) of Gpr19 in 
Macaca mulatta, Mus musculus, Pan troglodytes, and Xenopus tropicalis for binding 
of E2F transcription factors using ConSite, at least one possible binding site was 
retrieved in all these species (assuming the validity of the human E2F consensus DNA 
recognition site). 
In addition to the E2F family, the UCSC database depicted the theoretical binding of 
the POU100 family of transcription factors to the promoter region of Gpr19 at position  
-875 (reverse strand) strictly following the consensus DNA recognition sequence  
5’-A-T-G-C-A-A-A-T-3’ (Cook AL and Sturm RA, 2008). An excerpt of the Gpr19 
promoter sequence (1,000 bases upstream of the Gpr19 ORF) is shown in the 
Appendix section. 
 
 
                                                
98  asp.ii.uib.no:8090/cgi-bin/CONSITE/consite 
 
99  genome.ucsc.edu 
 
100  Transcription factors containing the POU (Pit1/Oct2/unc-86) domain are ubiquitously expressed proteins that 
function either in the regulation of housekeeping genes or in determining developmental or cell type-specific cell 
fate decisions (Cook AL and Sturm RA, 2008). 
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9.2.  Chromatin immunoprecipitation (ChIP) determines the 
recruitment of transcription factors E2F-1, E2F-2, E2F-3, and E2F-4 to 
the Gpr19 promoter 
 
ChIP analyses were performed with 5 µg of respective E2F antibodies as described in 
the Materials and Methods sections (Schebesta A et al., 2007). Genomic DNA was 
sheared by multiple rounds of sonication (30 sec pulse – 30 sec pause; DMS 53: four 
cycles at 75% intensity; NCI-H1703: eight cycles at 100% intensity; NCI-H446: four 
cycles at 100% intensity; SHP-77: two cycles at 100% intensity). Sonication typically 
resulted in chromatin fragments of 250 to 600 bp (figure 59, shown for NCI-H1703 
cells).  
 
 
Figure 59:  Chromatin fragmentation after sonication results in DNA fragments of 250 to 600 base pairs 
(bp). Shown is the result from agarose gel electrophoresis of an NCI-H1703 cell lysate (1:20 
dilution) for ChIP analysis sonicated with eight times 30 sec pulses at 100% intensity. The size 
marker is shown in bp. 
 
ChIP PCR was performed for 32 (NCI-H1703; NCI-H446), 33 (DMS 53), or 36 (SHP-77) 
cycles depending on the cell line examined. In any case, an overamplification of the 
PCR signal was avoided by sampling a dilution series of the unprecipitated genomic 
input material together with the precipitated DNA fragments.  
ChIP assays identified the binding of E2F-1, E2F-2, E2F-3, and E2F-4 to the promoter 
region of Gpr19 in NCI-H1703, DMS 53, NCI-H446 and SHP-77 cells (figure 60). They 
were either recruited to binding site -15 or -185 or to both of them. As typical 
chromatin fragmentation after sonication resulted in DNA fragments of 250 to 600 bp 
(figure 59), it was not possible to distinguish E2F binding on these two predicted 
binding sites from each other. However, E2Fs were not recruited to the suggested E2F 
binding sites at positions -3184 or -3769. Primer pairs for PCR amplification of all 
predicted E2F binding sites were chosen in a way that the PCR product did not 
contain any other site – except for primer pair GPR19 (-15; -185). With this primer pair, 
the resulting PCR product covered both these predicted E2F binding sites of the 
Gpr19 promoter. The expected binding of E2Fs to the promoter region of Cdc6 
served as positive control and could be recapitulated. Indeed, no binding of E2Fs to 
the coding sequence of Gpr19 or the promoter region of albumin was also 
confirmed (Wells J et al., 2000). Full-length agarose gels for NCI-H1703 are presented 
in figure 61. PCR primer sequences are listed in table 6 (Materials section).  
 
These data seem to argue that Gpr19 expression might be regulated by some 
members of the E2F family of transcription factors. Several facts suggest that the 
binding of E2F-1, E2F-2, E2F-3, and E2F-4 to the promoter sites at position -15 and/or  
-185 of the Gpr19 gene were specific: (i) Immunoprecipitation of these E2F-family 
1000‐
900‐
800‐
700‐
600‐
500‐
400‐
300‐
200‐
NCI‐H1703
Size marker
VI. Results 
143 
 
members did neither pull down the coding sequence of Gpr19 nor (ii) the promoter 
region of albumin. (iii) Several E2F-family members with repressor activity (E2F-5, E2F-6, 
E2F-7; Polager S and Ginsberg D, 2008; Chen HZ et al., 2009) did not pull down the 
Gpr19 promoter, either. 
 
 
 
 
Figure 60:  E2F family members 1 to 4 bind to the promoter of Gpr19. Chromatin immunoprecipitation 
(ChIP) was performed with antibodies against E2F family members (E2F-1, 2, 3, 4, 5, 6, and 7) 
and immunoglobulin G isotype control (IgG) assayed for binding to different Gpr19 promoter 
regions predicted to contain putative E2F binding sites (-15, -185, -3184, and -3769 bp 
upstream of the Gpr19 open reading frame (ORF)) in DMS 53, NCI-H1703, NCI-H446, and SHP-
77 cells. As an additional negative control, the immunoprecipitation was done in the 
absence of any antibody (no AB). DNA from the sheared chromatin input was serially diluted 
with nuclease-free water (undiluted, 1:5, 1:25, 1:125, water only). Internal controls also 
included amplification of the promoter of a known E2F target gene (cell division cycle 
(Cdc)6) and of an E2F-independent gene (albumin) as well as of a region lying in the coding 
sequence (CDS) of Gpr19. Forward and reverse primer sequences are listed in table 6 
(Materials section). Primer pair GPR19 (-15; -185) covered both predicted E2F binding sites of 
the Gpr19 promoter in the PCR product (primers 15rev1, 185fow1). Shown are the amplicons 
from a representative experiment, which was repeated twice with concurrent results. 
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Figure 61:  E2F family members 1 to 4 bind to the promoter of Gpr19. ChIP was done with antibodies 
against E2F family members (E2F-1, 2, 3, 4, 5, 6, and 7) as described in the legend of 
figure 60. Full-length agarose gel electrophoresis data for NCI-H1703 cells are shown and 
numbers in squared brackets indicate PCR product size (bp). The size marker is shown in bp.  
 
 
9.3.  Both E2F binding sites at positions -15 and -185 of the Gpr19 
promoter are crucial for luciferase reporter gene expression 
 
Fragments of the Gpr19 promoter (300 or 1,000 bp upstream of the Gpr19 ORF) were 
introduced upstream of a firefly luciferase reporter gene in order to evaluate their 
influence on gene expression (figure 62). In addition, the putative E2F transcription 
factor binding sites at positions -15 and/or -185 had been selectively removed in the 
pGL3-Basic-300GPR19-miniTK construct. Constructs are schematically shown in 
figure 62B. All constructs had been verified by sequencing. An excerpt of the Gpr19 
promoter sequence (1,000 bases upstream of the Gpr19 ORF) is shown in the 
Appendix section.   
Expression plasmids had been introduced into DMS 53, HEK-293, and NCI-H1703 cells 
by electroporation: 3 µg (5 µg for HEK-293 cells) of plasmid DNA had been applied to 
5 x 105 cells and 10,000 cells had been seeded per well of a poly-D-lysine-coated 96 
well culture plate. Cells were subjected to luciferase assay 14 h (DMS 53), 13 h (HEK-
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293), and 26 h (NCI-H1703) later. HEK-293 cells had been characterized to not express 
Gpr19 endogenously (figure 31). 
The transfection of the pGL3-Basic-CMV-miniTK construct was used as an assay 
contol and resulted in the massive expression of luciferase: Relative light units were 50 
to 100 times higher than for any Gpr19 promoter fragment-containing luciferase 
construct (data not shown). All constructs bearing fragments of the Gpr19 promoter 
were able to drive luciferase reporter gene expression in DMS 53, HEK-293, and NCI-
H1703 cells (figure 62A). The long promoter fragment of Gpr19 (1,000 bp) increased 
the light signal relative to the shorter fragment that contained only 300 bp in all cell 
lines. The removal of the putative E2F binding site at position -15 alone or in 
combination with the one at position -185 negatively affected reporter gene 
expression clearly in HEK-293 and NCI-H1703 cells, as a decrease in the light signal 
was observed (figure 62A, left and centrefold graphs). However, luciferase 
expression was not completely abolished. In contrast, the knockout of the putative 
E2F binding site at position -185 alone did not diminish luciferase expression in HEK-293 
and NCI-H1703 cells. The opposite was true for DMS 53 cells: The predicted E2F 
binding site at position -185 was more important for luciferase reporter gene 
expression here (figure 62A, right graph). Removal of the E2F consensus site at 
position -185 from the Gpr19 promoter sequence diminished luciferase expression. 
This signal reduction was further enhanced when the E2F consensus site at position  
-15 had also been erased. Again, eradication of E2F consensus sites from the Gpr19 
promoter did not completely abolish luciferase expression. 
 
Hence, the consensus motif for the recruitment of E2F transcription factors to the 
promoter of Gpr19 at both positions -15 and -185 upstream of the Gpr19 ORF seemed 
to be important for luciferase reporter gene expression. The preferred usage might 
be cell line-dependent. However, based on the remaining basal expression levels 
observed with mutated E2F binding sites, E2F transcription factors might not be 
exclusively responsible for Gpr19 gene expression.   
 
 
9.4.  The expression levels of E2f-1, E2f-2, and E2f-3 are increased in 
SCLC patient samples relative to normal lung controls 
 
The recovery of the Gpr19 promoter in ChIP assays using E2F-1 to E2F-4 antibodies 
and the results from Gpr19 promoter fragment-controlled luciferase reporter 
expression indicated a cause-and-effect relation between the action of E2F 
transcription factors and the expression of Gpr19. This association is further fostered 
by gene expression data of E2f-1, E2f-2, and E2f-3 in samples from SCLC patients in 
comparison to samples from NSCLC patients and normal lung controls analyzed by 
Affymetrix microarray analysis (figure 63; Human Exon 1.0 ST Array; samples were 
obtained from OriGene Technologies, details are listed in table 12). High levels of 
Gpr19 expression had been shown in SCLC samples (figure 27; figure 63, upper left 
panel). Likewise, the expression of E2f-1, E2f-2, and E2f-3 followed the pattern 
observed for Gpr19: Expression levels were highest in patient samples derived from 
SCLC. 
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Figure 62:  Both E2F binding sites in the Gpr19 promoter at position -15 and -185 upstream of the Gpr19 
open reading frame (ORF) are important for luciferase reporter gene expression. (A) HEK-293, 
NCI-H1703, and DMS 53 cells were transiently transfected with control (pGL3-Basic-miniTK) or 
Gpr19 promoter fragment-containing luciferase reporter constructs (pGL3-Basic-300GPR19-
miniTK, pGL3-Basic-1000GPR19-miniTK (300/1,000 bp of the Gpr19 promoter upstream of the 
Gpr19 ORF)). Besides, cells were transfected with constructs in which the putative E2F 
transcription factor binding sites at position -15 and/or -185 upstream of the Gpr19 ORF had 
been eliminated (pGL3-Basic-300GPR19-miniTK (mut 15), pGL3-Basic-300GPR19-
miniTK (mut 185), pGL3-Basic-300GPR19-miniTK (mut 15+185)). A schematic representation of 
all constructs is given in B. Cells were harvested for luciferase assay 13 h (HEK-293), 26 h (NCI-
H1703), and 14 h (DMS 53) after transfection. Data are mean values + standard deviation 
(error bar) of six replicates per condition (96 well plate) from a representative experiment. 
Differences across all experimental groups were determined by one way ANOVA followed 
by Tukey’s test. P values of GPR19-mutated constructs 15 and/or 185 refer to the comparison 
with the non-mutant promoter construct pGL3-Basic-300GPR19-miniTK (*p < 0.05; **p < 0.01; 
***p < 0.001). The experiments were repeated yielding concurrent results. CMV – 
cytomegalovirus; Mini TK – minimal thymidine kinase promoter.  
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Figure 63:  Gpr19, E2f-1, E2f-2, and E2f-3 are overexpressed in samples from SCLC patients. The results 
for Gpr19, E2f-1, E2f-2, and E2f-3 gene expression from Affymetrix GeneChip® analysis 
(Human Exon 1.0 ST Array; probe sets NM_006143_at (Gpr19), NM_005225_at (E2f-1), 
NM_004091_at (E2f-2), NM_001949_at (E2f-3)) of human NSCLC, SCLC, and normal lung 
samples are shown per histological group. Expression data were combined for all cases per 
group (box (interquartile range; middle 50% of all expression values) and whiskers (minimum-
maximum) plot with median (central bar)). Detailed sample information is listed in table 12. 
Statistically significant differences were determined by a Kruskal-Wallis test followed by 
Dunn’s multiple comparison (**p < 0.01; ***p < 0.001).  
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VII.  Discussion 
 
1. G protein-coupled receptor 19 (GPR19) – an exceptional 
GPCR difficult to pigeonhole  
 
GPR19 is a member of the family of G protein-coupled receptors (GPCRs) and 
predicted to harbor a seven transmembrane (7TM) structure. When transmembrane 
core sequences of human GPCRs had been compared for receptor classification, 
GPR19 was assigned to the rhodopsin family of GPCRs (Vassilatis DK et al., 2003). In 
fact, the search for paralogs of this receptor (full-length amio acid sequence) in 
Homo sapiens identified only members of the rhodopsin family as its GPCR relatives 
(figure 14). However, those relatives did not seem to be very close. Its classification 
into the rhodopsin family was therefore not confirmed when full-length receptor 
sequences had been applied for GPCR classification – GPR19 was not assigned to 
any of the five GRAFS (glutamate – rhodopsin – adhesion – frizzled/taste2 – secretin) 
GPCR families (Fredriksson R et al., 2003). Moreover, GPR19 lacks features 
characteristic for each of these five families: It does neither harbor a strict E/DRY 
motif at the boundary of transmembrane (TM) region 3 and intracellular loop region 
2 nor a strict NPxxY-motif at the boundary of TM region 7 and the intracellular 
carboxy-terminus characteristic for rhodopsin family members (figure 6; Krishnan A et 
al., 2012). Further, it lacks a very long amino-terminus not to mention any structural 
protein domains therein – features that would support its classification into the 
adhesion, secretin, glutamate, or frizzled/taste2 family. In addition, the GPR19 amino-
terminus does not contain multiple Cys residues seen in most glutamate or secretin 
family receptors (Lagerström MC and Schiöth HB, 2008; Krishnan A et al., 2012). 
Thus, the search for relatives in various species identified GPR19 as a highly 
conserved GPCR. Orthologs were found in euarchontoglires (supra-primates) as well 
as many species that are evolutionary very distant to mammals like the sea 
anemone, sea urchin, lancelet, or the fly (figure 13). The fact that many diverse 
species are equipped with GPR19 points towards an important role for this receptor 
in multicellular organisms, it is likely required to perform an important cellular function. 
Further, GPR19 might have been present in the genome of common ancestor 
species during the times of their evolutional differentiation (Lipman DJ et al., 2002).  
Phylogenetic analyses within one species can be used to determine the closest 
relatives of a protein within a larger protein family. It might therefore be possible to 
narrow down the nature of a putative ligand for a receptor. GPR19 was found to 
have closest GPCR paralogs in receptors activated by biogenic amines and 
peptides in phylogenetic analyses performed with complete receptor primary 
sequences (table 14). Similar results were obtained in five different species: Homo 
sapiens, Pan troglodytes, Macaca mulatta, Mus musculus, and Danio rerio (figure 14 
and figure 15). However, GPR19 was mostly found on branches that separated both 
these receptor subtypes or very distant from any other GPCR. When the 
transmembrane core of GPCRs had been used for sequence alignment, GPR19 was 
found within a bigger cluster of peptide-activated GPCRs and its designated ligand 
was therefore proposed to be a peptide (Vassilatis DK et al., 2003). Sequence 
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similarities were reported between GPR19 and the dopamine D2 and neuropeptide 
Y GPCRs. Yet, as GPR19 is deficient in both an Asp residue within TM region 3 as well 
as two conserved Ser residues within TM region 5, which, on the other hand, are 
characteristic features for functional catecholaminergic receptors (Ji TH et al., 1998), 
its endogenous ligand is unlikely to be aminergic. Neither dopamine nor serotonin nor 
epinephrine (among other biogenic amines) affected adenylyl cyclase activity in 
GPR19-transfected COS (short for ‘CV-1 origin, Simian Virus (SV)40-immortalized’) cells 
(O’Dowd BF et al., 1996). In contrast, GPR19 does not harbor a DxxCR motif in the 
extracellular loop region 1 which is highly conserved among peptidergic GPCRs 
(Peeters MC et al., 2011).  
Thus, the plethora of potential ligands described to act on GPCRs might be 
narrowed down for GPR19 to biogenic amines and peptides on the basis of various 
phylogenetic analyses. However, GPR19 often seemed to lie on the interconnection 
between these two groups of GPCRs. Nevertheless, the data underlying the 
phylogenetic analysis of GPCR transmembrane domains might justify a tendency 
towards a peptide ligand for GPR19 (Vassilatis DK et al., 2003).  
 
When transiently overexpressed, GPR19 localized to the plasma membrane in HEK-
293, NCI-H2170 (non-small cell lung cancer (NSCLC)), and DMS 53 (small cell lung 
cancer (SCLC)) cells (figure 34 and figure 35). In some cells, the GPR19-derived signal 
was also found in an area lying next to the nucleus. This could likely indicate its 
secretion and maturation through the secretory pathway to the plasma membrane 
employing the endoplasmic reticulum and the Golgi apparatus. Most GPCRs are in 
fact found at the plasma membrane where they engage their ligand(s) and initiate 
downstream signaling cascades upon activation (Achour L et al., 2008). Whether 
localization to the plasma membrane in general or to specialized areas within the 
plasma membrane is important for ligand binding/activation of GPR19 remains 
elusive. Some GPCRs are known to preferentially remain in lipid microdomains such 
as membrane rafts or caveolae (Drake MT et al., 2006; Paila YD and Chattopadhyay 
A, 2010). As many signaling components of multiple protein interaction pathways are 
present and pre-organized in rafts/caveolae, GPCRs can rapidly convey 
extracellular signals into the activation of downstream signaling cascades (Patel HH 
et al., 2008). The fact that GPR19 harbors a strict cholesterol consensus motif might 
argue in favor of its preferred homing to these cholesterol-rich microdomains 
(Hanson MA et al., 2008).  
 
The resolution of GPCR structures as well as the production of high affinity antibodies 
against GPCRs is very challenging (Peeters MC et al., 2011). Sources of 
conformational heterogeneity include glycosylation, phosphorylation, and highly 
flexible loops next to the transmembrane regions causing an equilibrium of different 
conformations in GPCRs – one reason why the availability of highly purified GPCR 
preparations and antibodies against GPCRs is limited (Rosenbaum DM et al., 2009; 
Peeters MC et al., 2011).  
In addition, the immunogenicity of GPCRs is low. Most of them are highly 
glycosylated and – generally speaking – they share a high degree of sequence 
homology among each other and among different species (Gupta A et al., 2008). 
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These characteristics could prevent the generation of high and specific serum titers. 
Nevertheless, the most successful strategy pursued to circumvent this problem uses 
short peptides coupled to antigenicity-increasing carrier proteins for immunization. 
Here, peptide sequences of the amino- or carboxy-terminus or the third intracellular 
loop region have revealed most promising results as these regions are highly diverse 
among different receptors and even receptor subtypes (Gupta A et al., 2008). 
This strategy for the production of a GPCR-specific antiserum was also followed for 
GPR19 (peptides used for immunization were located in the amino- or carboxy-
terminus, predicted intracellular loop regions 2 or 3, or the predicted extracellular 
loop region 3; table 11). However, purified antisera raised against GPR19 peptides 
and commercially available GPR19 antibodies failed to specifically detect this 
receptor in lysates from both HEK-293 cells transfected with Gpr19 expression 
plasmids and the NSCLC cell line NCI-H1703 on Western Blots (figure 24 and 
figure 25). Besides, the exact molecular weight of GPR19 was hard to predict due to 
likely posttranslational modifications (O’Dowd BF et al., 1996). HEK-293 cells did not 
express Gpr19 messenger ribonucleic acid (mRNA) which allowed for the evaluation 
of unspecific signals seen in receptor-transfected cells. Endogenous Gpr19 mRNA 
expression was high in NCI-H1703 cells (figure 31) and short interfering ribonucleic 
acid (siRNA)-mediated Gpr19 knockdown should have unmasked GPR19 detection 
(expected signal decline), which was not the case. Nevertheless, the decay in gene 
message by RNA interference might not strictly correlate with an equally reduced 
protein level (Alemán LM et al., 2007). Yet, as an undisputed decision for the specific 
detection of GPR19 on Western Blots could not be made, this method was not 
pursued in subsequent experiments. The proprietary Boehringer Ingelheim Next 
Generation Sequencing cell line database retrieved a wildtype Gpr19 gene status 
for NCI-H1703 cells, which excludes the possibility that non-synonymous single 
nucleotide polymorphisms (SNPs) in GPR19 might account for the lack of antisera 
specificity. 
 
 
2.    High Gpr19 mRNA expression is associated with malignant 
diseases 
 
Gpr19 was first described to be expressed in the central nervous system (CNS; 
O’Dowd BF et al., 1996; Hoffmeister-Ullerich SA et al., 2004). In the present work, it was 
shown that GPR19 can also be associated with lung cancer. This conclusion is based 
on (i) an unbiased approach that found Gpr19 specifically overexpressed in SCLC, 
(ii) database mining comparing Gpr19 expression levels in normal and malignant 
tissues and (iii) the presence of high Gpr19 mRNA levels in several human lung 
cancer-derived cell lines. Illegitimately high expression of GPCRs in tissues different 
from their primary sites of expression suggests that they may have more diversified 
cell-biological roles (Deshpande DA et al., 2010). 
When comparing gene expression ratios between SCLC and NSCLC patients relative 
to normal lung samples, a cluster analysis revealed various expression signatures for 
the members of the vast family of GPCRs. Different clusters existed indicating that 
some of these GPCRs were either up- or downregulated in either SCLC or NSCLC. 
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Gpr19 formed part of a subcluster in which proteins with GPCR activity showed a high 
message upregulation in SCLC patient samples whereas their mRNA levels were 
rather unaltered in NSCLC samples compared to normal lung controls (figure 26).  
This general specificity – high Gpr19 expression in SCLC but not in NSCLC patient 
samples or samples from normal lung – was further confirmed by a database mining 
approach utilizing the BioExpress® database that allowed for comparisons of gene 
expression profiles in various human normal and cancerous tissues. High levels of 
Gpr19 mRNA were not only detectable in SCLC patient samples but also in samples 
from patients suffering from pancreas islet cell carcinoma (figure 28 and figure 29). 
Both these carcinoma types are often characterized by the presence of 
neuroendocrine markers, e.g., chromogranin A or synaptophysin (Wiedenmann B et 
al., 1986; Nakakura EK and Bergsland EK, 2007; Modlin IM et al., 2010). This is also true 
for subsets of NSCLC called large cell neuroendocrine carcinoma (LCNEC; Beasley 
MB et al., 2005) and NSCLC with neuroendocrine features (Rekhtman N, 2010). In 
fact, a slight increase in Gpr19 message could also be observed in large cell lung 
carcinoma (comprising both neuroendocrine and non-neuroendocrine cancers) 
relative to normal lung samples when utilizing the BioExpress® database (figure 28 
and figure 29). Moreover, the correct classification of lung cancers into SCLC or 
NSCLC is sometimes disputable. An exemplary study revealed approximately 30% of 
SCLC-classified cancers which were in fact associated with NSCLC elements 
(Nicholson SA et al., 2002). Among other human NSCLC-derived cell lines, NCI-H1703 
also showed high levels of Gpr19 mRNA expression. It is not clear whether this reflects 
either misclassification, a neuroendocrine phenotype, or de novo illegitimate 
expression. Thus, the discrimination between Gpr19 high and Gpr19 low expression 
lung cancers might not strictly follow histological boundaries. Whether GPR19 might 
serve as additional neuroendocrine marker in these malignancies would require 
further elucidation. Therefore, its expression status in other neuroendocrine 
carcinomas such as medullary thyroid carcinoma would be of interest (Adams MS 
and Bronner-Fraser M, 2009). Additionally, the detection of high levels of GPR19 
protein using immunohistochemistry would argue in favor of its expression (and also 
functionality) being a crucial hallmark for these types of Gpr19-overexpressing 
carcinomas.  
High Gpr19 expression seen in SCLC patient-derived samples was also reflected on 
the cell line level. Gpr19 expression was not evenly distributed among lung-derived 
cell lines. Moreover, an on average bias towards higher Gpr19 expression was 
observed in SCLC- versus NSCLC- or normal lung-derived cells (figure 30 and 
figure 31). A few cell lines such as the SCLC cell line DMS 53 and the NSCLC cell line 
NCI-H1703 could be characterized by a genomic amplification of the chromosomal 
region covering the Gpr19 gene locus (figure 32). Thus, genomic abnormalities are 
unlikely to be the sole cause of Gpr19 overexpression as some of the cell lines 
showing highest Gpr19 mRNA levels (e.g., NCI-H187 or NCI-H446) had no 
amplification of the Gpr19 locus in their genome. In addition, the amplification of 
Gpr19 detected in DMS 53 and NCI-H1703 cells was not a focal event as huge parts 
of the chromosome were found amplified (figure 33). 
 
VII. Discussion 
152 
 
When comparing gene expression profiles of primary and metastatic melanoma, 
former reports had found Gpr19 to be overexpressed in the metastases (Li S et al., 
2005; Riker AI et al., 2008). Samples from metastatic melanoma patients were not 
included in the sample panel from the BioExpress® database. However, samples 
from malignant melanoma did show a higher Gpr19 mRNA expression when 
compared to samples from normal skin (figure 28 and figure 29). These findings are 
further supported by many melanoma-derived cell lines being part of the proprietary 
Boehringer Ingelheim cell line gene expression database which highly expressed 
Gpr19 mRNA (data not shown). Besides, Gpr19 expression in melanoma fosters the 
notion of the cell type-specific expression of this receptor in neuroendocrine tumors 
(Takeda K et al., 2007). 
 
 
3. GPR19 is involved in proliferation and cell cycle regulation 
 
3.1. GPR19 contributes to cell proliferation in human lung cancer-
derived cell lines 
 
Investigations on the role of GPR19 in lung cancer cell proliferation conferred a 
growth advantage in these cells. Regardless of the histological classification of the 
cell line (SCLC or NSCLC), knockdown of Gpr19 mRNA depressed cell proliferation 
and induced apoptosis. These effects were assessed by the use of different 
experimental techniques such as confluence measurement, determination of 
metabolic cell activity, examination of cell morphology, and poly (adenosine 
diphosphate (ADP)-ribose) polymerase 1 (PARP1) cleavage (figure 36, figure 38, 
figure 39, and figure 41). Additionally, they were supported by proliferation and 
apoptotic indices which had been calculated on the basis of a multiple cellular 
parameter analysis (high content screening (HCS); figure 51). The validation of 
different Gpr19-targeting siRNAs was a prerequisite for these experiments, as the 
transfection of siRNAs can cause off-target effects not related to the knockdown of 
the gene of interest (Collinet C et al., 2010).  
These findings were consistent with earlier observations that proposed a role for 
GPR19 in cellular proliferation. During mouse embryogenesis, in particular in the 
developing brain, high levels of Gpr19 mRNA were initially observed in germ cell 
layers of the embryo (neuroepithelium, neural plate) as determined by in situ 
hybridization. Subsequently, Gpr19 mRNA accumulated in the neural plate, the 
subventricular zone, and other sites of cellular proliferation, from which neuronal cells 
emerge in the differentiating CNS. After embryogenesis, overall Gpr19 signals in the 
adult mouse brain declined (Hoffmeister-Ullerich SA et al., 2004). Additionally, 
spermatogonia stem cells – the type of proliferating cells in the testes that account 
for the constant production of sperms – were proposed as a source of Gpr19 
expression (Hoffmeister-Ullerich SA et al., 2004). High Gpr19 expression was also 
assigned to human embryonic stem cells (hESC; Assou S et al., 2007). 
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Tumors can be considered as heterogeneous ‘organs’ as they do not only harbor 
malignant cells but also stromal cells such as tumor fibroblasts, cells of the immune 
system such as inflammatory cells as well as endothelial cells that form the inner lining 
of blood vessels needed for a tumor’s blood supply. This heterogeneity can be partly 
modeled in vitro using 3-dimensional (3D) cell culture techniques (e.g., spheroid 
culture) that include the co-cultivation of cancer-associated fibroblasts (CAFs). With 
regards to the cellular phenotype, migration, signal transduction, and gene 
expression, cells grown as a 3D culture might differ from their counterparts growing 
adherently on the bottom of a culture plate (2D). Here, the modulation of the 
cytoskeleton might account for changes in signal transduction affecting in turn cell 
growth, migration, or apoptosis. Hence, a 3D culture would resemble the real 
situation in vivo more closely where cells interact with their surrounding neighbors 
and the extracellular matrix (Smalley KS et al., 2006; Fischbach C et al., 2007; Dolznig 
H et al., 2011). 
Gpr19 knockdown reduced proliferation in lung cancer cells growing adherently in 
2D. However, many SCLC-derived cell lines formed floating clusters and did not 
attach to the culture plate bottom (e.g., NCI-H209, NCI-H345). Studies using 3D cell 
cultures combined with GPR19 loss of function (e.g., achieved via inducible Gpr19 
knockdown techniques) might assist in characterizing the contribution of this GPCR 
to the formation and proliferation of 3D tumor spheroids in the future. Additionally, 
the enclosed use of (cancer-associated) fibroblasts might help to unravel a potential 
involvement of the tumor stroma in this respect.  
 
 
3.2. GPR19 plays a role during cell cycle progression in gap 2 
(G2)/mitosis (M) phase and is the first GPCR to show differential 
mRNA expression over the course of the cell cycle  
 
In the NSCLC cell line NCI-H1703 and the SCLC cell line DMS 53, the involvement of 
GPR19 not only in proliferation but also in cell cycle regulation could be 
demonstrated with the help of RNA interference. GPCRs control signaling pathways 
that are typically associated with the recruitment of quiescent cells into the cell 
cycle (gap 0 (G0)-gap 1 (G1) phase transition) or with accelerated progression 
through G1 (Dorsam RT and Gutkind JS, 2007; Spiegelberg BD and Hamm HE, 2007). 
Surprisingly, knockdown of Gpr19 affected progression through the cell cycle at a 
later stage, namely in G2/M. The conclusion that GPR19 might play a role during the 
G2/M phase of the cell cycle is based on two independent lines of evidence, 
namely (i) the determination of deoxyribonucleic acid (DNA) content by flow 
cytometry and high content screening and (ii) the quantification of the G2/M phase 
marker cyclin B1 and the mitosis marker phosphorylated histone H3 by 
immunocytochemistry. The mechanistic link between a GPCR and cell division during 
G2/M phase is not intuitively evident. It is, however, worth pointing out that 
heterotrimeric G proteins of the Gi/Go-subfamily are involved in the control of the 
mitotic spindle; they are thought to regulate the mitotic force generator and thus to 
promote chromosomal segregation (Wilkie TM and Kinch L, 2005). Furthermore, the 
CXC chemokine receptor 3 (CXCR3) was found to exhibit a differential protein 
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expression pattern during the cell cycle in primary cultures of human microvascular 
endothelial cells (HMVECs) with peaking protein levels in late DNA synthesis (S)/G2/M 
phases and this GPCR directly controlled cell proliferation (Romagnani P et al., 2001). 
 
The fact that Gpr19 siRNA-treated cell populations showed increased numbers of 
cells with a DNA content characteristic for the G2/M phase points towards a role of 
GPR19 in late stage cell cycle checkpoint control or cellular division. The population 
of cells in G2/M phase was found to be increased in both HCS and flow cytometry 
studies (figure 46, figure 47, and figure 48). Yet, in the HCS, NCI-H1703 cell population 
shiftings towards the G2/M phase were mostly at the expense of cells in G1 phase, 
whereas flow cytometry identified a diminished S phase population. Discrepancies in 
accompanying effects on G1 and S phase populations might be due to different 
detection methods used for discriminating cells in different cell cycle phases 
between HCS and flow cytometry. DNA content data (propidium iodide staining) 
obtained by flow cytometry were allocated to different cell cycle phases using a 
curve-fitting model for G1, S, and G2/M phase populations. In contrast, HCS analysis 
(Hoechst 33342 DNA staining) assigned cells to either sub G1, G1, S, G2/M, or above 
G2/M phase based on clear-cut phase discrimination of cell cycle phases from a 
control population (untreated cells).  
In this context, it is of note that in both methods (HCS and flow cytometry), 
incompletely separated cells had been excluded at best from subsequent analyses. 
Multiparametric HCS analysis allowed the exclusion of nuclei from further analyses 
when they were too large/too close together/overlapping (e.g., cells with a 
polylobed nuclear phenotype; figure 50). The exclusion of cells bearing a 4n DNA 
content inspite of not being in the G2/M phase of the cell cycle due to improper cell 
separation could also be achieved by flow cytometry. Here, cell doublets 
corresponding to data points with an untypical fluorescence signal in the propidium 
iodide area versus width graph allowed for their exclusion from the contribution to 
the G2/M phase cell population. Nevertheless, it is possible that some binucleated 
cells could not be excluded efficiently enough in order to rule out their contribution 
to the population of cells in G2/M phase in both HCS and flow cytometry. This is 
particularly true for cells treated with Gpr19 siRNAs which resulted in the occurrence 
of binucleated and polylobed cells (figure 50).   
The less prominent effect on the G2/M cell population seen upon Gpr19 siRNA 
treatment in DMS 53 in comparison to NCI-H1703 cells might be due to the less 
efficient knockdown of Gpr19 in DMS 53 cells (figure 46 and figure 47). This 
explanation is further fostered by the fact that polo-like kinase 1 (Plk1) siRNA-induced 
increases in the relative number of cells with a G2/M DNA content in flow cytometry 
were also more pronounced in NCI-H1703 than in DMS 53 cells. When the siRNA-
mediated knockdown of Plk1 had been examined on the message level, remaining 
Plk1 levels in DMS 53 cells were higher compared to those in NCI-H1703 cells on day 2 
after transfection (data not shown). Hence, DMS 53 cells might in general be less 
amenable to siRNA transfection than NCI-H1703 cells – at least regarding the 
optimized transfection procedure used in these studies. 
In addition to an increased number of cells with G2/M phase DNA content, cell 
populations treated with Gpr19 siRNAs contained more cells that could be stained 
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positively for the G2/M phase marker cyclin B1 and the mitosis marker 
phosphorylated histone H3 (figure 49). Cyclin B1 – together with its preferred binding 
partner cyclin-dependent kinase (CDK)1 – accounts for the regulation of proteins 
during late G2 phase and early mitosis (Brown NR et al., 2007). The phosphorylation of 
histone H3 at Ser10 starts during late G2 phase but is mainly observed during mitosis 
when chromosome condensation occurs (Hendzel MJ et al., 1997). Thus, these 
observations are consistent with a model where GPR19 impinges on checkpoint 
controls that allow for the transition through G2 and entry into mitosis (checkpoint for 
G2-M transition) or for the initiation of the separation of daughter cells (metaphase-
to-anaphase transition; spindle assembly checkpoint).  
However, the fact that the mitosis marker phosphorylated histone H3 was present in 
cells upon Gpr19 knockdown might argue in favor of a role for this receptor during 
mitosis. It further supports the notion that the Gpr19 knockdown-mediated increase 
in G2/M cells observed by flow cytometry and HCS might actually be a block of 
these cells in mitosis. Both flow cytometry and HCS could not allow for an accurate 
discrimination between cells in the G2 phase and cells in mitosis. Furthermore, as 
Gpr19 knockdown induced cell death in lung cancer cells, these cells might undergo 
a mitotic-linked form of cell death called mitotic catastrophe which could result from 
the premature or inappropriate entry of cells into mitosis (Vakifahmetoglu H et al., 
2008). Indeed, Gpr19 knockdown resulted in polylobed cells, and these nuclear 
aberrations could indicate the induction of mitotic catastrophe (Vakifahmetoglu H 
et al., 2008; Caruso R et al., 2011). Yet, the elucidation of the exact mode of cell 
death would require more detailed cell/nuclear morphology and biochemical 
characterizations.  
 
Earlier findings also suggested that GPR19 might play a role in cell division. High 
Gpr19 expression was found in murine spermatogonia stem cells of the testes 
(Hoffmeister-Ullerich SA et al., 2004) and in spermatocytes undergoing meiotic cell 
division (Rossi P et al., 2004)101. Besides, a meta-analysis comparing the transcriptome 
from human embryonic stem cells with differentiated cells found Gpr19 to be 
upregulated in hESC (Assou S et al., 2007). In a genome-wide siRNA screen, Gpr19 
was identified as a potential cell division gene (Neumann B et al., 2010). Henrietta 
Lacks (HeLa) cells treated with two out of five siRNAs directed against Gpr19 showed 
a binuclear or polylobed nuclear phenotype. However, it is of note that the 
proprietary Boehringer Ingelheim cell line gene expression database reported only a 
very weak expression of Gpr19 in HeLa cells (data not shown). Nevertheless, similar 
nuclear phenotypic changes were also seen in the HCS analysis when NCI-H1703 
cells highly expressing Gpr19 had been treated with Gpr19 siRNAs (figure 50). But a 
reliable automated detection and quantification of these cells was unsuccessful due 
to the limited accuracy of available algorithms for HCS data procession with regards 
to this specific problem. 
As GPR19 is part of the GPCR protein family, its knockdown is supposed to interfere 
with an early stage of signal transduction. In contrast, the knockdown of Plk1, which 
                                                
101  The sperm maturation process consists of spermatogonia undergoing mitotic cell division, spermatocytes 
undergoing meiotic cell division and spermatids undergoing differentiation into mature sperms (Rossi P et al., 
2004). 
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was included as positive control for an increase in the number of cells with a G2/M 
phase-specific DNA content, directly interferes with an essential downstream effector 
kinase that has various roles in M phase progression control (Petronczki M et al., 
2008). The depletion or knockdown of Plk1 results in metaphase arrest but does not 
induce G2 arrest (Liu X and Erikson RL, 2003). This difference in pathway intervention 
might account for the more prominent effects (e.g., the increase in the cell 
population with a (G2/)M phase-specific DNA content and the increase in (G2/)M 
protein marker expression) seen with Plk1 compared to Gpr19 siRNAs (figure 46, 
figure 47, figure 48, and figure 49). Hence, in contrast to the pleiotropic effects of PLK1 
during the cell cycle, GPR19 might have a more focused function in cell cycle 
regulation. 
 
Proteins involved in cell cycle progression can be functionally regulated by various 
means such as subcellular location, posttranslational modification, protein-protein 
interaction, or de novo synthesis (Ohtsubo M et al., 1995; Brown NR et al., 2007). The 
family of cyclins represents the classical example of proteins involved in cell cycle 
regulation. They interact specifically with CDKs and owe their name to their 
differential expression patterns throughout the cell cycle. When investigating Gpr19 
mRNA expression over the course of the cell cycle, a similar differential expression 
pattern was observed for this GPCR. The expression levels of the mRNA encoding 
GPR19 peaked when most cells were in S phase (figure 54, figure 55, and figure 56). 
Rising levels of Gpr19 mRNA could further be correlated with the increase in the 
relative numbers of cells in S phase and the decrease of the G1 population 
(figure 58). Besides, the known differential expression patterns of the mRNAs 
encoding cyclin B1 and cyclin E1 could be recapitulated (Maity A et al., 1995; 
Ohtsubo M et al., 1995; Maity A et al., 1997; Penelova A et al., 2005). The use of 
multiple stably expressed reference genes for data normalization as well as different 
cell synchronization agents further contributed to the validity of this method. 
Synchronization of NCI-H1703 cells with nocodazole was only partially successful (the 
propidium iodide histogram peaks reflecting cells in G1 and G2/M phase were 
almost evenly high after nocodazole treatment) which could therefore explain only 
subtle changes observed for the control expression patterns of cyclin B1 and cyclin 
E1 here (figure 57). This finding provides additional – albeit circumstantial – evidence 
for a role of GPR19 in the regulation of the cell cycle.  
For soluble proteins, the observed mRNA expression pattern (peak expression in S 
phase) typically implies that the proteins are required for S phase transition. However, 
overexpression of GPR19 revealed that this receptor localizes to the plasma 
membrane (figure 34 and figure 35). Members of the GPCR family must mature 
through the secretory pathway to reach their presumed site of action where 
receptor activation leads to the initiation of a downstream signaling cascade (Dong 
C et al., 2007; Achour L et al., 2008). Transcription and translation are rapid processes 
(less than 1 min for a protein of 400 amino acids), but folding in the endoplasmic 
reticulum imposes a time lag of up to several hours (Hebert DN and Molinari M, 2007). 
Besides, subsequent trafficking through and maturation steps in the secretory 
pathway result in an additional delay prior to insertion of the protein into the cell 
membrane. While there are no concrete estimates for GPR19, pharmacochaperone-
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triggered folding of the A1-adenosine receptor suggests that more than 5 hours are 
required for this receptor to reach the cell surface (Málaga-Diéguez L et al., 2010). 
Thus, assuming the validity of these underlying features for GPR19, a delay of several 
hours is to be anticipated between induction of mRNA expression and accumulation 
of GPR19 at the cell surface. Given this inherent delay from mRNA translation to 
effector function, the expression of the GPR19 protein from Gpr19 mRNA (peak 
expression during S phase) is timely for a membrane protein required for the G2/M 
phase.  
 
GPR19 is not the only GPCR whose expression is cell cycle-dependent. In primary 
cultures of HMVECs, the protein level of the chemokine receptor CXCR3 was found to 
be highest when cells exited S phase and entered G2/M (Romagnani P et al., 2001). 
However, the data shown in the present study refer to mRNA levels of Gpr19 rather 
than accumulation of the protein at the cell surface. CXCR3 was also shown to be 
directly involved in the proliferation of endothelial cells: Engagement of its ligands 
interferon-γ-inducible protein of 10 kDa (IP-10) and monokine induced by interferon-γ 
(MIG) stalled cell proliferation in HMVECs. This effect could be reversed by a CXCR3-
specific antibody.  
Another example of cell cycle-dependent receptor expression was attributed to the 
cell surface nerve growth factor (NGF) receptors tropomyosin-related kinase A (TrkA) 
and p75 neurotrophin receptor (p75NTR) in PC-12 cells derived from a rat adrenal 
medulla tumor (Urdiales JL et al., 1998). TrkA protein expression started to rise during 
mitosis and peaked during early G1 phase. In contrast, the protein levels of p75NTR 
declined at these stages of the cell cycle. The NGF-elicited cell cycle-dependent 
responses were proposed to be linked to the differential expression pattern of these 
receptors. Differentiation of PC-12 cells into cells with a neuronal phenotype was 
promoted by NGF stimulation during G1 phase (attributed to the action of TrkA). 
When added at subsequent stages of the cell cycle, NGF promoted progression 
through the cell cycle, attributed to its action on p75NTR. 
 
 
3.3. Overexpression of GPR19 influences neither proliferation nor cell 
cycle progression  
 
In contrast to the inhibition of proliferation observed upon Gpr19 message 
knockdown in both the SCLC cell line DMS 53 and the NSCLC cell line NCI-H1703, 
neither HEK-293 nor NCI-H1703 cells were conferred an advantage regarding 
proliferation when they had been transiently transfected with GPR19 expression 
plasmids compared to control cells (figure 42 and figure 43). This was true for both 
the gain in confluence (investigated only in HEK-293 cells) and the metabolic activity 
of these cells indicative of cell proliferation. The effects of transient receptor 
overexpression are thought to be most striking at early time points after transfection – 
transient gene expression usually bursts after 0.5 to 3 days (Colosimo A et al., 2000). 
Upon cell division, the expression plasmids encoding for GPR19 are expected to be 
excluded from genomic duplication and subjected to subsequent loss. Therefore, a 
potential gain-of-function effect resulting from transient GPR19 overexpression might 
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not be detectable for multiple days after transfection. Overall effects were not 
expected to be as prominent as if these cells had been forced to overexpress GPR19 
from a genome-integrated vector (permanent overexpression; stable transfection). 
Moreover, the transfection efficiency for both NCI-H1703 and HEK-293 cells was 
below 50% (turbo green fluorescent protein (tGFP) positive, propidium iodide 
negative cells). Hence, only less than half the cells in the whole cell population would 
be allowed to exhibit an altered proliferative phenotype at early time points after 
GPR19 expression plasmid transfection. Here, a possible pro-proliferative effect might 
be unraveled by the combination of stable GPR19 expression and 3D organotypic 
cultures in the future.  
Transient plasmid transfection slightly influenced proliferation negatively in both HEK-
293 and NCI-H1703 cells compared to untreated cells or cells treated only with 
transfection reagent but without any plasmid (figure 42 and figure 43). This effect was 
more prominent in NCI-H1703 cells and independent of whether the transfected 
vectors encoded any sort of GPR19 or tGFP or none of the above. Cells consume 
high amounts of energy when they are obliged to express proteins at high levels by 
genetic engineering. The energy needed for the artificial expression of proteins is 
taken away from the energy needed for cell growth and proliferation. Therefore, 
those cells often exhibit a slower than normal growth rate102. 
Similarly, neither HEK-293 nor NCI-H1703 cells showed impairments in cell cycle 
phase progression upon transient transfection with GPR19 expression plasmids in 
comparison to control plasmid-transfected cells (figure 52 and figure 53). Again – as 
it was argued for the investigation of proliferation – the gain-of-function effects 
resulting from transient receptor overexpression (the transfection efficiency (relative 
number of tGFP positive, propidium iodide negative cells) for HEK-293 cells was 52.4% 
and for NCI-H1703 cells 36.3%) were not expected to be as evident as if gene 
overexpression had been achieved from a genome-integrated vector source. 
Nevertheless, cell cycle effects due to GPR19 overexpression could have been 
detected at early time points (e.g., day 2) after transfection when the transfected 
plasmids had not yet been subjected to serious dilution caused by non-propagation 
during cell division or nuclease-mediated degradation. However, this was not the 
case. The above mentioned impairments in energy homeostasis through the forced 
protein expression from a transfected plasmid might in turn have also affected the 
relative distribution of cells during the cell cycle. 
The knockdown of Gpr19 message mostly ablated the receptor and therefore 
diminished its designated signaling function in any case, either upon ligand binding 
or as a scaffolding protein, for instance. Overexpression of the receptor, however, 
did not necessarily need to result in its overactivation – unless the receptor could be 
rendered constitutively active. A GPCR at the cell surface might rather require other 
functional members of the receptor activation apparatus (e.g., putative ligand(s), 
GPCR-interacting proteins (GIPs), potential heteromerization partners, etc.) in order 
to execute its designated downstream signaling resulting in phenotypical changes. 
These prerequisites might have not been fully accounted for by the sole 
overexpression of GPR19. In addition, overexpression of a GPCR could interfere with 
                                                
102  www.korambiotech.com/upload/bbs/2/tb07.pdf 
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signal transduction of other GPCRs and might therefore lead to the attenuation of 
their signaling action (Tubio MR et al., 2010). These results might further argue against 
GPR19 being a constitutively active receptor. 
 
 
4. E2 promoter binding factor (E2F) family members might 
regulate Gpr19 gene expression in human lung cancer-
derived cell lines 
 
Gpr19 revealed a differential expression pattern during the course of the cell cycle in 
both the SCLC cell line DMS 53 and the NSCLC cell line NCI-H1703 with peaking 
mRNA levels during S phase. The regulation of gene expression essentially involves 
the recruitment of transcription factors to the promoter region, which in turn can 
engage other factors necessary for the initiation of gene transcription.   
E2F transcription factors are known to activate the expression of genes at the G1-S 
transition crucial for cell cycle progression (Wells J et al., 2000; Polager S and 
Ginsberg D, 2008; Poznic M, 2009) and could therefore account for cellular 
proliferation (Chen HZ et al., 2009). A high number of genes whose involvement in 
cell cycle progression was shown are in fact E2F targets (Chen HZ et al., 2009). 
Among the genes with an E2F target sequence in their promoter are genes involved 
in DNA synthesis (e.g., DNA polymerase α (Gorgoulis VG et al., 2002), dihydrofolate 
reductase, or thymidine kinase (Wells J et al., 2000)) and cell cycle control (e.g., cell 
division cycle (Cdc)6 and Cdc25 (Brown KC et al., 2010), E and A-type cyclins, cyclin-
dependent kinase inhibitor 2a (Cdkn2a), and Cdk2/4 (Gorgoulis VG et al., 2002)) as 
well as transcription factors (e.g., the proto-oncogene Myc (Rabinovich A et al., 
2008), E2f-1, or E2f-2 (Gorgoulis VG et al., 2002)). 
Based on an in silico approach, the promoter region of the gene encoding GPR19 in 
Homo sapiens was found to contain several candidate binding sites for E2F 
transcription factors. In concurrence with the situation in Homo sapiens, potential E2F 
binding sites within the Gpr19 promoter region could also be detected in Pan 
troglodytes, Macaca mulatta, Mus musculus, and Xenopus tropicalis. Chromatin 
immunoprecipitation (ChIP) performed with antibodies against E2F family members 1, 
2, 3, and 4 allowed for the recovery of the Gpr19 promoter in human lung cancer-
derived cell lines DMS 53 (SCLC), NCI-H1703 (NSCLC), NCI-H446 (SCLC), and SHP-77 
(SCLC; figure 60). Hence, these results provide conclusive evidence that at least one 
of the predicted E2F binding sites – namely at position -15 and/or -185 upstream of 
the Gpr19 open reading frame (ORF) – was in fact occupied by E2F-1, E2F-2, E2F-3, 
and E2F-4 in these cells. Binding sites for E2F-1 and E2F-4 were shown to lie mostly 
within 2 kilobases (kb) of a transcription start site (Xu X et al., 2007) and this was also 
true for the E2Fs binding to the Gpr19 promoter. Further, the cloning of Gpr19 
promoter fragments of different length with and without E2F binding site integrity at 
positions -15 and/or -185 upstream of a luciferase reporter identified the E2F 
consensus sequence at -15 to be predominantly important for sustained gene 
expression in HEK-293 and NCI-H1703 cells. In contrast, the E2F binding site at position 
-185 was more important for reporter gene expression in DMS 53 cells (figure 62). It 
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might be possible that both E2F binding sites are in use for the activation of Gpr19 
gene expression in a cell-specific manner. In all three cell lines tested, the combined 
abolition (positions -15 and -185) led to the most pronounced reduction of luciferase 
reporter expression. Nevertheless, reporter gene expression was not completely 
attenuated when these positions had been removed from the promoter fragment 
indicating the involvement of yet unknown additional transcriptional regulators in 
Gpr19 gene expression. 
HEK-293 cells did not express Gpr19 endogenously (figure 31). Nevertheless, a similar 
luciferase expression pattern as observed in NCI-H1703 cells was recovered when 
HEK-293 cells had been transiently transfected with Gpr19 promoter fragment-
containing luciferase reporter plasmids. This could be due to the fact that 
transcription factors might unrestrictedly engage a promoter region on plasmids 
whereas chromatin structures induced by histone tail methylation and acetylation 
patterns, for instance, might normally render the same promoter region inaccessible. 
 
The regulation of gene expression by transcription factors is very complex as their 
pure binding to the promoter region of a gene does not necessarily account for its 
expression. Transcription factors can be regulated by interaction with 
heteromerization partners, activators, or repressors; their action depends on 
chromatin structure or the presence of enhancer elements. Besides, the binding of 
different transcription factors to the same promoter region or even the same 
consensus sequence may mediate different effects on gene transcription 
(Paranjape SM et al., 1994; Boyd KE and Farnham PJ, 1999).  
Apart from the confirmed binding of E2F transcription factors to the promoter region 
of Gpr19, additional transcription factors might be involved in the regulation of Gpr19 
gene expression. In the murine striatum and hippocampus, Gpr19 mRNA expression 
was linked to the functional presence of cyclic adenosine monophosphate (cAMP)-
responsive element modulator (CREM) and cAMP-responsive element binding 
protein (CREB; Lemberger T et al., 2008). CREM and CREB are classically activated by 
phosphorylation through kinases upon cellular stimulation with cAMP, Ca2+, or growth 
factor signals (De Cesare D et al., 1999). They bind with high affinity to the cAMP-
responsive element (CRE) on a palindromic 5’-T-G-A-C-G-T-C-A-3’ site and with lower 
affinity to the so-called half-CRE site (consensus sequence 5’-C-G-T-C-A-3’). 
However, gene transcription can be fostered by the recruitment of the CREB-binding 
protein (CBP; Piera-Velazquez S et al., 2007). This co-activator of transcription 
possesses histone acetyltransferase activity rendering the local chromatin more 
accessible to its self-mediated recruitment of the general transcription machinery 
(De Cesare D et al., 1999). The Gpr19 promoter also harbors a half-CRE site at position 
-587 upstream of exon 1, whose contribution to the regulation of gene expression 
might be explained by the attenuation of Gpr19 transcription when CREM and CREB 
had been inactivated (Lemberger T et al., 2008). CBP was further described to 
interact with E2F-1 and to function as its co-activator (Trouche D et al., 1996).  
In addition, theoretical binding of the Pit1/Oct2/unc-86 (POU) family of transcription 
factors to the Gpr19 promoter at position -875 upstream of the Gpr19 ORF was 
retrieved by the University of California, Santa Cruz (UCSC) genome browser in silico 
search. Those transcription factors are ubiquitously-expressed and were assigned 
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diverse cellular roles such as the regulation of housekeeping genes or the 
determination of developmental or cell type-specific cell fate decisions. They are 
expressed in many different cancer tissues and one family member, BRN2, was 
shown to be involved in melanoma cell proliferation. Their contribution to 
tumorigenesis is likely mediated by direct or downstream transcriptional targets 
(Cook AL and Sturm RA, 2008). POU proteins have further shown their ability to 
interact with the p300/CBP co-activators of transcription (Sugihara TM et al., 2001; 
Cook AL and Sturm RA, 2008).  
The hypothesis that the E2F family of transcription factors is not exclusively responsible 
for Gpr19 gene expression is fostered by results obtained from the luciferase reporter 
study in which the reporter gene was set under the control of Gpr19 promoter 
fragments (figure 62). The first 300 base pairs (bp) of the Gpr19 promoter, which 
contain potential E2F binding sites (positions -15 and -185), were sufficient for reporter 
gene expression in HEK-293, NCI-H1703 and DMS 53 cells. However, the larger 
promoter fragment (1,000 bp) augmented this expression. This 1,000 bp fragment not 
only harbors both predicted E2F binding sites but also the hypothesized half-CRE 
(position -587) and POU (position -875) binding sites. Thus, in addition to the action of 
E2F family members, a synergistic role of both the CREM/CREB/CBP-recruiting half-
CRE site and a potential POU binding site in the promoter of Gpr19 might be 
conceivable. ChIP assays as well as reporter gene expression using Gpr19 promoters 
deficient for these respective transcription factor binding sites would shed more light 
on their involvement in Gpr19 gene expression regulation.  
 
The family of E2F transcription factors can be subdivided into activators (E2F-1, E2F-2, 
and E2F-3) and repressors (E2F-4, E2F-5, E2F-6, E2F-7, and E2F-8) of gene transcription 
– a classification also reflected by their primary structure (Polager S and Ginsberg D, 
2008; Chen HZ et al., 2009). Transactivation and repression result from interactions 
with different cofactors. E2F-4 and E2F-5 are recruited to promoters during G0 and 
early G1 phase. They prevent quiescent and differentiated cells from entering the 
cell cycle or progressing through G1 phase (Chen HZ et al., 2009). Upon mitogenic 
stimulation, E2F-1, E2F-2, and E2F-3 accumulate in late G1 phase and cause a 
pattern of gene expression that drives cells into S phase. Their combined loss induces 
cell cycle arrest and an oncogenic role has been described for them in many 
cancers (Attwooll C et al., 2004; Chen HZ et al., 2009). During late S phase, these cell 
cycle-promoting signals are attenuated by E2F-6, E2F-7, and E2F-8 (Chen HZ et al., 
2009). Classification of E2Fs into activators and repressors of gene transcription is an 
oversimplification, because some isoforms can mediate both transactivation and 
repression. Another level of complexity and target promoter specificity is added by 
the heterodimerization of E2F members E2F-1 to E2F-6 with dimerization partner 
proteins (DP1, DP2, DP3, and DP4; E2F-7 and E2F-8 only form homodimers or E2F-7–
E2F-8 heterodimers; Polager S and Ginsberg D, 2008). However, ChIP results 
documented the binding of three activating E2F isoforms (E2F-1, E2F-2, and E2F-3) to 
the Gpr19 promoter in unsynchronized cell populations of human lung cancer-
derived cell lines (figure 60). Binding of the repressor E2F-4 might reflect its recruitment 
to the Gpr19 promoter during early G1 phase and subsequent displacement with 
activator E2Fs in late G1 and early S phase leading to Gpr19 transcription. Besides, 
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E2f-1, E2f-2, and E2f-3 expression levels in SCLC patient samples were equally high as 
observed for Gpr19 compared to NSCLC samples and samples from normal lung 
controls (figure 63). Thus, it appears justified to conclude that there might be a cause-
and-effect relation between E2F binding to the Gpr19 promoter and the observed 
accumulation of the mRNA coding for GPR19 during S phase.  
E2Fs can be regulated by the retinoblastoma (RB) protein family (retinoblastoma-
associated protein 1 (RB1), retinoblastoma-like protein 1 (p107), and retinoblastoma-
like protein 2 (p130)). Activator E2Fs (E2F-1, E2F-2, and E2F-3) are preferentially bound 
by RB1 which inhibits their transcription-activating ability. This is abrogated when RB1 
gets hyperphosphorylated (Chen HZ et al., 2009). E2Fs mediating transcriptional 
repression when bound to a promoter either associate with all three RB family 
proteins (E2F-4) or preferentially interact with p130 (E2F-5) leading to the recruitment 
of co-repressors such as histone deacetylases and gene silencing. The activity of E2F-
6, E2F-7, and E2F-8 is presumably not regulated by RB proteins (Attwooll C et al., 2004; 
Chen HZ et al., 2009). 
Inactivation of the RB1 regulatory pathway – the main regulator of E2F activity at the 
G1-S transition of the cell cycle – was described to happen in most lung cancers 
(Wikenheiser-Brokamp KA, 2006). Both overexpression of activator E2Fs and loss of 
RB1 protein function occur very frequently in SCLC (Kitamura H et al., 2008; 
Pleasance ED et al., 2010). In NSCLC, however, RB1 is preferentially rendered inactive 
due to accelerated phosphorylation by CDK4 or CDK6 whose upstream regulator 
CDKN2A (p16 family member) is often inactivated. Besides, cyclin D1, the 
coactivator of CDK4 and CDK6, was found overexpressed in many NSCLC cases 
(Wikenheiser-Brokamp KA, 2006; Kitamura H et al., 2008). 
DMS 53 (SCLC) and NCI-H1703 (NSCLC) cells harbor no mutation in the Rb1 gene 
which is the result from Next Generation Sequencing approaches on cancer cell lines 
(proprietary Boehringer Ingelheim Next Generation Sequencing cell line genomic 
database; data not shown). However, elements upstream of RB1 could render it 
inactive. All these events would equip a lung cancer cell with increased levels of free 
activator E2Fs destined to drive proliferation by selective gene expression. As 
activator E2Fs, which are mainly linked to G1-S specific gene transcription, were 
shown to bind to the promoter region of Gpr19, the paradigm of Gpr19 expression 
being regulated by E2Fs in lung cancer cells is fostered. 
The observation that Gpr19 mRNA was present at high levels in the immortalized cell 
line IB3-1 further supports the conclusion that Gpr19 was under the control of the RB1-
E2F regulatory pathway (figure 31). This cell line was derived from the lung epithelium 
of a patient suffering from cystic fibrosis with the help of a hybrid virus. Accordingly, 
IB3-1 cells contain high levels of SV40 large T antigen (Zeitlin PL et al., 1991), which 
inactivates RB1 and therefore derepresses E2F-dependent transcription (Jha KK et al., 
1998).  
Hence, RB1- and E2F-dependent transcription may not only regulate S phase-
specific genes but also control the expression of genes that are required at later 
stages, e.g., during G2/M phase. This might be particularly true for membrane 
proteins subjected to intracellular trafficking like GPR19. 
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5. GPR19 might exhibit different functional characteristics in the 
central nervous system than in lung cancer 
 
Various parts and cell types of the CNS have been described to be the predominant 
site of Gpr19 expression (O’Dowd BF et al., 1996; Hoffmeister-Ullerich SA et al., 2004). 
This could also be confirmed by Gpr19 gene expression data from normal and 
cancerous tissue samples as part of the BioExpress® database (figure 28 and 
figure 29). Further, GPR19 was associated with proliferation in lung cancer-derived 
cell lines as Gpr19 message abrogation by RNA interference caused growth 
inhibition and cell death. In contrast, the CNS is not characterized by the presence of 
highly proliferating cells; the potential of neurons to regenerate after tissue injury is 
rather limited as observed in many neurodegenerative diseases such as stroke, spinal 
cord injury, or amyotrophic lateral sclerosis (Cavallucci V and D’Amelio M, 2011). 
Further, the expression of Gpr19 in glioblastoma was slightly reduced in comparison 
to normal tissues of the CNS (figure 28 and figure 29). What seems to be 
contradictory at first glance might be explained by the action of different types of 
transcription factors in different tissues. In lung cancer-derived cells, the expression of 
Gpr19 was found to be differentially regulated during the course of the cell cycle 
with a peak expression during S phase which is likely mediated by some members of 
the E2F family of transcription factors acting during G1-S transition. However, in cells 
of the CNS, different promoter regions of Gpr19 and therefore different transcription 
factors might be in preferential use for the expression of this GPCR. Disparities among 
different tissues in promoter usage for gene expression have been demonstrated 
(Mahendroo MS et al., 1993; Sun H et al., 2011).  
On the other hand, lineage-specific effects have also been shown for E2F family 
members in the CNS and the roles of E2F-1 and E2F-3 differ in the developing and in 
the adult brain. During CNS development, proliferating cells were found to express 
E2f-1, E2f-2, and E2f-5, whereas only differentiated cells allowed for the detection of 
E2f-4 expression (Swiss VA and Casaccia P, 2010). Differential E2f expression patterns 
might further account for the differences in Gpr19 expression seen in the developing 
and adult murine CNS (Hoffmeister-Ullerich SA et al., 2004). 
In addition, GPR19 might have cellular functions different from the regulation of 
proliferation and cell cycle progression observed in lung cancer-derived cell lines. 
These functions might be more important in cells of the adult CNS. They might 
therefore repress the proliferation-promoting action of GPR19 through the use of 
different transcriptional regulators or through proteins that counteract this function, 
for instance. Hence, differences in GPCR phosphorylation can occur in a tissue-
specific manner leading in turn to the employment of different signaling pathways 
and receptor regulatory features (Tobin AB et al., 2008). 
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6. GPR19 ligand engagement and G protein coupling remain 
elusive  
 
Gpr19 knockdown by siRNAs resulted in growth inhibition of human lung cancer cell 
lines. The expression of a GPCR does not per se render a cell susceptible to 
regulation by the receptor – the ligand must also be present. It might therefore be 
possible that GPR19-expressing cells could also synthesize and release its agonist 
which could lead to an autocrine receptor stimulation loop. Alternatively, the 
receptor could have a high level of basal activity and engage its cognate G 
protein(s) in the absence of an agonist (Freissmuth M et al., 1991; Schütz W and 
Freissmuth M, 1992). GPR19 was previously proposed to couple to Gi therefore 
inhibiting adenylyl cyclase because it engaged a chimeric fusion protein comprised 
of Gαq and the last five amino acids of Gαi (Bresnick JN et al., 2003). In an attempt to 
verify Gi-dependent inhibition of cAMP formation via GPR19, it was not possible to 
detect an effect of pertussis toxin on cAMP accumulation in NCI-H1703 cells 
(figure 45). As the pertussis toxin-catalyzed carboxy-terminal ADP-ribosylation of 
Gαi/Gαo blocks the access of receptors to these G proteins, this manipulation ought to 
have unmasked constitutive inhibition of cAMP accumulation (Seifert R and Wieland 
T, 2006). The pertussis toxin-induced increase in cAMP accumulation observed in HEK-
293 cells transfected only with CRHR1 proves that constitutive G protein coupling of 
GPR19 ought to have been detectable, if it had occurred. Furthermore, pertussis 
toxin has been described to abolish A1R-mediated inhibition of cAMP accumulation 
(Waldhoer M et al., 1999). Similarly, conditioned medium (supernatants from cell lines 
NCI-H1703 and NCI-H345 which were found to highly express Gpr19 mRNA) did not 
have any effect on cAMP accumulation in HEK-293 cells that had been transfected 
with GPR19 expression plasmids (figure 44). Either the putative ligand of GPR19 was 
not present in conditioned media or GPR19 does not couple to a G protein with 
modulating effects on cellular cAMP levels.  
Thus, it appears unlikely that the action of GPR19 in the G2/M phase of the cell cycle 
could arise from coupling to Gi/Go. Here, the examination of different second 
messengers such as inositol-1,4,5-trisphosphate (IP3) might help to unmask the 
coupling of GPR19 to different G proteins than Gi/Go in the future. Further progress in 
this area is contingent on the identification of the cognate agonist(s) of GPR19. 
Finally, a function different from direct signaling via G proteins might also be 
conceivable for GPR19, e.g., recruiting G protein-independent pathways via β-
arrestins (Shukla AK et al., 2011), via direct binding of tyrosine kinases (Venema RC et 
al., 1998), exchange factors for small G proteins (Gsandtner I et al., 2005), or lipid 
kinases (Bousquet C et al., 2006), or by acting as a scaffold protein (Schmid MC et 
al., 2011). Based on its primary sequence, GPR19 harbors a type I PSD-95/DLP/ZO-1 
(PDZ)-binding motif at its carboxy-terminus (figure 6; Liu M and Horowitz A, 2006). This 
motif could serve as a ligand for proteins containing a PDZ domain leading to their 
recruitment to GPR19 and subsequent G protein-independent signaling (Bockaert J 
et al., 2004).     
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7. GPR19 – a receptor applicable for targeted cancer therapy 
 
Chemotherapy plays a major role in the treatment of multiple types of cancer. 
However, many long-serving agents lack tumor specificity. They interfere with the 
ability of cells to proliferate and divide. Among them are for example topoisomerase 
inhibitors (e.g., topothecan, etoposide), DNA intercalating agents (e.g., cisplatinum), 
anti-mitotic substances (e.g., paclitaxel), or anti-metabolites (e.g., methotrexate). 
Hence, proliferating cancer cells are preferentially hit by these compounds but their 
cytotoxic potential also affects non-transformed cells and can cause severe side 
effects (Chari RV, 2008).  
These indiscriminating cell killing strategies are more and more replaced by targeted 
tumor therapy in which tumor-associated features resulting from genetic changes 
are hit by pharmaceutical agents (Sharma SV and Settleman J, 2010). This concept 
promises to allow for a better therapeutic effect as normal cells would be affected 
less severely. Examples in which targeted tumor therapy has been applied to inhibit 
the enzymatic activity of a kinase include epidermal growth factor receptor (EGFR)-
targeting in NSCLC patients with EGFR mutation (Yoshida T et al., 2010), targeting of 
the fusion protein kinase BCR-ABL1 (short for ‘breakpoint cluster region’ on 
chromosome 22 and ‘Abelson murine leukemia viral oncogene homolog 1’ on 
chromosome 9) prevalent in chronic myeloid leukemia (CML; Maekawa T et al., 
2007), or B-Raf (rapidly accelerated fibrosarcoma isoform B)-targeting in melanoma 
patients with B-Raf mutation (Wellbrock C and Hurlstone A, 2010), for instance. 
Another strategy aims at targeting cell surface markers specific for or overexpressed 
in tumors with antibodies to which cytotoxic drugs are conjugated (Chari RV, 2008). 
Further, antisense molecules such as siRNAs could interfere specifically with the 
expression of oncogenes to which a tumor has become addicted (Wacheck V and 
Zangemeister-Wittke U, 2006).  
Much of the expected success of targeted tumor therapy is linked to the concept of 
oncogene addiction, which describes the dependence of a cancer cell on the 
sustained activity of one or a few genes for the maintenance of its malignant 
phenotype (Weinstein IB and Joe A, 2008). Hence, many approaches in targeted 
tumor therapy aim at specifically inhibiting the activity of an oncogene. When the 
Gpr19 message in Gpr19-expressing lung cancer-derived cell lines was attenuated 
by the use of RNA interference, proliferation of these cells was diminished eventually 
leading to cell death (figure 36, figure 38, figure 39, and figure 41). Thus, it seems 
justified to speak of GPR19 as a vulnerable target, which – when overexpressed in 
lung cancer cells – is involved in cell proliferation. However, Gpr19 expression did not 
result in any gain of proliferation in neither HEK-293 nor NCI-H1703 cells transiently 
transfected with GPR19 expression plasmids. These studies have not been performed 
in non-malignant cells, but they indicate that GPR19 might lack the ability to 
transform cells into a malignant phenotype. In very few lung cancer-derived cell lines 
examined (including DMS 53 and NCI-H1703), the overexpression of Gpr19 could be 
explained by amplification of the Gpr19-containing chromosomal region. None of 
the lung cancer-derived cell lines listed in the proprietary Boehringer Ingelheim Next 
Generation Sequencing cell line database had any mutation in the gene encoding 
GPR19. These findings might argue against the strict categorization of Gpr19 as an 
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oncogene (Croce CM, 2008). Instead, its overexpression particularly seen in human 
lung cancer-derived cell lines and SCLC patient samples might be accounted for by 
the deregulated action of members of the E2F family of transcription factors, which is 
very often observed in lung cancer (Wikenheiser-Brokamp KA, 2006; Kitamura H et 
al., 2008). 
 
The present work highlights GPR19 as a potential drug target for the treatment of a 
subset of Gpr19-overexpressing lung cancers. Although mainly SCLC and not NSCLC 
patient samples exhibited high levels of Gpr19 mRNA in this study, all experiments 
conducted in both the SCLC cell line DMS 53 and the NSCLC cell line NCI-H1703 led 
to concordant results. Hence, individual screening of lung cancer patients for Gpr19 
expression status might be an important necessity regardless of histological typing.  
The CNS is the predominant tissue where high Gpr19 expression was found in healthy 
individuals. Due to the existence of the blood-brain-barrier, the limited accessibility 
of the CNS for the delivery of pharmaceutical compounds is often a problem when 
their site of action lies in the CNS (Witt KA and Davis TP, 2006). Here, this physical and 
enzymatic barrier could be made use of to protect the CNS from drugs targeting 
GPR19 in cancerous tissues. 
When looking at target identification and validation programs for the treatment of 
cancer patients, the main focus of research falls into the area of elucidating the 
contributions of effector kinases and membrane-spanning receptor tyrosine kinases 
to tumorigenesis (Sharma SV and Settleman J, 2010). The large family of human G 
protein-coupled receptors with more than 800 predicted members, however, seems 
to be left aside here. Though some GPCRs have revealed their potential as well-
druggable targets for the treatment of various diseases (Schlyer S and Horuk R, 2006; 
Lundstrom K, 2009) – a fact that is generating growing interest in GPCRs when 
searching for novel therapeutic strategies also in oncology. The results described in 
this work strongly support the notion of GPR19 as a specific drug target when 
overexpressed in lung cancer.  
 
 
8. Summary 
 
Taken together, the described observations point to a role for GPR19 in cellular 
proliferation of human lung cancer cells which overexpress Gpr19 mRNA. They further 
argue in favor of a contribution of GPR19 in cell cycle regulation – possibly at late 
stages of the G2 phase but more likely during mitosis – as Gpr19 mRNA levels peak 
during S phase. This cell cycle-dependent expression pattern is likely to be mediated 
by E2F transcription factors. To the best of knowledge, GPR19 is the first GPCR whose 
mRNA has been shown to be expressed in a cell cycle-dependent manner and to 
impinge on G2/M transition in human tumor cells. It can hereby be called a 
‘cycloceptor’. However, insights into signal transduction mechanisms that account 
for its proliferation and cell cycle regulatory effects as well as a physiological ligand 
for this orphan receptor remain to be determined. So far, only little is known about 
possible effector activation pathways of GPR19. Finally, the insights from this work 
could also be of relevance to understand the physiological role of GPR19 during 
embryogenesis and brain development. 
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VIII.  Appendix 
 
1. Gpr19 genomic sequence 
 
The National Center for Biotechnology Information (NCBI) gene identification 
number for human Gpr19 is 2842 and the Ensembl gene identification number is 
ENSG00000183150. Gpr19 is located on the reverse strand of chromosome 12 (short 
arm; 12p12.3) at the position 12,849,121 to 12,813,995 and the exon-intron structure is 
shown in table 15. 
 
Table 15:  The gene structure of human Gpr19. Gpr19 is composed of four exons (purple; coding 
sequence (CDS) in black) spaced by three introns (blue). The table further includes the end 
of the 5’ upstream and the beginning of the 3’downstream sequence (green). This gene 
structure is adopted from Ensembl.  
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2. Gpr19 messenger ribonucleic acid (mRNA) sequence 
 
The NCBI accession number for the mRNA (5’ to 3’ direction) of human Gpr19 is 
NM_006143. It is composed of four exons (exon 1: position 1 to 123; exon 2: 124 to 176; 
exon 3: 177 to 333; exon 4: 334 to 1743) and the coding sequence lies entirely in 
exon 4 (356 to 1603, bold). This excession number encodes the GPR19 protein variant 
with Ile at amino acid position 189 (A at transcript position 920; see non-synonymous 
single nucleotide polymorphisms (SNPs) in table 16). 
       
   1 CUUUCCGCCU AGUGAGAGGC GGUCCGAUUU GGCCCUUGGG GAGUGUCCGU CGCGUUGAUC  
 
  61 UGAUGGAUUC ACGUACACAA CACCACAUUC UAUGAGAUUU UGCAGGCAAA AGUCCACAAG  
 
 121 CUCGAUAUAU GGGACACCUG CACCGGCAUU GGAUUUGGCC CCGCAACAUC UUAAAGGAAG  
 
 181 CAGGCUGUGA GCCAAGGGGA AGGCAGAGGA CAGAAAUGAA UGUGUUUCCA GGCUUUCCUG  
 
 241 GUGGUUUAUG GCAUUCUCCA AACUCCUAUG CAAGGGCUAU UCCUGACCAA GAAGAUCUAA  
 
 301 AGAGAACGUC UCUGAAAUCA AGUCCGGAUG AAGAAUUAAG AGAAAAAAAG UGAAUAUGGU  
 
 361 UUUUGCUCAC AGAAUGGAUA ACAGCAAGCC ACAUUUGAUU AUUCCUACAC UUCUGGUGCC  
 
 421 CCUCCAAAAC CGCAGCUGCA CUGAAACAGC CACACCUCUG CCAAGCCAAU ACCUGAUGGA  
 
 481 AUUAAGUGAG GAGCACAGUU GGAUGAGCAA CCAAACAGAC CUUCACUAUG UGCUGAAACC  
 
 541 CGGGGAAGUG GCCACAGCCA GCAUCUUCUU UGGGAUUCUG UGGUUGUUUU CUAUCUUCGG  
 
 601 CAAUUCCCUG GUUUGUUUGG UCAUCCAUAG GAGUAGGAGG ACUCAGUCUA CCACCAACUA  
 
 661 CUUUGUGGUC UCCAUGGCAU GUGCUGACCU UCUCAUCAGC GUUGCCAGCA CGCCUUUCGU  
 
 721 CCUGCUCCAG UUCACCACUG GAAGGUGGAC GCUGGGUAGU GCAACGUGCA AGGUUGUGCG  
 
 781 AUAUUUUCAA UAUCUCACUC CAGGUGUCCA GAUCUACGUU CUCCUCUCCA UCUGCAUAGA  
 
 841 CCGGUUCUAC ACCAUCGUCU AUCCUCUGAG CUUCAAGGUG UCCAGAGAAA AAGCCAAGAA  
 
 901 AAUGAUUGCG GCAUCGUGGA UCUUUGAUGC AGGCUUUGUG ACCCCUGUGC UCUUUUUCUA  
 
 961 UGGCUCCAAC UGGGACAGUC AUUGUAACUA UUUCCUCCCC UCCUCUUGGG AAGGCACUGC  
 
1021 CUACACUGUC AUCCACUUCU UGGUGGGCUU UGUGAUUCCA UCUGUCCUCA UAAUUUUAUU  
 
1081 UUACCAAAAG GUCAUAAAAU AUAUUUGGAG AAUAGGCACA GAUGGCCGAA CGGUGAGGAG  
 
1141 GACAAUGAAC AUUGUCCCUC GGACAAAAGU GAAAACUAUC AAGAUGUUCC UCAUUUUAAA  
 
1201 UCUGUUGUUU UUGCUCUCCU GGCUGCCUUU UCAUGUAGCU CAGCUAUGGC ACCCCCAUGA  
 
1261 ACAAGACUAU AAGAAAAGUU CCCUUGUUUU CACAGCUAUC ACAUGGAUAU CCUUUAGUUC  
 
1321 UUCAGCCUCU AAACCUACUC UGUAUUCAAU UUAUAAUGCC AAUUUUCGGA GAGGGAUGAA  
 
1381 AGAGACUUUU UGCAUGUCCU CUAUGAAAUG UUACCGAAGC AAUGCCUAUA CUAUCACAAC  
 
1441 AAGUUCAAGG AUGGCCAAAA AAAACUACGU UGGCAUUUCA GAAAUCCCUU CCAUGGCCAA  
 
1501 AACUAUUACC AAAGACUCGA UCUAUGACUC AUUUGACAGA GAAGCCAAGG AAAAAAAGCU  
 
1561 UGCUUGGCCC AUUAACUCAA AUCCACCAAA UACUUUUGUC UAAGUUCUCA UUCUUUCAAU  
 
1621 UGUUAUGCAC CAGAGAUUAA AAAGCUUUAA CUAUAAAAAC AGAAGCUAUU UACAUAUUUG  
 
1681 UUUUCACUCA ACUUUCCAAG GGAAAUGUUU UAUUUUGUAA AAUGCAUUCA UUUGUUUACU  
 
1741 GUA 
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3. Gpr19 codon-optimized coding sequence (mRNA) 
 
The codon-optimized Gpr19 coding sequence (5’ to 3’ direction) was introduced in 
the pcDNA3.1 (+) expression vector downstream of a cytomegalovirus (CMV) 
promoter for the expression of GPR19 (see table 5).  
 
   1 AUGGUGUUCG CCCACCGGAU GGACAACAGC AAGCCCCACC UGAUCAUCCC CACCCUGCUG 
  
  61 GUGCCCCUGC AGAACAGAAG CUGCACCGAG ACAGCCACCC CCCUGCCCAG CCAGUACCUG 
 
 121 AUGGAACUGA GCGAGGAACA CAGCUGGAUG AGCAACCAGA CCGACCUGCA CUACGUGCUG   
 
 181 AAGCCCGGCG AAGUGGCUAC CGCCAGCAUC UUUUUCGGCA UCCUGUGGCU GUUCAGCAUC 
 
 241 UUCGGCAACA GCCUCGUGUG CCUGGUCAUC CACAGAUCUC GGCGGACCCA GAGCACCACC  
 
 301 AACUACUUCG UGGUGUCCAU GGCCUGCGCC GACCUGCUGA UCAGCGUGGC CAGCACCCCC  
 
 361 UUCGUGCUGC UGCAGUUCAC CACAGGCCGG UGGACACUGG GCAGCGCCAC CUGUAAAGUC  
 
 421 GUGCGGUACU UUCAGUACCU GACCCCUGGC GUGCAGAUCU ACGUGCUGCU GAGCAUCUGC  
 
 481 AUCGACCGGU UCUACACCAU CGUGUACCCC CUGAGCUUCA AGGUGUCCCG CGAGAAGGCC  
 
 541 AAGAAGAUGA UCGCCGCCAG CUGGGUGUUC GACGCCGGCU UUGUGACCCC CGUGCUGUUC  
 
 601 UUCUACGGCA GCAACUGGGA CAGCCACUGC AACUACUUUC UGCCUAGCAG CUGGGAGGGC  
 
 661 ACCGCCUACA CCGUGAUCCA CUUUCUCGUG GGCUUCGUGA UCCCCAGCGU GCUGAUCAUC  
 
 721 CUGUUCUACC AGAAAGUGAU CAAGUACAUC UGGCGGAUCG GCACCGACGG CCGGACCGUG  
 
 781 CGGCGGACCA UGAACAUCGU GCCCCGGACC AAAGUCAAGA CCAUCAAGAU GUUUCUGAUC  
 
 841 CUGAACCUGC UGUUCCUGCU GAGCUGGCUG CCCUUCCACG UGGCCCAGCU GUGGCACCCC  
 
 901 CACGAGCAGG ACUACAAGAA AAGCAGCCUG GUGUUCACCG CCAUCACCUG GAUCAGCUUC  
 
 961 AGCAGCAGCG CCUCCAAGCC CACCCUGUAC AGCAUCUACA ACGCCAACUU CAGACGGGGG  
 
1021 AUGAAGGAAA CCUUCUGCAU GAGCAGCAUG AAGUGCUACA GAAGCAACGC UUACACCAUC  
 
1081 ACCACCAGCA GCCGGAUGGC CAAGAAAAAC UACGUGGGCA UCAGCGAGAU CCCCAGCAUG  
 
1141 GCCAAGACAA UCACCAAGGA CUCCAUCUAC GACAGCUUCG ACAGAGAGGC CAAAGAGAAG  
 
1201 AAGCUGGCCU GGCCCAUCAA UAGCAACCCC CCCAACACCU UCGUGUGA 
 
 
 
 
 
 
 
 
 
 
 
 
VIII. Appendix 
170 
 
4. GPR19 protein sequence  
 
The UniProt identification number for human GPR19 is Q15760. The NCBI protein 
reference sequence is NP_006134.1 (protein variant V189I). The sequence is arranged 
from the amino- to the carboxy-terminus. 
 
        10         20         30         40         50         60  
MVFAHRMDNS KPHLIIPTLL VPLQNRSCTE TATPLPSQYL MELSEEHSWM SNQTDLHYVL  
 
        70         80         90        100        110        120  
KPGEVATASI FFGILWLFSI FGNSLVCLVI HRSRRTQSTT NYFVVSMACA DLLISVASTP  
 
       130        140        150        160        170        180  
FVLLQFTTGR WTLGSATCKV VRYFQYLTPG VQIYVLLSIC IDRFYTIVYP LSFKVSREKA  
 
       190        200        210        220        230        240  
KKMIAASWVF DAGFVTPVLF FYGSNWDSHC NYFLPSSWEG TAYTVIHFLV GFVIPSVLII  
   
       250        260        270        280        290        300  
LFYQKVIKYI WRIGTDGRTV RRTMNIVPRT KVKTIKMFLI LNLLFLLSWL PFHVAQLWHP  
 
       310        320        330        340        350        360  
HEQDYKKSSL VFTAITWISF SSSASKPTLY SIYNANFRRG MKETFCMSSM KCYRSNAYTI  
 
       370        380        390        400        410  
TTSSRMAKKN YVGISEIPSM AKTITKDSIY DSFDREAKEK KLAWPINSNP PNTFV  
 
According to Ensembl103, 24 SNPs exist within the coding sequence of Gpr19. Twelve 
SNPs do not affect the protein sequence (synonymous), whereas the other twelve 
cause an amino acid substitution (non-synonymous). The latter ones are listed in 
table 16.  
 
Table 16:  Non-synonymous SNPs in the Gpr19 coding sequence according to Ensembl. Only those 
SNPs listed in the NCBI SNP database104 were included. The feature-specified positions of 
amino acid substitutions (external amino (N)-terminus, cytoplasmic carboxy (C)-terminus, 
transmembrane (TM), or intracellular loop (IL) regions) are hypothetical and refer to the 
UniProt human GPR19 protein ID Q15760 (figure 6). Amino acid substitutions that were 
considered to be deleterious (i.e., affecting protein function) are shown in red (Sorting 
Intolerant From Tolerant (SIFT) score < 0.05). 
 
Identification 
number Amino acid substitution 
Allele 
(transcript 
position) 
Frequency 
[%] SIFT
105 
rs143657544 S27N (N-terminus) G435A 0.022 0 
rs148944358 S48I (N-terminus) G498T 0.022 0.05 
rs41276680 V116I (TM2) G701A 1.203 0.46 
rs139420660 V155I (TM3) G818A 0.022 0.08 
                                                
103  useast.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?g=ENSG00000183150;r=12:12813825-
12849141#NON_SYNONYMOUS_CODING_tablePanel 
 
104  www.ncbi.nlm.nih.gov/snp 
 
105 The Sorting Intolerant From Tolerant (SIFT) algorithm evaluates the effect of non-synonymous SNPs on protein 
function. Based on sequence homology of the protein of interest to related protein family members, amino acid 
substitutions are judged according to their position in the protein and their effect on physicochemical properties. 
The SIFT score indicates the normalized probability that the amino acid substitution caused by the SNP does not 
affect protein function (Ng PC and Henikoff S, 2003). 
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Identification 
number Amino acid substitution 
Allele 
(transcript 
position) 
Frequency 
[%] SIFT
105 
rs115836857 V168I (IL2) G857A 0.519 0.51 
rs4763862 V189I (TM4) G920A 13.444 0.93 
rs147196823 T224A (TM5) A1025G 0.022 0.84 
rs149524125 V272L (IL3) G1169C 0.022 0.08 
rs140470262 K351R (C-terminus) A1407G 0.022 0.24 
rs145071913 V372A (C-terminus) T1470C 0.022 0 
rs138857972 K398R (C-terminus) A1548G 0.198 0.25 
rs61733942 P411T (C-terminus) C1586A 1.389 0.01 
 
 
5. Gpr19 promoter sequence 
 
The first 1,000 bases (5’ to 3’ direction) of the Gpr19 promoter (located on the reverse 
strand of chromosome 12 (short arm; 12p12.3) at the position 12,850,121 to 
12,849,122) are listed below. Potential E2 promoter binding factor (E2F), 
Pit1/Oct2/unc-86 (POU), and half-cyclic adenosine monophosphate (cAMP)-
responsive element (CRE) transcription factor binding sites as explained in the Results 
and Discussion sections are highlighted. 
       
 
  1 GCATGGCTGC TTTTTTTTTT TTTTTTTTTT TTTTACTTCG CTTCAAGAGT CAGTCTTAAA  
 
 61 TCATGTAGGT TTTGCTTGAG GTTTGCTCGA GCAAGAGGAC CTTAGGTTTG GTCTTATTTG  
                                                                POU(-875) 
121 CATTTTTACC ATAACTAGGC CTACATTCTA AATAAGTAAC TAAATGCCAC CTATGAGTTT  
 
181 CATTAACTGT GGCTGCTTGC CACTTTTTAG TTCTGGTTAG GGTGGTGCTA TTGTTTTCCT  
 
241 CAGGTTCATT AGAAACATCT TCCGTGACAG CTCTGACGCG GCACCGATTT CTGAGTGTCC  
 
301 AGTGTTTTCC CTACCATTAT TTTCTTTGGT CTGAAGTTGA CACTTAAACT GTCCAGTTTT  
 
361 AAACCTCCGA TCCGTGTTCC CAAATGAAAA CATGACTTTC ATTACGAATT ACACGTCAAG  
                                                              halfCRE(-587) 
421 GGAGCAAACC AAGGCGCTCG GGGCGGCGAG AACCGCGACA CAGCGCTTCG CCTGGACTGG  
 
481 TAAACAAACC GCCGCGCAGG CGCAATGGCA ACAGGACGGT AACCTGGGTA GCCGCCAATG  
 
541 GGCTTTTTCG TAGAGTGAAA AGCGGAAAAG CCAAACAAAA CGCTGGTTCC AAGGTGATAA  
 
601 ACTGGCTGAC TTCCTCTATT TTTACTTTTT TAAAAAATTT TGTTTCTGAA GAAGTAGTTG  
 
661 TGCGGCCTTC TGGGCCTCGC AGAGATCTTC TTCGTGGAAT TCCTCGGCCC CAGAGAAATG  
 
721 CCGCTAGCCT GTCGGCTAGT TATATTAGCC TAATTTTTTG TCTTGATCTT TTTCATTTGA  
 
781 CTGCAGCACT AATCCTAATC CACTGGGGCA GCAAAAAAAA AAAAAAAAAA AAAAAAAAAA  
                                 E2F(-185) 
841 AAAAAAAAGG GCGGGTGGGA TCTCAACGCC ACGGAAAACC TTCATACTAG CCGGCCATCA  
 
901 CCAAACCACG CGAGATCTGC CTGAGGAGAA GCGCCACCCC GGGAGTGCAC GTTTGCGCAT 
  
961 GCGTCTGGCT CATCATTTTT AGCGCGCAAA AGTTTCAAAA CTTTCCGCCT AGTGAGAGGC 
                      E2F(-15)                  Start of exon 1   
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